1 00:00:05,938 --> 00:00:08,174 >> GOOD MORNING WELCOME TO THE 2 00:00:08,174 --> 00:00:12,545 37th MEET FOR THE NATIONAL 3 00:00:12,545 --> 00:00:15,081 CENTER FOR ADVANCING 4 00:00:15,081 --> 00:00:15,748 TRANSLATIONAL SCIENCES ADVISORY 5 00:00:15,748 --> 00:00:20,687 COUNCIL IS NOW IN SESSION. 6 00:00:20,687 --> 00:00:22,155 I'LL GAVEL US IN. 7 00:00:22,155 --> 00:00:26,859 >> LET'S BEGIN WITH ROLL CALL 8 00:00:26,859 --> 00:00:28,961 PAUL HARRIS. 9 00:00:28,961 --> 00:00:30,329 AMY KARLY. 10 00:00:30,329 --> 00:00:31,898 KELLY McBERRY. 11 00:00:31,898 --> 00:00:33,599 ROBIN MIDDLESTEIN. 12 00:00:33,599 --> 00:00:34,967 KEITH MILLER. 13 00:00:34,967 --> 00:00:36,102 >> HERE. 14 00:00:36,102 --> 00:00:37,437 >> PAULA SHIREMAN. 15 00:00:37,437 --> 00:00:40,606 >> WE HAVE ALL MEMBERS IN 16 00:00:40,606 --> 00:00:44,744 ATTENDANCE AND NO AD HOCS 17 00:00:44,744 --> 00:00:46,846 PARTICIPATING. 18 00:00:46,846 --> 00:00:48,915 SO, OPEN SESSION IS ONE DAY, 19 00:00:48,915 --> 00:00:50,316 TODAY. 20 00:00:50,316 --> 00:00:53,553 THE ACTIVITY WILL BE THE 21 00:00:53,553 --> 00:00:55,521 DIRECTOR'S REPORT AND WE'LL THEN 22 00:00:55,521 --> 00:00:57,623 HAVE A 45 MINUTE LUNCH BREAK. 23 00:00:57,623 --> 00:01:01,394 AFTER LUNCH WE HAVE A SPECIAL 24 00:01:01,394 --> 00:01:06,399 TOPIC PRESENTATION AND 25 00:01:06,399 --> 00:01:10,036 DISCUSSIONS AND THEN MOVE INTO 26 00:01:10,036 --> 00:01:11,671 TWO UPDATES AND THE FIRST WILL 27 00:01:11,671 --> 00:01:16,943 BE THE DIVISION OF CLINICAL 28 00:01:16,943 --> 00:01:22,381 INNOVATION PRESENTED BY MIKE AND 29 00:01:22,381 --> 00:01:24,117 THEN THE DRUG DEVELOPMENT 30 00:01:24,117 --> 00:01:27,320 PARTNERSHIP PROGRAMS BY 31 00:01:27,320 --> 00:01:29,422 CHRISTINE AND THEN CONCEPT 32 00:01:29,422 --> 00:01:30,256 PRESENTATIONS THE FIRST BY THE 33 00:01:30,256 --> 00:01:33,559 OFFICE OF DRUG DEVELOPMENT 34 00:01:33,559 --> 00:01:34,160 PARTNERSHIP PROGRAMS AND THE 35 00:01:34,160 --> 00:01:35,595 SECOND WILL BE PRESENTED BY THE 36 00:01:35,595 --> 00:01:38,097 OFFICE OF SPECIAL INITIATIVES 37 00:01:38,097 --> 00:01:40,967 AND THE LAST FOR THE DAY WILL BE 38 00:01:40,967 --> 00:01:46,139 PRESENTED BY THE DIVISION OF 39 00:01:46,139 --> 00:01:46,773 RARE DISEASES RESEARCH 40 00:01:46,773 --> 00:01:48,174 INNOVATION. 41 00:01:48,174 --> 00:01:52,245 ANNOUNCEMENTS TODAY, THIS IS A 42 00:01:52,245 --> 00:01:53,112 HYBRID MEETING. 43 00:01:53,112 --> 00:01:54,881 THOSE ON SITE ARE NOT LOGGING 44 00:01:54,881 --> 00:01:58,117 INTO THE ZOOM NECESSARY. 45 00:01:58,117 --> 00:01:59,886 AND IF YOU DO MAKE SURE YOU ARE 46 00:01:59,886 --> 00:02:03,956 NOT CONNECTED TO YOUR AUDIO. 47 00:02:03,956 --> 00:02:06,492 THE CONFERENCE ROOM IS CONNECTED 48 00:02:06,492 --> 00:02:08,661 TO ZOOM AND THAT'S ATTENDEES 49 00:02:08,661 --> 00:02:10,263 PARTICIPATING AND BEING SEEN. 50 00:02:10,263 --> 00:02:12,131 IF YOU ARE PARTICIPATING 51 00:02:12,131 --> 00:02:15,501 VIRTUALLY, PLEASE RAISE YOUR 52 00:02:15,501 --> 00:02:17,603 HAND OR CHAT AND WAIT UNTIL 53 00:02:17,603 --> 00:02:19,338 YOU'RE CALLED UPON TO PROVIDE 54 00:02:19,338 --> 00:02:19,539 INPUT. 55 00:02:19,539 --> 00:02:21,174 ALL PARTICIPANTS PLEASE ALLOW 56 00:02:21,174 --> 00:02:23,309 SPEAKERS TO MOVE THROUGH THEIR 57 00:02:23,309 --> 00:02:24,110 PRESENTATIONS. 58 00:02:24,110 --> 00:02:25,578 NOTING YOUR COMMENTS AND/OR 59 00:02:25,578 --> 00:02:26,512 QUESTIONS AND PRESENTING YOUR 60 00:02:26,512 --> 00:02:29,715 COMMENTS WHEN CALLED UPON. 61 00:02:29,715 --> 00:02:34,420 ANY VIRTUAL PARTICIPANTS MUST 62 00:02:34,420 --> 00:02:36,389 ENSURE DURING THE MEETINGS -- 63 00:02:36,389 --> 00:02:38,858 EXCUSE ME, SO WE'RE USING 64 00:02:38,858 --> 00:02:39,258 VIDEOCAST FEATURE. 65 00:02:39,258 --> 00:02:41,861 THE AUDIENCE MEMBERS MAY SUBMIT 66 00:02:41,861 --> 00:02:43,129 COMMENTS UNTIL OCTOBER 3 BY 67 00:02:43,129 --> 00:02:44,630 USING THE E-MAIL FUNCTION 68 00:02:44,630 --> 00:02:46,399 AVAILABLE ON THE NIH VIDEOCAST 69 00:02:46,399 --> 00:02:46,599 SITE. 70 00:02:46,599 --> 00:02:52,238 YOU HAVE AN E-MAIL ADDRESS NCATS 71 00:02:52,238 --> 00:02:59,312 COUNCIL INPUT AT MAIL DOT NIH 72 00:02:59,312 --> 00:03:00,213 DOTGOV. 73 00:03:00,213 --> 00:03:01,814 IF YOU ARE NOT ON CAMERA WHAT 74 00:03:01,814 --> 00:03:02,915 HAPPENS IS THE PREVIOUS SPEAKER 75 00:03:02,915 --> 00:03:09,155 IS SPOTLIGHTED IN THE VIDEOCAST. 76 00:03:09,155 --> 00:03:12,992 THE FUTURE MEETING DATES 2025 77 00:03:12,992 --> 00:03:15,595 ARE JANUARY 30-31. 78 00:03:15,595 --> 00:03:19,765 MAY 22 AND MAY 23, SEPTEMBER 18 79 00:03:19,765 --> 00:03:25,338 AND 19 AND 2026, JANUARY 29 AND 80 00:03:25,338 --> 00:03:27,840 MAY 21 AND 22 AND SEPTEMBER 17 81 00:03:27,840 --> 00:03:31,410 AND 18 AND THE JANUARY MEETINGS 82 00:03:31,410 --> 00:03:32,645 ARE VIRTUAL MEETINGS. 83 00:03:32,645 --> 00:03:35,681 NOW I'M GOING TO HAND IT BACK TO 84 00:03:35,681 --> 00:03:40,319 OUR I.C. DIRECTOR DR. JONI 85 00:03:40,319 --> 00:03:42,388 RUTTER FOR OUR REPORT TO 86 00:03:42,388 --> 00:03:42,622 COUNCIL. 87 00:03:42,622 --> 00:03:43,522 >> A QUICK MIKE CHECK. 88 00:03:43,522 --> 00:03:46,492 CAN YOU HEAR ME OKAY? 89 00:03:46,492 --> 00:03:56,669 THANK YOU. 90 00:04:01,507 --> 00:04:04,977 THIS IS THE FIRST TIME IN THE 91 00:04:04,977 --> 00:04:06,646 SHADY GROVE CAMPUS AND I'M 92 00:04:06,646 --> 00:04:10,016 LOVING THIS AND THE FOURTH 93 00:04:10,016 --> 00:04:11,017 MEETING IS ALWAYS THE MEETING 94 00:04:11,017 --> 00:04:12,652 THAT HAS SO MUCH ACTIVITY 95 00:04:12,652 --> 00:04:14,387 RUNNING UP TO IT THOUGH IT 96 00:04:14,387 --> 00:04:16,656 COVERS THE SUMMER PERIOD. 97 00:04:16,656 --> 00:04:17,523 THERE'S A LOT OF ACTIVITY 98 00:04:17,523 --> 00:04:21,994 HAPPENING IN WHAT WE DO BUSINESS 99 00:04:21,994 --> 00:04:22,995 WISE FOR THE GRANTS MANAGEMENT 100 00:04:22,995 --> 00:04:23,229 REVIEW. 101 00:04:23,229 --> 00:04:28,167 I WANT TO GIVE A BIG ROUND OF 102 00:04:28,167 --> 00:04:30,770 APPLAUSE AND SHOUT OUT TO OUR 103 00:04:30,770 --> 00:04:31,604 COUNCIL TEAM FOR ORGANIZING AT 104 00:04:31,604 --> 00:04:33,205 THE SAME TIME THEY'RE WORKING ON 105 00:04:33,205 --> 00:04:34,974 THE REVIEWS AND GRANTS 106 00:04:34,974 --> 00:04:36,876 MANAGEMENT WORK WE DO IN THE 107 00:04:36,876 --> 00:04:38,377 DIVISION OF EXTRAMURAL AFFAIRS. 108 00:04:38,377 --> 00:04:45,117 SO THANK YOU ALL. 109 00:04:45,117 --> 00:04:46,619 THANK YOU FOR THAT IMPORTANT 110 00:04:46,619 --> 00:04:48,120 WORK AND THERE'S QUITE A LOT TO 111 00:04:48,120 --> 00:04:49,522 DISCUSS AND I'M NOT SEEING MY 112 00:04:49,522 --> 00:04:53,693 SLIDES ON MY SCREEN SO I MIGHT 113 00:04:53,693 --> 00:04:55,261 BE A LITTLE BIT DISCOMBOBULATED 114 00:04:55,261 --> 00:04:57,330 BUT HOPEFULLY I CAN FIGURE OUT 115 00:04:57,330 --> 00:05:07,673 HOW TO ADVANCE THEM. 116 00:05:09,842 --> 00:05:09,976 OKAY. 117 00:05:09,976 --> 00:05:14,380 I USUALLY DO A RECAP WHAT WE DO 118 00:05:14,380 --> 00:05:15,414 FROM OUR LAST COUNCIL. 119 00:05:15,414 --> 00:05:17,283 I'M NOT GOING THROUGH THE ENTIRE 120 00:05:17,283 --> 00:05:18,818 SLIDE BECAUSE WE TALKED ABOUT 121 00:05:18,818 --> 00:05:19,318 QUITE A LOT. 122 00:05:19,318 --> 00:05:24,857 WELL GO OVER SOME OF THIS AGAIN 123 00:05:24,857 --> 00:05:26,892 JUST AS RELATED TO UPDATES I 124 00:05:26,892 --> 00:05:27,460 WANTED TO MENTION. 125 00:05:27,460 --> 00:05:30,663 IN TERMS OF OUR BUCKET I'LL TALK 126 00:05:30,663 --> 00:05:32,498 ABOUT THAT BUT WE HAVE 11 DAYS 127 00:05:32,498 --> 00:05:33,065 LEFT. 128 00:05:33,065 --> 00:05:35,434 WE STILL DON'T HAVE A BUDGET YET 129 00:05:35,434 --> 00:05:36,369 BUT HOPING WE'LL HAVE A 130 00:05:36,369 --> 00:05:42,308 CONTINUING RESOLUTION TO GET US 131 00:05:42,308 --> 00:05:43,743 THROUGH BUT I'LL GIVE A SENSE OF 132 00:05:43,743 --> 00:05:45,511 WHERE WE ARE AND TO REMIND YOU 133 00:05:45,511 --> 00:05:46,679 THE LAST ROUND WE TOLD YOU FOR 134 00:05:46,679 --> 00:05:51,617 THE BUDGET YEAR OF FY24 WE HAD A 135 00:05:51,617 --> 00:05:53,552 $5 MILLION INCREASE IN OUR 136 00:05:53,552 --> 00:05:55,588 ACTIVITIES THAT IS SUPPORTING 137 00:05:55,588 --> 00:05:58,991 AND BOLSTERING OUR TEAM THERAPY 138 00:05:58,991 --> 00:06:00,292 EFFORTS AND IN PARTICULAR 139 00:06:00,292 --> 00:06:04,597 DISEASE CALLED MMA101 AND WE'RE 140 00:06:04,597 --> 00:06:06,265 PUSHING FORWARD AND HOPEFULLY 141 00:06:06,265 --> 00:06:08,334 WE'LL BE ABLE TO UPDATE YOU. 142 00:06:08,334 --> 00:06:09,602 IT WON'T BE TODAY BUT WANTED TO 143 00:06:09,602 --> 00:06:10,403 REMIND YOU. 144 00:06:10,403 --> 00:06:11,837 AND WE TALKED ABOUT OUR 145 00:06:11,837 --> 00:06:14,206 STRATEGIC PLAN. 146 00:06:14,206 --> 00:06:15,307 I'LL GIVE AN UPDATE AS WELL 147 00:06:15,307 --> 00:06:20,679 BECAUSE I'M EXCITED WE HAVE 148 00:06:20,679 --> 00:06:22,314 PUBLISHED OUR STRATEGIC PLAN. 149 00:06:22,314 --> 00:06:23,983 HANG TIGHT. 150 00:06:23,983 --> 00:06:26,385 WE'LL TALK ABOUT THAT IN A 151 00:06:26,385 --> 00:06:27,386 MINUTE. 152 00:06:27,386 --> 00:06:27,653 ALL RIGHT. 153 00:06:27,653 --> 00:06:30,389 TODAY WE ARE -- WE HAVE A 154 00:06:30,389 --> 00:06:31,891 VARIETY OF OTHER PRESENTATIONS 155 00:06:31,891 --> 00:06:34,393 AFTER ME BEFORE WE DO CONCEPT 156 00:06:34,393 --> 00:06:42,401 CLEARANCES BUT I'M EXCITED TO 157 00:06:42,401 --> 00:06:51,877 WELCOME -- YOU'RE WONDERING WHO 158 00:06:51,877 --> 00:07:01,687 WE'RE GOING TO WELCOME TODAY. 159 00:07:01,687 --> 00:07:01,887 OKAY. 160 00:07:01,887 --> 00:07:04,723 HE HAD TO WALK OVER TO MAKE IT 161 00:07:04,723 --> 00:07:06,025 WORK. 162 00:07:06,025 --> 00:07:10,996 SO WE HAVE A SPECIAL 163 00:07:10,996 --> 00:07:16,502 PRESENTATION TODAY FROM JANINE 164 00:07:16,502 --> 00:07:17,803 PRITCHETT CLAY AND I'VE BEEN 165 00:07:17,803 --> 00:07:19,338 WAITING FOR THE PRESENTATION AND 166 00:07:19,338 --> 00:07:21,307 I'M EXCITED YOU'LL BE ABLE TO 167 00:07:21,307 --> 00:07:23,075 HEAR IT TODAY. 168 00:07:23,075 --> 00:07:24,443 I'M NOT GOING TO SAY MORE 169 00:07:24,443 --> 00:07:26,312 BECAUSE I DON'T WANT TO STEAL 170 00:07:26,312 --> 00:07:28,447 THEIR THUNDER BUT HOPE YOU'LL BE 171 00:07:28,447 --> 00:07:30,349 AS IMPRESSED AS I AM IN THE WORK 172 00:07:30,349 --> 00:07:30,783 THEY'VE BEEN DOING. 173 00:07:30,783 --> 00:07:32,518 WE HAVE OTHER UPDATES IN TERMS 174 00:07:32,518 --> 00:07:34,386 OF OUR PROGRAMATIC ACTIVITIES 175 00:07:34,386 --> 00:07:35,654 WITH THE DIVISION OF CLINICAL 176 00:07:35,654 --> 00:07:38,257 INNOVATION AND THE OFFICE OF 177 00:07:38,257 --> 00:07:39,925 DRUG DEVELOPMENT PARTNERSHIP 178 00:07:39,925 --> 00:07:40,292 PROGRAMS. 179 00:07:40,292 --> 00:07:44,597 MIKE WILL BE PRESENTING FROM DCI 180 00:07:44,597 --> 00:07:49,502 AND CHRISTINE AND KARLIE WILL BE 181 00:07:49,502 --> 00:07:51,303 TALKING ABOUT THE OFFICE OF DRUG 182 00:07:51,303 --> 00:07:53,005 DEVELOPMENT PARTNERSHIPS 183 00:07:53,005 --> 00:07:53,639 PROGRAM. 184 00:07:53,639 --> 00:07:55,374 WE HAVE SOME REALLY GREAT 185 00:07:55,374 --> 00:07:56,408 PRESENTATIONS FOR YOU HERE TODAY 186 00:07:56,408 --> 00:07:56,575 TOO. 187 00:07:56,575 --> 00:07:59,912 I ALSO WANTED TO SHOW THIS GREEN 188 00:07:59,912 --> 00:08:02,047 BOX UP HERE IS THE ONLY 189 00:08:02,047 --> 00:08:05,017 REMAINING BOX WE HAVE NOT QUITE 190 00:08:05,017 --> 00:08:08,287 FILLED IN TERMS OF OUR HIRES BUT 191 00:08:08,287 --> 00:08:11,023 WE CONTINUE TO HAVE THE 192 00:08:11,023 --> 00:08:16,562 EXPERTISE OF BECCA GIGER AS OUR 193 00:08:16,562 --> 00:08:18,397 EXECUTIVE OFFICER. 194 00:08:18,397 --> 00:08:24,270 WE'RE HOPING TO FINALIZE THE 195 00:08:24,270 --> 00:08:26,405 ROLE OTHERWISE WE'RE SET IN OUR 196 00:08:26,405 --> 00:08:28,707 LEADERSHIP AND I COULDN'T BE 197 00:08:28,707 --> 00:08:29,642 MORE HAPPY. 198 00:08:29,642 --> 00:08:31,544 WE'LL CONTINUE TO KEEP HUMMING 199 00:08:31,544 --> 00:08:33,679 ALONG BUT AT A BETTER CLIP. 200 00:08:33,679 --> 00:08:41,020 I'M SUPER EXCITED ABOUT THAT. 201 00:08:41,020 --> 00:08:45,224 SO I ALSO WANT TO GO OVER 202 00:08:45,224 --> 00:08:46,725 UPDATES AND I CIRCLED HER IN 203 00:08:46,725 --> 00:08:50,029 GREEN BECAUSE THIS IS THE FIRST 204 00:08:50,029 --> 00:08:53,332 COUNCIL THAT WE HAVE ANIKA 205 00:08:53,332 --> 00:08:55,401 WAYMAN AS THE OFFICIAL DEPUTY 206 00:08:55,401 --> 00:08:56,302 DIRECTOR OF NCATS. 207 00:08:56,302 --> 00:08:58,003 I'D LIKE TO TURN IT OVER TO HER 208 00:08:58,003 --> 00:08:59,371 TO INTRODUCE HERSELF AS THE 209 00:08:59,371 --> 00:09:00,839 DEPUTY DIRECTOR AND SAY A FEW 210 00:09:00,839 --> 00:09:02,508 WORDS BECAUSE SHE HAS A UNIQUE 211 00:09:02,508 --> 00:09:07,079 ROLE HERE. 212 00:09:07,079 --> 00:09:08,347 >> GOOD MORNING, EVERYONE. 213 00:09:08,347 --> 00:09:10,649 THANKS FOR THE INTRODUCTION. 214 00:09:10,649 --> 00:09:12,518 REALLY EXCITED TO BE HERE. 215 00:09:12,518 --> 00:09:13,986 IT FEELS KIND OF STRANGE BEING 216 00:09:13,986 --> 00:09:17,223 ON THE OTHER SIDE BUT I DID 217 00:09:17,223 --> 00:09:18,390 ENJOY MY ROLE AS COUNCIL MEMBER 218 00:09:18,390 --> 00:09:22,228 SO MUCH SO I WANTED TO DIG IN 219 00:09:22,228 --> 00:09:22,461 FURTHER. 220 00:09:22,461 --> 00:09:26,599 SO JUST A REMINDER OF MY 221 00:09:26,599 --> 00:09:27,967 BACKGROUND AND WHY THE ROLE 222 00:09:27,967 --> 00:09:30,769 SEEMS SO PERFECT IS I'VE HAD A 223 00:09:30,769 --> 00:09:32,471 BLEND OF EXPERIENCES UP TERMS OF 224 00:09:32,471 --> 00:09:34,373 MY BACKGROUND. 225 00:09:34,373 --> 00:09:36,976 THAT ALL LENT ITSELF TOWARDS 226 00:09:36,976 --> 00:09:38,377 TRANSLATIONAL SCIENCE. 227 00:09:38,377 --> 00:09:41,013 I FEEL LIKE I'M ABLE TO LEVERAGE 228 00:09:41,013 --> 00:09:43,349 ALL THAT AND I'M AN ENGINEER. 229 00:09:43,349 --> 00:09:45,551 I DID RESEARCH IN BIO PHYSICS 230 00:09:45,551 --> 00:09:46,385 AND WORKED IN THE PRIVATE SECTOR 231 00:09:46,385 --> 00:09:48,153 AND IN GOVERNMENT. 232 00:09:48,153 --> 00:09:50,456 STARTED A TRANSLATIONAL SCIENCE 233 00:09:50,456 --> 00:09:54,893 UNDERGRADUATE PROGRAM AT UMBC 234 00:09:54,893 --> 00:09:56,095 RIGHT WHERE I CAME FROM BEFORE 235 00:09:56,095 --> 00:09:58,397 HERE AND EXCITED TO WORK 236 00:09:58,397 --> 00:10:00,733 ALONGSIDE JONI. 237 00:10:00,733 --> 00:10:02,368 IT'S BEEN REALLY INTERESTING 238 00:10:02,368 --> 00:10:06,372 THUS FAR. 239 00:10:06,372 --> 00:10:08,674 AS A COUNCIL MEMBER YOU SAW THE 240 00:10:08,674 --> 00:10:10,442 GREAT WORK AND NOW I HAVE AN 241 00:10:10,442 --> 00:10:11,910 OPPORTUNITY TO SEE IT AS A 242 00:10:11,910 --> 00:10:15,114 DEEPER LEVEL AND IT'S 243 00:10:15,114 --> 00:10:17,850 FASCINATING WORK. 244 00:10:17,850 --> 00:10:19,251 I LOVE ALONG WITH THE STRATEGIC 245 00:10:19,251 --> 00:10:22,388 PLAN WHERE NCATS IS GOING SO 246 00:10:22,388 --> 00:10:24,523 IT'S EXCITING TO BE PART OF 247 00:10:24,523 --> 00:10:31,563 NCATS AND THE PEOPLE ARE PAS 248 00:10:31,563 --> 00:10:33,766 PASSIONATE AND COUNCIL REAL AND 249 00:10:33,766 --> 00:10:34,767 AUTHENTIC AND I'VE ENJOYED MY 250 00:10:34,767 --> 00:10:38,070 TIME SO FAR AND HAVE IDEAS AND 251 00:10:38,070 --> 00:10:39,738 THOUGHTS HOW TO LEVERAGE COUNCIL 252 00:10:39,738 --> 00:10:40,172 MORE. 253 00:10:40,172 --> 00:10:42,374 I DON'T KNOW IF YOU GUYS FELT 254 00:10:42,374 --> 00:10:42,574 THAT. 255 00:10:42,574 --> 00:10:44,109 I FELT AT COUNCIL I WANTED TO 256 00:10:44,109 --> 00:10:45,477 FIGURE OUT HOW TO DO MORE WHICH 257 00:10:45,477 --> 00:10:49,248 IS WHY I THEN CAME TO NCATS BUT 258 00:10:49,248 --> 00:10:51,984 I THINK AS A COUNCIL MEMBER 259 00:10:51,984 --> 00:10:53,852 THERE'S ALSO OTHER OPPORTUNITIES 260 00:10:53,852 --> 00:10:55,154 AS TO HOW COUNCIL COULD BE 261 00:10:55,154 --> 00:10:56,355 LEVERAGED. 262 00:10:56,355 --> 00:11:00,459 SO LOOKING FORWARD TO HELPING 263 00:11:00,459 --> 00:11:01,593 NCATS IN TERMS OF THAT PIECE AS 264 00:11:01,593 --> 00:11:01,794 WELL. 265 00:11:01,794 --> 00:11:04,363 THANK YOU FOR THE WELCOME. 266 00:11:04,363 --> 00:11:06,398 >> THANK YOU, ANIKA. 267 00:11:06,398 --> 00:11:16,542 WELCOME. 268 00:11:19,912 --> 00:11:21,080 SO THAT'S GOOD NEWS BUT NOW WE 269 00:11:21,080 --> 00:11:23,849 HAVE TO SAY GOOD-BYE TO A 270 00:11:23,849 --> 00:11:25,684 COUNCIL MEMBER ANNIE KENNEDY WHO 271 00:11:25,684 --> 00:11:30,389 HAS BEEN A DYNAMIC PARTNER I 272 00:11:30,389 --> 00:11:32,624 THINK WITH THE COUNCIL TEAM AND 273 00:11:32,624 --> 00:11:34,293 MEMBERS AND HAVE BENEFITTED FROM 274 00:11:34,293 --> 00:11:37,096 HER LEADERSHIP NOT JUST WITHIN 275 00:11:37,096 --> 00:11:40,733 COUNCIL BUT EVEN IN THE BROADER 276 00:11:40,733 --> 00:11:41,133 COMMUNITIES. 277 00:11:41,133 --> 00:11:42,434 EVEN THOUGH SHE'LL BE ROTATING 278 00:11:42,434 --> 00:11:46,405 OFF OUR COUNCIL, I KNOW SHE 279 00:11:46,405 --> 00:11:48,407 WON'T BE FAR. 280 00:11:48,407 --> 00:11:50,042 I ALSO WANT TO GIVE A ROUND OF 281 00:11:50,042 --> 00:11:51,410 APPLAUSE FOR ANNIE AND HER WORK 282 00:11:51,410 --> 00:11:51,710 ON COUNCIL. 283 00:11:51,710 --> 00:11:57,750 THANK YOU SO MUCH. 284 00:11:57,750 --> 00:11:59,752 I'LL GIVE YOU A FEW MOMENTS AT 285 00:11:59,752 --> 00:12:01,053 THE END OF THE MEETING IF THAT'S 286 00:12:01,053 --> 00:12:02,988 OKAY BUT IF YOU'D LIKE TO SAY 287 00:12:02,988 --> 00:12:04,623 ANYTHING NOW, HAPPY TO HEAR 288 00:12:04,623 --> 00:12:07,126 THOUGHTS OR WOULD LIKE TO 289 00:12:07,126 --> 00:12:09,061 WAIT -- OKAY. 290 00:12:09,061 --> 00:12:09,495 FAIR ENOUGH. 291 00:12:09,495 --> 00:12:10,863 SO THEN ON TO THE BUDGET. 292 00:12:10,863 --> 00:12:13,832 THIS IS WHERE THINGS STAND NOW 293 00:12:13,832 --> 00:12:14,767 WITH OUR BUDGET. 294 00:12:14,767 --> 00:12:19,905 ON I THINK IT WAS MARCH 11 THE 295 00:12:19,905 --> 00:12:22,374 PRESIDENT'S BUDGET WAS RELEASED 296 00:12:22,374 --> 00:12:25,911 AND REQUESTED $926.1 MILLION FOR 297 00:12:25,911 --> 00:12:30,115 NCATS FOR FY25 A 0.3% INCREASE 298 00:12:30,115 --> 00:12:32,317 OVER FY23. 299 00:12:32,317 --> 00:12:36,255 AS YOU MAY RECALL IT'S A LITTLE 300 00:12:36,255 --> 00:12:38,257 BIT FUNNY HOW IT WORKED OUT. 301 00:12:38,257 --> 00:12:39,992 THE TIMING WAS TIGHT IN TERMS OF 302 00:12:39,992 --> 00:12:41,560 THE WHEN THE PRESIDENT'S BUDGET 303 00:12:41,560 --> 00:12:44,897 WAS RELEASED AND THE FY24 304 00:12:44,897 --> 00:12:45,230 BUDGETS. 305 00:12:45,230 --> 00:12:48,500 THE FY24 BUDGET WAS BASED ON 306 00:12:48,500 --> 00:12:50,402 FY23 BECAUSE IT WAS JUST PRIOR 307 00:12:50,402 --> 00:12:53,839 TO THE PASSAGE OF THE BUDGET. 308 00:12:53,839 --> 00:12:58,377 THAT'S WHY IT MAY LOOK ODD AND 309 00:12:58,377 --> 00:13:05,017 THE HOUSE AND SENATE PASSED 310 00:13:05,017 --> 00:13:08,253 BILLS BUT NOT BY THE FULL 311 00:13:08,253 --> 00:13:08,520 COMMITTEE. 312 00:13:08,520 --> 00:13:10,989 THAT WILL HAVE TO HAPPEN BEFORE 313 00:13:10,989 --> 00:13:12,691 OCTOBER 1 OR THERE WILL NEED TO 314 00:13:12,691 --> 00:13:13,992 BE A CONTINUING RESOLUTION OR WE 315 00:13:13,992 --> 00:13:16,128 MAY RUN OUT OF MONEY IN 11 DAYS 316 00:13:16,128 --> 00:13:18,597 BUT HOPEFULLY THAT WON'T HAPPEN 317 00:13:18,597 --> 00:13:21,200 AND WE'LL GET A C.R. TO PREVENT 318 00:13:21,200 --> 00:13:23,335 A LAPSE IN FUNDING IN THE 319 00:13:23,335 --> 00:13:24,269 GOVERNMENT AND KEEP US OPEN A 320 00:13:24,269 --> 00:13:30,075 BIT LONGER. 321 00:13:30,075 --> 00:13:33,178 THE HOUSE PROPOSED A CONTINUING 322 00:13:33,178 --> 00:13:35,714 RESOLUTION THROUGH THE 28th THAT 323 00:13:35,714 --> 00:13:38,917 HASN'T HAPPENED SO STAY TUNED 324 00:13:38,917 --> 00:13:40,319 AND WE'LL KEEP YOU POSTED. 325 00:13:40,319 --> 00:13:41,620 IF THERE'S A C.R. WE'LL TELL YOU 326 00:13:41,620 --> 00:13:42,721 WHAT'S GOING ON WITH THE BUDGET 327 00:13:42,721 --> 00:13:43,956 NEXT TIME WE MEET. 328 00:13:43,956 --> 00:13:44,957 IF YOU'RE INTERESTED IN OTHER 329 00:13:44,957 --> 00:13:48,927 ACTIVITIES ED TO -- RELATED TO 330 00:13:48,927 --> 00:13:51,730 THE BUDGET SEE OUR QR CODE SHOWN 331 00:13:51,730 --> 00:13:52,998 HERE AND THAT'S WHERE WE ARE IN 332 00:13:52,998 --> 00:13:53,832 THE BUDGET. 333 00:13:53,832 --> 00:13:56,668 ON TO OTHER NCATS RELATED 334 00:13:56,668 --> 00:13:57,769 ACTIVITIES. 335 00:13:57,769 --> 00:14:00,239 THERE WILL BE I THINK 336 00:14:00,239 --> 00:14:00,839 HIGH-PROFILE AND INTERESTING 337 00:14:00,839 --> 00:14:03,909 MEETINGS I WANTED TO 338 00:14:03,909 --> 00:14:04,543 HIGHLIGHTED. 339 00:14:04,543 --> 00:14:09,781 FIRST AN ASSAY GUIDANCE NETWORK 340 00:14:09,781 --> 00:14:12,284 FOR HIGH THROUGHPUT SCREENING 341 00:14:12,284 --> 00:14:14,553 AND IT'S BEEN A HUGE SUCCESS 342 00:14:14,553 --> 00:14:16,688 FROM DAY ONE . 343 00:14:16,688 --> 00:14:17,623 I THINK THEY KEEP GETTING BETTER 344 00:14:17,623 --> 00:14:18,023 AND BETTER. 345 00:14:18,023 --> 00:14:21,093 SO IF YOU HAVE A CHANCE TO 346 00:14:21,093 --> 00:14:22,995 REGISTER FOR THESE PLEASE DO SO. 347 00:14:22,995 --> 00:14:25,597 QR CODE IS HERE. 348 00:14:25,597 --> 00:14:27,266 AND THESE ALREADY HAVE QUITE A 349 00:14:27,266 --> 00:14:29,001 BIG REGISTRATION FOR THEM. 350 00:14:29,001 --> 00:14:30,369 THEY'RE ALL VIRTUAL. 351 00:14:30,369 --> 00:14:33,071 I HOPE YOU'LL BE ABLE TO ATTEND. 352 00:14:33,071 --> 00:14:35,007 THE SECOND WORKSHOP WE'RE DOING 353 00:14:35,007 --> 00:14:42,381 IN OCTOBER IS ON IN SILICO DRUG 354 00:14:42,381 --> 00:14:44,816 DISCOVERY. 355 00:14:44,816 --> 00:14:48,420 NAMS OR COMPLEMENTARY PREDICTIVE 356 00:14:48,420 --> 00:14:51,256 MODELS ARE A BIG EMPHASIS AND 357 00:14:51,256 --> 00:14:52,925 THE WORKSHOP WILL BE RELATED TO 358 00:14:52,925 --> 00:14:56,461 IN SILICO DRUG DISCOVERY AND 359 00:14:56,461 --> 00:14:59,831 THINK IT WILL BE COMPANION TO 360 00:14:59,831 --> 00:15:01,967 THE NAM PREDICTIVE MODELS WE 361 00:15:01,967 --> 00:15:02,968 DEVELOPED AS WELL. 362 00:15:02,968 --> 00:15:04,703 THESE IDEAS GO HAND IN HAND BUT 363 00:15:04,703 --> 00:15:07,673 THIS ONE SPECIFICALLY IS 364 00:15:07,673 --> 00:15:10,375 FOCUSSED ON IN SILICO DRUG 365 00:15:10,375 --> 00:15:10,742 DISCOVERY. 366 00:15:10,742 --> 00:15:12,945 MUCH OF THE EFFORT WILL BE 367 00:15:12,945 --> 00:15:14,379 AROUND A.I. AND MACHINE LEARNING 368 00:15:14,379 --> 00:15:14,713 ETCETERA. 369 00:15:14,713 --> 00:15:17,683 PLEASE, IF YOU'RE ABLE TO JOIN 370 00:15:17,683 --> 00:15:18,850 IN CONSIDER REGISTERING THERE 371 00:15:18,850 --> 00:15:19,384 TOO. 372 00:15:19,384 --> 00:15:21,119 A FEW OTHER ACTIVITIES WE'VE 373 00:15:21,119 --> 00:15:22,888 DONE OVER THE SUMMER -- I FEEL 374 00:15:22,888 --> 00:15:24,056 LIKE THIS IS A REPORT OF WHAT I 375 00:15:24,056 --> 00:15:28,293 DID OVER THE SUMMER LIKE BACK TO 376 00:15:28,293 --> 00:15:28,527 SCHOOL. 377 00:15:28,527 --> 00:15:32,097 BUT WE HAVE EVERY YEAR A GROUP 378 00:15:32,097 --> 00:15:34,633 FROM JAPAN CALLED THE MANSFIELD 379 00:15:34,633 --> 00:15:35,033 SCHOLARS. 380 00:15:35,033 --> 00:15:39,204 IT'S A RESEARCH SCHOLARS 381 00:15:39,204 --> 00:15:39,638 PROGRAM. 382 00:15:39,638 --> 00:15:42,374 ABOUT A DOZEN DIFFERENT EARLY 383 00:15:42,374 --> 00:15:44,009 CAREER SCIENTISTS FROM JAPAN GET 384 00:15:44,009 --> 00:15:45,344 TOGETHER AND WANT TO COME TO THE 385 00:15:45,344 --> 00:15:47,346 U.S. AND LEARN ABOUT 386 00:15:47,346 --> 00:15:49,581 TRANSLATIONAL SCIENCE. 387 00:15:49,581 --> 00:15:51,016 THEY ALWAYS COME TO NCATS. 388 00:15:51,016 --> 00:15:51,817 IT'S ONE OF THEIR FAVORITE STOPS 389 00:15:51,817 --> 00:15:56,054 SO THEY SAY. 390 00:15:56,054 --> 00:15:57,222 IT'S A REALLY WONDERFUL EXCHANGE 391 00:15:57,222 --> 00:15:58,991 PROGRAM WHERE THEY GET TO SEE 392 00:15:58,991 --> 00:16:01,693 THE LABS AND HEAR FROM SOME OF 393 00:16:01,693 --> 00:16:03,061 OUR TRANSLATIONAL SCIENTISTS ON 394 00:16:03,061 --> 00:16:04,630 A VARIETY OF PROJECTS. 395 00:16:04,630 --> 00:16:07,866 OUR GOAL IS TO SHARE BEST 396 00:16:07,866 --> 00:16:08,133 PRACTICES. 397 00:16:08,133 --> 00:16:12,704 I'M A BIG BELIEVER WE CAN DO 398 00:16:12,704 --> 00:16:14,272 MORE WITH SCIENTIFIC DIPLOMACY 399 00:16:14,272 --> 00:16:20,912 AND THE MORE RELATIONSHIPS TO 400 00:16:20,912 --> 00:16:22,414 THE MORE ADVANCES WE CAN MAKE 401 00:16:22,414 --> 00:16:23,615 AND THIS IS WHERE I LIKE TO 402 00:16:23,615 --> 00:16:24,750 SUPPORT AND THEY'RE EAGER TO 403 00:16:24,750 --> 00:16:25,917 COME TALK TO US. 404 00:16:25,917 --> 00:16:28,587 THAT WAS ONE OF THE THINGS. 405 00:16:28,587 --> 00:16:30,389 ANOTHER INTERNATIONAL GROUP THAT 406 00:16:30,389 --> 00:16:33,425 CAME TO VISIT JUST YESTERDAY WAS 407 00:16:33,425 --> 00:16:36,928 THE PARIS BRAIN INSTITUTE. 408 00:16:36,928 --> 00:16:38,397 ORGANIZED BY THE FRENCH EMBASSY 409 00:16:38,397 --> 00:16:41,967 THE COUNSELOR OF SCIENCE AND 410 00:16:41,967 --> 00:16:43,869 TECHNOLOGY AND WE DISCUSSED 411 00:16:43,869 --> 00:16:44,703 POTENTIAL COLLABORATIONS 412 00:16:44,703 --> 00:16:46,338 OVERLAPPING WITH TRANSLATIONAL 413 00:16:46,338 --> 00:16:48,440 SCIENCE AND ALSO A BIG INTEREST 414 00:16:48,440 --> 00:16:50,876 IN THE BRAIN, HENCE THE TITLE, 415 00:16:50,876 --> 00:16:54,546 BUT A LOT OF AREAS RELATED TO 416 00:16:54,546 --> 00:16:55,414 NEUROLOGY AND DISORDERS. 417 00:16:55,414 --> 00:16:56,782 AGAIN WE WANTED TO MEET WITH 418 00:16:56,782 --> 00:16:57,816 THEM TO TALK ABOUT DIFFERENT 419 00:16:57,816 --> 00:17:00,552 IDEAS AND WHERE WE MIGHT BE ABLE 420 00:17:00,552 --> 00:17:01,253 TO PARTNER. 421 00:17:01,253 --> 00:17:02,854 SOMETIMES THESE LEAD TO GOOD 422 00:17:02,854 --> 00:17:03,689 PARTNERSHIP OPPORTUNITIES. 423 00:17:03,689 --> 00:17:06,391 SOMETIMES THEY DON'T. 424 00:17:06,391 --> 00:17:09,594 AS YOU ALL KNOW WITH ANYTHING WE 425 00:17:09,594 --> 00:17:11,997 DO WITH COMMUNITY ENGAGEMENT 426 00:17:11,997 --> 00:17:13,365 IT'S NOT NECESSARILY WE LOOK FOR 427 00:17:13,365 --> 00:17:15,200 ONE TIME TO HAVE AN IMPACT BUT 428 00:17:15,200 --> 00:17:17,035 IT'S THE COLLECTION OF ENGAGING 429 00:17:17,035 --> 00:17:19,371 WITH INDIVIDUALS OVER TIME AND 430 00:17:19,371 --> 00:17:20,672 BUILDING THE RELATIONSHIPS. 431 00:17:20,672 --> 00:17:21,606 THAT'S WHAT MAKES IT SO 432 00:17:21,606 --> 00:17:22,240 POWERFUL. 433 00:17:22,240 --> 00:17:24,843 WE HOPE WE CAN GET RELATIONSHIPS 434 00:17:24,843 --> 00:17:26,378 OUT OF THIS BUT NONETHELESS I 435 00:17:26,378 --> 00:17:28,013 THINK WE MADE GOOD FRIENDS AND 436 00:17:28,013 --> 00:17:29,014 WILL CONTINUE TO HAVE 437 00:17:29,014 --> 00:17:36,655 INTERACTIONS WITH THESE GROUPS. 438 00:17:36,655 --> 00:17:40,492 IN ADDITION WE DID AN A.I. 439 00:17:40,492 --> 00:17:41,126 DEMONSTRATION FOR THE SENATE 440 00:17:41,126 --> 00:17:42,394 LAST TIME WAS FOR THE HOUSE. 441 00:17:42,394 --> 00:17:44,796 THIS TIME WE DID ONE FOR THE 442 00:17:44,796 --> 00:17:45,697 SENATE IN JULY. 443 00:17:45,697 --> 00:17:51,803 I HAD AN OPPORTUNITY TO DISCUSS 444 00:17:51,803 --> 00:17:53,038 A LOT OF TO THE WORK WE'RE DOING 445 00:17:53,038 --> 00:17:58,243 THROUGH 3-D MODELLING AND SOME 446 00:17:58,243 --> 00:18:00,545 OTHER A.I. AND ML PROJECTS AND 447 00:18:00,545 --> 00:18:02,447 GOT INTEREST FROM STAFFERS FROM 448 00:18:02,447 --> 00:18:03,582 THE SENATE. 449 00:18:03,582 --> 00:18:06,318 THESE ARE JUST PHOTOS FROM SOME 450 00:18:06,318 --> 00:18:06,952 CONVERSATIONS WE HAD. 451 00:18:06,952 --> 00:18:10,188 NCATS IS ONE OF TWO I.C.s THERE 452 00:18:10,188 --> 00:18:16,962 THAT DAY NABIB OUR NEIGHBOR NEXT 453 00:18:16,962 --> 00:18:22,367 DOOR AND A WONDERFUL 454 00:18:22,367 --> 00:18:23,268 COLLABORATIVE OPPORTUNITY TO 455 00:18:23,268 --> 00:18:25,403 TALK WITH THE SENATE AND IT'S 456 00:18:25,403 --> 00:18:26,371 ALWAYS IMPORTANT TO TALK ABOUT 457 00:18:26,371 --> 00:18:29,407 THE ACTIVITIES BECAUSE IN THE 458 00:18:29,407 --> 00:18:31,209 SPACE OF A.I. BIO MEDICINE ISN'T 459 00:18:31,209 --> 00:18:32,978 ALWAYS AT THE FOREFRONT. 460 00:18:32,978 --> 00:18:35,881 IT MIGHT BE PHYSICS ENGINEERING 461 00:18:35,881 --> 00:18:37,883 AND THE OTHER KINDS OF SCIENCES 462 00:18:37,883 --> 00:18:41,953 THAT ARE DONE. 463 00:18:41,953 --> 00:18:46,458 BUT FOR US HAVING A.I. AND M.L. 464 00:18:46,458 --> 00:18:48,393 AT THE FOREFRONT OF TRANSPARENCY 465 00:18:48,393 --> 00:18:50,061 AND DATA CAPTURE AND THESE 466 00:18:50,061 --> 00:18:52,197 THINGS IS INCREDIBLY IMPORTANT 467 00:18:52,197 --> 00:18:56,234 FOR US TO COMMUNICATE TO OUR 468 00:18:56,234 --> 00:18:57,002 SENATE AND CONGRESS 469 00:18:57,002 --> 00:18:58,837 CONGRESSIONAL MEMBERS ABOUT THE 470 00:18:58,837 --> 00:19:00,005 IMPORTANCE FOR BIO MEDICINE TO 471 00:19:00,005 --> 00:19:02,240 MAKE SURE WE'RE AT THE TABLE TO 472 00:19:02,240 --> 00:19:02,774 MOVE THESE TOPICS FORWARD 473 00:19:02,774 --> 00:19:05,010 TOGETHER. 474 00:19:05,010 --> 00:19:10,248 SO THAT WAS A REALLY EXCITING 475 00:19:10,248 --> 00:19:12,250 DAY AND MORE RECENTLY ON 476 00:19:12,250 --> 00:19:14,786 SEPTEMBER 11 I HAD A WONDERFUL 477 00:19:14,786 --> 00:19:20,258 OPPORTUNITY TO SPEND SOME TIME 478 00:19:20,258 --> 00:19:24,930 WITH CONGRESSWOMAN DEGETTE WITH 479 00:19:24,930 --> 00:19:26,331 THE CURES IDEA. 480 00:19:26,331 --> 00:19:28,900 IT WAS PART OF WHAT NCATS IS 481 00:19:28,900 --> 00:19:30,936 BUILT FROM AND IT TURNS OUT AS I 482 00:19:30,936 --> 00:19:34,606 WAS SITTING IN HER OFFICE I KEPT 483 00:19:34,606 --> 00:19:36,775 SEEING THIS BLANKET ON THE END 484 00:19:36,775 --> 00:19:37,309 OF HER CHAIR. 485 00:19:37,309 --> 00:19:39,711 TURNS OUT IT'S NOT A BLANKET, 486 00:19:39,711 --> 00:19:40,078 IT'S A CAPE. 487 00:19:40,078 --> 00:19:46,084 IT ALSO TURNS OUT A CHILD WITH A 488 00:19:46,084 --> 00:19:50,388 RARE DISEASE MADE THIS CAPE FOR 489 00:19:50,388 --> 00:20:00,899 THE CAN CONGRESSWOMAN AND IT 490 00:20:01,499 --> 00:20:06,171 TURNS OUT MAX IS THE SON OF LISA 491 00:20:06,171 --> 00:20:07,005 SHIELD ON OUR BOARD. 492 00:20:07,005 --> 00:20:09,608 IT WAS NICE TO SEE THAT COME 493 00:20:09,608 --> 00:20:10,375 FULL CIRCLE. 494 00:20:10,375 --> 00:20:11,810 HE MADE THE CAPE FOR THE 495 00:20:11,810 --> 00:20:13,178 REPRESENTATIVE AND IT WAS A 496 00:20:13,178 --> 00:20:14,346 WONDERFUL COMING TOGETHER OF 497 00:20:14,346 --> 00:20:15,547 THESE THINGS. 498 00:20:15,547 --> 00:20:16,381 IT WAS A GREAT CONVERSATION AND 499 00:20:16,381 --> 00:20:17,382 AGAIN THIS IS ONE OF THOSE 500 00:20:17,382 --> 00:20:22,387 THINGS WHERE WE HOPE WE CAN HAVE 501 00:20:22,387 --> 00:20:23,955 CONTINUING CONVERSATIONS AND 502 00:20:23,955 --> 00:20:24,990 BUILDING RELATIONSHIPS AND BE 503 00:20:24,990 --> 00:20:26,791 ABLE TO TELL MORE STORIES OF 504 00:20:26,791 --> 00:20:30,362 WHAT WE'RE DOING AT NCATS. 505 00:20:30,362 --> 00:20:31,129 AND THEN ANOTHER IMPORTANT 506 00:20:31,129 --> 00:20:36,067 MEETING WE HAD OVER THE SUMMER 507 00:20:36,067 --> 00:20:39,204 WAS GETTING TOGETHER WITH THE 508 00:20:39,204 --> 00:20:43,742 FDA AS WELL AS CMS LEADERSHIP 509 00:20:43,742 --> 00:20:46,378 AND NIH THIS IS THE GROUP OF 510 00:20:46,378 --> 00:20:52,317 PEOPLE AT THE MEETING AT THE FDA 511 00:20:52,317 --> 00:20:55,153 AND IT WAS FOR THE PURPOSE OF 512 00:20:55,153 --> 00:20:57,689 HOW THE AGENCIES CAN THINK ABOUT 513 00:20:57,689 --> 00:20:58,323 BETTER COORDINATION IN THE SPACE 514 00:20:58,323 --> 00:21:00,692 OF RARE DISEASES. 515 00:21:00,692 --> 00:21:02,494 AND SO DURING THE CONVERSATION 516 00:21:02,494 --> 00:21:08,433 WE HAD A VARIETY OF TOPICS WE 517 00:21:08,433 --> 00:21:10,602 DISCUSSED AND AT THE BEGINNING 518 00:21:10,602 --> 00:21:13,471 WE HAD A LIST OF TOPICS ON THE 519 00:21:13,471 --> 00:21:14,873 BLACK AND IN RED AT THE END OF 520 00:21:14,873 --> 00:21:16,041 THE CONVERSATION IS WHERE WE 521 00:21:16,041 --> 00:21:16,908 STARTED TO CHANGE THINGS. 522 00:21:16,908 --> 00:21:23,014 THIS IS WHERE WE WANT TO SKATE 523 00:21:23,014 --> 00:21:29,087 TO THE PUCK AND CONTINUE TO MOVE 524 00:21:29,087 --> 00:21:29,688 FORWARD. 525 00:21:29,688 --> 00:21:31,523 IT WAS AN EXCITING MEETING. 526 00:21:31,523 --> 00:21:32,824 SOME THINGS WE ARE DOING TO MOVE 527 00:21:32,824 --> 00:21:34,492 FORWARD ARE ON THE LIST AND OVER 528 00:21:34,492 --> 00:21:36,394 THE NEXT COUPLE OF YEARS YOU'LL 529 00:21:36,394 --> 00:21:38,396 START TO SEE MORE OF THAT 530 00:21:38,396 --> 00:21:39,798 FRUITION COME TO HAPPEN. 531 00:21:39,798 --> 00:21:45,804 IN ADDITION TO OUR PARTNERSHIP 532 00:21:45,804 --> 00:21:56,281 WITH THE FDA AND CMS IS THE 533 00:21:56,548 --> 00:21:58,383 TRANSLATIONAL SCIENCE 534 00:21:58,383 --> 00:22:02,120 INTERAGENCY FELLOWSHIP PROGRAMS. 535 00:22:02,120 --> 00:22:04,089 THEY SPEND 18 MONTHS AT NCATS 536 00:22:04,089 --> 00:22:05,991 AND FDA. 537 00:22:05,991 --> 00:22:07,125 IT'S INTERMIXED. 538 00:22:07,125 --> 00:22:07,826 GENERALLY SPEAKING THAT'S THE 539 00:22:07,826 --> 00:22:09,828 POINT OF THE WHOLE PROGRAM AND 540 00:22:09,828 --> 00:22:13,498 THE IDEA IS DO UPSCALE PEOPLE 541 00:22:13,498 --> 00:22:15,333 WHO ARE IN REGULATORY SCIENCE 542 00:22:15,333 --> 00:22:24,075 WITH TRANSLATIONAL SCIENCE OR UP 543 00:22:24,075 --> 00:22:26,177 SKILL PEOPLE TO SCIENCE AND 544 00:22:26,177 --> 00:22:27,645 BRING THEM INTO A FELLOWSHIP 545 00:22:27,645 --> 00:22:29,414 PROGRAM AS THE PEOPLE GO OUT IN 546 00:22:29,414 --> 00:22:32,484 THE WORLD AND GET THEIR NEXT FEW 547 00:22:32,484 --> 00:22:33,485 JOBS, THEY'LL BE ABLE TO BRING 548 00:22:33,485 --> 00:22:34,619 THAT EXPERIENCE WITH THEM. 549 00:22:34,619 --> 00:22:36,087 THIS IS IS ONE OF THE PREMIER 550 00:22:36,087 --> 00:22:38,156 PROGRAMS WE HAVE. 551 00:22:38,156 --> 00:22:39,524 IT'S VERY SMALL BUT I'M REALLY 552 00:22:39,524 --> 00:22:41,026 EXCITED ABOUT THIS PROGRAM. 553 00:22:41,026 --> 00:22:42,127 THESE ARE THREE INDIVIDUALS WHO 554 00:22:42,127 --> 00:22:44,896 JUST GRADUATED FROM THE PROGRAM 555 00:22:44,896 --> 00:22:45,430 VERY RECENTLY. 556 00:22:45,430 --> 00:22:49,901 AND ONE IS GOING INTO A BIO TECH 557 00:22:49,901 --> 00:22:50,135 COMPANY. 558 00:22:50,135 --> 00:22:55,440 ONE IS STAYING AT NCATS AND ONE 559 00:22:55,440 --> 00:22:56,241 GOING TO THE FDA. 560 00:22:56,241 --> 00:22:57,876 I'M EXCITE ABOUT THE PROGRAM AND 561 00:22:57,876 --> 00:23:03,882 WE HAVE A FEW MORE COMING I HOPE 562 00:23:03,882 --> 00:23:11,756 TO TALK ABOUT IN THE FUTURE AND 563 00:23:11,756 --> 00:23:13,091 ONE TOPIC IS IN THE SPACE OF 564 00:23:13,091 --> 00:23:14,592 NEWBORN SCREENING. 565 00:23:14,592 --> 00:23:18,396 THIS IS A BIG AREA FOR NCATS 566 00:23:18,396 --> 00:23:19,464 WE'RE INTERESTED IN IN MOVING 567 00:23:19,464 --> 00:23:21,299 THE NEEDLE. 568 00:23:21,299 --> 00:23:26,638 THERE'S BEEN TOPICS THROUGH THE 569 00:23:26,638 --> 00:23:29,941 CTSA SCREENING IN NEWBORN 570 00:23:29,941 --> 00:23:31,743 SCREENING SETTING THE STAGE FOR 571 00:23:31,743 --> 00:23:35,647 WHY IT'S SO IMPORTANT. 572 00:23:35,647 --> 00:23:38,316 THROUGH THE COMMON FUND PROGRAM 573 00:23:38,316 --> 00:23:39,217 AND LAUNCHED A NEW COMMON FUND 574 00:23:39,217 --> 00:23:42,320 PROGRAM THAT IS LIKE A VENTURE 575 00:23:42,320 --> 00:23:43,054 COMMON FUND PROGRAM. 576 00:23:43,054 --> 00:23:45,390 THEY'RE MEANT TO BE SMALLER BUT 577 00:23:45,390 --> 00:23:51,729 MIGHTIER AND IT'S MEANT TO BE A 578 00:23:51,729 --> 00:23:53,031 LITTLE BIT OF SEED MONEY CAN 579 00:23:53,031 --> 00:23:55,133 HELP MOVE IT AND ONE TOPIC THAT 580 00:23:55,133 --> 00:23:58,369 GOT SELECTED IS AROUND NEWBORN 581 00:23:58,369 --> 00:24:00,138 SCREENING AND THIS TOPIC WAS 582 00:24:00,138 --> 00:24:03,074 THOUGHT OF AND PRESENTED TO THEM 583 00:24:03,074 --> 00:24:09,280 FROM OUR DEAR DRI DIRECTOR AND 584 00:24:09,280 --> 00:24:10,381 THEY'LL BE LEADING THE PROGRAM 585 00:24:10,381 --> 00:24:13,918 FOR NIH BUT PARTNERS WILL BE 586 00:24:13,918 --> 00:24:21,559 NICHD AND DIANA BIANCHI WILL BE 587 00:24:21,559 --> 00:24:25,997 PART OF THIS AND AN INVESTMENT 588 00:24:25,997 --> 00:24:27,932 FOR FIVE YEARS SHOWING SCREENING 589 00:24:27,932 --> 00:24:31,469 AS A POTENTIAL WAY OF A NEW 590 00:24:31,469 --> 00:24:33,938 PARADIGM OF DOING NEWBORN 591 00:24:33,938 --> 00:24:34,205 SCREENING. 592 00:24:34,205 --> 00:24:35,406 WE'RE DEMONSTRATING FEASIBILITY 593 00:24:35,406 --> 00:24:36,641 FOR A SMALLER PROGRAM BUT MAYBE 594 00:24:36,641 --> 00:24:41,012 HOW THAT COULD BE SCALED TO AN 595 00:24:41,012 --> 00:24:41,846 ACTION PROGRAM. 596 00:24:41,846 --> 00:24:43,815 AND IMPORTANTLY EQUITABLE ACCESS 597 00:24:43,815 --> 00:24:47,519 AND THEN HOW WE CAN THEN DRIVE 598 00:24:47,519 --> 00:24:49,320 THE PACE OF THERAPEUTIC 599 00:24:49,320 --> 00:24:50,788 DEVELOPMENT BASED ON THE 600 00:24:50,788 --> 00:24:53,925 DIAGNOSTIC DEVELOPMENT WE HAVE. 601 00:24:53,925 --> 00:24:56,094 AS YOU KNOW MANY PEOPLE WITH 602 00:24:56,094 --> 00:24:57,996 RARE DISEASES HAVE A LONG 603 00:24:57,996 --> 00:25:00,298 DIAGNOSTIC ODYSSEY IF WE CAN 604 00:25:00,298 --> 00:25:00,999 SHORTEN THE DIAGNOSTIC ODYSSEY 605 00:25:00,999 --> 00:25:03,701 IT MEANS WE'LL HAVE A LONGER 606 00:25:03,701 --> 00:25:08,139 TREATMENT ODYSSEY LIKELY AND 607 00:25:08,139 --> 00:25:09,507 NEED TO BE ADD THE READY TO 608 00:25:09,507 --> 00:25:11,042 THINK HOW TO MOVE TREATMENT FOR 609 00:25:11,042 --> 00:25:12,243 RARE DISEASES. 610 00:25:12,243 --> 00:25:14,879 I THINK THIS IS A VERY EXCITING 611 00:25:14,879 --> 00:25:16,748 PROGRAM TO PUSH THE ENVELOPE IN 612 00:25:16,748 --> 00:25:17,015 THE SPACE. 613 00:25:17,015 --> 00:25:21,419 STAY TUNED ON THAT. 614 00:25:21,419 --> 00:25:23,254 ANOTHER EXCITING PROGRAM WE HAVE 615 00:25:23,254 --> 00:25:24,155 GOING ON AND I'VE TALK ABOUT 616 00:25:24,155 --> 00:25:27,192 BEFORE IS THE AREA OF THE 617 00:25:27,192 --> 00:25:28,693 BESPOKE GENE THERAPY CONSORTIUM. 618 00:25:28,693 --> 00:25:31,963 AN ACCELERATED MEDICINES 619 00:25:31,963 --> 00:25:33,231 PARTNERSHIP WITH THE PARTNERSHIP 620 00:25:33,231 --> 00:25:35,033 OF THE NIH AND A LARGER PROGRAM 621 00:25:35,033 --> 00:25:37,502 IN THE SPACE WITH A VARIETY OF 622 00:25:37,502 --> 00:25:41,539 INDUSTRY READERS, BIO TECH 623 00:25:41,539 --> 00:25:42,173 LEADERS, PATIENT ORGANIZATIONS 624 00:25:42,173 --> 00:25:43,841 AS WELL AS 11 DIFFERENT 625 00:25:43,841 --> 00:25:49,113 INSTITUTES AND CENTERS AT THE 626 00:25:49,113 --> 00:25:49,280 NIH. 627 00:25:49,280 --> 00:25:51,916 AND WITH THIS PROGRAM WE'RE 628 00:25:51,916 --> 00:25:55,086 LOOKING TO HAVE GENE THERAPIES 629 00:25:55,086 --> 00:25:58,389 FOR EIGHT RARE DISEASES. 630 00:25:58,389 --> 00:25:59,457 THAT'S SORT OF THE CEILING. 631 00:25:59,457 --> 00:26:02,393 WE HOPE WE CAN MAKE THE CEILING 632 00:26:02,393 --> 00:26:06,664 BUT THESE ARE COMPLICATED 633 00:26:06,664 --> 00:26:06,931 PROGRAMS. 634 00:26:06,931 --> 00:26:08,533 WE'RE GOING TO DO OUR BEST TO 635 00:26:08,533 --> 00:26:09,667 GET TO EIGHT. 636 00:26:09,667 --> 00:26:12,070 SIX OF THESE RARE DISEASES ARE 637 00:26:12,070 --> 00:26:13,037 ONES NIH WILL BE PUSHING ON. 638 00:26:13,037 --> 00:26:15,540 THE UPDATE I WANTED TO SHARE 639 00:26:15,540 --> 00:26:19,143 WITH YOU TODAY IS THROUGH THE 640 00:26:19,143 --> 00:26:22,380 BGTC WE SUBMITTED RARE PEDIATRIC 641 00:26:22,380 --> 00:26:24,148 DISEASE DESIGNATIONS IN ORPHAN 642 00:26:24,148 --> 00:26:25,850 DRUG DISEASE DESIGNATIONS AND 643 00:26:25,850 --> 00:26:28,720 SIX OF OUR RRPDs WERE GRANTED BY 644 00:26:28,720 --> 00:26:31,356 THE FDA AND THREE OF OUR ORPHAN 645 00:26:31,356 --> 00:26:34,492 DRUG DESIGNATIONS GRANTED BY THE 646 00:26:34,492 --> 00:26:36,094 FDA. 647 00:26:36,094 --> 00:26:37,262 IN A MATTER OF ABOUT A PUBLIC 648 00:26:37,262 --> 00:26:37,629 HEALTH. 649 00:26:37,629 --> 00:26:39,697 THE FIRST APPROVAL WAS ABOUT A 650 00:26:39,697 --> 00:26:41,032 MONTH AGO. 651 00:26:41,032 --> 00:26:44,402 WE HOPE THE NEXT THREE ORPHAN 652 00:26:44,402 --> 00:26:48,806 DRUG DESIGNATIONS WILL HAPPEN 653 00:26:48,806 --> 00:26:51,175 RELATIVELY SOON AND WANT TO SAY 654 00:26:51,175 --> 00:26:52,844 WHY THEY'RE IMPORTANT. 655 00:26:52,844 --> 00:26:53,711 THESE ARE RARE DISEASES THAT ARE 656 00:26:53,711 --> 00:26:55,413 VERY RARE. 657 00:26:55,413 --> 00:26:58,383 WE HAVE TO DEMONSTRATE THE 658 00:26:58,383 --> 00:26:59,684 PREVALENCE DATA ARE INDICATIVE 659 00:26:59,684 --> 00:27:00,351 THESE ARE RARE DISEASES. 660 00:27:00,351 --> 00:27:04,656 IF THE DRUG IS APPROVED THROUGH 661 00:27:04,656 --> 00:27:06,190 RARE PEDIATRIC DISEASE 662 00:27:06,190 --> 00:27:11,029 DESIGNATION IT'S ELIGIBLE FOR A 663 00:27:11,029 --> 00:27:13,464 PRIORITY REVIEW VOUCHER. 664 00:27:13,464 --> 00:27:19,203 THIS WAS NOT A GIVEN A FEW DAYS 665 00:27:19,203 --> 00:27:20,305 AGO. 666 00:27:20,305 --> 00:27:21,205 CONGRESS PASSED THE PRIORITY 667 00:27:21,205 --> 00:27:22,373 REVIEW VOUCHER. 668 00:27:22,373 --> 00:27:27,011 THIS WILL ALLOW IT TO BE SOLD 669 00:27:27,011 --> 00:27:28,980 FOR PRICES THAT EXCEED OVER $100 670 00:27:28,980 --> 00:27:29,347 MILLION. 671 00:27:29,347 --> 00:27:32,517 THIS IS A BIG DEAL FOR THE 672 00:27:32,517 --> 00:27:33,418 COMMUNITY. 673 00:27:33,418 --> 00:27:35,853 THIS HELPS US DERISK WHAT WE'RE 674 00:27:35,853 --> 00:27:36,521 DEVELOPING SO COMPANIES CAN TAKE 675 00:27:36,521 --> 00:27:38,389 THEM UP IN A WAY THAT WILL 676 00:27:38,389 --> 00:27:41,025 SUPPORT THEM IN THAT PROCESS. 677 00:27:41,025 --> 00:27:44,929 THE ORPHAN DRUG DESIGNATION 678 00:27:44,929 --> 00:27:46,397 SIMILARLY ENCOURAGES THE 679 00:27:46,397 --> 00:27:47,065 DEVELOPMENT OF THE TREATMENT FOR 680 00:27:47,065 --> 00:27:47,932 THE RARE DISEASES. 681 00:27:47,932 --> 00:27:50,635 SO SEVEN YEARS OF MARKET 682 00:27:50,635 --> 00:27:52,370 EXCLUSIVITY, TAX CREDITS AND 683 00:27:52,370 --> 00:27:54,906 WAIVER OF FDA FEES. 684 00:27:54,906 --> 00:27:56,841 AGAIN, THESE ARE REAL TANGIBLE 685 00:27:56,841 --> 00:27:58,176 BENEFITS FOR DEVELOPING THESE 686 00:27:58,176 --> 00:28:00,011 TREATMENTS AND SO WE'RE VERY 687 00:28:00,011 --> 00:28:01,713 EXCITED TO BE CONTRIBUTING TO 688 00:28:01,713 --> 00:28:03,348 THIS PROGRAM AND SO FAR THE 689 00:28:03,348 --> 00:28:05,316 SUCCESS WE HAVE GIVES US EVEN 690 00:28:05,316 --> 00:28:06,384 MORE CONFIDENCE AND EXCITEMENT 691 00:28:06,384 --> 00:28:10,388 TO MOVE FORWARD IN THE BGTC 692 00:28:10,388 --> 00:28:10,588 SPACE. 693 00:28:10,588 --> 00:28:15,059 THIS IS A VILLAGE BUT I HAVE TO 694 00:28:15,059 --> 00:28:19,630 SAY PG AND DOMINIQUE AND THE FDA 695 00:28:19,630 --> 00:28:23,701 FOLKS ARE INCREDIBLE IN MOVING 696 00:28:23,701 --> 00:28:24,936 THE FIELD FORWARD. 697 00:28:24,936 --> 00:28:27,004 IT'S A BIG EFFORT FOR US ALL. 698 00:28:27,004 --> 00:28:28,106 IT'S A VILLAGE. 699 00:28:28,106 --> 00:28:29,507 I WANTED TO MAKE SURE EVERYONE 700 00:28:29,507 --> 00:28:39,984 GETS CREDIT AS A BIG DEAL. 701 00:28:39,984 --> 00:28:41,319 AND ANOTHER AREA I'VE SPOKEN ON 702 00:28:41,319 --> 00:28:44,155 IS THE ACTIVE CLINICAL PROGRAMS 703 00:28:44,155 --> 00:28:47,058 AND THE NATIONAL CLINICAL COHORT 704 00:28:47,058 --> 00:28:47,392 COLLABORATIVE. 705 00:28:47,392 --> 00:28:50,395 THESE TWO PROGRAMS HAVE SORT OF 706 00:28:50,395 --> 00:28:54,198 MERGED INTO ONE AS THE ACTIVE IS 707 00:28:54,198 --> 00:28:55,133 NOW CLOSING OUT, IT TOOK 708 00:28:55,133 --> 00:28:57,935 ADVANTAGE OF THE FACT WE HAVE 709 00:28:57,935 --> 00:29:00,338 THE N3C COHORT. 710 00:29:00,338 --> 00:29:02,507 AND SO WHAT I WANTED TO SHARE IS 711 00:29:02,507 --> 00:29:04,876 THE ACTIVE SIX CLINICAL TRIALS, 712 00:29:04,876 --> 00:29:06,577 THERE WERE SEVEN ARMS IN THE 713 00:29:06,577 --> 00:29:10,348 CLINICAL TRIAL AND ALL HAVE 714 00:29:10,348 --> 00:29:12,884 COMPLETED ENROLLMENT, ON TIME, 715 00:29:12,884 --> 00:29:16,621 UNDER BUDGET AND WE'RE VERY 716 00:29:16,621 --> 00:29:18,389 EXCITED THAT THE FINAL CLINICAL 717 00:29:18,389 --> 00:29:21,993 TRIAL HAS FINISHED THE METFORMIN 718 00:29:21,993 --> 00:29:24,162 ARM OF THIS TRIAL FINISHED. 719 00:29:24,162 --> 00:29:26,364 WE SHOULD BE SEEING TOP LINE 720 00:29:26,364 --> 00:29:31,469 RESULTS FOR THE TRIAL FOR 28 DAY 721 00:29:31,469 --> 00:29:32,703 COVID RESPONSE. 722 00:29:32,703 --> 00:29:34,839 I THINK IT'S BY OCTOBER, 723 00:29:34,839 --> 00:29:37,008 NOVEMBER IS WHEN WE EXPECT TO 724 00:29:37,008 --> 00:29:38,509 SEE THE TOP LINE RESULTS AND 725 00:29:38,509 --> 00:29:40,611 THEY'RE ALSO LOOKING AT LONG 726 00:29:40,611 --> 00:29:41,813 COVID FOR THE PARTICULAR ARM. 727 00:29:41,813 --> 00:29:44,682 THAT'S AN EXCITING FEATURE OF 728 00:29:44,682 --> 00:29:45,516 THIS PARTICULAR ACTIVE TRIAL 729 00:29:45,516 --> 00:29:47,285 WITH METFORMIN IS GOING A LITTLE 730 00:29:47,285 --> 00:29:50,955 BIT LONGER. 731 00:29:50,955 --> 00:29:52,790 THAT'S PARTLY THE REASON WE DID 732 00:29:52,790 --> 00:29:55,560 THAT IS BECAUSE THERE WAS A 733 00:29:55,560 --> 00:29:57,361 PRELIMINARY EVIDENCE IN THE 734 00:29:57,361 --> 00:30:01,499 COVID CLINICAL TRIAL THAT SHOWED 735 00:30:01,499 --> 00:30:04,635 METFORMIN SHOWED REDUCED 736 00:30:04,635 --> 00:30:06,170 INCIDENTS OF MORE THAN 28 DAY 737 00:30:06,170 --> 00:30:08,940 COVID RESPONSE IN LONG COVID. 738 00:30:08,940 --> 00:30:11,642 SO THERE'S AN INKLING METFORMIN 739 00:30:11,642 --> 00:30:12,477 MAY BE DOING SOMETHING. 740 00:30:12,477 --> 00:30:14,312 IF THAT'S THE CASE WE WANTED TO 741 00:30:14,312 --> 00:30:17,048 TEST IT IN A BIGGER TRIAL. 742 00:30:17,048 --> 00:30:18,516 THAT'S WHAT WE DID. 743 00:30:18,516 --> 00:30:22,186 WE ALSO TESTED THIS IN THE M3C 744 00:30:22,186 --> 00:30:27,792 COHORT AND DID A TRIAL EMULATION 745 00:30:27,792 --> 00:30:34,365 TRIAL AND WE CAN LOOK IN AT TH 746 00:30:34,365 --> 00:30:35,700 COMPUTER TO LOOK AT THE OUTCOME 747 00:30:35,700 --> 00:30:37,134 OF THE INDIVIDUALS IN ADDITION 748 00:30:37,134 --> 00:30:39,403 TO THE RANDOMIZED TRIAL TO 749 00:30:39,403 --> 00:30:41,572 COMPARE AND CONTRAST THE VALUE 750 00:30:41,572 --> 00:30:44,041 OF THE EMULATION TRIALS AND WHAT 751 00:30:44,041 --> 00:30:46,377 ARE WE MISSING AND ARE THERE 752 00:30:46,377 --> 00:30:48,479 BIASES IN THE DATA WE SHOULD 753 00:30:48,479 --> 00:30:48,980 LOOK FOR. 754 00:30:48,980 --> 00:30:51,949 IT WILL HELP SET THE STAGE FOR 755 00:30:51,949 --> 00:30:54,185 HOW TO USE ELECTRONIC HEALTH 756 00:30:54,185 --> 00:30:56,387 RECORDS AND DATA SCIENCE TO 757 00:30:56,387 --> 00:30:57,522 IMPACT HOW WE DESIGN CLINICAL 758 00:30:57,522 --> 00:30:58,222 TRIALS IN THE FUTURE. 759 00:30:58,222 --> 00:30:59,824 THAT'S ONE OF THE KEY VALUES 760 00:30:59,824 --> 00:31:02,360 THAT WE'RE SEEING OUT OF THIS 761 00:31:02,360 --> 00:31:07,131 PARTICULAR PROGRAM. 762 00:31:07,131 --> 00:31:10,067 THE N3C USE OF THIS IS THROUGH 763 00:31:10,067 --> 00:31:11,969 OUR FASTER PROGRAM AND LOOKING 764 00:31:11,969 --> 00:31:17,608 AT WHETHER METFORMIN REDUCES THE 765 00:31:17,608 --> 00:31:20,311 THREAT OF DEATH THROUGH LONG 766 00:31:20,311 --> 00:31:28,085 COVID AND THE PAPER IS I THINK 767 00:31:28,085 --> 00:31:30,054 FINALIZED AND I DON'T WANT TO 768 00:31:30,054 --> 00:31:32,523 STEAL HER THUNDER. 769 00:31:32,523 --> 00:31:33,991 IT REMAINS TO BE SEEN HOW IT 770 00:31:33,991 --> 00:31:37,695 PLAYS OUT WITH THE RANDOMIZED 771 00:31:37,695 --> 00:31:38,696 CLINICAL TRIAL. 772 00:31:38,696 --> 00:31:39,230 STAY TUNED. 773 00:31:39,230 --> 00:31:40,898 IT'S A GOOD EMERGING STORY. 774 00:31:40,898 --> 00:31:42,400 THE RCT IS COMING SOON. 775 00:31:42,400 --> 00:31:44,101 I WANT TO ROUND OUT HIGHLIGHTS 776 00:31:44,101 --> 00:31:46,837 THAT HAVE HAPPENED OVER THE PAST 777 00:31:46,837 --> 00:31:48,306 SUMMER WITH ANOTHER KEY 778 00:31:48,306 --> 00:31:48,873 ENGAGEMENT AROUND COMMUNITY 779 00:31:48,873 --> 00:31:59,083 ENGAGEMENT. 780 00:32:04,188 --> 00:32:09,060 THERE'S AN EXTRACT ADVISORY 781 00:32:09,060 --> 00:32:10,394 COMMITTEE AND THE PROJECT IS 782 00:32:10,394 --> 00:32:14,265 THEY'RE ENGAGING THE PUBLIC IN 783 00:32:14,265 --> 00:32:19,337 PARTNERS IN CLINICAL RESEARCH. 784 00:32:19,337 --> 00:32:21,038 WE KNOW COMMUNITIES TO ENGAGE 785 00:32:21,038 --> 00:32:22,607 THEM IT'S NOT A ONE SIZE FITS 786 00:32:22,607 --> 00:32:23,274 ALL APPROACH. 787 00:32:23,274 --> 00:32:31,415 THIS WILL TAKE A LOOK AT HOW NIH 788 00:32:31,415 --> 00:32:34,385 IS MATURING FOR THOSE 789 00:32:34,385 --> 00:32:34,885 PARTNERSHIPS. 790 00:32:34,885 --> 00:32:37,221 I WORKED WITH A TEAM ACROSS THE 791 00:32:37,221 --> 00:32:46,797 NIH AND NOW SARA DUNSMORE AND 792 00:32:46,797 --> 00:32:52,303 DEVELOPED STUDIES IN THIS SPACE. 793 00:32:52,303 --> 00:32:54,271 THESE WERE USED TO DEVELOP A 794 00:32:54,271 --> 00:32:57,508 RESOURCE FOR PEOPLE ACROSS THE 795 00:32:57,508 --> 00:33:01,812 NIH TO UNDERSTAND THE REALM OF 796 00:33:01,812 --> 00:33:06,384 COMMUNITY ENGAGEMENT AND HOW 797 00:33:06,384 --> 00:33:07,284 PEOPLE USED THEM BEFORE AND 798 00:33:07,284 --> 00:33:10,354 DON'T HAVE TO REINVENT THE 799 00:33:10,354 --> 00:33:10,921 WHEEL. 800 00:33:10,921 --> 00:33:19,630 WE PUT THEM IN ONE AREA AND IT'S 801 00:33:19,630 --> 00:33:21,766 PARTNERS IN RESEARCH DOT NIH 802 00:33:21,766 --> 00:33:23,868 DOT-GOV AND GIVE YOU THE QR CODE 803 00:33:23,868 --> 00:33:27,104 IF YOU'RE INTERESTED. 804 00:33:27,104 --> 00:33:29,473 THESE SHOW FOR EXAMPLE THE TOOL 805 00:33:29,473 --> 00:33:31,342 KIT FOR PATIENT FOCUSSED 806 00:33:31,342 --> 00:33:35,012 DEVELOPMENT IN DRDRI HELPING 807 00:33:35,012 --> 00:33:35,579 PATIENTS FIND RESEARCHERS 808 00:33:35,579 --> 00:33:36,280 INVOLVED UP RARE DISEASES 809 00:33:36,280 --> 00:33:37,314 THEY'RE INTERESTED IN. 810 00:33:37,314 --> 00:33:39,850 WE HAVE FASTER TOGETHER WHICH IS 811 00:33:39,850 --> 00:33:46,357 A TRIAL INNOVATIONS NETWORK 812 00:33:46,357 --> 00:33:51,629 PRODUCT HELPING RESEARCHERS 813 00:33:51,629 --> 00:33:54,865 UNDERSTAND HOW TO ENSURE THEY 814 00:33:54,865 --> 00:33:56,801 PARTICIPATE IN CLINICAL TRIALS. 815 00:33:56,801 --> 00:34:01,405 CEAL IS REPRESENTED IN THESE USE 816 00:34:01,405 --> 00:34:01,605 CASES. 817 00:34:01,605 --> 00:34:03,140 THESE ARE A VARIETY THING I 818 00:34:03,140 --> 00:34:04,341 WANTED TO GIVE A FLAVOR FOR OF 819 00:34:04,341 --> 00:34:05,242 WHAT WE TRY TO PULL TOGETHER IN 820 00:34:05,242 --> 00:34:06,010 THE COMMUNITY. 821 00:34:06,010 --> 00:34:07,945 THIS IS MEANT TO BE A DYNAMIC 822 00:34:07,945 --> 00:34:09,280 SPACE. 823 00:34:09,280 --> 00:34:11,582 SO IF YOU BOOKMARK THIS TAP 824 00:34:11,582 --> 00:34:15,820 YOU'LL SEE THIS GROW OVER TIME. 825 00:34:15,820 --> 00:34:18,289 LYRIC AND I DID A BLOG TO 826 00:34:18,289 --> 00:34:19,457 HIGHLIGHT THESE USE CASES. 827 00:34:19,457 --> 00:34:21,158 SO IF YOU'RE INTERESTED IN THAT 828 00:34:21,158 --> 00:34:24,762 AS A BRIEF SUMMARY I SHOW THE QR 829 00:34:24,762 --> 00:34:26,363 CODE THERE AS WELL. 830 00:34:26,363 --> 00:34:28,299 ANOTHER ACTIVE WE'VE MENTIONED 831 00:34:28,299 --> 00:34:31,435 IN THE PAST IS ON CARE FOR 832 00:34:31,435 --> 00:34:31,669 HEALTH. 833 00:34:31,669 --> 00:34:33,938 THIS WAS LAUNCHED EARLIER THIS 834 00:34:33,938 --> 00:34:36,140 YEAR THROUGH THE COUNCIL OF 835 00:34:36,140 --> 00:34:36,407 COUNCILS. 836 00:34:36,407 --> 00:34:40,811 THIS IS A KEY PRIORITY FOR 837 00:34:40,811 --> 00:34:43,481 DR. BERTAGNOLLI TO DEVELOP 838 00:34:43,481 --> 00:34:45,116 NETWORK HUBS TO GET IN THE 839 00:34:45,116 --> 00:34:48,519 PRIMARY CARE SETTINGS AND IN 840 00:34:48,519 --> 00:34:50,121 COLLABORATION WITH CLINICAL 841 00:34:50,121 --> 00:34:51,322 STRENGTHS WITHIN THE NIH. 842 00:34:51,322 --> 00:34:53,791 PARTICIPANTS AND COMMUNITY 843 00:34:53,791 --> 00:34:57,828 ENGAGEMENT IS A KEY PILLAR AND 844 00:34:57,828 --> 00:34:58,996 WE WANT INNOVATIVE CLINICAL 845 00:34:58,996 --> 00:35:00,898 TRIAL DESIGNS AND WANT TO 846 00:35:00,898 --> 00:35:01,766 INCORPORATE PRIMARY CARE 847 00:35:01,766 --> 00:35:03,234 COMMUNITIES. 848 00:35:03,234 --> 00:35:04,335 THAT'S NOT GOING TO TO BE VERY 849 00:35:04,335 --> 00:35:05,069 STRAIGHTFORWARD TO DO. 850 00:35:05,069 --> 00:35:08,205 IT'S GOING TO BE A HEAVY LIFT. 851 00:35:08,205 --> 00:35:09,406 I DON'T THINK THERE'S A MORE 852 00:35:09,406 --> 00:35:11,075 IMPORTANT ACTIVITY WE COULD BE 853 00:35:11,075 --> 00:35:11,876 DOING AT THE NIH. 854 00:35:11,876 --> 00:35:17,081 I'M VERY EXCITED ABOUT MOVING 855 00:35:17,081 --> 00:35:21,051 THIS PROJECT FORWARD I'M A 856 00:35:21,051 --> 00:35:22,887 CO-CHAIR AND WE HAVE NIBCB AND 857 00:35:22,887 --> 00:35:28,726 WE'RE THE CO-CHAIRS AND MIKE IS 858 00:35:28,726 --> 00:35:31,162 THE DIVISION OF CLINICAL 859 00:35:31,162 --> 00:35:32,663 INNOVATIONS AND HELPING GUIDE 860 00:35:32,663 --> 00:35:33,664 EFFORTS AS WELL. 861 00:35:33,664 --> 00:35:38,369 THE FIRST AWARDS FOR THE 862 00:35:38,369 --> 00:35:39,570 PARTICULAR PROGRAM ARE COMING 863 00:35:39,570 --> 00:35:39,904 OUT SOON. 864 00:35:39,904 --> 00:35:42,373 I HOPE WITHIN THE FIRST 11 DAYS. 865 00:35:42,373 --> 00:35:44,942 THAT WILL BE VERY IMPORTANT. 866 00:35:44,942 --> 00:35:49,246 SO, I WANT TO ALSO END UP GOING 867 00:35:49,246 --> 00:35:50,347 THROUGH THESE QUICKLY. 868 00:35:50,347 --> 00:35:52,116 I KNOW YOU READ THE STRATEGIC 869 00:35:52,116 --> 00:35:55,052 PLAN AND PROBABLY MEMORIZED IT. 870 00:35:55,052 --> 00:35:56,353 I WON'T SPEND A LOT OF TIME ON 871 00:35:56,353 --> 00:36:01,559 THIS BUT WANT TO END ON THIS 872 00:36:01,559 --> 00:36:01,826 NOTE. 873 00:36:01,826 --> 00:36:04,161 SO, THE STRATEGIC PLAN IS OUT. 874 00:36:04,161 --> 00:36:06,363 AS YOU KNOW THIS WAS A LONG 875 00:36:06,363 --> 00:36:11,068 PROCESS INCORPORATING A VARIETY 876 00:36:11,068 --> 00:36:17,575 OF DISCUSSIONS THIS SLIDE IS 877 00:36:17,575 --> 00:36:21,345 MEANT TO GIVE A SPECIAL SHOUT 878 00:36:21,345 --> 00:36:23,547 OUT TO ALL OF YOU AND NCATS 879 00:36:23,547 --> 00:36:25,115 STAFF AND MOST IMPORTANTLY THE 880 00:36:25,115 --> 00:36:33,424 PEOPLE WHO DID THE BULK OF THE 881 00:36:33,424 --> 00:36:34,358 WORK. 882 00:36:34,358 --> 00:36:41,065 THEY HIT IT OUT OF THE PARK AND 883 00:36:41,065 --> 00:36:42,132 COULDN'T BE MORE PROUD OF THE 884 00:36:42,132 --> 00:36:43,901 STRATEGIC PLAN AND IF YOU 885 00:36:43,901 --> 00:36:44,568 HAVEN'T TAKEN A LOOK, PLEASE DO 886 00:36:44,568 --> 00:36:48,072 SO. 887 00:36:48,072 --> 00:36:48,873 I'LL GO THROUGH A LITTLE BIT OF 888 00:36:48,873 --> 00:36:50,975 WHAT IT LOOKS LIKE IN CASE YOU 889 00:36:50,975 --> 00:36:51,375 HAVEN'T. 890 00:36:51,375 --> 00:36:53,744 HERE ARE THE GOALS OF THE PLAN 891 00:36:53,744 --> 00:36:56,780 AND IT MAY LOOK FAMILIAR TO YOU. 892 00:36:56,780 --> 00:36:57,681 AUDACIOUS GOALS ARE MORE 893 00:36:57,681 --> 00:36:59,483 TREATMENT FOR MORE PEOPLE 894 00:36:59,483 --> 00:36:59,750 QUICKLY. 895 00:36:59,750 --> 00:37:03,754 THOSE ARE THE FIRST THREE GOALS 896 00:37:03,754 --> 00:37:04,822 BUT SET MORE STRATEGIC PLANNING 897 00:37:04,822 --> 00:37:07,524 LIKE AND THEN ADDED A FEW MORE 898 00:37:07,524 --> 00:37:08,125 GOALS. 899 00:37:08,125 --> 00:37:11,896 THE FOURTH GOAL IS CROSS CUTTING 900 00:37:11,896 --> 00:37:13,297 STRATEGIES TO ENHANCE POLICY 901 00:37:13,297 --> 00:37:15,633 DEVELOPMENT AND DATA SCIENCE, 902 00:37:15,633 --> 00:37:15,900 ETCETERA. 903 00:37:15,900 --> 00:37:20,204 AND EFFECTIVE STEWARDSHIP OF 904 00:37:20,204 --> 00:37:21,372 TRANSLATIONAL SCIENCE INTEGRITY 905 00:37:21,372 --> 00:37:22,339 AND SOCIAL RESPONSIBILITY. 906 00:37:22,339 --> 00:37:24,675 THOSE ARE OUR KEY FEATURES OF 907 00:37:24,675 --> 00:37:26,210 WHAT WILL HAPPEN IN THE PLAN. 908 00:37:26,210 --> 00:37:28,479 YOU'LL SEE OR PROBABLY EXPECT 909 00:37:28,479 --> 00:37:30,714 MANY OF THESE GOALS ACTUALLY 910 00:37:30,714 --> 00:37:33,984 OVERLAP WITH ONE ANOTHER. 911 00:37:33,984 --> 00:37:34,351 AND THAT'S OKAY. 912 00:37:34,351 --> 00:37:35,252 WE DON'T NECESSARILY NEED THEM 913 00:37:35,252 --> 00:37:37,755 TO BE VERY DEFINED IN ONE 914 00:37:37,755 --> 00:37:38,355 PARTICULAR GOAL. 915 00:37:38,355 --> 00:37:42,993 IN FACT IF THEY'RE INTEGRIGRATEE 916 00:37:42,993 --> 00:37:44,762 MAY BE ABLE TO LIFT MORE BOATS 917 00:37:44,762 --> 00:37:45,696 AND ADVANCE DEVELOPMENT OF AN 918 00:37:45,696 --> 00:37:49,466 ACCESS TO MORE TREATMENTS. 919 00:37:49,466 --> 00:37:51,101 PARTICULARLY WITH THE UNMET 920 00:37:51,101 --> 00:37:51,302 NEEDS. 921 00:37:51,302 --> 00:37:53,938 HERE WE'RE FOCUSSING ON 922 00:37:53,938 --> 00:37:56,473 DIAGNOSIS AND THERAPIES. 923 00:37:56,473 --> 00:38:02,379 NEW MOLECULES AND TARGETS AND 924 00:38:02,379 --> 00:38:03,914 CRITICAL ACTIVITIES WITH THE 925 00:38:03,914 --> 00:38:05,115 CTSAs ARE SO IMPORTANT IN THE 926 00:38:05,115 --> 00:38:08,886 WORK WE DO AND THE ACTIVITIES IN 927 00:38:08,886 --> 00:38:10,054 PRECLINICAL TESTING. 928 00:38:10,054 --> 00:38:17,995 FOR GOAL NUMBER 2 BENEFITING 929 00:38:17,995 --> 00:38:18,696 FROM INCLUSIONARY SCIENCE AND 930 00:38:18,696 --> 00:38:19,830 RESEARCH AND CLINICAL TRIALS AND 931 00:38:19,830 --> 00:38:20,864 BRINGING COMMUNITIES AND 932 00:38:20,864 --> 00:38:23,200 PATIENTS AS PARTNERS AND HEARING 933 00:38:23,200 --> 00:38:26,136 VOICES LISTENING TO THOSE NEEDS. 934 00:38:26,136 --> 00:38:27,671 ADDRESSING HEALTH DISPARITIES 935 00:38:27,671 --> 00:38:31,475 AND USING IT ALSO TO HELP 936 00:38:31,475 --> 00:38:34,111 SUPPORT A LARGER TRANSLATIONAL 937 00:38:34,111 --> 00:38:36,547 SCIENCE WORKFORCE AND BREAKING 938 00:38:36,547 --> 00:38:37,247 BARRIERS AND BOOSTING 939 00:38:37,247 --> 00:38:37,548 EFFICIENCY. 940 00:38:37,548 --> 00:38:41,051 EFFICIENCY IS A BIG DEAL FOR US 941 00:38:41,051 --> 00:38:42,453 AT NCATS. 942 00:38:42,453 --> 00:38:44,888 REALLY BREAKING DOWN THE 943 00:38:44,888 --> 00:38:46,390 BARRIERS OF SCIENTIFIC 944 00:38:46,390 --> 00:38:47,725 INNOVATIONS IS CRITICAL USING 945 00:38:47,725 --> 00:38:49,493 DATA SCIENCE APPROACHES FOR 946 00:38:49,493 --> 00:38:50,394 EXAMPLE, PLATFORM TECHNOLOGIES 947 00:38:50,394 --> 00:38:51,962 AND PREDICTIVE MODELS. 948 00:38:51,962 --> 00:38:53,664 THERE'S ALSO KEY OPERATIONAL 949 00:38:53,664 --> 00:38:56,467 PIECES WE DO. 950 00:38:56,467 --> 00:38:58,369 HOW WE WORK WITHIN NCATS IS 951 00:38:58,369 --> 00:39:01,472 IMPORTANT AND MODERNIZING THOSE 952 00:39:01,472 --> 00:39:02,373 AND ENHANCING THOSE FOR MORE 953 00:39:02,373 --> 00:39:04,308 EFFICIENT ACTIVITIES ARE KEY 954 00:39:04,308 --> 00:39:04,708 PIECES AS WELL. 955 00:39:04,708 --> 00:39:07,611 GOAL NUMBER FOUR IS THE CROSS 956 00:39:07,611 --> 00:39:08,012 CUTTING TEAMS. 957 00:39:08,012 --> 00:39:11,548 TEAM SCIENCE, PARTNERSHIPS, 958 00:39:11,548 --> 00:39:12,950 COLLABORATIONS, PUBLIC-PRIVATE 959 00:39:12,950 --> 00:39:14,184 PARTNERSHIPS AND DATA SCIENCE 960 00:39:14,184 --> 00:39:16,020 STANDARD AND SUPPORTING THE WORK 961 00:39:16,020 --> 00:39:19,089 WE DO AND DEVELOPING PRINCIPLES 962 00:39:19,089 --> 00:39:22,393 AND USE THOSE TO SUPPORT THE 963 00:39:22,393 --> 00:39:23,660 SCIENCE WE DO AS WELL. 964 00:39:23,660 --> 00:39:27,664 AND GOAL 5 IS CHAMPIONING THE 965 00:39:27,664 --> 00:39:29,833 EFFECTIVE STEWARDSHIP OF SEENS 966 00:39:29,833 --> 00:39:31,101 THROUGH TRANSPARENCY. 967 00:39:31,101 --> 00:39:32,870 OPEN AND TRANSPARENT DATA 968 00:39:32,870 --> 00:39:35,672 ACCESS, REPRODUCIBLE AND ETHICAL 969 00:39:35,672 --> 00:39:35,939 RESEARCH. 970 00:39:35,939 --> 00:39:36,673 DEVELOPING POLICIES AND 971 00:39:36,673 --> 00:39:38,809 GUIDANCES FOR THE WORK WE DO AND 972 00:39:38,809 --> 00:39:39,443 DEVELOPING THAT INFRASTRUCTURE 973 00:39:39,443 --> 00:39:41,578 FOR IMPACT. 974 00:39:41,578 --> 00:39:43,113 I ALWAYS SAY THAT A LOT OF THE 975 00:39:43,113 --> 00:39:50,054 WORK WE DO IS SUPPORTING DEEP 976 00:39:50,054 --> 00:39:51,755 INFRASTRUCTURE AND WITHOUT THAT 977 00:39:51,755 --> 00:39:53,090 DEEP INFRASTRUCTURE WE DO NOT 978 00:39:53,090 --> 00:39:55,225 HAVE A CHANCE OF BUILDING UPON 979 00:39:55,225 --> 00:39:56,593 IN TERMS OF THE INNOVATIONS WE 980 00:39:56,593 --> 00:39:57,561 WANT TO HAVE. 981 00:39:57,561 --> 00:39:58,362 SO INFRASTRUCTURE IS INCREDIBLY 982 00:39:58,362 --> 00:39:59,897 IMPORTANT. 983 00:39:59,897 --> 00:40:02,366 SO THESE ARE THE KEY FEATURES OF 984 00:40:02,366 --> 00:40:05,069 OUR ACTIVITIES WITHIN THE 985 00:40:05,069 --> 00:40:07,037 STRATEGIC PLAN. 986 00:40:07,037 --> 00:40:09,440 AND I THINK -- I SET A SIMILAR 987 00:40:09,440 --> 00:40:10,974 VERSION OF THIS YESTERDAY BUT 988 00:40:10,974 --> 00:40:12,910 WANT TO -- I LIKED IT SO MUCH I 989 00:40:12,910 --> 00:40:14,378 WANT TO SAY IT TODAY BECAUSE I 990 00:40:14,378 --> 00:40:21,318 FEEL STRONGLY ABOUT THIS. 991 00:40:21,318 --> 00:40:26,356 AS MUCH WE FOCUS ON THE PROJECT, 992 00:40:26,356 --> 00:40:28,092 PROTOCOLS IT'S THE PEOPLE WHO 993 00:40:28,092 --> 00:40:29,126 MAKE IT POSSIBLE FROM PUSHING 994 00:40:29,126 --> 00:40:31,929 THE BOUNDARIES TO THOSE WITH 995 00:40:31,929 --> 00:40:32,996 LIVED EXPERIENCES WHO STAND TO 996 00:40:32,996 --> 00:40:34,631 BENEFIT FROM OUR COLLECTIVE WORK 997 00:40:34,631 --> 00:40:35,766 AND ALSO BY LISTENING TO THEM 998 00:40:35,766 --> 00:40:37,534 AND LEARNING FROM THEM. 999 00:40:37,534 --> 00:40:39,670 TO THE PATIENT SCIENTISTS 1000 00:40:39,670 --> 00:40:42,139 INVOLVED IN THE WORK WE SUPPORT 1001 00:40:42,139 --> 00:40:44,575 AND TO ALL OF OUR PUBLIC AND 1002 00:40:44,575 --> 00:40:46,443 PRIVATE SECTOR PARTNERS IN THESE 1003 00:40:46,443 --> 00:40:47,077 ACTIVITIES. 1004 00:40:47,077 --> 00:40:50,347 YOU ALL ARE THE HEARTBEAT OF 1005 00:40:50,347 --> 00:40:51,048 WHAT NCATS DOES. 1006 00:40:51,048 --> 00:40:52,950 AT THE END OF THE DAY IT'S NOT 1007 00:40:52,950 --> 00:40:53,784 JUST ABOUT ADVANCING THE SCIENCE 1008 00:40:53,784 --> 00:40:54,918 WE DO BUT ADVANCING THE LIVES 1009 00:40:54,918 --> 00:41:00,224 WE'RE HERE TO HELP. 1010 00:41:00,224 --> 00:41:01,458 AND PEOPLE DRIVE THE PURPOSE. 1011 00:41:01,458 --> 00:41:03,527 I FEEL STRONGLY THAT THE 1012 00:41:03,527 --> 00:41:05,762 STRATEGIC PLAN IS A REFLECTION 1013 00:41:05,762 --> 00:41:06,163 OF THAT SENTIMENT. 1014 00:41:06,163 --> 00:41:09,666 SO I WANTED TO RELAY THAT HERE 1015 00:41:09,666 --> 00:41:09,933 TODAY. 1016 00:41:09,933 --> 00:41:11,969 WHAT'S NEXT FOR OUR STRATEGIC 1017 00:41:11,969 --> 00:41:14,071 PLAN? 1018 00:41:14,071 --> 00:41:15,172 WE'RE NOT OVER. 1019 00:41:15,172 --> 00:41:17,074 OUR NEXT PLANS ARE TO HAVE A 1020 00:41:17,074 --> 00:41:18,375 SERIES OF ROUNDTABLES TO DISCUSS 1021 00:41:18,375 --> 00:41:23,080 WHAT TO DO NEXT AS A COMMUNITY. 1022 00:41:23,080 --> 00:41:27,117 AND SO -- THOSE WILL BE 1023 00:41:27,117 --> 00:41:28,418 HAPPENING OVER THE COURSE AT THE 1024 00:41:28,418 --> 00:41:30,087 END OF THE MONTH AND EARLY 1025 00:41:30,087 --> 00:41:30,320 OCTOBER. 1026 00:41:30,320 --> 00:41:34,324 IF YOU HAVEN'T HAD A CHANCE TO 1027 00:41:34,324 --> 00:41:34,758 REGISTER, PLEASE DO. 1028 00:41:34,758 --> 00:41:37,361 SO THAT'S MY PRESENTATION IN A 1029 00:41:37,361 --> 00:41:40,364 NUTSHELL TODAY AND JUST TO 1030 00:41:40,364 --> 00:41:42,299 SUMMARIZE AGAIN THE ACTIVITIES 1031 00:41:42,299 --> 00:41:43,367 WE'VE GONE OVER ARE SHOWN HERE. 1032 00:41:43,367 --> 00:41:46,370 I DON'T NEED TO GO THROUGH IT 1033 00:41:46,370 --> 00:41:50,107 BUT ALSO WANT TO RE-HIGHLIGHT WE 1034 00:41:50,107 --> 00:41:52,276 HAVE A FEW OTHER TOPICS 1035 00:41:52,276 --> 00:41:54,945 DISCUSSED TODAY FROM JANINE AND 1036 00:41:54,945 --> 00:42:04,788 SHARI AND MIKE AND CHRISTINE SO 1037 00:42:04,788 --> 00:42:15,299 STAY TUNED FOR THOSE EVERY SO 1038 00:42:16,900 --> 00:42:19,169 OFTEN WE RECEIVE LETTERS AND WE 1039 00:42:19,169 --> 00:42:21,872 RECEIVED SUCH A LETTER TODAY AND 1040 00:42:21,872 --> 00:42:22,906 EARLIER THIS WEEK. 1041 00:42:22,906 --> 00:42:25,576 THIS LETTER CAME FROM OUR NCATS 1042 00:42:25,576 --> 00:42:26,577 COUNCIL I'M PRESENTING A LETTER 1043 00:42:26,577 --> 00:42:31,048 FROM THE COUNCIL TO THE COUNCIL 1044 00:42:31,048 --> 00:42:33,083 WHICH FEELS A LITTLE ODD. 1045 00:42:33,083 --> 00:42:35,085 IT ALSO SOUNDS OMINOUS BUT IT'S 1046 00:42:35,085 --> 00:42:35,352 NOT. 1047 00:42:35,352 --> 00:42:37,254 IT'S QUITE THE OPPOSITE. 1048 00:42:37,254 --> 00:42:38,956 IT'S VERY INSPIRING. 1049 00:42:38,956 --> 00:42:43,227 IT'S A FORMAL REQUEST TO 1050 00:42:43,227 --> 00:42:44,861 INITIATE THE PROCESS OF A 1051 00:42:44,861 --> 00:42:46,029 TRANSITION OF NCATS TO AN 1052 00:42:46,029 --> 00:42:46,296 INSTITUTE. 1053 00:42:46,296 --> 00:42:49,266 THIS CAME UP VERY BRIEFLY AT OUR 1054 00:42:49,266 --> 00:42:51,034 LAST COUNCIL GATHERING AND SO 1055 00:42:51,034 --> 00:42:52,302 THE COUNCIL GOT TOGETHER TO 1056 00:42:52,302 --> 00:42:53,637 WRITE AND SIGN THIS LETTER. 1057 00:42:53,637 --> 00:42:55,672 AND I WANT TO BRING A COUPLE 1058 00:42:55,672 --> 00:42:58,041 THINGS TO YOUR ATTENTION ABOUT 1059 00:42:58,041 --> 00:42:58,242 THIS. 1060 00:42:58,242 --> 00:43:01,511 FIRST OF ALL THE LETTER HAS BEEN 1061 00:43:01,511 --> 00:43:03,547 SIGNED BY ALL COUNCIL MEMBERS 1062 00:43:03,547 --> 00:43:04,147 PRESENT AND ALSO MANY COUNCIL 1063 00:43:04,147 --> 00:43:07,651 MEMBERS PAST. 1064 00:43:07,651 --> 00:43:09,386 AND SO VERY HEARTWARMING TO HAVE 1065 00:43:09,386 --> 00:43:12,389 SUCH A ROBUST RESPONSE. 1066 00:43:12,389 --> 00:43:14,391 IT PRESENTS A COMPELLING SET OF 1067 00:43:14,391 --> 00:43:18,228 ARGUMENTS THAT ARE BASED ON 1068 00:43:18,228 --> 00:43:19,963 PRECEDENT AND AS TO WHY NCATS 1069 00:43:19,963 --> 00:43:21,632 SHOULD BECOME AN INSTITUTE AND 1070 00:43:21,632 --> 00:43:23,533 OTHER CURRENT INSTITUTES THAT 1071 00:43:23,533 --> 00:43:25,335 HAVE GONE THROUGH THE PROCESS AS 1072 00:43:25,335 --> 00:43:28,138 WELL ARE HIGHLIGHTED. 1073 00:43:28,138 --> 00:43:33,777 NHGRI AND NIMHD AND NINR HAVE 1074 00:43:33,777 --> 00:43:34,311 GONE THROUGH IT. 1075 00:43:34,311 --> 00:43:36,913 I'M IMPRESSED BY THE 1076 00:43:36,913 --> 00:43:37,948 THOUGHTFULNESS IN THE LETTER AND 1077 00:43:37,948 --> 00:43:40,117 THE FACT IT'S BUILT ON 1078 00:43:40,117 --> 00:43:40,417 PRECEDENCE. 1079 00:43:40,417 --> 00:43:42,185 BEFORE I ASK ANNIE KENNEDY TO 1080 00:43:42,185 --> 00:43:43,887 SAY A FEW WORDS ABOUT THIS 1081 00:43:43,887 --> 00:43:45,789 BECAUSE SHE WAS THE ONE WHO SENT 1082 00:43:45,789 --> 00:43:48,091 IT TO ME SO I GUESS SHE'S ON THE 1083 00:43:48,091 --> 00:43:48,292 HOOK. 1084 00:43:48,292 --> 00:43:50,961 I WANT TO SAY HOW HUMBLED I AM 1085 00:43:50,961 --> 00:43:51,728 WITH THIS OVERWHELMING SUPPORT 1086 00:43:51,728 --> 00:44:01,004 FROM OUR COUNCIL. 1087 00:44:01,004 --> 00:44:04,541 IT'S AN IMMENSE HONOR TO LEAD 1088 00:44:04,541 --> 00:44:06,977 NCATS AND WOULD BE AN HONOR TO 1089 00:44:06,977 --> 00:44:08,679 LEAD NCATS TO ACCOMPLISH MORE 1090 00:44:08,679 --> 00:44:11,148 AND WITH THAT BECAUSE WE'RE IN 1091 00:44:11,148 --> 00:44:14,117 THE FIRST QUARTER I KNOW MANY OF 1092 00:44:14,117 --> 00:44:15,752 US ARE STRUGGLING AND DRAINED 1093 00:44:15,752 --> 00:44:21,591 AND WANT TO READ JUST ONE 1094 00:44:21,591 --> 00:44:22,225 PARAGR 1095 00:44:22,225 --> 00:44:22,492 PARAGRAPH. 1096 00:44:22,492 --> 00:44:23,760 THE NCATS ADVISORY COMMITTEE 1097 00:44:23,760 --> 00:44:26,730 APPLAUDS THE LEADERSHIP FOR YOUR 1098 00:44:26,730 --> 00:44:28,198 SCIENCE AND UNWAVERING TO YOUR 1099 00:44:28,198 --> 00:44:29,232 COMMITMENT TO DELIVERING MORE 1100 00:44:29,232 --> 00:44:30,367 TREATMENTS FOR ALL PEOPLE MORE 1101 00:44:30,367 --> 00:44:30,600 QUICKLY. 1102 00:44:30,600 --> 00:44:34,371 AS AN ENTITY, YOU ARE 1103 00:44:34,371 --> 00:44:35,405 UNSURPASSED IN INNOVATION, 1104 00:44:35,405 --> 00:44:37,874 COLLABORATIVE SCIENCE AND 1105 00:44:37,874 --> 00:44:39,543 STIMULATING BIOMEDICAL RESEARCH, 1106 00:44:39,543 --> 00:44:41,078 THERAPY DEVELOPMENT AND 1107 00:44:41,078 --> 00:44:42,379 IMPACTFUL HEALTH OUTCOMES. 1108 00:44:42,379 --> 00:44:44,548 SO, THANK YOU TO OUR COUNCIL FOR 1109 00:44:44,548 --> 00:44:46,483 THESE WONDERFUL WORDS. 1110 00:44:46,483 --> 00:44:48,385 THEY'RE INSPIRING. 1111 00:44:48,385 --> 00:44:50,253 SO, WITH THAT I WANT TO TAKE A 1112 00:44:50,253 --> 00:44:52,222 MOMENT TO THANK YOU ALL AND ASK 1113 00:44:52,222 --> 00:44:53,724 FOR ANY QUESTIONS AND WOULD ALSO 1114 00:44:53,724 --> 00:44:55,392 LIKE TO GIVE ANNIE KENNEDY A 1115 00:44:55,392 --> 00:44:56,693 MOMENT TO RESPOND TO THE 1116 00:44:56,693 --> 00:44:57,794 COMMENTS AND MAYBE WE'LL DO THAT 1117 00:44:57,794 --> 00:45:08,271 FIRST BUT THANK YOU SEARCH. 1118 00:45:09,873 --> 00:45:11,308 >> LET'S LET AMY GO FIRST IF 1119 00:45:11,308 --> 00:45:11,842 THAT'S OKAY. 1120 00:45:11,842 --> 00:45:13,610 >> FIRST, THANK YOU VERY MUCH 1121 00:45:13,610 --> 00:45:16,546 DR. RUTTER FOR THE DIRECTOR'S 1122 00:45:16,546 --> 00:45:19,383 REPORT WHICH I THINK SPEAKS TO 1123 00:45:19,383 --> 00:45:20,384 WHY THE COUNCIL FELT IT WAS TIME 1124 00:45:20,384 --> 00:45:23,587 TO BRING THIS FORWARD. 1125 00:45:23,587 --> 00:45:25,789 AS NCATS BEGINS TO IMPLEMENT THE 1126 00:45:25,789 --> 00:45:27,391 THOUGHTFUL AND COMPREHENSIVE 1127 00:45:27,391 --> 00:45:28,458 STRATEGIC PLANS YOU JUST 1128 00:45:28,458 --> 00:45:30,660 PRESENTED TO US AND TO THE 1129 00:45:30,660 --> 00:45:33,497 COMMUNITY, WE FELT THAT IT WAS 1130 00:45:33,497 --> 00:45:35,065 REALLY IMPORTANT THAT IN ORDER 1131 00:45:35,065 --> 00:45:37,467 TO ENABLE NCATS TO DELIVER MORE 1132 00:45:37,467 --> 00:45:41,872 TREATMENTS FOR ALL PEOPLE MORE 1133 00:45:41,872 --> 00:45:43,140 QUICKLY, THAT OUR ADVISORY 1134 00:45:43,140 --> 00:45:44,174 COUNCIL CONSIDER THE 1135 00:45:44,174 --> 00:45:49,246 UNPARALLELED WORK AND LEADERSHIP 1136 00:45:49,246 --> 00:45:50,147 OF NCATS AS WELL AS PAST 1137 00:45:50,147 --> 00:45:51,948 PRECEDENCE YOU JUST OUTLINED 1138 00:45:51,948 --> 00:45:54,184 FROM OTHER NIH INSTITUTES AS 1139 00:45:54,184 --> 00:45:57,921 THEY EVOLVED WHEN THEY HAD 1140 00:45:57,921 --> 00:46:01,158 INITIALLY BEEN IMPLEMENTED AND 1141 00:46:01,158 --> 00:46:02,692 BRING STRONGLY THAT THE 1142 00:46:02,692 --> 00:46:04,094 IMPLEMENTATION OF NCATS MISSION 1143 00:46:04,094 --> 00:46:06,563 GOING FORWARD WILL BEST BE 1144 00:46:06,563 --> 00:46:08,298 ACHIEVED FOR NCATS TO BE 1145 00:46:08,298 --> 00:46:10,300 ELEVATED FROM CENTER TO AN 1146 00:46:10,300 --> 00:46:10,567 INSTITUTE. 1147 00:46:10,567 --> 00:46:12,736 I'VE TAKEN NOTES THIS MORNING 1148 00:46:12,736 --> 00:46:14,070 FOR YOUR DIRECTOR'S REPORT AND 1149 00:46:14,070 --> 00:46:16,706 FROM SOME OF THE PRESENTATIONS 1150 00:46:16,706 --> 00:46:19,576 WE'VE BEEN HEARING AND NCATS 1151 00:46:19,576 --> 00:46:29,085 UNIQUELY STANDS AT A CROSSROADS 1152 00:46:29,085 --> 00:46:29,920 OF SCIENCE. 1153 00:46:29,920 --> 00:46:32,722 NCATS LEADERSHIP IS 1154 00:46:32,722 --> 00:46:33,056 UNPARALLELED. 1155 00:46:33,056 --> 00:46:35,392 SOME IMPACT PORTFOLIOS WITHIN 1156 00:46:35,392 --> 00:46:41,631 NIH YOU LEAD ARE ADVANCING 1157 00:46:41,631 --> 00:46:51,741 A.I./M.L., QUANTUM COMPUTING, 1158 00:46:51,741 --> 00:46:54,344 HIGH THROUGHPUT CRISPR AND 1159 00:46:54,344 --> 00:46:56,646 TRANS-NIH COLLABORATIONS, 1160 00:46:56,646 --> 00:46:57,981 SPURRING INNOVATION AND 1161 00:46:57,981 --> 00:47:00,951 EXPANDING THE DRUG LANDSCAPE AND 1162 00:47:00,951 --> 00:47:03,119 RESEARCH INNOVATION, LEADING THE 1163 00:47:03,119 --> 00:47:05,689 NATION'S LARGEST CLINICAL AND 1164 00:47:05,689 --> 00:47:06,156 TRANSLATIONAL SCIENCE 1165 00:47:06,156 --> 00:47:12,262 INFRASTRUCTURE AND SO MUCH MORE. 1166 00:47:12,262 --> 00:47:14,364 WE BELIEVE IT'S TIME TO INITIATE 1167 00:47:14,364 --> 00:47:19,870 THE PROCESS AND FEEL STRONGLY 1168 00:47:19,870 --> 00:47:22,305 THERE'S COMPELLING EVIDENCE THAT 1169 00:47:22,305 --> 00:47:23,940 NCATS' MIRRORS PAST PRECEDENT 1170 00:47:23,940 --> 00:47:25,242 WITH THE POTENTIAL OPPORTUNITIES 1171 00:47:25,242 --> 00:47:28,311 THAT EXIST WITHIN DESIGNATION OF 1172 00:47:28,311 --> 00:47:28,912 AN INSTITUTE. 1173 00:47:28,912 --> 00:47:31,248 IN DOING SOME OF THE RESEARCH TO 1174 00:47:31,248 --> 00:47:34,017 BRING THIS LETTER FORWARD WE 1175 00:47:34,017 --> 00:47:36,686 WENT THROUGH THE CONGRESSIONAL 1176 00:47:36,686 --> 00:47:38,021 RECORDS THAT LED TO THE 1177 00:47:38,021 --> 00:47:39,322 EVOLUTION OF SOME OF THOSE 1178 00:47:39,322 --> 00:47:39,990 INSTITUTES YOU NAMED. 1179 00:47:39,990 --> 00:47:44,761 AND I'D LIKE TO READ ONE OF THE 1180 00:47:44,761 --> 00:47:50,667 QUOTES FROM THE CONGRESSIONAL 1181 00:47:50,667 --> 00:47:50,901 RECORDS. 1182 00:47:50,901 --> 00:47:52,502 IF NCATS CAN OPERATE UNDER THE 1183 00:47:52,502 --> 00:47:54,404 STATEMENT LEGISLATIVE 1184 00:47:54,404 --> 00:47:55,605 AUTHORITIES AS OTHER NIH 1185 00:47:55,605 --> 00:47:58,208 RESEARCH INSTITUTES, END QUOTE, 1186 00:47:58,208 --> 00:48:01,378 SUCH AS CONDUCTING TRIALS BEYOND 1187 00:48:01,378 --> 00:48:04,080 PHASE II B WE BELIEVE IT WOULD 1188 00:48:04,080 --> 00:48:05,582 BOOST NCATS FUTURE AND UNLOCK 1189 00:48:05,582 --> 00:48:06,349 ITS FULL CAPACITY TO DELIVER 1190 00:48:06,349 --> 00:48:10,220 MORE TREATMENTS FOR ALL PEOPLE 1191 00:48:10,220 --> 00:48:10,554 MORE QUICKLY. 1192 00:48:10,554 --> 00:48:12,455 SO WE THANK YOU FOR YOUR WORK 1193 00:48:12,455 --> 00:48:13,857 AND FEEL STRONGLY AND STAND 1194 00:48:13,857 --> 00:48:14,457 READY TO SUPPORT YOU IN THIS 1195 00:48:14,457 --> 00:48:24,634 ENDEAVOR. 1196 00:48:25,035 --> 00:48:27,370 >> SO WITH THAT LETTER THIS IS 1197 00:48:27,370 --> 00:48:32,509 AN IMPORTANT STEP FOR THIS TO 1198 00:48:32,509 --> 00:48:33,009 HAPPEN. 1199 00:48:33,009 --> 00:48:34,678 BUT THERE ARE MANY STEPS THAT 1200 00:48:34,678 --> 00:48:36,246 WILL BE REQUIRED TO MAKE IT 1201 00:48:36,246 --> 00:48:36,580 HAPPEN. 1202 00:48:36,580 --> 00:48:39,149 MANY KNOW THIS WOULD BE A 1203 00:48:39,149 --> 00:48:42,352 CONGRESSIONAL CHANGE AND SO THE 1204 00:48:42,352 --> 00:48:46,323 PATH TO GET THERE CAN BE VARIED. 1205 00:48:46,323 --> 00:48:48,592 WE'LL DO WHAT WE CAN TO MOVE IT 1206 00:48:48,592 --> 00:48:49,359 FORWARD INTERNALLY AND SEE WHAT 1207 00:48:49,359 --> 00:48:50,860 WE CAN DO WITH THAT. 1208 00:48:50,860 --> 00:48:53,096 THIS PROVIDES US WITH THE VERY 1209 00:48:53,096 --> 00:48:54,431 STRONG LANGUAGE TO HELP SUPPORT 1210 00:48:54,431 --> 00:48:56,833 THAT AND SO IT IS REALLY A BIG 1211 00:48:56,833 --> 00:48:59,569 STEP SO THANK YOU VERY MUCH FOR 1212 00:48:59,569 --> 00:49:03,406 YOUR CONFIDENCE IN NCATS AND IN 1213 00:49:03,406 --> 00:49:04,107 OUR ABILITY TO MOVE TO AN 1214 00:49:04,107 --> 00:49:05,842 INSTITUTE. 1215 00:49:05,842 --> 00:49:09,579 IT'S EXCITING TO THINK ABOUT. 1216 00:49:09,579 --> 00:49:11,281 I WILL SAY THAT THIS LETTER IN 1217 00:49:11,281 --> 00:49:17,420 ITS ENTIRETY WILL BE PUCK LIB ON 1218 00:49:17,420 --> 00:49:20,323 OUR WEBSITE SO WITH THAT I'D 1219 00:49:20,323 --> 00:49:22,726 LIKE TO OPEN IT UP TO ANY OTHER 1220 00:49:22,726 --> 00:49:23,827 QUESTIONS RELATED TO THAT OR ANY 1221 00:49:23,827 --> 00:49:34,337 OTHER COMMENTS YOU MIGHT HAVE. 1222 00:49:34,604 --> 00:49:41,311 IF NONE, THAT'S OKAY TOO. 1223 00:49:41,311 --> 00:49:42,178 ALL RIGHT. 1224 00:49:42,178 --> 00:49:42,879 VERY GOOD. 1225 00:49:42,879 --> 00:49:52,822 IN THAT CASE, SHALL WE MOVE ON? 1226 00:49:52,822 --> 00:49:55,659 OH, IS IT LUNCH NEXT? 1227 00:49:55,659 --> 00:49:56,359 OKAY. 1228 00:49:56,359 --> 00:49:56,693 COULDN'T HEAR. 1229 00:49:56,693 --> 00:49:56,960 THANK YOU. 1230 00:49:56,960 --> 00:50:00,296 SO YES, WE SHOULD MOVE ON. 1231 00:50:00,296 --> 00:50:02,365 PLEASE, HAVE LUNCH AND WE'LL BE 1232 00:50:02,365 --> 00:50:07,537 BACK AT WHAT TIME? 1233 00:50:07,537 --> 00:50:07,771 1:10. 1234 00:50:07,771 --> 00:50:10,373 SO THANK YOU. 1235 00:50:10,373 --> 00:50:12,491 WE'LL SEE YOU SOON. 1236 00:50:12,491 --> 00:50:14,126 ALL RIGHT, I HOPE EVERYONE HAD A 1237 00:50:14,126 --> 00:50:14,426 GOOD LUNCH. 1238 00:50:14,426 --> 00:50:15,260 WELCOME BACK. 1239 00:50:15,260 --> 00:50:17,429 WE ARE GOING TO START OUR NEXT 1240 00:50:17,429 --> 00:50:19,164 SEGMENT FOR THE PRESENTATIONS 1241 00:50:19,164 --> 00:50:19,598 MOVING FORWARD. 1242 00:50:19,598 --> 00:50:25,103 FIRST UP AGAIN VERY EXCITED 1243 00:50:25,103 --> 00:50:27,139 ABOUT THIS PRESENTATION AND I'LL 1244 00:50:27,139 --> 00:50:29,942 TURN IT OVER TO JEANITA. 1245 00:50:29,942 --> 00:50:30,742 >> AWESOME. 1246 00:50:30,742 --> 00:50:31,743 GOOD AFTERNOON, EVERYONE. 1247 00:50:31,743 --> 00:50:34,079 I HAVE THE PLEASURE OF KICKING 1248 00:50:34,079 --> 00:50:35,747 OFF TODAY'S AFTERNOON SESSION 1249 00:50:35,747 --> 00:50:39,251 AFTER LUNCH SO HOPEFULLY YOU'RE 1250 00:50:39,251 --> 00:50:40,085 FEELING ENERGIZED AND HAD YOUR 1251 00:50:40,085 --> 00:50:42,654 SECOND CUP OF COFFEE AND HERE TO 1252 00:50:42,654 --> 00:50:45,257 TALK ABOUT THE EFFORTS IN THE 1253 00:50:45,257 --> 00:50:49,328 SPACE OF DIVERSITY, EQUITY AND 1254 00:50:49,328 --> 00:50:49,962 INCLUSION AND ACCESSIBILITY IN 1255 00:50:49,962 --> 00:50:50,395 NCATS AND BEYOND. 1256 00:50:50,395 --> 00:50:52,030 I'LL KICK OFF THE CONVERSATIONS 1257 00:50:52,030 --> 00:50:55,133 AND HAND IT OVER TO MY DEAR 1258 00:50:55,133 --> 00:50:57,069 COLLEAGUE TO TALK ABOUT SPECIFIC 1259 00:50:57,069 --> 00:50:59,404 WORK SHE'S DOING IN THE 1260 00:50:59,404 --> 00:51:01,373 PRECLINICAL SPACE. 1261 00:51:01,373 --> 00:51:03,909 TO GIVE A QUICK OVERVIEW OF WHAT 1262 00:51:03,909 --> 00:51:07,079 WE'LL BE DIVING INTO IN THE 1263 00:51:07,079 --> 00:51:08,080 CONVERSATION WE'LL BE EXPLORING 1264 00:51:08,080 --> 00:51:10,182 THE DIFFERENT STRATEGIC 1265 00:51:10,182 --> 00:51:11,883 INITIATIVES WE'VE BEEN UTILIZING 1266 00:51:11,883 --> 00:51:14,252 TO NOT ONLY CULTIVATE A DIVERSE 1267 00:51:14,252 --> 00:51:15,954 WORKFORCE BUT FOSTERING 1268 00:51:15,954 --> 00:51:17,756 INCLUSIVE LEADERSHIP AND 1269 00:51:17,756 --> 00:51:20,158 THINKING OF WAYS TO INTEGRATE 1270 00:51:20,158 --> 00:51:21,259 EQUITY IN OUR RESEARCH PROGRAMS 1271 00:51:21,259 --> 00:51:23,862 AND DEVELOPING IMPACTFUL AND 1272 00:51:23,862 --> 00:51:29,768 SUSTAINABILITY DEIA PROGRAMS AT 1273 00:51:29,768 --> 00:51:30,302 NCATS. 1274 00:51:30,302 --> 00:51:34,806 SO EARLIER WE TALKED ABOUT THE 1275 00:51:34,806 --> 00:51:36,508 STRATEGIC PLAN AND YOU CAN SEE 1276 00:51:36,508 --> 00:51:39,978 AN OUTLINE OF NOT ONLY OUR GOALS 1277 00:51:39,978 --> 00:51:41,747 OF MORE TREATMENTS FOR ALL 1278 00:51:41,747 --> 00:51:46,284 PEOPLE MORE QUICKLY BUT A NOD IT 1279 00:51:46,284 --> 00:51:49,021 OUR TRANSLATIONAL SCIENCE 1280 00:51:49,021 --> 00:51:50,255 PRINCIPLES AND GUIDES US IN WAYS 1281 00:51:50,255 --> 00:51:51,857 TO APPROACH THE WORK TO OVERCOME 1282 00:51:51,857 --> 00:51:55,427 LONG STANDING CHALLENGES WITH 1283 00:51:55,427 --> 00:51:57,796 TRANSLATIONAL RESEARCH PIPELINE. 1284 00:51:57,796 --> 00:52:00,032 YOU CAN SEE THE EIGHT PRINCIPLES 1285 00:52:00,032 --> 00:52:00,298 DEVELOPED. 1286 00:52:00,298 --> 00:52:02,768 AND MANY LIKELY SEEM FAMILIAR TO 1287 00:52:02,768 --> 00:52:05,604 YOU, TEAM SCIENCE, BOUNDARY 1288 00:52:05,604 --> 00:52:07,139 CROSSING PARTNERSHIPS AND 1289 00:52:07,139 --> 00:52:08,006 CROSS-CUTTING SOLUTIONS BUT IF 1290 00:52:08,006 --> 00:52:10,075 YOU LOOK TO THE FAR RIGHT OF THE 1291 00:52:10,075 --> 00:52:12,711 SCREEN YOU SEE ONE AROUND 1292 00:52:12,711 --> 00:52:13,879 ADVANCING DIVERSITY, EQUITY, 1293 00:52:13,879 --> 00:52:14,513 INCLUSION AND ACCESSIBILITY IN 1294 00:52:14,513 --> 00:52:19,785 RESEARCH. 1295 00:52:19,785 --> 00:52:21,253 THAT'S GOING TO BE THE CRUX IN 1296 00:52:21,253 --> 00:52:22,654 HOW WE'RE DOING THAT AND WHAT'S 1297 00:52:22,654 --> 00:52:25,190 THAT LOOK LIKE AND HOW DOES DEIA 1298 00:52:25,190 --> 00:52:26,591 IN A SCIENTIFIC DOMAIN LOOK 1299 00:52:26,591 --> 00:52:26,792 LIKE. 1300 00:52:26,792 --> 00:52:28,527 IT GOES BEYOND JUST LOOKING AT 1301 00:52:28,527 --> 00:52:30,762 OUR WORKFORCE AND ENSURING THAT 1302 00:52:30,762 --> 00:52:31,596 IS REPRESENTATIVE AND REFLECTIVE 1303 00:52:31,596 --> 00:52:33,965 OF THE COMMUNITIES WE SERVE AND 1304 00:52:33,965 --> 00:52:36,034 THINKING ABOUT INCLUDING DIVERSE 1305 00:52:36,034 --> 00:52:39,137 PERSPECTIVES ALONG OUR RESEARCH 1306 00:52:39,137 --> 00:52:40,872 PROCESS TO ENSURE THOUGHTS AND 1307 00:52:40,872 --> 00:52:41,640 VALUES ARE HEARD. 1308 00:52:41,640 --> 00:52:44,342 IT LOOKS LIKE ENSURING A 1309 00:52:44,342 --> 00:52:45,110 WORKFORCE INCLUSIVE WHERE PEOPLE 1310 00:52:45,110 --> 00:52:47,212 FEEL THEY BELONG AND CREATING 1311 00:52:47,212 --> 00:52:48,246 SPACE FOR EXTERNAL COMMUNITY 1312 00:52:48,246 --> 00:52:50,749 PARTNERS KNOW HOW TO ACCESS 1313 00:52:50,749 --> 00:52:51,349 RESOURCES AND OPPORTUNITIES. 1314 00:52:51,349 --> 00:52:53,218 IT LOOKS LIKE ENSURING WE HAVE 1315 00:52:53,218 --> 00:52:55,987 EQUITY IN OUR PROCESSES AND 1316 00:52:55,987 --> 00:52:57,089 MAKING SURE WE ARE CREATING 1317 00:52:57,089 --> 00:52:59,925 SPACES THAT ARE FAIR FOR ALL 1318 00:52:59,925 --> 00:53:01,226 PEOPLE TO THRIVE. 1319 00:53:01,226 --> 00:53:04,729 I WANTED TO TALK ABOUT MY ROLE 1320 00:53:04,729 --> 00:53:06,565 AS THE INAUGURAL CHIEF DIVERSITY 1321 00:53:06,565 --> 00:53:07,933 OFFICER FOR MANY IT MAY BE A NEW 1322 00:53:07,933 --> 00:53:08,900 ROLE TO HELP UNDERSTAND WHAT IT 1323 00:53:08,900 --> 00:53:10,769 IS I DO IN THIS SPACE. 1324 00:53:10,769 --> 00:53:12,838 SO YOU CAN SEE ON THE SLIDE HERE 1325 00:53:12,838 --> 00:53:14,272 A NUMBER OF DIFFERENT THINGS BUT 1326 00:53:14,272 --> 00:53:16,108 REALLY WHEN IT COMES DOWN TO IT, 1327 00:53:16,108 --> 00:53:17,609 MY ROLE IS TO FOCUS ON WAYS IN 1328 00:53:17,609 --> 00:53:20,512 WHICH I CAN HARMONIZE, ELEVATE 1329 00:53:20,512 --> 00:53:23,482 AND ALIGN VARIOUS DEIA EFFORTS 1330 00:53:23,482 --> 00:53:26,284 HAPPENING NOT ONLY AT NCATS BUT 1331 00:53:26,284 --> 00:53:27,486 TO NIH AT LARGE. 1332 00:53:27,486 --> 00:53:29,521 I DO THIS BY SERVING AS A 1333 00:53:29,521 --> 00:53:31,256 THOUGHT PARTNER AND CONNECTING 1334 00:53:31,256 --> 00:53:32,924 WITH DIVISIONS AND OFFICES, 1335 00:53:32,924 --> 00:53:34,092 HELPING TO BRAIN STORM IN WAYS 1336 00:53:34,092 --> 00:53:36,495 IN WHICH WE CAN INTEGRATE 1337 00:53:36,495 --> 00:53:37,762 VARIOUS PRINCIPLES INTO THE WORK 1338 00:53:37,762 --> 00:53:38,563 STREAMS. 1339 00:53:38,563 --> 00:53:41,066 LEVERAGING DATA TO HELP INFORM 1340 00:53:41,066 --> 00:53:42,234 THE DIFFERENT INITIATIVES WE'RE 1341 00:53:42,234 --> 00:53:43,401 PUTTING FORTH AND THINKING ABOUT 1342 00:53:43,401 --> 00:53:46,338 WAYS IN WHICH WE CAN GET IN THE 1343 00:53:46,338 --> 00:53:48,039 COMMUNITY AND PROMOTE OURSELVES 1344 00:53:48,039 --> 00:53:49,641 AS AN EMPLOYEE OR AGENCY OF 1345 00:53:49,641 --> 00:53:54,146 CHOICE FOR COLLABORATION AND FOR 1346 00:53:54,146 --> 00:53:55,747 POTENTIAL WORKFORCE NEEDS. 1347 00:53:55,747 --> 00:53:56,948 SO, ON THE NEXT SLIDE WE'LL TALK 1348 00:53:56,948 --> 00:54:00,485 ABOUT THE DIFFERENT STRATEGIES 1349 00:54:00,485 --> 00:54:01,686 WE'VE BEEN DOING HOLISTICALLY 1350 00:54:01,686 --> 00:54:03,955 ACROSS THE BOARD THINKING ABOUT 1351 00:54:03,955 --> 00:54:05,390 DIVERSITY, EQUITY AND INCLUSION 1352 00:54:05,390 --> 00:54:05,991 AND ACCESSIBILITY. 1353 00:54:05,991 --> 00:54:07,626 I LOVE THIS SLIDE BECAUSE FOR ME 1354 00:54:07,626 --> 00:54:10,295 IT HELPS TAKE A STEP BACK AND 1355 00:54:10,295 --> 00:54:12,264 THINK BROADLY ABOUT ALL THE 1356 00:54:12,264 --> 00:54:14,332 DIFFERENT PLACES THIS WORK 1357 00:54:14,332 --> 00:54:14,699 INTERSECTS. 1358 00:54:14,699 --> 00:54:16,401 MOST PEOPLE WHEN THEY HEAR DEIA 1359 00:54:16,401 --> 00:54:21,640 THINK ABOUT RECRUITMENT, WHICH 1360 00:54:21,640 --> 00:54:25,410 IS A PART OF THE PRINCIPLES. 1361 00:54:25,410 --> 00:54:26,311 BUT DEIA EXPANDS BEYOND OUR 1362 00:54:26,311 --> 00:54:29,648 WORKFORCE AND RESOURCES, 1363 00:54:29,648 --> 00:54:32,150 RESEARCH, THE WAY WE ENGAGE WITH 1364 00:54:32,150 --> 00:54:32,984 EXTERNAL COMMUNITIES. 1365 00:54:32,984 --> 00:54:37,155 THE SLIDE DEMONSTRATE WHAT I 1366 00:54:37,155 --> 00:54:39,257 CALL BRIGHT IDEAS, DIVERSION, 1367 00:54:39,257 --> 00:54:40,392 INCLUSION AND EQUITY STRATEGIES. 1368 00:54:40,392 --> 00:54:42,794 YOU CAN SEE ON THE SLIDE THERE'S 1369 00:54:42,794 --> 00:54:44,763 A GAMUT OF DIFFERENT ACTIVITIES. 1370 00:54:44,763 --> 00:54:45,931 WE'LL WALK THROUGH MANY 1371 00:54:45,931 --> 00:54:46,965 THROUGHOUT THE CONVERSATION BUT 1372 00:54:46,965 --> 00:54:48,433 I WANT TO HIGHLIGHT A FEW. 1373 00:54:48,433 --> 00:54:50,068 YES, WE'RE GOING TO BE TALKING 1374 00:54:50,068 --> 00:54:52,070 ABOUT SOME OF OUR OUTREACH AND 1375 00:54:52,070 --> 00:54:53,371 ENGAGEMENT STRATEGIES AND 1376 00:54:53,371 --> 00:54:54,806 RECRUITMENT EFFORTS AND THINKING 1377 00:54:54,806 --> 00:54:56,808 ONCE WE GET PEOPLE IN THE FOLD, 1378 00:54:56,808 --> 00:55:02,314 WHAT ARE WE DOING TO GROW THEM 1379 00:55:02,314 --> 00:55:08,954 INTO LEADERS OF THE FUTURE. 1380 00:55:08,954 --> 00:55:10,088 THINKING ABOUT OUR DISPARITY 1381 00:55:10,088 --> 00:55:11,957 RESEARCH WE'RE LEADING AND HOW 1382 00:55:11,957 --> 00:55:13,625 WE'RE ENGAGING WITH THE PATIENT 1383 00:55:13,625 --> 00:55:14,092 GROUPS AND COMMUNITY 1384 00:55:14,092 --> 00:55:24,336 ORGANIZATIONS. 1385 00:55:31,409 --> 00:55:32,477 TO START TO GET PEOPLE IN THE 1386 00:55:32,477 --> 00:55:33,511 FOLD AND IN OUR WORKFORCE WE 1387 00:55:33,511 --> 00:55:40,252 WANT TO REACH OUT AND CONNECT. 1388 00:55:40,252 --> 00:55:50,729 WE'VE DONE A HUGE LIFT OUR 1389 00:56:01,473 --> 00:56:02,707 RESEARCH AND GET OUT IN THE 1390 00:56:02,707 --> 00:56:04,542 COMMUNITY AND YOU SEE A FEW I 1391 00:56:04,542 --> 00:56:07,078 WANT TO POINT OUT. 1392 00:56:07,078 --> 00:56:09,314 THESE ARE UNTAPPED AREAS WE'VE 1393 00:56:09,314 --> 00:56:11,116 BEEN REACHING OUT TO MAKE SURE 1394 00:56:11,116 --> 00:56:13,718 WE'RE POSITIONING NCATS AS A 1395 00:56:13,718 --> 00:56:14,452 MODEL EMPLOYER FOR FUTURE 1396 00:56:14,452 --> 00:56:17,022 EMPLOYEES OR STAFF MEMBERS. 1397 00:56:17,022 --> 00:56:20,225 YOU CAN SEE RECENTLY WE'VE DONE 1398 00:56:20,225 --> 00:56:22,227 ENGAGEMENTS THE PRIDE FESTIVAL 1399 00:56:22,227 --> 00:56:25,664 AND AT GALLAUDET UNIVERSITY 1400 00:56:25,664 --> 00:56:27,565 TAPPING INTO THE DEAF OR HARD OF 1401 00:56:27,565 --> 00:56:29,034 HEARING COMMUNITY AND SERVING AS 1402 00:56:29,034 --> 00:56:30,669 THOUGHT LEADERS IN THE DIVERSITY 1403 00:56:30,669 --> 00:56:33,338 SPACE, CONNECTING WITH VARIOUS 1404 00:56:33,338 --> 00:56:34,739 CHEMISTS AND CONNECTING WITH 1405 00:56:34,739 --> 00:56:36,975 DIFFERENT VENUES SUCH AS THE 1406 00:56:36,975 --> 00:56:38,810 NATIONAL URBAN LEAGUE OR THE 1407 00:56:38,810 --> 00:56:49,020 CAREER FAIR. 1408 00:56:50,655 --> 00:56:51,923 THERE'S INITIATIVES AND GETTING 1409 00:56:51,923 --> 00:56:53,091 THE NEXT GENERATION EXCITED 1410 00:56:53,091 --> 00:56:54,125 ABOUT TRANSLATIONAL SCIENCE. 1411 00:56:54,125 --> 00:56:57,362 SO WE'VE STARTED A K-12 OUTREACH 1412 00:56:57,362 --> 00:56:59,964 AND ENGAGEMENT PROGRAM THAT'S 1413 00:56:59,964 --> 00:57:00,665 ALLOWED US TO GET IN THE 1414 00:57:00,665 --> 00:57:02,300 COMMUNITY AND SHOW PEOPLE IT'S 1415 00:57:02,300 --> 00:57:03,034 OKAY TO FAIL WHILE DOING 1416 00:57:03,034 --> 00:57:03,968 RESEARCH AND GET THEM EXCITED 1417 00:57:03,968 --> 00:57:06,338 ABOUT THE IDEA OF TEAM SCIENCE 1418 00:57:06,338 --> 00:57:09,341 AND COLLABORATING WITH ONE 1419 00:57:09,341 --> 00:57:12,243 ANOTHER. 1420 00:57:12,243 --> 00:57:14,212 BEYOND RECRUITMENT WE WANT TO 1421 00:57:14,212 --> 00:57:14,846 LEVERAGE DATA TO UNDERSTAND HOW 1422 00:57:14,846 --> 00:57:18,850 WE'RE DOING. 1423 00:57:18,850 --> 00:57:22,220 AND LOOKING AT DATA ASSOCIATED 1424 00:57:22,220 --> 00:57:23,521 WITH THE WORKFORCE AND YOU SEE 1425 00:57:23,521 --> 00:57:26,324 THE RACE AND ETHNICITY DATA AND 1426 00:57:26,324 --> 00:57:31,529 SETS AND DISABILITY DATA FOR 1427 00:57:31,529 --> 00:57:31,963 STAFF. 1428 00:57:31,963 --> 00:57:34,466 THIS IS UPDATED FROM THE OFFICE 1429 00:57:34,466 --> 00:57:38,236 OF EQUITY, DIVERSITY AND 1430 00:57:38,236 --> 00:57:38,737 INCLUSION AND LOOK AT 1431 00:57:38,737 --> 00:57:39,971 INFORMATION FROM SURVEYS AND 1432 00:57:39,971 --> 00:57:42,140 FOCUS GROUPS TO UNDERSTAND HOW 1433 00:57:42,140 --> 00:57:43,041 WE'RE DOING ONCE WE UNDERSTAND 1434 00:57:43,041 --> 00:57:45,343 HOW OUR STAFF IS HERE. 1435 00:57:45,343 --> 00:57:47,245 WE'RE WORKING DILIGENTLY TO 1436 00:57:47,245 --> 00:57:51,349 DEVELOP A RECRUITMENT AND HIRING 1437 00:57:51,349 --> 00:57:52,884 TOOLKIT TO MAKE SURE WE'RE 1438 00:57:52,884 --> 00:57:54,018 BAKING IN EQUITY THROUGHOUT THE 1439 00:57:54,018 --> 00:57:55,120 PROCESSES AND EXPANDING THE POOL 1440 00:57:55,120 --> 00:58:00,291 OF POTENTIAL APPLICANTS. 1441 00:58:00,291 --> 00:58:02,761 AND LEVERAGING THINGS LIKE AND 1442 00:58:02,761 --> 00:58:04,362 HOW THEY PERCEIVE WE'RE DOING 1443 00:58:04,362 --> 00:58:06,331 AND IF IT'S AN ORGANIZATION OF 1444 00:58:06,331 --> 00:58:07,332 CHOICE AND HOW WE'RE DOING IN 1445 00:58:07,332 --> 00:58:17,709 THE IMPLEMENTATIONEST. 1446 00:58:18,209 --> 00:58:21,646 AND ALL THE SEMINARS WE LISTED 1447 00:58:21,646 --> 00:58:24,249 AND I'LL POINT TO WHAT THEY'RE 1448 00:58:24,249 --> 00:58:26,151 REPRESENTING ARE BASED OFF 1449 00:58:26,151 --> 00:58:28,753 FEEDBACK WE SAW IN THINGS LIKE 1450 00:58:28,753 --> 00:58:29,821 OUR FEDERAL EMPLOYEE VIEW POINT 1451 00:58:29,821 --> 00:58:31,022 SURVEY AND THINGS WE'RE SEEING 1452 00:58:31,022 --> 00:58:37,328 FROM OUR STAFF OF POTENTIAL 1453 00:58:37,328 --> 00:58:38,997 OPPORTUNITIES AND TRAIN TO THE 1454 00:58:38,997 --> 00:58:42,367 TRAINERS SESSIONS IN MIC 1455 00:58:42,367 --> 00:58:46,404 MICROAGGRESSIONS TO GETTING 1456 00:58:46,404 --> 00:58:47,639 STAFF COMFORTABLE AND CONTENT ON 1457 00:58:47,639 --> 00:58:50,308 THE TOPIC. 1458 00:58:50,308 --> 00:58:52,143 WE PARTNERED WITH THE DIVERSITY, 1459 00:58:52,143 --> 00:58:54,212 EQUITY AND INCLUSION OFFICE TO 1460 00:58:54,212 --> 00:58:55,079 EXPLORE ACCESSIBILITY REALIZING 1461 00:58:55,079 --> 00:58:56,981 AN AREA OF OPPORTUNITY TO 1462 00:58:56,981 --> 00:58:58,082 UNDERSTAND HOW TO IMPLEMENT 1463 00:58:58,082 --> 00:59:00,819 COMPLIANCE INTO YOUR WORK 1464 00:59:00,819 --> 00:59:02,320 PRODUCTS AND DIGITAL 1465 00:59:02,320 --> 00:59:02,654 ACCESSIBILITY. 1466 00:59:02,654 --> 00:59:04,055 ON THE FAR RIGHT YOU SEE SOME OF 1467 00:59:04,055 --> 00:59:06,324 THE GROUND WORK WE'VE BEEN DOING 1468 00:59:06,324 --> 00:59:07,125 AND HELPING PEOPLE UNDERSTAND 1469 00:59:07,125 --> 00:59:08,927 SYSTEMIC BARRIERS THAT HAVE 1470 00:59:08,927 --> 00:59:10,829 CHALLENGED US IN THE SPACE AND 1471 00:59:10,829 --> 00:59:12,197 HELPING PEOPLE GROW AND 1472 00:59:12,197 --> 00:59:14,332 UNDERSTAND AND BECOMING MORE 1473 00:59:14,332 --> 00:59:24,642 ENGAGED EMPLOYEES. 1474 00:59:42,160 --> 00:59:43,695 COUNCIL IS MADE UP OF 1475 00:59:43,695 --> 00:59:44,963 REPRESENTATION FOCUSSED ON 1476 00:59:44,963 --> 00:59:45,830 INITIATIVES TO ADVANCE DEIA 1477 00:59:45,830 --> 00:59:47,732 THROUGH VARIOUS WORKING GROUPS 1478 00:59:47,732 --> 00:59:49,133 AND WE HAVE OUR EMPLOYEE 1479 00:59:49,133 --> 00:59:50,768 ENGAGEMENT COMMITTEE FOCUSSED ON 1480 00:59:50,768 --> 00:59:51,536 CREATING POSITIVE WORK BY 1481 00:59:51,536 --> 00:59:54,038 CULTURE THROUGH A VARIETY OF 1482 00:59:54,038 --> 00:59:54,539 ACTIVITIES LIKE NCATS 1483 00:59:54,539 --> 00:59:57,442 ASSOCIATION WHICH IS COMING UP 1484 00:59:57,442 --> 00:59:58,910 SOON AND PROFESSIONAL 1485 00:59:58,910 --> 01:00:01,112 DEVELOPMENT THROUGH OUR BACK 1486 01:00:01,112 --> 01:00:11,556 CLUBS AND SEMINAR SERIES. 1487 01:00:19,531 --> 01:00:21,199 AND THE ASSISTANT COMMITTEE 1488 01:00:21,199 --> 01:00:24,202 FOCUSSED ON FOSTERING INCLUSIVE 1489 01:00:24,202 --> 01:00:25,837 WORKPLACE FOR MEMBERS TO BRAIN 1490 01:00:25,837 --> 01:00:29,007 STORM ON IDEAS AND COME UP WITH 1491 01:00:29,007 --> 01:00:29,574 COLLABORATIVE SOLUTIONS FOR 1492 01:00:29,574 --> 01:00:31,109 THEIR WORK PROFILES. 1493 01:00:31,109 --> 01:00:33,311 AND THE LAST PIECE I WANTED TO 1494 01:00:33,311 --> 01:00:35,780 HIGHLIGHT ARE SOME OF THE THINGS 1495 01:00:35,780 --> 01:00:38,283 WE'RE DOING IN CONTRIBUTIONS TO 1496 01:00:38,283 --> 01:00:38,716 THE LITERATURE. 1497 01:00:38,716 --> 01:00:40,718 FROM VARIOUS STAFF MEMBERS WE 1498 01:00:40,718 --> 01:00:46,324 HAD JOURNAL ARTICLES PUBLISHED. 1499 01:00:46,324 --> 01:00:47,525 . 1500 01:00:47,525 --> 01:00:50,895 . 1501 01:00:50,895 --> 01:00:54,198 OPINION PIECES AND AN ARTICLE 1502 01:00:54,198 --> 01:00:54,966 THAT HIGHLIGHTS STRATEGIES 1503 01:00:54,966 --> 01:00:57,201 AROUND WAYS IN WHICH TO 1504 01:00:57,201 --> 01:00:58,169 INTEGRATE DEIA IN THE 1505 01:00:58,169 --> 01:00:59,871 TRANSLATIONAL SCIENCE SPECTRUM 1506 01:00:59,871 --> 01:01:02,373 AND A MORE RECENT -- WELL, END 1507 01:01:02,373 --> 01:01:08,112 OF LAST YEAR AN ARTICLE THAT WAS 1508 01:01:08,112 --> 01:01:09,781 AUTHORED EXPLORING SICKLE CELL 1509 01:01:09,781 --> 01:01:11,449 DISEASE AND IMPLICATION AROUND 1510 01:01:11,449 --> 01:01:13,518 THAT DISEASE AND FUTURE 1511 01:01:13,518 --> 01:01:13,785 DISEASES. 1512 01:01:13,785 --> 01:01:16,154 YOU CAN SEE WE'RE APPROACHING 1513 01:01:16,154 --> 01:01:18,923 DEIA FROM SO MANY FACETS IN THE 1514 01:01:18,923 --> 01:01:19,257 ORGANIZATION. 1515 01:01:19,257 --> 01:01:21,793 AND SO I'VE GIVEN YOU A SNAPSHOT 1516 01:01:21,793 --> 01:01:23,094 OF WHERE WE'VE BEEN AND WHAT 1517 01:01:23,094 --> 01:01:24,829 WE'RE DOING AND NOW I WANT TO 1518 01:01:24,829 --> 01:01:27,131 TALK ABOUT WHERE WE'RE GOING. 1519 01:01:27,131 --> 01:01:28,600 IN ORDER TO BE SUSTAINABLE IN 1520 01:01:28,600 --> 01:01:29,634 THE SPACE IT'S IMPORTANT TO 1521 01:01:29,634 --> 01:01:32,737 LEVERAGE THE OUTPUT FROM THE 1522 01:01:32,737 --> 01:01:34,339 STRATEGIC PLAN AS A LAUNCHING 1523 01:01:34,339 --> 01:01:36,674 PAD FOR WHAT WE'LL BE DOING IN 1524 01:01:36,674 --> 01:01:37,976 THIS DEIA REALM. 1525 01:01:37,976 --> 01:01:40,578 SO OVER THE LAST YEAR WE SPENT A 1526 01:01:40,578 --> 01:01:43,314 LOT OF TIME GATHERING 1527 01:01:43,314 --> 01:01:44,716 INFORMATION EXPLORING DIFFERENT 1528 01:01:44,716 --> 01:01:46,217 DATA SOURCES EMPOWERING OUR 1529 01:01:46,217 --> 01:01:48,786 LEADERS AND SUPERVISORS TO BE 1530 01:01:48,786 --> 01:01:50,088 EQUIPPED IN THE SPACE AND NOW 1531 01:01:50,088 --> 01:01:51,623 POSITIONED TO DEVELOP A ROAD MAP 1532 01:01:51,623 --> 01:01:53,925 THAT'S GOING TO OUTLINE THINGS 1533 01:01:53,925 --> 01:01:58,162 WE'RE DOING IN THIS SPACE THAT 1534 01:01:58,162 --> 01:02:00,798 WILL SPECIFICALLY FOCUS ON OUR 1535 01:02:00,798 --> 01:02:02,300 ORGANIZATIONAL CAN CULTURE AND 1536 01:02:02,300 --> 01:02:04,602 RELATING THAT TO OUR DEIA 1537 01:02:04,602 --> 01:02:05,637 EFFORTS. 1538 01:02:05,637 --> 01:02:08,539 IN THE ROAD MAP WHICH IS AN 1539 01:02:08,539 --> 01:02:10,241 EARLY OUTPUT OF OUR STRATEGIC 1540 01:02:10,241 --> 01:02:12,243 PLANS WE'LL OUTLINE PILLARS AND 1541 01:02:12,243 --> 01:02:13,845 OBJECTIVES WE'LL FOCUS ON IN THE 1542 01:02:13,845 --> 01:02:14,812 NEXT COUPLE YEARS AS WELL AS 1543 01:02:14,812 --> 01:02:17,782 STRATEGIES AND ACTIONS WE CAN 1544 01:02:17,782 --> 01:02:21,586 USE DURING THE IMPLEMENTATION 1545 01:02:21,586 --> 01:02:22,320 PHASE. 1546 01:02:22,320 --> 01:02:24,689 WE GATHERED DATA FROM DIFFERENT 1547 01:02:24,689 --> 01:02:24,922 SOURCES. 1548 01:02:24,922 --> 01:02:26,991 I'VE BEEN ON BOARD ALMOST A 1549 01:02:26,991 --> 01:02:27,191 YEAR. 1550 01:02:27,191 --> 01:02:29,427 I'VE HAD MORE THAN 95 MEET AND 1551 01:02:29,427 --> 01:02:33,031 GREETS, CONVERSATIONS, REALLY 1552 01:02:33,031 --> 01:02:34,132 TRYING TO UNDERSTAND THE 1553 01:02:34,132 --> 01:02:35,400 LANDSCAPE WE'VE HAD ASSESSMENTS 1554 01:02:35,400 --> 01:02:36,968 DONE AND SURVEY DATA AND HAVE 1555 01:02:36,968 --> 01:02:38,302 BEEN ABLE TO COME UP WITH 1556 01:02:38,302 --> 01:02:40,405 PROPOSED PILLARS FOR OUR ROAD 1557 01:02:40,405 --> 01:02:40,672 MAP. 1558 01:02:40,672 --> 01:02:42,774 KEEPING IN MIND OUR NORTH STAR 1559 01:02:42,774 --> 01:02:44,308 OF THAT MORE TREATMENTS FOR MORE 1560 01:02:44,308 --> 01:02:45,677 PEOPLE MORE QUICKLY. 1561 01:02:45,677 --> 01:02:48,146 ON THE SCREEN YOU CAN SEE OUR 1562 01:02:48,146 --> 01:02:49,113 FOUR COMPOSED PILLARS FOR OUR 1563 01:02:49,113 --> 01:02:49,614 ROAD MAP. 1564 01:02:49,614 --> 01:02:52,216 YOU CAN SEE AGAIN THEY FOCUS NOT 1565 01:02:52,216 --> 01:02:53,251 ONLY ON OUR WORKFORCE BUT 1566 01:02:53,251 --> 01:02:54,385 EVERYTHING WE DO. 1567 01:02:54,385 --> 01:02:56,554 THE FIRST PILLAR IS AROUND 1568 01:02:56,554 --> 01:02:58,923 CULTIVATING A DIVERSE AND 1569 01:02:58,923 --> 01:03:00,158 INCLUSIVE AND REPRESENTATIVE 1570 01:03:00,158 --> 01:03:02,126 WORKFORCE TO ACHIEVE THE NCATS 1571 01:03:02,126 --> 01:03:02,360 MISSION. 1572 01:03:02,360 --> 01:03:04,429 IN THE SECOND PILLAR WE'RE GOING 1573 01:03:04,429 --> 01:03:05,797 BEYOND GETTING PEOPLE HERE BUT 1574 01:03:05,797 --> 01:03:07,365 THINKING HOW TO CREATE AN 1575 01:03:07,365 --> 01:03:09,200 ENVIRONMENT THAT'S SAFE AND 1576 01:03:09,200 --> 01:03:09,934 WELCOMING SO PEOPLE KNOW THEY 1577 01:03:09,934 --> 01:03:13,838 BELONG AND HAVE THE ABILITY TO 1578 01:03:13,838 --> 01:03:14,439 GROW WITHIN THE ORGANIZATION. 1579 01:03:14,439 --> 01:03:15,840 THE THIRD PILLAR IS FOCUSSING ON 1580 01:03:15,840 --> 01:03:16,507 OUR RESEARCH. 1581 01:03:16,507 --> 01:03:18,142 WE'LL HEAR A LOT ABOUT THE 1582 01:03:18,142 --> 01:03:20,278 EFFORTS WE'RE DOING IN THE 1583 01:03:20,278 --> 01:03:22,613 RESEARCH SHORTLY BUT HERE WE'RE 1584 01:03:22,613 --> 01:03:23,915 LOOKING TO INVEST AND SUPPORT 1585 01:03:23,915 --> 01:03:26,317 RESEARCH AREAS AND INITIATIVES 1586 01:03:26,317 --> 01:03:30,288 THAT REDUCE HEALTH INEQUITIES 1587 01:03:30,288 --> 01:03:32,123 AND THE FINAL PILLAR IS ON 1588 01:03:32,123 --> 01:03:32,957 RESOURCES FUNDING OPPORTUNITIES 1589 01:03:32,957 --> 01:03:35,393 AND DATABASES AND ENSURING USING 1590 01:03:35,393 --> 01:03:36,961 THEM TO ENGAGE COMMUNITIES, 1591 01:03:36,961 --> 01:03:38,830 RAISE AWARENESS AND SUPPORT 1592 01:03:38,830 --> 01:03:41,733 INNOVATION ACROSS OUR ENTIRE 1593 01:03:41,733 --> 01:03:43,334 TRANSLATIONAL SCIENCE SPECTRUM. 1594 01:03:43,334 --> 01:03:44,669 SO WE'VE BEEN REALLY EXCITED 1595 01:03:44,669 --> 01:03:46,771 WITH THE ENGAGEMENT WE'VE BEEN 1596 01:03:46,771 --> 01:03:48,573 ABLE TO HAVE OVER THE LAST FEW 1597 01:03:48,573 --> 01:03:51,175 MONTHS WITH STAFF AS WE'RE 1598 01:03:51,175 --> 01:03:52,276 BUILDING, CO-CREATE THE ROAD MAP 1599 01:03:52,276 --> 01:03:55,847 AND OBJECTIVES AND PILLARS THAT 1600 01:03:55,847 --> 01:03:56,681 WILL BE REPRESENTED. 1601 01:03:56,681 --> 01:03:58,316 SO WE'RE GOING TO BE PUTTING 1602 01:03:58,316 --> 01:04:02,720 THAT OUT BY END OF FIRST QUARTER 1603 01:04:02,720 --> 01:04:05,823 OF FY25. 1604 01:04:05,823 --> 01:04:06,157 SO STAY TUNED. 1605 01:04:06,157 --> 01:04:07,592 THE LAST THING I WANT TO TALK 1606 01:04:07,592 --> 01:04:09,327 ABOUT BEFORE HANDING IT OVER TO 1607 01:04:09,327 --> 01:04:10,528 MY COUNTERPART IS TO TALK A 1608 01:04:10,528 --> 01:04:11,395 LITTLE BIT ABOUT ONE OTHER THING 1609 01:04:11,395 --> 01:04:11,996 YOU'LL FIND IN THE STRATEGIC 1610 01:04:11,996 --> 01:04:22,106 PLAN. 1611 01:04:23,941 --> 01:04:29,347 WE NOW HAVE CORE VALUES IN THE 1612 01:04:29,347 --> 01:04:30,815 STRATEGIC PLAN. 1613 01:04:30,815 --> 01:04:35,386 THEY HELP AND HOW TO ENGAGE WITH 1614 01:04:35,386 --> 01:04:35,853 EXTERNAL PARTNERS. 1615 01:04:35,853 --> 01:04:38,322 I LOVE THE GRAPHIC BECAUSE IT 1616 01:04:38,322 --> 01:04:45,329 HELPS CONNECT ALL THE WORK IN 1617 01:04:45,329 --> 01:04:46,597 THE STRATEGIC PLAN AND WILL HELP 1618 01:04:46,597 --> 01:04:51,869 DRIVE US AS WE'RE DEVELOPING THE 1619 01:04:51,869 --> 01:05:02,380 ROAD MAP YOU CAN SEE THE TEAM 1620 01:05:23,334 --> 01:05:25,269 SCIENCE AND COLLABORATION AND 1621 01:05:25,269 --> 01:05:27,004 INNOVATION AND CREATIVITY AND 1622 01:05:27,004 --> 01:05:29,974 GENERALIZABLE SOLUTIONS AND 1623 01:05:29,974 --> 01:05:31,142 INTEGRITY AND DIVERSITY, 1624 01:05:31,142 --> 01:05:37,882 INCLUSION AND ACCESSIBILITY AND 1625 01:05:37,882 --> 01:05:38,382 LOCK 1626 01:05:38,382 --> 01:05:38,683 OUR VISION. 1627 01:05:38,683 --> 01:05:40,651 AS I GET READY TO HAND IT OVER 1628 01:05:40,651 --> 01:05:44,522 I'LL CLOSE IT UP WITH ONE OF MY 1629 01:05:44,522 --> 01:05:45,189 FAVORITE SLIDES BECAUSE THE 1630 01:05:45,189 --> 01:05:46,958 BRINGS TOGETHER THE IDEAS OF 1631 01:05:46,958 --> 01:05:50,161 DIVERSITY, EQUITY, INCLUSION, 1632 01:05:50,161 --> 01:05:51,562 ACCESSIBILITY AND HOW THEY CAN 1633 01:05:51,562 --> 01:05:52,930 LEAD TO BELONGING BUT TALKING 1634 01:05:52,930 --> 01:05:54,098 ABOUT EVERYTHING THAT IS GOING 1635 01:05:54,098 --> 01:05:55,233 TO BE NECESSARY TO BE 1636 01:05:55,233 --> 01:05:55,766 SUSTAINABILITY. 1637 01:05:55,766 --> 01:05:57,101 IT'S GOING TO TAKE US -- 1638 01:05:57,101 --> 01:05:57,869 CONTINUE TO HAVE CONVERSATIONS 1639 01:05:57,869 --> 01:05:59,904 LIKE THIS AND INTEGRATING IT 1640 01:05:59,904 --> 01:06:02,673 INTO OUR ORGANIZATIONAL FABRIC. 1641 01:06:02,673 --> 01:06:03,975 HAVING LEADERS WILLING TO LEAD 1642 01:06:03,975 --> 01:06:06,510 BY EXAMPLE AND BE TRANSPARENT 1643 01:06:06,510 --> 01:06:08,179 ALONG THE WAY AND PRIMARILY ONE 1644 01:06:08,179 --> 01:06:09,313 OF THE BIGGEST THINGS IS GRACE 1645 01:06:09,313 --> 01:06:11,382 AS WE'RE GOING THROUGH THIS 1646 01:06:11,382 --> 01:06:11,582 SPACE. 1647 01:06:11,582 --> 01:06:13,651 WE NEED TO LEND EACH OTHER GRACE 1648 01:06:13,651 --> 01:06:15,319 TO REALLY BE WORKING TOWARDS 1649 01:06:15,319 --> 01:06:16,687 CREATING THE SPACE WHERE WE HAVE 1650 01:06:16,687 --> 01:06:18,322 COMMUNITY AND BELONGING. 1651 01:06:18,322 --> 01:06:20,324 SO I HOPE AS I'VE SET THE STAGE 1652 01:06:20,324 --> 01:06:22,126 FOR SOME OF THE VARIOUS THINGS 1653 01:06:22,126 --> 01:06:24,729 WE'VE BEEN DOING IN DEIA ACROSS 1654 01:06:24,729 --> 01:06:31,235 NCATS I'VE HELPED TO OPEN YOUR 1655 01:06:31,235 --> 01:06:33,204 APERTURE FOR LOOKING AT IT AS A 1656 01:06:33,204 --> 01:06:35,573 THING AS A WAY OF THINKING AND 1657 01:06:35,573 --> 01:06:36,941 IT TOUCHES EVERYTHING WE DO 1658 01:06:36,941 --> 01:06:37,775 WITHIN OUR ORGANIZATION. 1659 01:06:37,775 --> 01:06:39,143 WITH THAT I LOOK FORWARD TO 1660 01:06:39,143 --> 01:06:40,778 QUESTIONS YOU MIGHT HAVE BUT 1661 01:06:40,778 --> 01:06:42,813 HAND IT OVER TO DR. HAUGABOOK 1662 01:06:42,813 --> 01:06:43,915 FOR HER PRESENTATION ABOUT WHAT 1663 01:06:43,915 --> 01:06:44,782 SHE'S DOING IN THE PRECLINICAL 1664 01:06:44,782 --> 01:06:44,982 SPACE. 1665 01:06:44,982 --> 01:06:55,293 THANK YOU SO MUCH. 1666 01:07:17,114 --> 01:07:21,319 >> I'M DR. SHARRIE HAUGABOOK AND 1667 01:07:21,319 --> 01:07:25,056 THE ACTING HEAD OVER SCIENTIFIC 1668 01:07:25,056 --> 01:07:26,924 MANAGEMENT GROUP IN THE 1669 01:07:26,924 --> 01:07:28,526 THERAPEUTIC DEVELOPMENT BRANCH. 1670 01:07:28,526 --> 01:07:30,061 MAY I JUST ASK FOR MY NOTES, 1671 01:07:30,061 --> 01:07:40,204 PLEASE? 1672 01:08:21,078 --> 01:08:28,919 >> THANK YOU. 1673 01:08:28,919 --> 01:08:32,289 FIRST A PARALLEL FOR BIO MEDICAL 1674 01:08:32,289 --> 01:08:34,325 LEADER RESEARCH PERSPECTIVE. 1675 01:08:34,325 --> 01:08:38,329 PROVIDE A BROAD OVERVIEW IN THE 1676 01:08:38,329 --> 01:08:39,363 BIOMEDICAL RESEARCH ENTERPRISE 1677 01:08:39,363 --> 01:08:41,399 AND WHY ADVANCING EQUITY AT THAT 1678 01:08:41,399 --> 01:08:45,336 STAGE WE CONDUCT RESEARCH 1679 01:08:45,336 --> 01:08:47,872 EQUALLY IMPORTANT FOLLOWED BY 1680 01:08:47,872 --> 01:08:58,249 WHAT WHAT WE'RE DOING. 1681 01:09:03,788 --> 01:09:05,389 FIRST LET'S WHAT IS DEPICTED. 1682 01:09:05,389 --> 01:09:08,159 IT SHOWS A BASEBALL GAME WITH 1683 01:09:08,159 --> 01:09:09,293 ONLOOKERS OF DIFFERENT TYPES 1684 01:09:09,293 --> 01:09:11,829 PEERING OVER A FENCE. 1685 01:09:11,829 --> 01:09:14,432 THE SCENERY CHANGES FROM REALITY 1686 01:09:14,432 --> 01:09:17,935 TO EQUALITY TO EQUITY AND THEN 1687 01:09:17,935 --> 01:09:28,412 JUSTICE AS THE BOXES DIFFER. 1688 01:09:52,603 --> 01:09:53,771 ADVANCING EQUITY LEADS TO 1689 01:09:53,771 --> 01:09:56,607 JUSTICE. 1690 01:09:56,607 --> 01:09:57,641 THAT'S WHEN ALL THE SUPPORTS ARE 1691 01:09:57,641 --> 01:10:01,178 THERE AND YOU DON'T NEED THAT TO 1692 01:10:01,178 --> 01:10:05,783 SEE THE GAME IN THE CASE. 1693 01:10:05,783 --> 01:10:08,419 IN THE CONTEXT OF BIOMEDICAL 1694 01:10:08,419 --> 01:10:11,155 RESEARCH THERE'S A SIMILAR 1695 01:10:11,155 --> 01:10:11,455 PERSPECTIVE. 1696 01:10:11,455 --> 01:10:12,623 IN THE ADAPTATION THE DIFFERENT 1697 01:10:12,623 --> 01:10:14,358 COLORS REPRESENT THE FOUNDATION 1698 01:10:14,358 --> 01:10:15,326 OF SCIENTIFIC EFFECTIVENESS AND 1699 01:10:15,326 --> 01:10:20,931 PROGRESS. 1700 01:10:20,931 --> 01:10:26,036 THEY ARE RESEARCH CAPACITY AND S 1701 01:10:26,036 --> 01:10:30,341 AND PRESTIGE OR PRIVILEGE OR 1702 01:10:30,341 --> 01:10:31,842 YELLOW AND OPEN SCIENCE 1703 01:10:31,842 --> 01:10:32,710 PRACTICES IN GREEN. 1704 01:10:32,710 --> 01:10:36,947 THE BOX REPRESENT ACCESS AND 1705 01:10:36,947 --> 01:10:39,717 AVAILABILITY TO THE RESOURCE AND 1706 01:10:39,717 --> 01:10:41,519 DISTRIBUTION VARIED BY HIGH, 1707 01:10:41,519 --> 01:10:46,824 MIDDLE OR LOW RESOURCE 1708 01:10:46,824 --> 01:10:47,158 INSTITUTIONS. 1709 01:10:47,158 --> 01:10:57,701 THE IS WHERE EFFECTIVENESS MEANS 1710 01:10:58,536 --> 01:10:58,736 SOCIETAL. 1711 01:10:58,736 --> 01:10:59,737 FOR US THAT'S IN THE PUBLIC 1712 01:10:59,737 --> 01:11:01,805 HEALTH AND COMES AS A RESULT OF 1713 01:11:01,805 --> 01:11:03,974 RESEARCH FINDINGS AND BEING ABLE 1714 01:11:03,974 --> 01:11:05,376 TO MAKE RESEARCH OUTPUT 1715 01:11:05,376 --> 01:11:07,144 AVAILABLE TO OTHERS INCLUDING 1716 01:11:07,144 --> 01:11:07,945 THOSE FOR WHOM THE RESEARCH IS 1717 01:11:07,945 --> 01:11:10,781 CONDUCTED. 1718 01:11:10,781 --> 01:11:13,784 ADDING TO THE AUTHOR'S 1719 01:11:13,784 --> 01:11:15,653 INTERPRETATION, I'D LIKE TO ADD 1720 01:11:15,653 --> 01:11:16,554 THE GRAY FENCE ALSO REPRESENTS 1721 01:11:16,554 --> 01:11:19,557 TRANSPARENCY. 1722 01:11:19,557 --> 01:11:22,226 AND FROM AN ADVANCING EQUITY 1723 01:11:22,226 --> 01:11:26,297 PERSPECTIVE IF THERE'S A LACK OF 1724 01:11:26,297 --> 01:11:27,331 TRANSPARENCY HOW CAN ONE CHANGE 1725 01:11:27,331 --> 01:11:29,400 THE DISTRIBUTION OF WHAT THE BOX 1726 01:11:29,400 --> 01:11:31,835 REPRESENT TO RISE ABOVE THE 1727 01:11:31,835 --> 01:11:33,170 THRESHOLD AND BE EFFECTIVE ON 1728 01:11:33,170 --> 01:11:36,073 YOUR RESEARCH AND HAVE AN IMPACT 1729 01:11:36,073 --> 01:11:38,709 ON PUBLIC HEALTH. 1730 01:11:38,709 --> 01:11:40,311 SO, WHEN THE CONVERSATIONS 1731 01:11:40,311 --> 01:11:43,414 DIVERT TO EQUITY AND DISPARITIES 1732 01:11:43,414 --> 01:11:45,950 IN BIOMEDICAL RESEARCH, THE LENS 1733 01:11:45,950 --> 01:11:49,386 TEND TO FOCUS WHERE THERE IS 1734 01:11:49,386 --> 01:11:51,288 MORE PATIENT OR RESEARCH 1735 01:11:51,288 --> 01:11:55,459 PARTICIPANTS INTERACTION. 1736 01:11:55,459 --> 01:11:57,328 HOWEVER, IT IS IMPORTANT TO 1737 01:11:57,328 --> 01:12:01,699 UNDERSTAND THAT ADVANCING EQUITY 1738 01:12:01,699 --> 01:12:03,567 IS NOT CONSEQUENTIAL IN THE 1739 01:12:03,567 --> 01:12:06,904 CLINICAL AND RESEARCH REALM FOR 1740 01:12:06,904 --> 01:12:08,239 DISPARITIES BUT IN THE BASIC 1741 01:12:08,239 --> 01:12:09,340 PRECLINICAL AND TRANSLATIONAL 1742 01:12:09,340 --> 01:12:12,543 SPACE. 1743 01:12:12,543 --> 01:12:17,314 IT IS CRITICAL TO IDENTIFY 1744 01:12:17,314 --> 01:12:18,449 OPPORTUNITIES ALONG AND WITHIN 1745 01:12:18,449 --> 01:12:20,718 THAT THERAPEUTIC DEVELOPMENT 1746 01:12:20,718 --> 01:12:21,418 PIPELINE TO POSITION AND 1747 01:12:21,418 --> 01:12:24,221 IMPLEMENT DEEPER STRATEGIES. 1748 01:12:24,221 --> 01:12:26,590 SO WHAT SPACE ARE WE TALKING 1749 01:12:26,590 --> 01:12:26,957 ABOUT? 1750 01:12:26,957 --> 01:12:29,026 THIS IS ONE ILLUSTRATION OF THE 1751 01:12:29,026 --> 01:12:29,660 CONTINUUM OF THE BIOMEDICAL 1752 01:12:29,660 --> 01:12:31,028 RESEARCH ENVIRONMENT. 1753 01:12:31,028 --> 01:12:31,195 ALL OF 1754 01:12:35,299 --> 01:12:38,168 DPI BETWEEN THE BOOK ENDS OF 1755 01:12:38,168 --> 01:12:40,404 HEALTH CARE DELIVERY AND 1756 01:12:40,404 --> 01:12:42,439 CLINICAL RESEARCH AND TDB 1757 01:12:42,439 --> 01:12:51,949 OCCUPIES THE PRE CLINICAL SPACE 1758 01:12:51,949 --> 01:12:54,318 WITH VARIATION LINES ON OTHER 1759 01:12:54,318 --> 01:12:57,721 END. 1760 01:12:57,721 --> 01:13:00,858 AND WHAT COMES THROUGH 1761 01:13:00,858 --> 01:13:01,992 COLLABORATIVE PARTNERSHIPS. 1762 01:13:01,992 --> 01:13:05,496 TO THE EXTENT WE'RE PART OF THE 1763 01:13:05,496 --> 01:13:06,563 ECO SYSTEM WE NEED TO BE 1764 01:13:06,563 --> 01:13:09,500 COGNIZANT HOW WE ENDEAVOR TO 1765 01:13:09,500 --> 01:13:14,204 ENGAGE AND STRIVE TO BE MORE 1766 01:13:14,204 --> 01:13:15,406 EQUITABLE WITH OUR COLLABORATION 1767 01:13:15,406 --> 01:13:16,540 PARTNERS AND ON THE PROJECTS WE 1768 01:13:16,540 --> 01:13:19,810 UNDERTAKE. 1769 01:13:19,810 --> 01:13:23,414 SO, WHAT DO WE DO? 1770 01:13:23,414 --> 01:13:26,684 WE ENGAGE THE HEALTH OPERATED TO 1771 01:13:26,684 --> 01:13:28,552 WORK WITH US TO DEVELOP AN 1772 01:13:28,552 --> 01:13:31,655 APPROACH TO EQUITY INTO THE 1773 01:13:31,655 --> 01:13:32,656 PRECLINICAL THERAPEUTIC 1774 01:13:32,656 --> 01:13:35,826 DEVELOPMENT SPACE UTILIZING RARE 1775 01:13:35,826 --> 01:13:38,662 DISEASES AS AN APPROACH 1776 01:13:38,662 --> 01:13:40,064 CONSISTING OF FIVE STEPS I'VE 1777 01:13:40,064 --> 01:13:44,435 SUMMARIZED IN THE CHEVRON. 1778 01:13:44,435 --> 01:13:45,903 DEVELOP AN ACTION PLAN. 1779 01:13:45,903 --> 01:13:47,338 EXPLORE THROUGH AN ENVIRONMENT 1780 01:13:47,338 --> 01:13:48,872 STAND, APPLY CRITICAL EQUITY 1781 01:13:48,872 --> 01:13:54,311 LENS TO THE POINTS OF ENGAGEMENT 1782 01:13:54,311 --> 01:13:57,948 IN TDB AND IMPLEMENT THE 1783 01:13:57,948 --> 01:13:58,315 RECOMMENDATIONS. 1784 01:13:58,315 --> 01:13:59,049 IT'S IMPORTANT TO UNDERSTAND 1785 01:13:59,049 --> 01:14:03,120 THIS IS NOT A ONE AND DONE. 1786 01:14:03,120 --> 01:14:06,323 STEPS 3-5 ARE INTENDED TO BE I 1787 01:14:06,323 --> 01:14:08,892 APROCESS OF ENGAGING, REVIVING 1788 01:14:08,892 --> 01:14:10,661 AND LEARNING TO TRULY COMMIT TO 1789 01:14:10,661 --> 01:14:16,800 ADVANCING EQUITY. 1790 01:14:16,800 --> 01:14:20,738 THIS THE OUTPUT PRODUCES SEVERAL 1791 01:14:20,738 --> 01:14:21,338 FINDINGS. 1792 01:14:21,338 --> 01:14:22,639 THE REMAINDER OF THE 1793 01:14:22,639 --> 01:14:24,441 PRESENTATION IS THE HIGH LEVEL 1794 01:14:24,441 --> 01:14:26,076 ACTIONS OUTLINED IN ORANGE WE'RE 1795 01:14:26,076 --> 01:14:27,311 WORKING ON IN RESPONSE TO THE 1796 01:14:27,311 --> 01:14:30,814 RECOMMENDATIONS. 1797 01:14:30,814 --> 01:14:31,982 AND THEY ARE THE EVALUATION 1798 01:14:31,982 --> 01:14:33,350 PROCESS FOR A NEW PROJECT, 1799 01:14:33,350 --> 01:14:34,318 COLLABORATIONS, ENGAGE THE 1800 01:14:34,318 --> 01:14:39,323 COMMUNITY AND SHARE KNOWLEDGE. 1801 01:14:39,323 --> 01:14:40,391 AND FOR THE FIRST ACTION WHICH 1802 01:14:40,391 --> 01:14:45,329 IS TO APPLY AN EQUITY LENS IN 1803 01:14:45,329 --> 01:14:46,997 THE EVALUATION PROCESS FOR 1804 01:14:46,997 --> 01:14:47,431 COLLABORATION. 1805 01:14:47,431 --> 01:14:49,433 THE FINDING IS DISEASES 1806 01:14:49,433 --> 01:14:54,304 AFFECTING UNDER SERVED 1807 01:14:54,304 --> 01:14:56,340 POPULATIONS STRUGGLE TO FIND TO 1808 01:14:56,340 --> 01:14:57,141 ATTRACT RESOURCES OR 1809 01:14:57,141 --> 01:14:58,308 INSTITUTIONAL SUPPORT FOR 1810 01:14:58,308 --> 01:15:01,545 PRECLINICAL DEVELOPMENT. 1811 01:15:01,545 --> 01:15:07,184 THE RECOMMENDATION IS TO AUGMENT 1812 01:15:07,184 --> 01:15:14,224 THE EVALUATION OF THE PROCESS 1813 01:15:14,224 --> 01:15:15,092 AND RESEARCH EFFECTIVENESS 1814 01:15:15,092 --> 01:15:24,435 OCCURS ABOVE THE FENCE. 1815 01:15:24,435 --> 01:15:29,640 AND SOCIETAL IMPACT ON PUBLIC 1816 01:15:29,640 --> 01:15:30,441 HEALTH. 1817 01:15:30,441 --> 01:15:38,715 TRANSPARENCY IS IT CRITICAL FOR 1818 01:15:38,715 --> 01:15:49,092 EQUITABLE ALLOCATION. 1819 01:15:52,863 --> 01:15:55,132 WE NEED TO SEE WHAT IS BEHIND 1820 01:15:55,132 --> 01:15:58,302 THE FENCE TO BETTER UNDERSTAND 1821 01:15:58,302 --> 01:16:00,304 THE PLURALITY FOR THOSE UNDER 1822 01:16:00,304 --> 01:16:05,509 SERVED AND UNDER REPRESENTED IN 1823 01:16:05,509 --> 01:16:05,976 RESEARCH. 1824 01:16:05,976 --> 01:16:14,651 IT'S NOT ENOUGH TO LOOK AT RARE 1825 01:16:14,651 --> 01:16:18,088 DISORDERS BUT FOR OUR PROPOSAL 1826 01:16:18,088 --> 01:16:18,755 AND EVALUATION PROCESS TO LIVE 1827 01:16:18,755 --> 01:16:21,358 UP TO THE IDEAL OF ALL 1828 01:16:21,358 --> 01:16:22,326 POPULATIONS AFFECTED BY A 1829 01:16:22,326 --> 01:16:27,264 DISEASE AND THOSE WHO MAY OR MAY 1830 01:16:27,264 --> 01:16:28,398 NOT BENEFIT FROM THE PROPOSED 1831 01:16:28,398 --> 01:16:28,866 TREATMENT NEEDS TO BE 1832 01:16:28,866 --> 01:16:39,076 IDENTIFIED. 1833 01:16:43,080 --> 01:16:44,915 AND THE DEMOGRAPHIC INFORMATION 1834 01:16:44,915 --> 01:16:45,649 THAT ACCOMPANIES THE 1835 01:16:45,649 --> 01:16:46,116 INFORMATION. 1836 01:16:46,116 --> 01:16:49,186 IT MEANS TO STRIVE FOR MORE 1837 01:16:49,186 --> 01:16:50,921 TREATMENT , MORE QUICKLY 1838 01:16:50,921 --> 01:16:53,891 CONSIDER WHEN ALLOCATING 1839 01:16:53,891 --> 01:16:55,425 RESOURCES FOR COLLABORATIVE 1840 01:16:55,425 --> 01:16:58,061 OPPORTUNITIES THAT HOLDS PROMISE 1841 01:16:58,061 --> 01:17:00,697 PROPOSALS THAT ARE NOT QUITE IND 1842 01:17:00,697 --> 01:17:05,335 READY FOR COLLABORATIONS THAT DO 1843 01:17:05,335 --> 01:17:08,138 REQUIRE CATALYTIC ENGAGEMENT TO 1844 01:17:08,138 --> 01:17:09,506 FULFILL GAPS AND ADVANCE 1845 01:17:09,506 --> 01:17:11,275 TRANSLATION ARE CONSIDERED SO 1846 01:17:11,275 --> 01:17:15,579 THAT THEY TOO CAN RISE ABOVE THE 1847 01:17:15,579 --> 01:17:16,079 VISIBILITY OF RESEARCH 1848 01:17:16,079 --> 01:17:20,217 EFFECTIVENESS. 1849 01:17:20,217 --> 01:17:23,554 IT ALSO MEANS TO DIVERSIFY OUR 1850 01:17:23,554 --> 01:17:25,289 EFFORTS IN TREATMENT MODALITIES 1851 01:17:25,289 --> 01:17:27,357 SO THERE'S A BALANCE INCLUSIVE 1852 01:17:27,357 --> 01:17:29,793 OF THERAPIES AND EQUAL ONE OR 1853 01:17:29,793 --> 01:17:30,661 FEW AND REPURPOSE OR REPOSITION 1854 01:17:30,661 --> 01:17:33,864 MOLECULES. 1855 01:17:33,864 --> 01:17:37,334 ANOTHER IMPORTANT ASPECT THAT IS 1856 01:17:37,334 --> 01:17:38,769 BOTH A CHALLENGE AND AN 1857 01:17:38,769 --> 01:17:41,838 OPPORTUNITY IS NCATS IS DISEASE 1858 01:17:41,838 --> 01:17:42,105 AGNOSTIC. 1859 01:17:42,105 --> 01:17:42,673 APPROXIMATELY 10,000 RARE 1860 01:17:42,673 --> 01:17:46,043 DISEASES AND OTHERS WE DON'T 1861 01:17:46,043 --> 01:17:48,445 KNOW SUCH AS COMMON DISORDERS WE 1862 01:17:48,445 --> 01:17:49,513 DON'T KNOW ANYTHING ABOUT ANY 1863 01:17:49,513 --> 01:17:49,846 GIVEN DISEASE. 1864 01:17:49,846 --> 01:17:52,316 IN ADDITION TO THE INFORMATION 1865 01:17:52,316 --> 01:17:54,885 PROVIDED IN THE PROPOSAL AND 1866 01:17:54,885 --> 01:17:56,219 THROUGHOUT THE EVALUATION 1867 01:17:56,219 --> 01:17:58,922 PROCESS WHAT CAN WE GET A MORE 1868 01:17:58,922 --> 01:18:00,724 CONSISTENT AND COMPLETE PICTURE 1869 01:18:00,724 --> 01:18:05,896 OF THE DISEASE LANDSCAPE AND 1870 01:18:05,896 --> 01:18:06,530 EXPLICITLY EQUITY BEYOND THE 1871 01:18:06,530 --> 01:18:08,865 SCIENTIFIC DIMENSIONS. 1872 01:18:08,865 --> 01:18:11,802 TO ADDRESS THAT SPECIFICALLY WE 1873 01:18:11,802 --> 01:18:13,437 CONCEPTUALIZE AN APPROACH TO 1874 01:18:13,437 --> 01:18:16,840 DEVELOP A PRECLINICAL EQUITY 1875 01:18:16,840 --> 01:18:18,075 INDEX OR PEI TO COMPLEMENT THE 1876 01:18:18,075 --> 01:18:21,645 EVALUATION PROCESS. 1877 01:18:21,645 --> 01:18:25,382 THE PRAECHLT IS AN INTERACTIVE 1878 01:18:25,382 --> 01:18:29,453 ACCATION THAT INTRODUCES A NEW 1879 01:18:29,453 --> 01:18:32,556 CRITERIA IN A BINARY 1880 01:18:32,556 --> 01:18:38,362 QUESTIONNAIRE AND THE PEI 1881 01:18:38,362 --> 01:18:42,666 PRODUCES QUANTITATIVE DIMENSION 1882 01:18:42,666 --> 01:18:44,067 TO EVALUATE EQUITY PROFILES. 1883 01:18:44,067 --> 01:18:48,805 FROM THE SCREEN SHOTS THE END 1884 01:18:48,805 --> 01:18:50,307 USER ENTERS A DISEASE AND 1885 01:18:50,307 --> 01:18:52,709 RESPONDS TO THE QUESTIONNAIRE 1886 01:18:52,709 --> 01:18:54,311 DIVIDED AMONGST THE NAME WILL 1887 01:18:54,311 --> 01:18:55,145 CATEGORIES ON THE RIGHT. 1888 01:18:55,145 --> 01:18:57,648 THE TWO ARE NOT INTENDED TO BE A 1889 01:18:57,648 --> 01:18:59,650 SOLUTION TO SPECIFIC PROBLEMS OR 1890 01:18:59,650 --> 01:19:02,319 PRESENT DIRECT GUIDANCE FOR 1891 01:19:02,319 --> 01:19:02,753 ACTIONS TO BE TAKEN. 1892 01:19:02,753 --> 01:19:07,290 ANOTHER FEATURE OF THE TWO IS 1893 01:19:07,290 --> 01:19:08,659 THE READ OUTS. 1894 01:19:08,659 --> 01:19:11,428 THIS IS THE OUTPUT. 1895 01:19:11,428 --> 01:19:12,996 ESSENTIALLY THE QUESTIONNAIRE 1896 01:19:12,996 --> 01:19:15,499 THAT IS ANSWERED WITH POSITIVE 1897 01:19:15,499 --> 01:19:17,801 YES ANSWERS ARE DISPLAYED IN A 1898 01:19:17,801 --> 01:19:19,336 RADAR GRAPH. 1899 01:19:19,336 --> 01:19:23,040 YOU CAN SEE THE EXAMPLE OF TWO 1900 01:19:23,040 --> 01:19:26,343 DISEASES AND THE AREA THAT IS 1901 01:19:26,343 --> 01:19:28,045 LARGER THAT REPRESENTS MOST THE 1902 01:19:28,045 --> 01:19:32,983 QUESTIONS WERE ANSWERED AND THAT 1903 01:19:32,983 --> 01:19:33,617 CATEGORY IS BEING -- THANK YOU 1904 01:19:33,617 --> 01:19:39,923 SO MUCH. 1905 01:19:39,923 --> 01:19:42,759 THAT REPRESENTS THAT CATEGORY. 1906 01:19:42,759 --> 01:19:44,828 AS YOU CAN SEE HERE AS YOU HOVER 1907 01:19:44,828 --> 01:19:47,764 OVER THE POINTS YOU CAN GET AN 1908 01:19:47,764 --> 01:19:48,665 INDICATION OF THE NUMBER OF 1909 01:19:48,665 --> 01:19:50,967 QUESTIONS THAT WERE ANSWERED. 1910 01:19:50,967 --> 01:19:53,236 AND ON THE RIGHT YOU CAN ALSO 1911 01:19:53,236 --> 01:19:58,141 SEE THAT THIS IS ONE PARTICULAR 1912 01:19:58,141 --> 01:19:59,976 DISEASE THAT DIDN'T HAVE A WIDE 1913 01:19:59,976 --> 01:20:00,944 AREA THAT THE COVERED. 1914 01:20:00,944 --> 01:20:03,013 ON THE LEFT YOU CAN ALSO OVERLAY 1915 01:20:03,013 --> 01:20:05,549 THAT GRAPH AS PART OF THE 1916 01:20:05,549 --> 01:20:05,816 OUTPUT. 1917 01:20:05,816 --> 01:20:08,218 THIS CAN GIVE A VERY GOOD 1918 01:20:08,218 --> 01:20:10,721 REPRESENTATION OF WHAT IS 1919 01:20:10,721 --> 01:20:12,656 HAPPENING IN THE SPACE FOR A 1920 01:20:12,656 --> 01:20:15,959 RESEARCHER AND IF YOU'RE 1921 01:20:15,959 --> 01:20:17,861 THINKING ABOUT A PROPOSAL THAT 1922 01:20:17,861 --> 01:20:20,630 IS NOT IND READY, THIS CAN GIVE 1923 01:20:20,630 --> 01:20:22,299 AN INDICATION OF WHAT WE CAN DO 1924 01:20:22,299 --> 01:20:22,966 TO HELP THAT PARTICULAR DISEASE 1925 01:20:22,966 --> 01:20:23,300 IN THAT SPACE. 1926 01:20:23,300 --> 01:20:29,473 ANOTHER FEATURE OF THE TOOL 1927 01:20:29,473 --> 01:20:32,142 ALLOWS USERS TO INPUT DATA ON 1928 01:20:32,142 --> 01:20:34,578 COMMUNITY RESEARCH FUNDING THAT 1929 01:20:34,578 --> 01:20:41,151 ALLOWS THE USERS TO PROVIDE THE 1930 01:20:41,151 --> 01:20:43,754 RELATIONSHIP BETWEEN DIAGNOSIS 1931 01:20:43,754 --> 01:20:46,323 AND TARGET DRUG ABILITY IS 1932 01:20:46,323 --> 01:20:49,159 DISPLAYED HERE. 1933 01:20:49,159 --> 01:20:54,297 FROM THE PREVIOUS SLIDE YOU CAN 1934 01:20:54,297 --> 01:20:56,800 INPUT THAT FUNDING INFORMATION 1935 01:20:56,800 --> 01:20:58,602 FROM AN NIH REPORTER AND PLOT 1936 01:20:58,602 --> 01:21:00,237 THAT AGAINST THE DIAGNOSIS AND 1937 01:21:00,237 --> 01:21:05,342 DRUG ABILITY DIMENSIONS. 1938 01:21:05,342 --> 01:21:06,309 MOVING ON THE SECOND ACTION IS 1939 01:21:06,309 --> 01:21:07,911 TO ENGAGE THE COMMUNITY. 1940 01:21:07,911 --> 01:21:11,481 THE FINDING IS THAT LIMITED 1941 01:21:11,481 --> 01:21:12,282 ENGAGEMENT WITH PATIENTS AND 1942 01:21:12,282 --> 01:21:13,917 DISEASE COMMUNITIES CAN OBSCURE 1943 01:21:13,917 --> 01:21:16,887 THEIR PRIORITIES FROM RESEARCH 1944 01:21:16,887 --> 01:21:17,220 INSTITUTIONS. 1945 01:21:17,220 --> 01:21:18,355 THE RECOMMENDATION IS TO SUSTAIN 1946 01:21:18,355 --> 01:21:20,857 AND EXPAND COMMUNITY ENGAGEMENT 1947 01:21:20,857 --> 01:21:22,793 TO ENSURE RESEARCH EFFORTS ARE 1948 01:21:22,793 --> 01:21:24,861 INFORMED AND FOCUS ON PATIENT'S 1949 01:21:24,861 --> 01:21:27,330 TOP PRIORITIES AND UNMET NEEDS. 1950 01:21:27,330 --> 01:21:30,300 THOUGH NCATS IS NOT SOLELY 1951 01:21:30,300 --> 01:21:32,202 FOCUSSED ON RARE DISEASES WE 1952 01:21:32,202 --> 01:21:33,403 EMPHASIS RARE DISEASE RESEARCH 1953 01:21:33,403 --> 01:21:37,274 BECAUSE OF THE UNMEET NEED. 1954 01:21:37,274 --> 01:21:39,342 THAT MEANS THE CONSTITUENCY 1955 01:21:39,342 --> 01:21:40,677 COMPRISES SEVERAL GROUPS OF 1956 01:21:40,677 --> 01:21:40,944 PATIENTS. 1957 01:21:40,944 --> 01:21:42,345 OUR APPROACH. 1958 01:21:42,345 --> 01:21:44,614 IF YOU RECALL FROM THE FIRST 1959 01:21:44,614 --> 01:21:46,316 SLIDE, EQUITY RECOGNIZES EACH 1960 01:21:46,316 --> 01:21:47,951 PERSON HAS DIFFERENT 1961 01:21:47,951 --> 01:21:49,886 CIRCUMSTANCES AND ALLOCATES THE 1962 01:21:49,886 --> 01:21:50,987 EXACT RESOURCES AND 1963 01:21:50,987 --> 01:21:54,324 OPPORTUNITIES NEEDED TO REACH AN 1964 01:21:54,324 --> 01:22:04,601 EQUITY OUTCOME. 1965 01:22:08,939 --> 01:22:09,973 IF YOU GET THE CHANCE PLEASE 1966 01:22:09,973 --> 01:22:12,008 LOOK AT THE VIDEO ON THE RIGHT 1967 01:22:12,008 --> 01:22:13,710 FROM THE U.K. 1968 01:22:13,710 --> 01:22:15,946 IT SUMMARIZES QUITE A BIT OF 1969 01:22:15,946 --> 01:22:16,613 THAT. 1970 01:22:16,613 --> 01:22:19,649 AND TO THAT END WE ESTABLISHED A 1971 01:22:19,649 --> 01:22:21,351 SEMINAR SERIES OF COLLABORATION 1972 01:22:21,351 --> 01:22:23,854 PROCESS THAT IS INCLUSIVE OF 1973 01:22:23,854 --> 01:22:26,790 MORE THAN JUST THE RESEARCHER'S 1974 01:22:26,790 --> 01:22:28,058 VOICE BUT THE PATIENT AND 1975 01:22:28,058 --> 01:22:29,659 ADVOCATE AND PHYSICIAN AND OTHER 1976 01:22:29,659 --> 01:22:33,363 PARTNERS OF INTEREST. 1977 01:22:34,731 --> 01:22:37,133 IT'S MEANT TO BE CONVERSATIONAL 1978 01:22:37,133 --> 01:22:39,703 AND EVOLVE AND WE ADAPT IT TO 1979 01:22:39,703 --> 01:22:40,871 THE SPEAKER'S PREFERENCE AND 1980 01:22:40,871 --> 01:22:42,305 HEAR FROM THE COMMUNITY AND 1981 01:22:42,305 --> 01:22:45,041 THEIR PERSPECTIVES AND WHAT 1982 01:22:45,041 --> 01:22:45,675 MATTERS AND WHAT IT MEANS AS A 1983 01:22:45,675 --> 01:22:49,980 COMMUNITY. 1984 01:22:49,980 --> 01:22:51,348 LET'S DISCUSS THE ACTION TO 1985 01:22:51,348 --> 01:22:52,315 SHARE KNOWLEDGE. 1986 01:22:52,315 --> 01:22:55,352 SPECIFICALLY, EASIER ACCESS TO 1987 01:22:55,352 --> 01:22:57,821 RESOURCES AND PROVIDING NEW 1988 01:22:57,821 --> 01:22:58,588 KNOWLEDGE RESOURCES AS IT TIES 1989 01:22:58,588 --> 01:22:59,956 TO RESEARCH AND DEVELOPMENT. 1990 01:22:59,956 --> 01:23:03,493 I WOULD LIKE TO ACKNOWLEDGE THAT 1991 01:23:03,493 --> 01:23:04,794 NCATS HAS MANY AWESOME DATA 1992 01:23:04,794 --> 01:23:06,296 TOOLS AND RESOURCES ALIGNED TO 1993 01:23:06,296 --> 01:23:08,932 SPECIFIC ASPECTS OF THE 1994 01:23:08,932 --> 01:23:11,001 TRANSLATIONAL SCIENCE PIPELINE. 1995 01:23:11,001 --> 01:23:13,937 ONE FINDING IS THAT PATIENTS, 1996 01:23:13,937 --> 01:23:15,105 COMMUNITIES AND ADVOCATES 1997 01:23:15,105 --> 01:23:16,473 FREQUENTLY FIND THEMSELVES 1998 01:23:16,473 --> 01:23:17,674 NAVIGATING THEIR DISEASES ON 1999 01:23:17,674 --> 01:23:19,643 THEIR OWN HAVING TO BECOME THEIR 2000 01:23:19,643 --> 01:23:22,312 OWN RESEARCHER, ADVISER, DATA 2001 01:23:22,312 --> 01:23:23,179 EXPERTS, SAMPLE COLLECTOR AND 2002 01:23:23,179 --> 01:23:25,248 KNOWLEDGE BROKER. 2003 01:23:25,248 --> 01:23:31,121 ONE EXAMPLE IS TO EXPAND ONE 2004 01:23:31,121 --> 01:23:34,291 RECOMMENDATION INVESTMENTS IN 2005 01:23:34,291 --> 01:23:37,193 LOUISVILLING AND EASIER ACCESS 2006 01:23:37,193 --> 01:23:40,764 TO IT FOR RARE DISEASES. 2007 01:23:40,764 --> 01:23:45,035 TDB IS DEVELOPING A RARE SOURCE 2008 01:23:45,035 --> 01:23:47,270 A BIO INFORMATIC FORM AND IS A 2009 01:23:47,270 --> 01:23:48,038 CONTINUAL WORK IN PROGRESS. 2010 01:23:48,038 --> 01:23:50,173 IN THE INTEREST OF TIME I WANTED 2011 01:23:50,173 --> 01:23:54,311 TO FOCUS ON ONE PARTICULAR MODGE 2012 01:23:54,311 --> 01:24:02,519 YOU'LL -- MODULE AND BRINGING IT 2013 01:24:02,519 --> 01:24:06,823 TOGETHER WITH PHENOTYPES, GENES, 2014 01:24:06,823 --> 01:24:13,096 PROTEINS AN RELATED CHEMISTRIES. 2015 01:24:13,096 --> 01:24:16,466 THOUGH THROUGH THESE 2016 01:24:16,466 --> 01:24:17,567 CONNECTIONS, WE BETTER 2017 01:24:17,567 --> 01:24:20,637 UNDERSTAND COMMONALITIES AMONG 2018 01:24:20,637 --> 01:24:22,305 DISORDERS AS COMMON MECHANISMS 2019 01:24:22,305 --> 01:24:24,674 AND APPROACHES TO PLATFORM 2020 01:24:24,674 --> 01:24:27,444 THERAPY DEVELOPMENT. 2021 01:24:27,444 --> 01:24:30,347 THE FOCUS FOR TODAY IS THE 2022 01:24:30,347 --> 01:24:31,982 LITERATURE A.I. 2023 01:24:31,982 --> 01:24:33,917 THIS MODULE IS TRULY AN 2024 01:24:33,917 --> 01:24:35,452 OPPORTUNITY TO LEVEL THE PLAYING 2025 01:24:35,452 --> 01:24:36,052 FIELD. 2026 01:24:36,052 --> 01:24:38,421 WHEN IT COMES TO GETTING ACCESS 2027 01:24:38,421 --> 01:24:40,290 TO PUBLISHED PEER REVIEW 2028 01:24:40,290 --> 01:24:42,058 INFORMATION ON RARE DISEASES. 2029 01:24:42,058 --> 01:24:44,294 DISEASES CAN HAVE MANY ALIASES 2030 01:24:44,294 --> 01:24:45,962 AND ALL THAT ARE KNOWN ARE 2031 01:24:45,962 --> 01:24:47,998 LINKED AND CURATED IN THE 2032 01:24:47,998 --> 01:24:48,398 BACKGROUND. 2033 01:24:48,398 --> 01:24:52,168 IF A USER ENTERS ONE, THE 2034 01:24:52,168 --> 01:24:56,773 ALGORITHM YOU DON'T HAVE TO KNOW 2035 01:24:56,773 --> 01:24:57,073 EVERY ALIAS. 2036 01:24:57,073 --> 01:24:57,974 WE'RE WORKING TOWARDS THAT. 2037 01:24:57,974 --> 01:25:00,443 IT'S A WORK IN PROGRESS AND IT'S 2038 01:25:00,443 --> 01:25:02,012 NOT PERFECT BUT WE'RE ATTEMPTING 2039 01:25:02,012 --> 01:25:03,380 TO DO THAT. 2040 01:25:03,380 --> 01:25:05,682 WE RECENTLY ADDED OPTION TO 2041 01:25:05,682 --> 01:25:06,950 FILTER AND CONTINUING TO IMPROVE 2042 01:25:06,950 --> 01:25:07,717 THE USER EXPERIENCE. 2043 01:25:07,717 --> 01:25:10,286 YOU CAN SEE THE TOP 10 JOURNALS 2044 01:25:10,286 --> 01:25:13,189 AND NUMBER OF PUBLICATIONS AND 2045 01:25:13,189 --> 01:25:14,557 WHICH JOURNALS PUBLISH MORE 2046 01:25:14,557 --> 01:25:15,392 OFTEN FOR THE RARE DISEASE ARE 2047 01:25:15,392 --> 01:25:21,364 ALSO SHOWN AT THE TOP. 2048 01:25:21,364 --> 01:25:22,732 IF YOU RECALL IN THE DIAGNOSIS 2049 01:25:22,732 --> 01:25:24,234 AND DRUGABILITY GRAPH WE CAN 2050 01:25:24,234 --> 01:25:25,902 ALSO LOOK AT RESEARCH 2051 01:25:25,902 --> 01:25:26,569 EFFECTIVENESS THROUGH THE NUMBER 2052 01:25:26,569 --> 01:25:29,906 OF PUBLICATIONS. 2053 01:25:29,906 --> 01:25:30,507 THAT DATA CAN BE PULLED FROM 2054 01:25:30,507 --> 01:25:36,446 HERE. 2055 01:25:36,446 --> 01:25:38,314 THE SECOND FINDING IS TO SHARE 2056 01:25:38,314 --> 01:25:38,581 KNOWLEDGE. 2057 01:25:38,581 --> 01:25:40,183 RESEARCH PARTNERS AND ADVOCATES 2058 01:25:40,183 --> 01:25:42,786 ARE UNFAMILIAR WITH SPECIFICS OF 2059 01:25:42,786 --> 01:25:46,289 PRECLINICAL ACTIVITIES AND 2060 01:25:46,289 --> 01:25:49,459 REQUIREMENTS AFTER INITIAL DRUG 2061 01:25:49,459 --> 01:25:52,495 DISCOVERY WORK. 2062 01:25:52,495 --> 01:25:55,765 THE RECOMMENDATION IS TO DEVELOP 2063 01:25:55,765 --> 01:25:57,067 AND DISSEMINATE EDUCATIONAL 2064 01:25:57,067 --> 01:25:59,402 RESOURCES THAT INTRODUCE 2065 01:25:59,402 --> 01:26:00,370 PRECLINICAL DEVELOPMENT PHASE 2066 01:26:00,370 --> 01:26:02,505 AND DETAILED GENERIC 2067 01:26:02,505 --> 01:26:05,075 REQUIREMENTS OF THE SUCCESSFUL 2068 01:26:05,075 --> 01:26:05,341 CANDIDATE. 2069 01:26:05,341 --> 01:26:12,015 NOT WITHIN THE POWER OF TDB TO 2070 01:26:12,015 --> 01:26:14,317 UNDERSTAND PROCESSES AND BEST 2071 01:26:14,317 --> 01:26:14,984 PRACTICES OF SUCCESSFUL 2072 01:26:14,984 --> 01:26:15,852 THERAPEUTIC DEVELOPMENT. 2073 01:26:15,852 --> 01:26:17,587 THE EFFORTS AND RESOURCES OF 2074 01:26:17,587 --> 01:26:18,721 THESE COMMUNITIES CAN TRANSLATE 2075 01:26:18,721 --> 01:26:20,990 TO REAL PROGRESS. 2076 01:26:20,990 --> 01:26:22,058 SO WE DEVELOPED A KNOWLEDGE 2077 01:26:22,058 --> 01:26:24,060 GUIDE THAT FOCUSES IN ON THE 2078 01:26:24,060 --> 01:26:25,361 SPECIFIC SCIENTIFIC ACTIVITIES 2079 01:26:25,361 --> 01:26:27,363 OF PRECLINICAL DRUG DEVELOPMENT 2080 01:26:27,363 --> 01:26:30,667 FROM CANDIDATE SELECTION TO IND. 2081 01:26:30,667 --> 01:26:35,705 WE CONCEPTUALIZED AND ADDRESSED 2082 01:26:35,705 --> 01:26:36,606 THE VOID IN KNOWLEDGE AND ON THE 2083 01:26:36,606 --> 01:26:38,241 SPECIFIC DETAILS OF THE SPACE. 2084 01:26:38,241 --> 01:26:39,976 IT'S OFTEN REFERRED TO AS THE 2085 01:26:39,976 --> 01:26:42,979 VALLEY OF DEATH BUT WE WANTED TO 2086 01:26:42,979 --> 01:26:44,681 PROVIDE A LANDSCAPE WHILE 2087 01:26:44,681 --> 01:26:48,251 CHALLENGING TO TA VERSE OB 2088 01:26:48,251 --> 01:26:50,320 STAC 2089 01:26:50,320 --> 01:26:55,091 STACKAL -- OBSTACLES AND LOOK AT 2090 01:26:55,091 --> 01:26:58,461 SUCCESS AND FAILURES AND I'D 2091 01:26:58,461 --> 01:27:00,563 LIKE TO ACKNOWLEDGE MY 2092 01:27:00,563 --> 01:27:06,269 COLLEAGUES WHO WORKED ON THE 2093 01:27:06,269 --> 01:27:08,671 PROJECT AND ALSO EXTENDED 2094 01:27:08,671 --> 01:27:11,241 ACKNOWLEDGEMENTS TO THE FOLKS 2095 01:27:11,241 --> 01:27:11,808 WHO WORKED ONLY THE SOURCE. 2096 01:27:11,808 --> 01:27:22,152 THANK YOU VERY MUCH. 2097 01:27:28,892 --> 01:27:30,059 >> THANK YOU. 2098 01:27:30,059 --> 01:27:31,194 ARE THERE ANY QUESTIONS? 2099 01:27:31,194 --> 01:27:31,794 >> GREAT PRESENTATIONS THANK 2100 01:27:31,794 --> 01:27:34,097 YOU. 2101 01:27:34,097 --> 01:27:36,799 I'M REALLY INTRIGUED BY THE WORK 2102 01:27:36,799 --> 01:27:37,767 THAT YOU'VE DONE THE PROTOTYPE 2103 01:27:37,767 --> 01:27:40,336 WORK YOU'VE DONE LOOKING AT 2104 01:27:40,336 --> 01:27:43,106 DIAGNOSIS VERSUS DRUG VERSUS NIH 2105 01:27:43,106 --> 01:27:43,373 SPENDING. 2106 01:27:43,373 --> 01:27:48,511 CAN YOU TALK A LITTLE BIT MORE 2107 01:27:48,511 --> 01:27:52,415 ABOUT HOW YOU USE THAT TOOL TO 2108 01:27:52,415 --> 01:27:57,287 INFORM NEXT STEPS? 2109 01:27:57,287 --> 01:28:07,430 >> YES. 2110 01:28:11,467 --> 01:28:13,503 I REFER TO US BEING DISEASE 2111 01:28:13,503 --> 01:28:14,304 AGNOSTIC AND UNDERSTANDING WHERE 2112 01:28:14,304 --> 01:28:16,506 THE RESOURCES HAVE BEEN PLACED 2113 01:28:16,506 --> 01:28:18,875 IN THE PAST WILL BE IMPORTANT 2114 01:28:18,875 --> 01:28:20,743 FOR HOW WE WOULD PUT OUR 2115 01:28:20,743 --> 01:28:22,111 RESOURCES ESPECIALLY FOR THE 2116 01:28:22,111 --> 01:28:24,881 RESOURCES THAT MAY NOT BE IND 2117 01:28:24,881 --> 01:28:26,316 READY AND THINKING ABOUT WELL, 2118 01:28:26,316 --> 01:28:34,090 THIS IS PROMISING. 2119 01:28:34,090 --> 01:28:35,391 AND UNDERSTANDING FROM THE 2120 01:28:35,391 --> 01:28:42,298 DIAGNOSIS AND DRUGABILITY ASPECT 2121 01:28:42,298 --> 01:28:45,001 WHETHER THE TARGETS ARE READY 2122 01:28:45,001 --> 01:28:49,072 FOR THE INVESTMENT OR TAKE A 2123 01:28:49,072 --> 01:28:50,473 STEP BACK AND HOW MUCH FUNDING 2124 01:28:50,473 --> 01:28:53,943 IS OUT THERE WITH ACADEMIC OR 2125 01:28:53,943 --> 01:28:54,510 OTHER INSTITUTIONS THE 2126 01:28:54,510 --> 01:28:57,146 GOVERNMENT HAS ALREADY PROVIDED. 2127 01:28:57,146 --> 01:28:58,581 WE CERTAINLY DON'T WANT TO 2128 01:28:58,581 --> 01:28:59,983 DUPLICATE EFFORTS. 2129 01:28:59,983 --> 01:29:01,117 ALL THAT IS IMPORTANT TO KNOW 2130 01:29:01,117 --> 01:29:01,985 AND USING A TOOL LIKE THAT IS 2131 01:29:01,985 --> 01:29:06,556 HELPFUL. 2132 01:29:06,556 --> 01:29:09,759 >> QUICKLY FOLLOWING UP ON THAT 2133 01:29:09,759 --> 01:29:10,059 ONE. 2134 01:29:10,059 --> 01:29:13,263 THE SIZE OF THE CIRCLES IN THAT 2135 01:29:13,263 --> 01:29:14,697 GRAPH WITH THE AMOUNT OF 2136 01:29:14,697 --> 01:29:15,999 FUNDING. 2137 01:29:15,999 --> 01:29:17,567 I THINK WHAT I'M HEARING YOU SAY 2138 01:29:17,567 --> 01:29:24,173 IS LOOKING FOR PATTERNS ON THE 2139 01:29:24,173 --> 01:29:26,075 X, Y AXIS WHERE THEY FALL AND IF 2140 01:29:26,075 --> 01:29:28,177 YOU SEE LITTLE CIRCLES WHERE 2141 01:29:28,177 --> 01:29:30,313 THERE SHOULD BE BIG CIRCLES IS A 2142 01:29:30,313 --> 01:29:31,781 RIPE AREA FOR INVESTMENT. 2143 01:29:31,781 --> 01:29:35,718 >> SO LET ME TAKE A STEP BACK. 2144 01:29:35,718 --> 01:29:40,390 THE PURPLE COMES TO US AND THEY 2145 01:29:40,390 --> 01:29:41,291 IT'S NOT A COMPARATIVE TOOL FROM 2146 01:29:41,291 --> 01:29:45,361 THAT PERSPECTIVE. 2147 01:29:45,361 --> 01:29:47,463 WHEN WE LOOK AT THE INDIVIDUAL 2148 01:29:47,463 --> 01:29:51,100 DISEASE -- AGAIN, THIS TOOL CAN 2149 01:29:51,100 --> 01:29:52,602 BE USED BY WHOEVER. 2150 01:29:52,602 --> 01:29:54,203 ANYONE CAN APPLY THIS TO THEIR 2151 01:29:54,203 --> 01:29:56,339 AREA BUT WHAT WE WANT TO 2152 01:29:56,339 --> 01:29:57,607 UNDERSTAND IS WE HAVE A CERTAIN 2153 01:29:57,607 --> 01:30:02,178 AMOUNT OF RESOURCES. 2154 01:30:02,178 --> 01:30:07,183 WE WANT TO UNDERSTAND THE 2155 01:30:07,183 --> 01:30:12,488 DISEASE AREA AND LANDSCAPE AND 2156 01:30:12,488 --> 01:30:15,391 YOU'RE LOOKING AT THE SIZE OF 2157 01:30:15,391 --> 01:30:18,828 THE FUNDING AND IS THE TARGET 2158 01:30:18,828 --> 01:30:19,929 READY FOR THAT INVESTMENT OR DO 2159 01:30:19,929 --> 01:30:27,370 WE NEED TO TAKE A STEP BACK? 2160 01:30:27,370 --> 01:30:32,275 YES, THAT COULD BE INDICATIVE OF 2161 01:30:32,275 --> 01:30:35,712 WHERE FUNDING COULD BE APPLIED. 2162 01:30:35,712 --> 01:30:38,514 THAT'S HOW WE INTEND TO USE IT. 2163 01:30:38,514 --> 01:30:41,184 COMPARING THE PURPLE IS NOT 2164 01:30:41,184 --> 01:30:42,685 SAYING OKAY GIVE ME DISEASE A 2165 01:30:42,685 --> 01:30:46,589 AND Y AND DECIDE THAT. 2166 01:30:46,589 --> 01:30:48,591 THAT'S NOT OUR INTENT. 2167 01:30:48,591 --> 01:30:50,827 >> I'D LIKE TO ADD PERHAPS MAYBE 2168 01:30:50,827 --> 01:30:51,828 THERE WILL COME A DAY TO HAVE 2169 01:30:51,828 --> 01:30:54,297 THE ABILITY AND RESOURCES TO BE 2170 01:30:54,297 --> 01:30:57,367 ABLE TO TAKE A LOOK AT SOME 2171 01:30:57,367 --> 01:30:59,068 GRAPHS LIKE THAT THAT PERHAPS 2172 01:30:59,068 --> 01:31:02,071 AREN'T BEING STUDIED BUT WE 2173 01:31:02,071 --> 01:31:04,340 MIGHT BE ABLE ADVANCE FOR 2174 01:31:04,340 --> 01:31:06,142 REASONS THAT ARE BEING UNDER 2175 01:31:06,142 --> 01:31:07,210 STUDIED FOR PARTICULAR REASONS 2176 01:31:07,210 --> 01:31:10,713 OR THERE'S AN EQUITY ISSUE WE 2177 01:31:10,713 --> 01:31:11,247 CAN PERHAPS INCREASE THE 2178 01:31:11,247 --> 01:31:21,557 KNOWLEDGE AROUND. 2179 01:31:37,240 --> 01:31:46,682 IF WE DO GET THIS WOULD SHINE A 2180 01:31:46,682 --> 01:31:48,818 LIGHT. 2181 01:31:48,818 --> 01:31:55,825 >> YOU CAN ADAPT IT FOR THEIR 2182 01:31:55,825 --> 01:31:56,659 OWN PURPOSES AND THERE'S AN 2183 01:31:56,659 --> 01:31:58,294 ASSESSMENT OF WHAT WAS PROPOSED. 2184 01:31:58,294 --> 01:31:59,495 >> A COMMENT. 2185 01:31:59,495 --> 01:32:02,298 I ENJOYED LEARNING ABOUT THE 2186 01:32:02,298 --> 01:32:03,032 TOOL. 2187 01:32:03,032 --> 01:32:04,934 ONE EXAMPLE SHE GAVE ME AS SHE'S 2188 01:32:04,934 --> 01:32:08,438 BEEN EDUCATING ME ON THE PROGRAM 2189 01:32:08,438 --> 01:32:09,806 SINCE I BECAME S.D. 2190 01:32:09,806 --> 01:32:11,374 IF SOMEONE COMES WITH A 2191 01:32:11,374 --> 01:32:12,141 CANDIDATE THERAPEUTIC FOR A 2192 01:32:12,141 --> 01:32:14,310 GIVEN TARGET THAT HELPS THEM 2193 01:32:14,310 --> 01:32:24,420 ZOOM OUT AND ASK WHAT OTHER 2194 01:32:24,420 --> 01:32:26,189 PATIENTS AND THINK ABOUT ALL PEOPLE AND ALL DISEASES AND 2195 01:32:26,189 --> 01:32:36,985 HELPED ME CONTEMPLATE AS DR. HAUGABOOK MADE CLEAR TO LOOK AT ALL THE INTRAMURAL PROGRAM. 2196 01:33:11,241 --> 01:33:14,644 IT'S NOT MEANT TO BE 2197 01:33:14,644 --> 01:33:15,746 COMPREHENSIVE. 2198 01:33:15,746 --> 01:33:19,149 IT CAN'T BE, UNFORTUNATELY. 2199 01:33:19,149 --> 01:33:20,283 WHILE WE LIKE TO SAY WE'RE 2200 01:33:20,283 --> 01:33:23,120 DISEASE AGNOSTIC WE'RE NOT 2201 01:33:23,120 --> 01:33:24,254 DISEASE ATHEISTS. 2202 01:33:24,254 --> 01:33:27,224 WE HAVE A WIDE VARIETY OF 2203 01:33:27,224 --> 01:33:27,724 DISEASES WE ARE IN FACT 2204 01:33:27,724 --> 01:33:37,934 ADDRESSING. 2205 01:33:51,214 --> 01:33:59,256 WE HAVE WHAT STAFF PUSHES AND 2206 01:33:59,256 --> 01:34:03,260 WHAT MY ECLECTIC TASTE FINDS 2207 01:34:03,260 --> 01:34:03,560 INTERESTING. 2208 01:34:03,560 --> 01:34:08,765 THIS IS BASICALLY TO REMIND 2209 01:34:08,765 --> 01:34:18,408 PEOPLE THAT RIGHT NOW THOUGH 2210 01:34:18,408 --> 01:34:23,547 BUDGET PEOPLE DOESN'T SHOW UP 2211 01:34:23,547 --> 01:34:25,916 AND WE HAVE A BUDGET IN PROCESS 2212 01:34:25,916 --> 01:34:30,754 AND COMING OFF AN FY24 A 0% 2213 01:34:30,754 --> 01:34:32,589 INCREASE. 2214 01:34:32,589 --> 01:34:33,490 [RECORDING IN PROGRESS] 2215 01:34:33,490 --> 01:34:35,292 >> WE'RE DOING WHAT WE CAN AND 2216 01:34:35,292 --> 01:34:40,597 THIS IS WHAT THE FY24 CTSA 2217 01:34:40,597 --> 01:34:43,066 PROGRAM LOOKS LIKE AS OF NOW. 2218 01:34:43,066 --> 01:34:44,167 I THINK EVERYTHING THAT'S 2219 01:34:44,167 --> 01:34:47,003 SUPPOSED TO GO OUT THE DOOR WILL 2220 01:34:47,003 --> 01:34:48,371 GO OUT THE DOOR OR WILL BY 2221 01:34:48,371 --> 01:34:51,808 FRIDAY. 2222 01:34:51,808 --> 01:34:56,146 UNDER OUR NEW UM1 PROGRAM WE HAD 2223 01:34:56,146 --> 01:35:04,888 11 CTSAs AWARDED IN FY24, I'M 2224 01:35:04,888 --> 01:35:07,457 HAPPY TO SAY. 2225 01:35:07,457 --> 01:35:09,326 DARTMOUTH HAD BEEN A PREVIOUS 2226 01:35:09,326 --> 01:35:10,827 ONE YEARS AGO BUT SUCCESSFULLY 2227 01:35:10,827 --> 01:35:16,166 CAME BACK IN AND DOWN IN 2228 01:35:16,166 --> 01:35:22,005 HOUSTON, BAYLOR IS OUR NEWEST 2229 01:35:22,005 --> 01:35:22,606 CTSA. 2230 01:35:22,606 --> 01:35:27,410 WITHIN OUR STAFF WHERE HE ADDED 2231 01:35:27,410 --> 01:35:30,647 TWO PEOPLE WITHIN OUR EDUCATION 2232 01:35:30,647 --> 01:35:36,152 AND TRAINING SESSION AND ANTHONY 2233 01:35:36,152 --> 01:35:38,288 AND KARINA HAS JOINED THE 2234 01:35:38,288 --> 01:35:41,491 CLINICAL AFFAIRS BRANCH AS AN 2235 01:35:41,491 --> 01:35:44,160 ADVISER AND HEATHER BAKER HAS 2236 01:35:44,160 --> 01:35:46,529 MOVED UP TO NOW FROM A HEALTH 2237 01:35:46,529 --> 01:35:49,366 POLICY ANALYST TO SENIOR PROGRAM 2238 01:35:49,366 --> 01:35:52,168 COORDINATOR IN THE OFFICE OF THE 2239 01:35:52,168 --> 01:35:54,504 DIRECTOR AND PROVIDING MUCH 2240 01:35:54,504 --> 01:35:56,139 NEEDED COORDINATION ACROSS THE 2241 01:35:56,139 --> 01:35:56,573 PROGRAM. 2242 01:35:56,573 --> 01:35:59,276 I'D LIKE TO START WITH 2243 01:35:59,276 --> 01:35:59,643 CONGRATULATIONS. 2244 01:35:59,643 --> 01:36:06,383 WE HAVE A NUMBER OF SIGNIFICANT 2245 01:36:06,383 --> 01:36:08,752 PLAYERS WITHIN THE CTSA. 2246 01:36:08,752 --> 01:36:12,155 SO JULIE AT VANDERBILT WAS 2247 01:36:12,155 --> 01:36:12,989 ELECTED VICE PRESIDENT OF THE 2248 01:36:12,989 --> 01:36:17,294 AMERICAN SOCIETY FOR CLINICAL 2249 01:36:17,294 --> 01:36:19,896 INVESTIGATION AND WILL 2250 01:36:19,896 --> 01:36:21,765 SUBSEQUENTLY SERVE AS PRESIDENT 2251 01:36:21,765 --> 01:36:26,002 ELECT AND THEN PRESIDENT. 2252 01:36:26,002 --> 01:36:28,171 SO, SHE'S BEEN OBLIGATED THE 2253 01:36:28,171 --> 01:36:30,807 NEXT SEVERAL YEARS. 2254 01:36:30,807 --> 01:36:34,077 SHE'S CURRENTLY THE P.I. FOR KL1 2255 01:36:34,077 --> 01:36:38,581 AND 2 AT VANDERBILT. 2256 01:36:38,581 --> 01:36:43,286 RHONDA IS AT CONVENIENCE AND 2257 01:36:43,286 --> 01:36:48,158 RECIPIENT OF THE CYSTIC FIBROSIS 2258 01:36:48,158 --> 01:36:51,394 CLINICIANS REWARD AND VESNA THE 2259 01:36:51,394 --> 01:37:01,838 P.I. AT MAYO AND FROM THE 2260 01:37:04,240 --> 01:37:08,111 RECIPIENT OF AWARDS AND NICOLE 2261 01:37:08,111 --> 01:37:09,546 IS THE EXECUTIVE DIRECTOR AT 2262 01:37:09,546 --> 01:37:13,350 NORTHWESTERN AND WAS AWARDED THE 2263 01:37:13,350 --> 01:37:14,617 AMERICAN SOCIETY FOR BIO 2264 01:37:14,617 --> 01:37:15,752 CHEMISTRY AND EMERGING 2265 01:37:15,752 --> 01:37:17,754 LEADERSHIP AWARD AND AT THIS 2266 01:37:17,754 --> 01:37:22,492 YEAR'S ACTS MEETING THOSE WHO 2267 01:37:22,492 --> 01:37:24,160 WENT HELD IN LAS VEGAS. 2268 01:37:24,160 --> 01:37:27,931 I'M TRULY HOPING IF IT'S EVER 2269 01:37:27,931 --> 01:37:32,102 HELD IN LAS VEGAS AGAIN I'LL BE 2270 01:37:32,102 --> 01:37:35,138 RETIRED BY THEN. 2271 01:37:35,138 --> 01:37:38,641 TERRENCE TSOU WON THE 2272 01:37:38,641 --> 01:37:41,144 OUTSTANDING TRAINING PREDOCTORAL 2273 01:37:41,144 --> 01:37:44,147 TRAINING AWARD AND A TRAINEE AT 2274 01:37:44,147 --> 01:37:45,048 JOHNS HOPKINS. 2275 01:37:45,048 --> 01:37:48,151 MOVING TO A NATIONAL LEVEL, ERIC 2276 01:37:48,151 --> 01:37:58,695 TOPOL PROBABLY ONE OF THE MAJOR 2277 01:38:01,631 --> 01:38:04,234 CROWN TOOLS PART OF THE SCRIPPS 2278 01:38:04,234 --> 01:38:05,869 RESEARCH WAS NAMED BY TIME AS 2279 01:38:05,869 --> 01:38:07,203 ONE OF THE MOST INFLUENTIAL 2280 01:38:07,203 --> 01:38:08,571 PEOPLE IN HEALTH AND WON THE 2281 01:38:08,571 --> 01:38:11,241 FRIEND OF THE NATIONAL OF 2282 01:38:11,241 --> 01:38:12,142 LIBRARY MEDICINES DISTINGUISHED 2283 01:38:12,142 --> 01:38:13,343 HEALTH COMMUNICATIONS AWARD. 2284 01:38:13,343 --> 01:38:18,681 AND THIS ONE IS INTERESTING. 2285 01:38:18,681 --> 01:38:22,852 DAVID HUANG AT OREGON SEE HIM 2286 01:38:22,852 --> 01:38:24,654 WINNING THE NATIONAL MEDAL OF 2287 01:38:24,654 --> 01:38:26,923 TECHNOLOGY AND INNOVATION AND HE 2288 01:38:26,923 --> 01:38:28,825 WON IT LATE LAST YEAR AND WAS 2289 01:38:28,825 --> 01:38:33,129 TOO LATE TO INCLUDE AT LAST 2290 01:38:33,129 --> 01:38:34,064 YEAR'S COUNCIL MEETING. 2291 01:38:34,064 --> 01:38:35,665 HE IS BEING RECOGNIZED FOR HIS 2292 01:38:35,665 --> 01:38:40,737 INITIAL WORK BACK IN '91 ON 2293 01:38:40,737 --> 01:38:42,639 OPTICAL COHERENCE TOMOGRAPHY 2294 01:38:42,639 --> 01:38:45,708 WHICH IS BASICALLY AN AMAZING 2295 01:38:45,708 --> 01:38:52,682 TECHNOLOGY THAT IF UTILIZED 2296 01:38:52,682 --> 01:38:55,819 MILLIONS OF TIMES A YEAR IN EYE 2297 01:38:55,819 --> 01:38:56,152 EXAMS. 2298 01:38:56,152 --> 01:38:58,788 HIS INVOLVEMENT WITH THE OREGON 2299 01:38:58,788 --> 01:39:04,060 CTSA IS PILOT AWARD AND THIS WAS 2300 01:39:04,060 --> 01:39:10,467 DEVELOPED FOR EYE EXAMINATIONS. 2301 01:39:10,467 --> 01:39:16,072 HE UTILIZED PILOT AWARDS TO LOOK 2302 01:39:16,072 --> 01:39:18,741 AT CARDIOVASCULAR AND CARDIOLOGY 2303 01:39:18,741 --> 01:39:21,611 AND DERMATOLOGY. 2304 01:39:21,611 --> 01:39:22,946 IT'S A SIGNIFICANT TECHNOLOGY IN 2305 01:39:22,946 --> 01:39:28,485 TERMS OF IMAGING POTENTIAL. 2306 01:39:28,485 --> 01:39:34,624 FINALLY, ELIZABETH OFILLI AT 2307 01:39:34,624 --> 01:39:35,291 MOREHOUSE COMPLETELY 2308 01:39:35,291 --> 01:39:35,992 INDEPENDENT. 2309 01:39:35,992 --> 01:39:37,527 WE WERE NOT CONTACTED UNTIL 2310 01:39:37,527 --> 01:39:40,163 ELIZABETH CALLED ME AND SAID 2311 01:39:40,163 --> 01:39:42,332 I'LL BE UP IN WASHINGTON AT THE 2312 01:39:42,332 --> 01:39:42,632 WHITE HOUSE. 2313 01:39:42,632 --> 01:39:46,736 CAN I STOP BY AND SEE YOU? 2314 01:39:46,736 --> 01:39:48,404 THAT'S HOW WE LEARNED. 2315 01:39:48,404 --> 01:39:50,840 THE OSTP AT THE WHITE HOUSE 2316 01:39:50,840 --> 01:39:54,477 ORGANIZED AN EVENT THAT WAS 2317 01:39:54,477 --> 01:39:55,879 TALKING ABOUT INNOVATIVE 2318 01:39:55,879 --> 01:39:58,314 APPROACHES TO MAKE INCLUSIVE 2319 01:39:58,314 --> 01:40:01,384 TRIALS MORE INCLUSIVE AND 2320 01:40:01,384 --> 01:40:03,353 ACCESSIBLE AND HIGHLIGHTED THE 2321 01:40:03,353 --> 01:40:10,393 HELP OF 360 A MOBILE AND 2322 01:40:10,393 --> 01:40:12,128 WEB-BASED REGISTRY WITH 2323 01:40:12,128 --> 01:40:12,962 CONGRUENT COACHING. 2324 01:40:12,962 --> 01:40:16,599 THIS WAS INITIALLY SUPPORTED AS 2325 01:40:16,599 --> 01:40:20,170 A SUPPLEMENT TO THE GEORGIA CTSA 2326 01:40:20,170 --> 01:40:25,108 AND FUNDED AS AN SBIR THROUGH 2327 01:40:25,108 --> 01:40:25,308 NCATS. 2328 01:40:25,308 --> 01:40:27,377 IT'S VERY GRATIFYING WHEN 2329 01:40:27,377 --> 01:40:28,344 OUTSIDE GROUPS LIKE THIS REALLY 2330 01:40:28,344 --> 01:40:33,816 RECOGNIZE THE UTILITY AND VALUE 2331 01:40:33,816 --> 01:40:38,788 OF WHAT WE'RE DOING THERE'S 2332 01:40:38,788 --> 01:40:40,590 PROBABLY MORE BUT THERE'S MORE 2333 01:40:40,590 --> 01:40:42,559 WE'VE BEEN INFORMED OF. 2334 01:40:42,559 --> 01:40:44,694 WE SUNK OUR TOE IN THE WATER IN 2335 01:40:44,694 --> 01:40:47,263 TERMS OF AN R PROGRAM AND WE 2336 01:40:47,263 --> 01:40:52,669 HAVE FOR FY24 THE AWARDEES. 2337 01:40:52,669 --> 01:40:56,105 THIS IS LIMITED COMPETITION TO 2338 01:40:56,105 --> 01:40:57,941 CTSK AND DIVERSITY SCHOLARS AND 2339 01:40:57,941 --> 01:41:00,009 WHAT YOU CAN SEE IS THERE'S A 2340 01:41:00,009 --> 01:41:05,415 WIDE RANGE OF ACTIVITIES FROM 2341 01:41:05,415 --> 01:41:09,185 SOME MODULATION OF T CELL 2342 01:41:09,185 --> 01:41:14,857 DIFFERENTIATION AND ANTI-TUMOR 2343 01:41:14,857 --> 01:41:16,559 IMMUNITY ALL THE WAY THROUGH THE 2344 01:41:16,559 --> 01:41:19,629 ENROLLMENT IN HEALTH SPENDING 2345 01:41:19,629 --> 01:41:23,099 AND UTILIZATIUTILIZATION. 2346 01:41:23,099 --> 01:41:24,267 A WIDE FACTOR OF ACTIVITIES 2347 01:41:24,267 --> 01:41:25,969 VALUABLE FOR THE PROGRAM. 2348 01:41:25,969 --> 01:41:29,305 OUR CCIAs WHICH ARE MECHANISM 2349 01:41:29,305 --> 01:41:31,207 FOR ALLOWING MULTIPLE CTSAs TO 2350 01:41:31,207 --> 01:41:33,776 COME TOGETHER TO WORK ON A JOINT 2351 01:41:33,776 --> 01:41:35,411 PROJECT THAT WOULD BE VERY 2352 01:41:35,411 --> 01:41:39,682 DIFFICULT FOR ANY INDIVIDUAL 2353 01:41:39,682 --> 01:41:41,184 CTSA TO BE CARED ABOUT. 2354 01:41:41,184 --> 01:41:45,888 WE HAD TWO. 2355 01:41:45,888 --> 01:41:50,460 ONE IS BYTES TO BEDSIDE FOR 2356 01:41:50,460 --> 01:41:53,296 CLINICAL TRANSLATIONAL SUPPORT. 2357 01:41:53,296 --> 01:41:55,431 I'LL IS PAUL IS THIS INFORMATICS 2358 01:41:55,431 --> 01:41:57,500 OR DATA SCIENCE. 2359 01:41:57,500 --> 01:41:59,168 WE HAD AN INTERESTING 2360 01:41:59,168 --> 01:41:59,502 CONVERSATION. 2361 01:41:59,502 --> 01:42:02,505 THE IDEA HERE IS AND THEY'VE 2362 01:42:02,505 --> 01:42:03,973 DUNK THE KOOL-AID. 2363 01:42:03,973 --> 01:42:05,675 AND DEVELOP, DEMONSTRATE AND 2364 01:42:05,675 --> 01:42:08,111 DISSEMINATE AND EVALUATE A 2365 01:42:08,111 --> 01:42:09,946 CENTRALIZED AND HIGHLY EFFICIENT 2366 01:42:09,946 --> 01:42:13,182 DATA SHARING INFRASTRUCTURE TO 2367 01:42:13,182 --> 01:42:15,351 SUPPORT TRANSLATIONAL CLINICAL 2368 01:42:15,351 --> 01:42:16,886 DECISION SUPPORT ANALYSIS. 2369 01:42:16,886 --> 01:42:17,920 SIX INSTITUTIONS ARE INVOLVED 2370 01:42:17,920 --> 01:42:27,063 WHICH I THINK IS A REAL CRITICAL 2371 01:42:27,063 --> 01:42:27,497 NE 2372 01:42:27,497 --> 01:42:27,697 NEED. 2373 01:42:27,697 --> 01:42:29,599 A SING AT INSTITUTION HAS 2374 01:42:29,599 --> 01:42:31,601 LIMITED AABILITY. 2375 01:42:31,601 --> 01:42:32,969 THIS IS IMPORTANT TO SHOW THE 2376 01:42:32,969 --> 01:42:33,469 UTILITY ACROSS MULTIPLE 2377 01:42:33,469 --> 01:42:36,172 INSTITUTIONS. 2378 01:42:36,172 --> 01:42:38,741 THE SECOND CCIA AWARD IS 2379 01:42:38,741 --> 01:42:41,177 FOCUSSED ON ANOTHER CRITICAL 2380 01:42:41,177 --> 01:42:42,445 ASPECT WE PUT EFFORT INTO IN 2381 01:42:42,445 --> 01:42:43,713 RECENT YEARS. 2382 01:42:43,713 --> 01:42:46,049 THIS IS IMPROVING EFFICIENCY, 2383 01:42:46,049 --> 01:42:50,987 QUALITY AND EQUITY, RANDOMIZED 2384 01:42:50,987 --> 01:42:55,958 REMOTE VERSUS CLINICAL IN TRIAL 2385 01:42:55,958 --> 01:42:56,192 METHODS. 2386 01:42:56,192 --> 01:42:58,027 CLEARLY COVID'S LED TO A 2387 01:42:58,027 --> 01:42:59,295 FOCUSSED EFFORT AROUND REMOTE 2388 01:42:59,295 --> 01:43:04,233 AND THERE'S A LOT OF ACTIVITIES 2389 01:43:04,233 --> 01:43:05,301 GOING TO ON IN THIS. 2390 01:43:05,301 --> 01:43:08,604 WHILE I DON'T THINK REMOTE WILL 2391 01:43:08,604 --> 01:43:11,307 GO WE AND CONVERT TO REMOTE 2392 01:43:11,307 --> 01:43:13,843 VERSUS IN PERSON I THINK IT'S 2393 01:43:13,843 --> 01:43:15,478 IMPORTANT WE UNDERSTAND THE 2394 01:43:15,478 --> 01:43:16,846 LIMITS AND THE POSSIBILITIES 2395 01:43:16,846 --> 01:43:18,614 WITH EACH OF THE DIFFERENT 2396 01:43:18,614 --> 01:43:20,183 MODALITIES GOING FORWARD SO IN 2397 01:43:20,183 --> 01:43:24,654 THE FUTURE WE CAN DESIGN TRIALS 2398 01:43:24,654 --> 01:43:26,856 OPTIMALLY TO TAKE THE FACTORS 2399 01:43:26,856 --> 01:43:28,024 INTO ACCOUNT. 2400 01:43:28,024 --> 01:43:30,426 WANTED TO HIGHLIGHT ONE PRIOR 2401 01:43:30,426 --> 01:43:30,827 CCIA. 2402 01:43:30,827 --> 01:43:32,228 I LIKE TO POINT OUT PAST ONES 2403 01:43:32,228 --> 01:43:33,496 BECAUSE WE SOMETIMES TELL YOU 2404 01:43:33,496 --> 01:43:35,098 ABOUT THE WONDERFUL THINGS WE'RE 2405 01:43:35,098 --> 01:43:36,866 FUNDING BUT WE DON'T NECESSARILY 2406 01:43:36,866 --> 01:43:38,134 TELL YOU WHAT THEY'VE DONE. 2407 01:43:38,134 --> 01:43:41,037 SO THIS IS AN INTERESTING ONE 2408 01:43:41,037 --> 01:43:44,807 BECAUSE IT ACTUALLY DOVETAILS 2409 01:43:44,807 --> 01:43:48,177 QUITE NICELY WITH JONI'S SLIDE 2410 01:43:48,177 --> 01:43:49,946 EARLIER ON THE VENTURE SPACE FOR 2411 01:43:49,946 --> 01:43:51,080 NEWBORN SCREENING. 2412 01:43:51,080 --> 01:43:55,651 THIS IS PRECISION MEDICINE AND 2413 01:43:55,651 --> 01:43:57,320 DIAGNOSIS OF GENETIC DISORDERS 2414 01:43:57,320 --> 01:43:57,920 IN NEONATES. 2415 01:43:57,920 --> 01:44:00,189 THIS IS AN AWARD BACK WE 2416 01:44:00,189 --> 01:44:02,291 INITIATED IN 2018. 2417 01:44:02,291 --> 01:44:07,663 WHILE IT'S NOT THE FIRST, IT IS 2418 01:44:07,663 --> 01:44:11,901 TO DATE THE LARGEST STUDY, 400 2419 01:44:11,901 --> 01:44:12,802 STUDENTS. 2420 01:44:12,802 --> 01:44:14,470 INFANTS THAT WERE BIRTHED THAT 2421 01:44:14,470 --> 01:44:20,109 END UP IN THE NICU AND COMPARE 2422 01:44:20,109 --> 01:44:23,212 WHOLE GENOME SECOND-CHANCE FOR 2423 01:44:23,212 --> 01:44:23,980 THE PANEL ANALYSIS FOR THE 2424 01:44:23,980 --> 01:44:25,515 POSSIBLE DISORDERS. 2425 01:44:25,515 --> 01:44:28,184 ALMOST HALF, 49% OF THOSE 400 2426 01:44:28,184 --> 01:44:31,954 WERE IDENTIFIED WITH A SPECIFIC 2427 01:44:31,954 --> 01:44:32,755 GENETIC DISORDER. 2428 01:44:32,755 --> 01:44:36,192 ABOUT 1 IN 5 RESULTED IN 2429 01:44:36,192 --> 01:44:37,560 CHANGING THE CARE THEY WERE 2430 01:44:37,560 --> 01:44:37,960 RECEIVING. 2431 01:44:37,960 --> 01:44:39,028 THE WHOLE GENOME SEQUENCING 2432 01:44:39,028 --> 01:44:41,998 WHILE IT MAY HAVE BEEN A DAY OR 2433 01:44:41,998 --> 01:44:44,901 TWO LATER THAN PANEL ANALYSIS, 2434 01:44:44,901 --> 01:44:46,669 IT CLEARLY WAS SUPERIOR SO 2435 01:44:46,669 --> 01:44:48,704 THERE'S VERY GOOD RCT DATA THAT 2436 01:44:48,704 --> 01:44:57,647 SHOWS THIS IS IN FACT SUPERIOR. 2437 01:44:57,647 --> 01:44:59,482 MANY PRIOR STUDIES LOOKED AT THE 2438 01:44:59,482 --> 01:45:04,420 COST OF CARE WITH WHOLE GENOME 2439 01:45:04,420 --> 01:45:05,521 INCLUDE FOR THE INITIAL STAY. 2440 01:45:05,521 --> 01:45:07,657 THEY DID A FOLLOW-UP ANALYSIS IN 2441 01:45:07,657 --> 01:45:09,258 THE FIRST YEAR OF LIFE AND FOUND 2442 01:45:09,258 --> 01:45:11,527 THE OVER ALL SAVINGS FOR THE 2443 01:45:11,527 --> 01:45:13,896 FIRST ENTIRE YEARLY OF THE 2444 01:45:13,896 --> 01:45:15,765 INFANT'S LIFE WAS OVER $150,000 2445 01:45:15,765 --> 01:45:17,600 IN TERMS OF CARE BECAUSE OF THE 2446 01:45:17,600 --> 01:45:18,901 WHOLE GENOME SEQUENCING. 2447 01:45:18,901 --> 01:45:22,138 AND WHEN I SPOKE TO STEVEN 2448 01:45:22,138 --> 01:45:24,073 KINGSMORE ABOUT THE PROGRAM I 2449 01:45:24,073 --> 01:45:28,744 SAID, WHAT ABOUT THE OTHER 51% 2450 01:45:28,744 --> 01:45:31,380 WHERE YOU DIDN'T IDENTIFY 2451 01:45:31,380 --> 01:45:35,184 GENOMIC ABNORMALITIES IS IT 2452 01:45:35,184 --> 01:45:36,486 POSSIBLE WE'LL IDENTIFY BENEFITS 2453 01:45:36,486 --> 01:45:39,255 AND HE SAID IT'S INTERESTING YOU 2454 01:45:39,255 --> 01:45:41,457 SAY THAT BECAUSE WE SECURED 2455 01:45:41,457 --> 01:45:43,459 ADDITIONAL FUNDING SO WE'RE 2456 01:45:43,459 --> 01:45:45,461 GOING TO TRACK THESE KIDS OVER 2457 01:45:45,461 --> 01:45:47,129 THE NEXT FIVE YEARS TO SEE IF 2458 01:45:47,129 --> 01:45:49,799 THEY COME DOWN. 2459 01:45:49,799 --> 01:45:51,234 IF WE RECOGNIZE SOMETHING THAT 2460 01:45:51,234 --> 01:45:53,769 THEY HAVE BECAUSE IT'S BEEN 2461 01:45:53,769 --> 01:45:54,904 SOMETHING THAT'S REPORTED IN THE 2462 01:45:54,904 --> 01:45:55,438 LITERATURE. 2463 01:45:55,438 --> 01:45:57,740 THE ARTICLE ON THE PUBLICATION 2464 01:45:57,740 --> 01:46:00,643 TON THE RIGHT-HAND SIDE AN 2465 01:46:00,643 --> 01:46:03,379 AUTOMATED 13.5 HOUR SYSTEM FOR 2466 01:46:03,379 --> 01:46:05,314 SCALABLE DIAGNOSIS CLEARLY I 2467 01:46:05,314 --> 01:46:07,216 DONT THINK THE EXPECTATION IS TO 2468 01:46:07,216 --> 01:46:10,186 HAVE A CHILD'S GENOME SEQUENCE 2469 01:46:10,186 --> 01:46:11,320 PRODUCED WHILE A CHILD IN THE 2470 01:46:11,320 --> 01:46:14,257 NICU AND HAVE THE CLINICIAN 2471 01:46:14,257 --> 01:46:17,627 TRYING TO FIGURE OUT WHAT IT ALL 2472 01:46:17,627 --> 01:46:17,827 MEANS. 2473 01:46:17,827 --> 01:46:20,730 THEY'VE CREATED AN AUTOMATED 2474 01:46:20,730 --> 01:46:22,131 SYSTEM WHERE THE SEQUENCING IS 2475 01:46:22,131 --> 01:46:24,200 DONE AND YOU CAN SEE THEY REFER 2476 01:46:24,200 --> 01:46:27,136 TO IT AS A GENOME TREATMENT AND 2477 01:46:27,136 --> 01:46:32,174 EVALUATING NEARLY 10,000 DRUG 2478 01:46:32,174 --> 01:46:36,178 DEVICES, DIETARY INTERVENTIONS 2479 01:46:36,178 --> 01:46:39,382 AHAVE OVER 1500 INTERVENTIONS SO 2480 01:46:39,382 --> 01:46:40,750 IT'S AUTOMATED. 2481 01:46:40,750 --> 01:46:41,717 ONCE IT'S DONE THE ANALYSIS CAN 2482 01:46:41,717 --> 01:46:44,186 TELL YOU IF YOU FALL INTO THE 2483 01:46:44,186 --> 01:46:47,557 SET, THIS IS WHAT YOU NEED TO 2484 01:46:47,557 --> 01:46:49,025 DO. 2485 01:46:49,025 --> 01:46:50,660 THIS IS NOT JUST BRINGING 2486 01:46:50,660 --> 01:46:52,194 SEQUENCING IN BUT HOW WE CAN USE 2487 01:46:52,194 --> 01:46:57,800 IT AND USE IT EFFECTIVELY ACROSS 2488 01:46:57,800 --> 01:47:02,471 A BROAD HEALTH CARE SYSTEM OR 2489 01:47:02,471 --> 01:47:06,943 CURRENT BALKANIZED SYSTEM. 2490 01:47:06,943 --> 01:47:10,313 WE HAVE CONTINUED TO DELIVER 2491 01:47:10,313 --> 01:47:13,649 OVER AND OVER AGAIN WITH N3C. 2492 01:47:13,649 --> 01:47:14,650 ONE Cs IS COVID. 2493 01:47:14,650 --> 01:47:16,185 WE'RE CONVERTING THAT TO 2494 01:47:16,185 --> 01:47:22,091 CLINICAL. 2495 01:47:22,091 --> 01:47:26,062 N3C IS STILL LIVING. 2496 01:47:26,062 --> 01:47:30,666 WE CONCEPTUALIZED THIS AND SENT 2497 01:47:30,666 --> 01:47:32,134 NOTICES ASKING FOR THE 2498 01:47:32,134 --> 01:47:33,169 INDIVIDUAL INSTITUTIONS 2499 01:47:33,169 --> 01:47:36,839 SUPPLYING DATA IF THEY WOULD SO 2500 01:47:36,839 --> 01:47:38,307 CHOOSE THEY COULD RE-ENLIST FOR 2501 01:47:38,307 --> 01:47:40,343 ANOTHER FIVE YEARS. 2502 01:47:40,343 --> 01:47:44,180 I CAN SAY MOST HAVE DONE THAT. 2503 01:47:44,180 --> 01:47:47,516 N3C COVID CONTINUES TO REMAIN 2504 01:47:47,516 --> 01:47:57,627 OPEN. 2505 01:47:59,762 --> 01:48:03,366 AND IN OUR TRANSLATION TO 2506 01:48:03,366 --> 01:48:05,234 CLINICAL WE HAVE THREE PILOTS 2507 01:48:05,234 --> 01:48:06,335 GOING ON. 2508 01:48:06,335 --> 01:48:11,173 ONE IS THE DATA SCIENCE ENCLAVE 2509 01:48:11,173 --> 01:48:15,011 WAS SOMETHING ODSS, THE NIH DATA 2510 01:48:15,011 --> 01:48:16,178 SCIENCE GROUP, CAME TO US AND 2511 01:48:16,178 --> 01:48:18,748 WAS LOOKING FOR AN EDUCATIONAL 2512 01:48:18,748 --> 01:48:19,115 RESOURCE. 2513 01:48:19,115 --> 01:48:25,021 ONE OF THE PROJECTS WITHIN N3C 2514 01:48:25,021 --> 01:48:28,391 HIT AND UTILIZED WITH THE 2515 01:48:28,391 --> 01:48:32,294 CREATION OF SYNTHETIC DATA. 2516 01:48:32,294 --> 01:48:35,631 THE ADVANTAGE IS THOUGH IT 2517 01:48:35,631 --> 01:48:38,034 EXACTLY REPLICATES WHAT IS 2518 01:48:38,034 --> 01:48:39,769 WITHIN AN E.H.R. YOU DO NOT NEED 2519 01:48:39,769 --> 01:48:41,971 TO GO TO AN IRB IN TERMS OF 2520 01:48:41,971 --> 01:48:45,341 USING IT SO IT'S AN EDUCATIONAL 2521 01:48:45,341 --> 01:48:48,344 TOOL AND A LARGE DATA SET THAT 2522 01:48:48,344 --> 01:48:49,245 BECOMES AVAILABLE FOR PEOPLE TO 2523 01:48:49,245 --> 01:48:51,047 LEARN HOW TO BEGIN WORKING ON 2524 01:48:51,047 --> 01:48:53,349 THE LARGE DATA SETS. 2525 01:48:53,349 --> 01:48:54,050 WE'RE NOT THE ONLY ONES 2526 01:48:54,050 --> 01:48:55,317 INTERESTED IN THIS. 2527 01:48:55,317 --> 01:48:58,054 I SHOULD ADD THE ONC, OFFICE OF 2528 01:48:58,054 --> 01:49:01,424 THE NATIONAL COORDINATOR HAS 2529 01:49:01,424 --> 01:49:02,825 BEEN VERY MUCH INTERESTED IN 2530 01:49:02,825 --> 01:49:03,693 SYNTHETIC DATA SETS BECAUSE 2531 01:49:03,693 --> 01:49:05,327 VENDORS WHO WOULD LIKE TO 2532 01:49:05,327 --> 01:49:10,332 OPERATE WITH E.H.R. DATA SHOW 2533 01:49:10,332 --> 01:49:14,503 THEY HAVE SOFTWARE AND NEED 2534 01:49:14,503 --> 01:49:16,038 SOMETHING TO WORK WITH AND THE 2535 01:49:16,038 --> 01:49:19,508 LAST THING YOU WANT TO DO IS 2536 01:49:19,508 --> 01:49:20,710 GIVE PERSONAL DATA. 2537 01:49:20,710 --> 01:49:31,220 SYNTHETIC DATA SET ARE USEFUL. 2538 01:49:31,587 --> 01:49:34,890 AND EXTEND THE ABILITIES OF 2539 01:49:34,890 --> 01:49:35,791 SYNTHETIC DATA. 2540 01:49:35,791 --> 01:49:39,328 THE OTHER A RENAL AND CANCER 2541 01:49:39,328 --> 01:49:39,562 ENCLAVE. 2542 01:49:39,562 --> 01:49:41,297 THERE'S A WHOLE ALPHABET SOUP OF 2543 01:49:41,297 --> 01:49:44,967 DIFFERENT GROUPS THAT HAVE BEEN 2544 01:49:44,967 --> 01:49:45,835 INTERESTED IN THIS NOT JUST 2545 01:49:45,835 --> 01:49:47,837 WITHIN NIH BUT OBVIOUSLY WITH 2546 01:49:47,837 --> 01:49:49,438 RENAL WE HAVE NIDDK AND WITH 2547 01:49:49,438 --> 01:49:54,376 CANCER WE HAVE NCI BUT OTHER 2548 01:49:54,376 --> 01:49:56,579 GROUPS INCLUDING THE FDA AND THE 2549 01:49:56,579 --> 01:49:58,581 ASSISTANT SECRETARY FOR PLANNING 2550 01:49:58,581 --> 01:50:00,483 AND EVALUATION AT HHS HAVE BEEN 2551 01:50:00,483 --> 01:50:01,250 VERY MUCH INTERESTED IN THESE 2552 01:50:01,250 --> 01:50:03,886 TYPES OF APPLICATIONS AND HAVE 2553 01:50:03,886 --> 01:50:05,788 PONIED UP FUNDING TO SUPPORT 2554 01:50:05,788 --> 01:50:06,355 THESE EFFORTS. 2555 01:50:06,355 --> 01:50:14,697 SO THESE PILOTS ARE REALLY A 2556 01:50:14,697 --> 01:50:15,397 CRITICAL EVALUATION TO 2557 01:50:15,397 --> 01:50:17,333 UNDERSTAND THE REQUIREMENTS FOR 2558 01:50:17,333 --> 01:50:19,935 THE INFRASTRUCTURE NEEDED TO 2559 01:50:19,935 --> 01:50:22,505 SUPPORT THIS TYPE OF WORK AS 2560 01:50:22,505 --> 01:50:23,606 WELL AS RESOURCES INSTITUTIONS 2561 01:50:23,606 --> 01:50:24,240 NEED TO BE ABLE TO TAKE 2562 01:50:24,240 --> 01:50:26,776 ADVANTAGE MUCH IT. 2563 01:50:26,776 --> 01:50:29,378 I THINK IT'S DEMONSTRATING THE 2564 01:50:29,378 --> 01:50:31,947 ABILITY OF THE LINKAGE OF 2565 01:50:31,947 --> 01:50:34,150 MULTIPLE DATA SETS TO PROVIDE 2566 01:50:34,150 --> 01:50:38,120 VALUABLE AND USEFUL INFORMATION 2567 01:50:38,120 --> 01:50:43,759 AND I THINK WE'VE GOTTEN 2568 01:50:43,759 --> 01:50:44,794 INQUIRIES ABOUT DIFFERENT 2569 01:50:44,794 --> 01:50:45,561 ENCLAVES. 2570 01:50:45,561 --> 01:50:50,466 ONE ADVANTAGE IS BECAUSE OF THE 2571 01:50:50,466 --> 01:50:52,067 HARMONIZATION TECHNOLOGY N3C 2572 01:50:52,067 --> 01:50:52,835 UTILIZES TO CONVERT THE 2573 01:50:52,835 --> 01:50:55,504 INDIVIDUAL E.H.R.s TO A SINGLE 2574 01:50:55,504 --> 01:50:57,673 STANDARD, WHAT IT MEANS IS THAT 2575 01:50:57,673 --> 01:51:00,576 IF AN INSTITUTION WERE TO BE IN 2576 01:51:00,576 --> 01:51:03,045 THE RENAL ENCLAVE, THEIR ENTIRE 2577 01:51:03,045 --> 01:51:05,247 E.H.R. DATA IS HARMONIZED AND 2578 01:51:05,247 --> 01:51:09,118 WHAT'S EXTRACTED IS JUST A 2579 01:51:09,118 --> 01:51:10,486 SPECIFIC RENAL PATIENT 2580 01:51:10,486 --> 01:51:11,821 INFORMATION THAT IS NECESSARY 2581 01:51:11,821 --> 01:51:15,658 BUT IF THEY CHOOSE AT A LATER 2582 01:51:15,658 --> 01:51:22,498 POINT TO ENTER THE ENCLAVE THEIR 2583 01:51:22,498 --> 01:51:25,835 DATA IS HARMONIZED SO THREES A 2584 01:51:25,835 --> 01:51:27,469 SCALABILITY HERE THAT MAKES IT 2585 01:51:27,469 --> 01:51:30,339 EASIER TO ADD MORE AND MORE 2586 01:51:30,339 --> 01:51:31,574 ENCLAVES AS WE GO. 2587 01:51:31,574 --> 01:51:32,842 THERE'S STILL AN INFRASTRUCTURE 2588 01:51:32,842 --> 01:51:35,277 AND COMPUTING COSTS ARE 2589 01:51:35,277 --> 01:51:36,345 SOMETHING THAT HAVE TO BE DEALT 2590 01:51:36,345 --> 01:51:36,912 WITH. 2591 01:51:36,912 --> 01:51:39,181 WITH THE ENCLAVES THEY'RE 2592 01:51:39,181 --> 01:51:40,850 TEACHING US AND WILL DEMONSTRATE 2593 01:51:40,850 --> 01:51:41,550 THE POWER OF WHAT BIG DATA CAN 2594 01:51:41,550 --> 01:51:44,186 ACCOMPLISH. 2595 01:51:44,186 --> 01:51:47,423 THESE ARE ALL CENTRALIZED 2596 01:51:47,423 --> 01:51:50,159 DATABASES AND WE HAVE A 2597 01:51:50,159 --> 01:51:50,993 FEDERATED EFFORT. 2598 01:51:50,993 --> 01:51:52,194 THE ENACT SYSTEM. 2599 01:51:52,194 --> 01:51:53,562 THEY'VE BEEN BRINGING THEMSELVES 2600 01:51:53,562 --> 01:51:56,332 ONLINE BUT THERE'S NOW MORE THAN 2601 01:51:56,332 --> 01:52:02,872 50 CTSAs UTILIZING OVER 140 2602 01:52:02,872 --> 01:52:06,408 MILLION PATIENT E.H.R.s. 2603 01:52:06,408 --> 01:52:07,977 THE IDEA WHILE THERE'S CERTAINLY 2604 01:52:07,977 --> 01:52:09,545 THE CAPABILITY FOR RESEARCH, 2605 01:52:09,545 --> 01:52:11,080 THIS WAS ALSO WITH THE INTENTION 2606 01:52:11,080 --> 01:52:14,350 TO MAKE THIS MORE PRACTICAL FOR 2607 01:52:14,350 --> 01:52:15,184 INDIVIDUAL CLINICIANS. 2608 01:52:15,184 --> 01:52:18,621 SOMEONE DOES NOT HAVE TO BE A 2609 01:52:18,621 --> 01:52:22,992 Ph.D. DATA SCIENTIST OR Ph.D. 2610 01:52:22,992 --> 01:52:23,692 INFORMATIC SPECIALIST TO TAKE 2611 01:52:23,692 --> 01:52:24,193 ADVANTAGE. 2612 01:52:24,193 --> 01:52:28,197 THESE THINGS SHOULD BE MUCH MORE 2613 01:52:28,197 --> 01:52:31,300 USER AVAILABLE IN TERMS OF 2614 01:52:31,300 --> 01:52:33,302 DECISION MAKING CAPABILITY. 2615 01:52:33,302 --> 01:52:35,404 WANTED TO HIGHLIGHT SOMETHING 2616 01:52:35,404 --> 01:52:41,410 THAT WAS STARTED PRE COVID AND 2617 01:52:41,410 --> 01:52:43,245 SIDE TRACKED A LITTLE BIT 2618 01:52:43,245 --> 01:52:47,416 BECAUSE OF COVID BUT HAS DONE 2619 01:52:47,416 --> 01:52:47,683 NICELY. 2620 01:52:47,683 --> 01:52:49,451 THE OPIOID CRISIS LEADING TO THE 2621 01:52:49,451 --> 01:52:51,120 NIH HEAL ACTIVITIES. 2622 01:52:51,120 --> 01:52:55,291 WE PRODUCED THE MAIN MANAGEMENT 2623 01:52:55,291 --> 01:52:56,825 EFFECTIVENESS RESEARCH NEXT OR 2624 01:52:56,825 --> 01:52:58,460 PAIN ERN. 2625 01:52:58,460 --> 01:53:01,830 THE IDEA IS THERE'S MANY AREAS 2626 01:53:01,830 --> 01:53:03,232 OF THE BIOMEDICAL SPACE THAT DO 2627 01:53:03,232 --> 01:53:08,737 NOT HAVE AN OBVIOUS HOME AT HNI 2628 01:53:08,737 --> 01:53:11,407 AND PAIN IS ONE OF THOSE. 2629 01:53:11,407 --> 01:53:14,276 ALMOST EVERY I.C. HAS PAIN. 2630 01:53:14,276 --> 01:53:15,678 BUT WE DON'T HAVE AN NATIONAL 2631 01:53:15,678 --> 01:53:18,113 INSTITUTE OF PAIN IN ANY WAY. 2632 01:53:18,113 --> 01:53:20,182 SO THE ABILITY FOR PAIN TO BE 2633 01:53:20,182 --> 01:53:23,886 EFFECTIVELY THE SPECTRUM OF PAIN 2634 01:53:23,886 --> 01:53:24,653 IS VARIABLE. 2635 01:53:24,653 --> 01:53:29,325 IF YOU'RE A WELL RESOURCED I.C. 2636 01:53:29,325 --> 01:53:32,094 LIKE SAY NCI YOU MAY BE ABLE TO 2637 01:53:32,094 --> 01:53:36,332 HANDLE THIS BUT OTHER SMALLER 2638 01:53:36,332 --> 01:53:40,169 I.C.s HAVE DIFFICULTIES. 2639 01:53:40,169 --> 01:53:47,009 YOU CAN SEE THE PARTNERS 2640 01:53:47,009 --> 01:53:47,409 INVOLVED. 2641 01:53:47,409 --> 01:53:50,179 THE FOUR BLUE ONES YOU SEE ALL 2642 01:53:50,179 --> 01:53:52,181 FULLY ENROLLED THOSE WERE 2643 01:53:52,181 --> 01:53:54,483 STARTED IN 2019. 2644 01:53:54,483 --> 01:53:59,288 THE ONE BEGAN IN 2020 AND GOT 2645 01:53:59,288 --> 01:54:01,390 MORE SIDE TRACKED BECAUSE OF 2646 01:54:01,390 --> 01:54:03,826 COVID IS NEARING COMPLETION. 2647 01:54:03,826 --> 01:54:06,462 THE SICKLE CELL WAS NOT AWARDED 2648 01:54:06,462 --> 01:54:10,432 UNTIL FY23 AND ANTICIPATE FIRST 2649 01:54:10,432 --> 01:54:13,869 PATIENT IN PROBABLY NEXT MONTH. 2650 01:54:13,869 --> 01:54:16,138 THE THREE LOWER ONES ARE WHAT WE 2651 01:54:16,138 --> 01:54:18,907 REFER TO AS LIFE TOUCH. 2652 01:54:18,907 --> 01:54:21,777 THEY DIDN'T INVOLVE THE FULL 2653 01:54:21,777 --> 01:54:22,945 PAIN NETWORK BUT WE DID PROVIDE 2654 01:54:22,945 --> 01:54:24,313 RESOURCES TO HELP THEM ACHIEVE 2655 01:54:24,313 --> 01:54:24,780 IT. 2656 01:54:24,780 --> 01:54:28,083 YOU CAN SEE EVEN WITH COVID THE 2657 01:54:28,083 --> 01:54:29,418 COMPLETION RATE HAS BEEN 2658 01:54:29,418 --> 01:54:34,957 ABSOLUTELY PHENOMENAL IN THIS 2659 01:54:34,957 --> 01:54:37,192 REGARD AND THERE'S MUCH 2660 01:54:37,192 --> 01:54:38,961 SATISFACTION ACROSS NIH FOR THE 2661 01:54:38,961 --> 01:54:41,163 ABILITY OF DIFFERENT INSTITUTES 2662 01:54:41,163 --> 01:54:41,797 TO BE ABLE TO PARTICIPATE IN 2663 01:54:41,797 --> 01:54:44,633 THIS EFFORT SUCH THAT WE'VE BEEN 2664 01:54:44,633 --> 01:54:51,774 ASKED TO BEGIN CONSIDERATIONS OF 2665 01:54:51,774 --> 01:54:52,508 RE-COMPETITION FOR THIS IN THE 2666 01:54:52,508 --> 01:54:54,276 NEXT COUPLE YEARS. 2667 01:54:54,276 --> 01:54:55,844 WE HAVE QUITE A BIT OF 2668 01:54:55,844 --> 01:54:56,445 RECOGNITION BEYOND NCATS. 2669 01:54:56,445 --> 01:54:59,415 WE DO HAVE A NUMBER OF 2670 01:54:59,415 --> 01:55:00,783 ADMINISTRATIVE SUPPLEMENTS THAT 2671 01:55:00,783 --> 01:55:03,585 COME FROM ACROSS NIH. 2672 01:55:03,585 --> 01:55:05,854 YOU CAN SEE NIDA PROVIDED SOME 2673 01:55:05,854 --> 01:55:10,392 FUNDING FOR US AND THEN A NUMBER 2674 01:55:10,392 --> 01:55:15,431 OF TRANS-NIH ACTIVITIES LARGELY 2675 01:55:15,431 --> 01:55:16,799 COMING FROM THE OFFICE OF 2676 01:55:16,799 --> 01:55:18,801 SCIENCE POLICY OR THE OF THE OF 2677 01:55:18,801 --> 01:55:22,438 THE DIRECTOR AT NIH. 2678 01:55:22,438 --> 01:55:26,809 THE TWO INCLUDE PART OF A DOWN 2679 01:55:26,809 --> 01:55:28,444 SYNDROME PROGRAM TRANS NIH AND 2680 01:55:28,444 --> 01:55:29,711 THEY'VE BEEN PLEASED WITH OUR 2681 01:55:29,711 --> 01:55:32,181 INVOLVEMENT IN THAT OVER THE 2682 01:55:32,181 --> 01:55:35,350 LAST SEVERAL YEARS. 2683 01:55:35,350 --> 01:55:37,419 I'M GOING TO RUN THROUGH 2684 01:55:37,419 --> 01:55:37,953 HIGHLIGHTS. 2685 01:55:37,953 --> 01:55:39,321 THESE ARE THINGS PEOPLE HAVE 2686 01:55:39,321 --> 01:55:44,560 BROUGHT TO MY ATTENTION RANDOMLY 2687 01:55:44,560 --> 01:55:45,160 PIQUED MY INTEREST. 2688 01:55:45,160 --> 01:55:47,996 SO THIS IS AN INTERESTING STORY 2689 01:55:47,996 --> 01:55:50,499 BECAUSE IF YOU LOOK AT THE 2690 01:55:50,499 --> 01:55:52,734 ATHEROSCLEROSIS ARTICLE ON THE 2691 01:55:52,734 --> 01:56:03,278 RIGHT PUBLISHED IN 2021, THE TWO 2692 01:56:08,784 --> 01:56:13,822 MAJOR OMEGA 3 FATTY ACIDS 2693 01:56:13,822 --> 01:56:17,493 REFERRED TO AS FISH OIL DIFFER 2694 01:56:17,493 --> 01:56:20,162 IN THEIR BEHAVIOR. 2695 01:56:20,162 --> 01:56:21,630 THE INTERESTING THING IS THIS 2696 01:56:21,630 --> 01:56:27,136 WAS NOT FUNDED BY NIH BUT THE 2697 01:56:27,136 --> 01:56:27,569 USDA. 2698 01:56:27,569 --> 01:56:29,404 I WOULDN'T HAVE THOUGHT TRADE BE 2699 01:56:29,404 --> 01:56:34,776 INTERESTED BUT THEY WERE. 2700 01:56:34,776 --> 01:56:37,746 THE SUBSEQUENT RESULTS OF THE 2701 01:56:37,746 --> 01:56:44,186 TRIALS LED TO A SERIES AND THE 2702 01:56:44,186 --> 01:56:48,056 2024 ARTICLE ON THE LEFT THEY'VE 2703 01:56:48,056 --> 01:56:53,929 ENGAGED CTSA S AND THIS IS SAY 2704 01:56:53,929 --> 01:56:54,663 COLLABORATION AND THE 2705 01:56:54,663 --> 01:56:57,833 INTERESTING FEATURE WITH THE 2706 01:56:57,833 --> 01:57:00,135 ANALYSIS IS WHILE EPA AND DHA 2707 01:57:00,135 --> 01:57:01,837 DIFFER IN TERMS OF BEHAVIOR, 2708 01:57:01,837 --> 01:57:04,139 WHICH MEANS IF YOU'RE LOOKING AT 2709 01:57:04,139 --> 01:57:07,276 CARDIOVASCULAR STUDIES THAT USED 2710 01:57:07,276 --> 01:57:09,011 FISH OIL WHETHER YOU USE PURE 2711 01:57:09,011 --> 01:57:16,018 EPA OR DHA OR A MIXTURE OF JUST 2712 01:57:16,018 --> 01:57:17,486 REGULAR FISH OIL YOU'LL GET 2713 01:57:17,486 --> 01:57:18,387 DIFFERENT RESULTS. 2714 01:57:18,387 --> 01:57:21,590 WHAT THEY'VE SHOWN RECENTLY IS 2715 01:57:21,590 --> 01:57:23,525 THAT MEN AND WOMEN DIFFER IN HOW 2716 01:57:23,525 --> 01:57:30,766 THEY RESPOND TO THIS. 2717 01:57:30,766 --> 01:57:34,002 THIS PROBABLY UNDER LIES THE 2718 01:57:34,002 --> 01:57:34,937 OBSERVED VARIABILITY IN RESPOND 2719 01:57:34,937 --> 01:57:39,975 TO EPA AND DHA IN WOMEN CAN 2720 01:57:39,975 --> 01:57:42,477 EXPLAIN CONFLICTING RESULTS IN 2721 01:57:42,477 --> 01:57:43,078 CARDIOVASCULAR DISEASE FROM 2722 01:57:43,078 --> 01:57:44,179 OTHER TRIALS. 2723 01:57:44,179 --> 01:57:46,548 THIS IS SORTING OUT WHY THERE'S 2724 01:57:46,548 --> 01:57:47,849 A DIFFERENCE IN REPORTING ON THE 2725 01:57:47,849 --> 01:57:54,289 EFFECTS OF EPA AND DHA. 2726 01:57:54,289 --> 01:57:57,593 AND IT'S MEN AND WOMEN DIFFERING 2727 01:57:57,593 --> 01:57:59,461 IN HOW THEY RESPOND AND IN THE 2728 01:57:59,461 --> 01:58:04,166 CASE OF MEN THEY TEND TO HAVE I 2729 01:58:04,166 --> 01:58:05,767 AGREATER PRODUCTION PRORESULTING 2730 01:58:05,767 --> 01:58:06,768 POLARIZATION AND WOMEN HAVE A 2731 01:58:06,768 --> 01:58:09,905 GREATER REDUCTION IN 2732 01:58:09,905 --> 01:58:11,173 PRO-INFLAMMATORY SIGNALLING 2733 01:58:11,173 --> 01:58:12,874 WHICH MEANS THERE MAY BE VERY 2734 01:58:12,874 --> 01:58:16,478 DIFFERENT RISK FACTORS GOING ON 2735 01:58:16,478 --> 01:58:18,447 IN THESE TWO. 2736 01:58:18,447 --> 01:58:20,048 THIS SHOULD BE TAKEN INTO 2737 01:58:20,048 --> 01:58:20,682 CONSIDERATION IN TERMS OF FUTURE 2738 01:58:20,682 --> 01:58:22,918 TRIALS. 2739 01:58:22,918 --> 01:58:25,454 WE HAVE A VERY INTERESTING GROUP 2740 01:58:25,454 --> 01:58:30,792 AT THE UNIVERSITY OF NEW MEXICO. 2741 01:58:30,792 --> 01:58:35,030 MATTHEW CAMPIN IS THE P.I. AND 2742 01:58:35,030 --> 01:58:39,101 HAS BEEN A LEADER IN THE MICRO 2743 01:58:39,101 --> 01:58:39,801 NANO PLASTICS ISSUE WE'RE 2744 01:58:39,801 --> 01:58:40,569 HEARING SO MUCH ABOUT. 2745 01:58:40,569 --> 01:58:42,337 THIS IS FROM A RECENT ARTICLE 2746 01:58:42,337 --> 01:58:45,507 THEY HAVE IN TERMS OF 2747 01:58:45,507 --> 01:58:45,874 QUANTIFICATION. 2748 01:58:45,874 --> 01:58:47,142 THEY PUT A LOT OF EFFORT INTO 2749 01:58:47,142 --> 01:58:52,080 DEVELOPING THE ASSAYS THAT ARE 2750 01:58:52,080 --> 01:58:55,817 ABLE TO MEASURE THE MICRO 2751 01:58:55,817 --> 01:58:58,353 PLASTICS IN A VARIETY OF TISSUE 2752 01:58:58,353 --> 01:58:59,554 AND LOOK AT THE LIGHT BLUE 2753 01:58:59,554 --> 01:59:01,757 COLUMN WITH THE BRAIN AND SHOULD 2754 01:59:01,757 --> 01:59:04,192 SEND RED FLAGS IMMEDIATELY AND 2755 01:59:04,192 --> 01:59:12,601 GET PEOPLE TO NOTICE. 2756 01:59:12,601 --> 01:59:14,136 THIS IS SOMETHING THAT I THINK 2757 01:59:14,136 --> 01:59:16,171 WILL GET MORE ATTENTION AND 2758 01:59:16,171 --> 01:59:21,009 NILES -- NICE TO SEE THE CTSA 2759 01:59:21,009 --> 01:59:23,912 DRAWING ATTENTION TO IT. 2760 01:59:23,912 --> 01:59:28,150 AT WASH-U THEY ARE DEVELOPED A 2761 01:59:28,150 --> 01:59:33,088 DIAGNOSTIC TEST BASED ON GENOME 2762 01:59:33,088 --> 01:59:35,557 SEQUENCING FOR MYELOID PLASTIC 2763 01:59:35,557 --> 01:59:46,301 SYNDROME AND LEUKEMIA CHOMEMOSI 2764 01:59:47,402 --> 01:59:51,707 THEY BECAME THE FIRST WHOLE 2765 01:59:51,707 --> 01:59:54,976 GENOME TESTING TO BE APPROVED BY 2766 01:59:54,976 --> 01:59:55,277 CMS. 2767 01:59:55,277 --> 01:59:59,481 IT'S SIGNIFICANT -- CHROMO SEQ 2768 01:59:59,481 --> 02:00:03,218 AND WE'RE SEEING THIS ACTUALLY 2769 02:00:03,218 --> 02:00:06,788 MANIFEST TO PATIENT CARE. 2770 02:00:06,788 --> 02:00:08,557 THIS IS AN INTERESTING STUDY OUT 2771 02:00:08,557 --> 02:00:12,627 OF DAVIS. 2772 02:00:12,627 --> 02:00:14,830 SO I CAN SAY THAT BACK WHEN I 2773 02:00:14,830 --> 02:00:17,232 WAS IN MEDICAL SCHOOL, GRANTED 2774 02:00:17,232 --> 02:00:22,804 WAS A LONG TIME AGO, I'LL ADMIT. 2775 02:00:22,804 --> 02:00:26,208 I WAS ONCE A CAESAREAN ALWAYS A 2776 02:00:26,208 --> 02:00:30,112 CAESAREAN AND THERE'S A TRIAL OF 2777 02:00:30,112 --> 02:00:31,580 LABOR ACT CAESAREAN. 2778 02:00:31,580 --> 02:00:35,584 RATHER THAN HAVING A WOMAN DO A 2779 02:00:35,584 --> 02:00:38,120 CAESAREAN AGAIN IT'S GIVING THE 2780 02:00:38,120 --> 02:00:39,855 OPTION OF DOING A TRIAL OF 2781 02:00:39,855 --> 02:00:40,055 LABOR. 2782 02:00:40,055 --> 02:00:40,922 THERE IS SOME CONCERN BUT THERE 2783 02:00:40,922 --> 02:00:47,596 HAD BEEN A CALCULATOR AND IN 2784 02:00:47,596 --> 02:00:52,267 2022 THE NICHD RELEASED 2785 02:00:52,267 --> 02:00:53,668 CALCULATOR WITH RACE AS A 2786 02:00:53,668 --> 02:00:59,574 VARIABLE AND THE UC DAVIS CTSA 2787 02:00:59,574 --> 02:01:00,642 WENT ON TO VALIDATE THE 2788 02:01:00,642 --> 02:01:03,011 CALCULATOR WITH THEIR OWN DATA 2789 02:01:03,011 --> 02:01:05,447 AND THEY FOUND THE RISK IT 2790 02:01:05,447 --> 02:01:08,183 SEEMED TO WORK AS WELL IN TERMS 2791 02:01:08,183 --> 02:01:09,251 OF PREDICTING RISK AND THE 2792 02:01:09,251 --> 02:01:13,255 AVERAGE PREDICTED SUCCESS OF 2793 02:01:13,255 --> 02:01:16,124 WHAT IS THE TRIAL OF LABOR AFTER 2794 02:01:16,124 --> 02:01:20,395 CAESAREAN IMPROVED FOR BLACK AND 2795 02:01:20,395 --> 02:01:21,963 HISPANIC WOMEN. 2796 02:01:21,963 --> 02:01:28,737 I THINK THEY ARE SATISFIED AND 2797 02:01:28,737 --> 02:01:35,677 UTILIZING AND COULD ADOPT THIS 2798 02:01:35,677 --> 02:01:42,050 MOVING IT FORWARD. 2799 02:01:42,050 --> 02:01:43,852 SERGIO TAUGHT ME THE DIFFERENCE 2800 02:01:43,852 --> 02:01:45,954 BETWEEN TRUST AND 2801 02:01:45,954 --> 02:01:46,321 TRUSTWORTHINESS. 2802 02:01:46,321 --> 02:01:51,426 THIS IS FROM THE UNIVERSITY OF 2803 02:01:51,426 --> 02:01:55,096 KENTUCKY CTSA AND IDENTIFYING 2804 02:01:55,096 --> 02:01:56,364 CHURCH LEADERS AND UNDERSTANDING 2805 02:01:56,364 --> 02:01:58,834 THEIR PERSPECTIVE IN TERMS OF 2806 02:01:58,834 --> 02:02:03,705 COLORECTAL CANCER SCREENING 2807 02:02:03,705 --> 02:02:04,239 PARTICULARLY FOR AFRICAN 2808 02:02:04,239 --> 02:02:05,607 AMERICAN PEOPLE FROM KENTUCKY 2809 02:02:05,607 --> 02:02:07,509 AND UTILIZING THE ADVANTAGES OF 2810 02:02:07,509 --> 02:02:09,711 THE CHURCH AS A TRUSTED CENTER 2811 02:02:09,711 --> 02:02:11,847 FOR COMMUNITY SUPPORT AND 2812 02:02:11,847 --> 02:02:13,215 EMPOWERMENT. 2813 02:02:13,215 --> 02:02:17,385 CLEARLY COLORECTAL CANCER 2814 02:02:17,385 --> 02:02:19,421 SCREENING IS INTENSE AND 2815 02:02:19,421 --> 02:02:23,225 INVOLVED AND YOU OBVIOUSLY NEED 2816 02:02:23,225 --> 02:02:24,793 QUITE A BIT OF SUPPORT AND 2817 02:02:24,793 --> 02:02:28,363 COACHING IN ORDER TO GET THROUGH 2818 02:02:28,363 --> 02:02:31,800 AND I THINK THE KENTUCKY CTSA AS 2819 02:02:31,800 --> 02:02:33,401 USED A CHURCH COMMUNITY AS A 2820 02:02:33,401 --> 02:02:38,907 MEANS FOR ACTUALLY IMPROVING 2821 02:02:38,907 --> 02:02:39,474 COLORECTAL SCREENING RATES. 2822 02:02:39,474 --> 02:02:42,844 I WANTED TO TALK ABOUT OUR MOST 2823 02:02:42,844 --> 02:02:45,280 VALUABLE PLAYERS, THE YOUNGER 2824 02:02:45,280 --> 02:02:46,014 CREW. 2825 02:02:46,014 --> 02:02:51,486 TO HIGHLIGHT ONE PARTICULAR KL2 2826 02:02:51,486 --> 02:02:57,125 SCHOLAR, CHIDIOGO AT CINCINNATI 2827 02:02:57,125 --> 02:02:59,661 CHILDREN'S HOSPITAL NAMED EMORY 2828 02:02:59,661 --> 02:03:04,165 UNIVERSITY'S NOTABLE 40 UNDER 40 2829 02:03:04,165 --> 02:03:08,169 ALUMNI AND SHE IS A KL2 SCHOLAR 2830 02:03:08,169 --> 02:03:18,346 CURRENTLY. 2831 02:03:27,088 --> 02:03:33,094 AND ALWAYS LIKE TO HIGHLIGHT 2832 02:03:33,094 --> 02:03:35,697 WHERE PEOPLE GO AFTERWARDS 2833 02:03:35,697 --> 02:03:40,368 WHAT'S IT MEAN TO HAVE A KL2 2834 02:03:40,368 --> 02:03:40,902 SCHOLAR. 2835 02:03:40,902 --> 02:03:43,672 THIS WAS A SCHOLAR FROM 2018 TO 2836 02:03:43,672 --> 02:03:46,775 2020 AND NOW THE ASSOCIATE 2837 02:03:46,775 --> 02:03:52,180 PROFESSOR OF ANESTHESIOLOGY 2838 02:03:52,180 --> 02:03:57,218 HUMAN IMPACT LAB AT WEILL 2839 02:03:57,218 --> 02:04:04,092 CORNELL AND HAS BEEN AWARDED THE 2840 02:04:04,092 --> 02:04:05,727 2023 NATIONAL ACADEMIES HEALTH 2841 02:04:05,727 --> 02:04:07,562 AND MEDICINE LONGEVITIES PRIZE 2842 02:04:07,562 --> 02:04:13,935 AND DIGITAL SOLUTIONS TO REDUCE 2843 02:04:13,935 --> 02:04:19,207 MATERNAL MORBIDITY AND MORTALITY 2844 02:04:19,207 --> 02:04:21,009 IN WOMEN AND THIS IS A MATTER OF 2845 02:04:21,009 --> 02:04:27,182 MEETING PEOPLE WHERE THEY ARE. 2846 02:04:27,182 --> 02:04:34,456 IN TERM OF T TRAINEES, CARLY IS 2847 02:04:34,456 --> 02:04:38,693 THE FIRST AUTHOR ON AN NIH 2848 02:04:38,693 --> 02:04:41,296 FUNDED RADX PROJECT. 2849 02:04:41,296 --> 02:04:42,530 THE INTERESTING RESULT OF THE 2850 02:04:42,530 --> 02:04:48,169 STUDY IS IT WAS LOOKING AT VIRAL 2851 02:04:48,169 --> 02:04:51,740 LOAD ACROSS INDIVIDUALS WITH 2852 02:04:51,740 --> 02:04:52,173 COVID. 2853 02:04:52,173 --> 02:04:56,177 AND FOUND THERE WAS A VIRAL LOAD 2854 02:04:56,177 --> 02:04:59,280 INCREASED AMONG BMI AMONG MALES 2855 02:04:59,280 --> 02:05:02,350 BUT IT REMAINS STABLE AMONG 2856 02:05:02,350 --> 02:05:05,286 FEMALES WHICH PLAY UNDER LIE 2857 02:05:05,286 --> 02:05:08,189 DIFFERENCES IN THE EFFECTS OF 2858 02:05:08,189 --> 02:05:08,923 VIRAL INFECTION DIFFERENCES 2859 02:05:08,923 --> 02:05:11,726 BETWEEN MEN AND WOMEN. 2860 02:05:11,726 --> 02:05:14,496 IT'S AN INTERESTING ANALYSIS. 2861 02:05:14,496 --> 02:05:19,234 SO IN TERMS OF A FORMER TL1 2862 02:05:19,234 --> 02:05:19,634 SCHOLAR. 2863 02:05:19,634 --> 02:05:21,002 ALISON IS A DOUBLE DIPPER 2864 02:05:21,002 --> 02:05:26,508 BECAUSE SHE WAS A T SCHOLAR AT 2865 02:05:26,508 --> 02:05:28,443 UCSF AND BECAME A CASE SCHOLAR 2866 02:05:28,443 --> 02:05:30,211 AT NORTHWESTERN AND NOW THE 2867 02:05:30,211 --> 02:05:31,413 ASSOCIATE DEAN OF RESEARCH AND 2868 02:05:31,413 --> 02:05:32,914 PROFESSOR OF CHILD, FAMILY AND 2869 02:05:32,914 --> 02:05:34,282 POPULATION HEALTH NURSING AT THE 2870 02:05:34,282 --> 02:05:35,750 UNIVERSITY OF WASHINGTON SCHOOL 2871 02:05:35,750 --> 02:05:37,752 OF NURSING. 2872 02:05:37,752 --> 02:05:40,488 SHE'S DONE QUITE A BIT IN THE 2873 02:05:40,488 --> 02:05:41,156 HIV FIELD. 2874 02:05:41,156 --> 02:05:43,558 YES, THE PEOPLE WE HIGHLIGHT WE 2875 02:05:43,558 --> 02:05:47,829 DO SUPPORT GO ON TO BIGGER AND 2876 02:05:47,829 --> 02:05:48,163 BETTER THINGS. 2877 02:05:48,163 --> 02:05:53,835 FOR OUR FY24 DIVERSION TI AND 2878 02:05:53,835 --> 02:05:56,971 RE-ENTRY SUPPLEMENT SCHOLARS WE 2879 02:05:56,971 --> 02:05:58,873 HAVE SIX. 2880 02:05:58,873 --> 02:06:01,876 TO HIGHLIGHT TWO, SUELEN IS 2881 02:06:01,876 --> 02:06:03,678 FOCUSSED ON PARKINSON'S DISEASE 2882 02:06:03,678 --> 02:06:07,115 AND DEEP BRAIN STIMULATION. 2883 02:06:07,115 --> 02:06:17,525 AND DA SHAUNDA LOOKS AT 2884 02:06:24,733 --> 02:06:28,503 MATERN 2885 02:06:28,503 --> 02:06:29,204 MATERNITY. 2886 02:06:29,204 --> 02:06:30,805 THIS PUBLICATION THAT CAME OUT 2887 02:06:30,805 --> 02:06:32,507 WHICH IS REDUCING DIAGNOSTIC 2888 02:06:32,507 --> 02:06:37,178 DELAYS IN ACUTE HEPATIC DISEASES 2889 02:06:37,178 --> 02:06:38,513 USING HEALTH RECORD DATA AND 2890 02:06:38,513 --> 02:06:43,551 MACHINE LEARNING THE SECOND 2891 02:06:43,551 --> 02:06:54,062 AUTHOR IS IS LOOKING AT THIS 2892 02:06:56,798 --> 02:07:04,773 ACUTE HEPATIC PORPHYRIA AND IT 2893 02:07:04,773 --> 02:07:07,242 CAN TAKE VERY LONG BECAUSE 2894 02:07:07,242 --> 02:07:09,210 SYMPTOMS ARE RELATIVELY NON 2895 02:07:09,210 --> 02:07:10,678 SPECIFIC. 2896 02:07:10,678 --> 02:07:13,281 SO THE ALGORITHM THEY DEVELOPED 2897 02:07:13,281 --> 02:07:15,750 WHICH IS INTRIGUING BECAUSE 2898 02:07:15,750 --> 02:07:17,051 RATHER THAN JUST LOOKING AT 2899 02:07:17,051 --> 02:07:19,387 POSITIVE AND NEGATIVE TEST 2900 02:07:19,387 --> 02:07:20,488 RESULTS THE IDEA IS LET'S LOOK 2901 02:07:20,488 --> 02:07:23,391 AT THE TESTS ORDERED TO GET AN 2902 02:07:23,391 --> 02:07:28,263 IDEA OF WHAT THE DIFFERENT 2903 02:07:28,263 --> 02:07:29,264 CLINICIANS WERE THINKING ABOUT 2904 02:07:29,264 --> 02:07:31,566 AND SEE IF WE CAN PUT IT ALL 2905 02:07:31,566 --> 02:07:32,200 TOGETHER AND COME UP WITH A 2906 02:07:32,200 --> 02:07:38,640 DIAGNOSIS EARLIER. 2907 02:07:38,640 --> 02:07:44,979 THE IDENTIFIED 71% OF THE CASES 2908 02:07:44,979 --> 02:07:46,815 A YEAR EARLIER THAN WHAT WAS 2909 02:07:46,815 --> 02:07:47,782 DONE CLINICALLY. 2910 02:07:47,782 --> 02:07:51,019 SHE WAS A SUMMER STUDENT WITH A 2911 02:07:51,019 --> 02:07:52,153 MEDICAL STUDENT AND DID THIS AS 2912 02:07:52,153 --> 02:07:53,087 A SUMMER PROJECT. 2913 02:07:53,087 --> 02:07:54,022 SHE JUST GRADUATED THIS PAST 2914 02:07:54,022 --> 02:08:01,162 MAY. 2915 02:08:01,162 --> 02:08:05,033 I'LL HAVE TO ALERT THE P.I. AT 2916 02:08:05,033 --> 02:08:08,169 DARTMOUTH AND SHE'S UP THERE NOW 2917 02:08:08,169 --> 02:08:14,008 BECAUSE IF YOU LOOK AT HER 2918 02:08:14,008 --> 02:08:14,642 LINKEDIN PROFILE THESE ALONG THE 2919 02:08:14,642 --> 02:08:15,443 LINES OF WHAT WE'RE TRYING TO DO 2920 02:08:15,443 --> 02:08:22,116 HERE. 2921 02:08:22,116 --> 02:08:26,988 THE GETS IT. 2922 02:08:26,988 --> 02:08:29,123 SHE AND TWO OTHER INDIVIDUALS 2923 02:08:29,123 --> 02:08:35,830 FOUNDED WHAT IS NOW CALLED ZEBRA 2924 02:08:35,830 --> 02:08:42,337 MD DOT ORG AND THEY HAVE THE TOP 2925 02:08:42,337 --> 02:08:51,946 THREE AFTER HEPATIC PORPHYRIA 2926 02:08:51,946 --> 02:08:53,615 AND THE DISEASE INDEX IS 2927 02:08:53,615 --> 02:08:54,749 INCREDIBLY LONG. 2928 02:08:54,749 --> 02:08:57,051 THE WEBSITE IS UP AND RUNNING 2929 02:08:57,051 --> 02:08:59,921 AND IT'S REALLY EXPLORING THE 2930 02:08:59,921 --> 02:09:03,057 POWER OF E.H.R.s TO IDENTIFY 2931 02:09:03,057 --> 02:09:03,791 UNRECOGNIZED AND UNDIAGNOSED 2932 02:09:03,791 --> 02:09:14,269 DISEASES AT THE THIS POINT. 2933 02:09:15,870 --> 02:09:18,773 AND TRAINING THE NEXT GENERATION 2934 02:09:18,773 --> 02:09:20,375 OF CUTTING EDGE PHYSICIAN 2935 02:09:20,375 --> 02:09:25,713 SCIENTISTS. 2936 02:09:25,713 --> 02:09:27,282 I HIGHLIGHT UNIVERSITY OF 2937 02:09:27,282 --> 02:09:29,550 PENNSYLVANIA HAS AN 2938 02:09:29,550 --> 02:09:31,052 UNDERGRADUATE TRANSLATIONAL 2939 02:09:31,052 --> 02:09:35,690 IMMERSION PROGRAM. 2940 02:09:35,690 --> 02:09:40,161 IN A SURVEY OF 22 PEOPLE WHO 2941 02:09:40,161 --> 02:09:42,263 HAVE GONE THROUGH THIS FROM THE 2942 02:09:42,263 --> 02:09:47,902 SURVEY THERE WERE 23 INDIVIDUALS 2943 02:09:47,902 --> 02:09:53,441 WHO GRADUATE PROGRAMS AND HALF 2944 02:09:53,441 --> 02:09:54,208 M.D.s. 2945 02:09:54,208 --> 02:09:58,579 THESE ARE TWO EXAMPLES. 2946 02:09:58,579 --> 02:10:00,081 SARA RAMIREZ AND JACKSON MALONE 2947 02:10:00,081 --> 02:10:03,184 ON THE TWO PAPERS LOOKING AT 2948 02:10:03,184 --> 02:10:05,887 GENE AND ENVIRONMENT S IN 2949 02:10:05,887 --> 02:10:06,587 MEDIATION INVOLVING ADVERSE 2950 02:10:06,587 --> 02:10:10,591 CHILDHOOD EVENTS, MOOD AND 2951 02:10:10,591 --> 02:10:14,495 ANXIETY DISORDERS AND A 2952 02:10:14,495 --> 02:10:15,129 PHENOTYPE SAMPLE AND SUBJECT USE 2953 02:10:15,129 --> 02:10:25,306 DISORDERS. 2954 02:10:25,773 --> 02:10:27,775 SARA IS AN A GRADUATE STUDENT IN 2955 02:10:27,775 --> 02:10:29,911 NEUROSCIENCE AND JACKSON JUST 2956 02:10:29,911 --> 02:10:40,254 STARTED HIS SENIOR YEAR. 2957 02:10:40,254 --> 02:10:44,425 AND THIS IS A NEW YORK 2958 02:10:44,425 --> 02:10:47,295 UNIVERSITY LANGONE CTSA. 2959 02:10:47,295 --> 02:10:49,397 PRECEDENCES IN HISTORICALLY 2960 02:10:49,397 --> 02:10:50,832 REDLINED DISTRICTS IN NEW YORK 2961 02:10:50,832 --> 02:10:53,334 CITY AREA HAVE MORE INDOOR 2962 02:10:53,334 --> 02:10:54,802 PARTICULATE AIR POLLUTION 2963 02:10:54,802 --> 02:10:56,471 POTENTIALLY REDUCIBLE BY 2964 02:10:56,471 --> 02:10:58,206 PORTABLE AIR CLEANERS. 2965 02:10:58,206 --> 02:11:01,342 WHILE WE FIND A LOT OF ISSUES WE 2966 02:11:01,342 --> 02:11:03,177 FIND IN TERMS OF REDLINE 2967 02:11:03,177 --> 02:11:04,979 DISTRICTS THIS IS ACTUALLY 2968 02:11:04,979 --> 02:11:11,953 IDENTIFYING WHAT IS A RELATIVELY 2969 02:11:11,953 --> 02:11:16,157 STRAIGHTFORWARD CORRECTIBLE 2970 02:11:16,157 --> 02:11:22,430 ASPECT OF PARTICULATE SOLUTIONS 2971 02:11:22,430 --> 02:11:28,169 AND IT'S ASSOCIATED WITH A WIDE 2972 02:11:28,169 --> 02:11:31,239 VARIETY CARDIOVASCULAR AND 2973 02:11:31,239 --> 02:11:33,741 PULMONARY PROBLEMS LATER IN LIFE 2974 02:11:33,741 --> 02:11:43,618 AND IS READILY ADDRESSABLE BY 2975 02:11:43,618 --> 02:11:44,318 CLEANING THE AIR. 2976 02:11:44,318 --> 02:11:46,854 THE TWO WON AND THEY WERE HIGH 2977 02:11:46,854 --> 02:11:48,990 SCHOOL STUDENTS AND THEY'RE 2978 02:11:48,990 --> 02:11:50,024 GIVING A PRESENTATION HERE OF 2979 02:11:50,024 --> 02:11:50,324 THEIR WORK. 2980 02:11:50,324 --> 02:11:55,096 THIS WAS A PILOT AWARD THROUGH 2981 02:11:55,096 --> 02:11:56,464 THE NYU. 2982 02:11:56,464 --> 02:12:02,003 AND LASTLY I'LL FINISH UP SO 2983 02:12:02,003 --> 02:12:03,004 KIDS SPEND TIME PLAYING VIDEO 2984 02:12:03,004 --> 02:12:06,074 GAMES AND MANY OF THEM ARE 2985 02:12:06,074 --> 02:12:07,341 PROBABLY FLYING UNMANNED DRONES 2986 02:12:07,341 --> 02:12:09,277 FOR THE MILITARY AT THIS POINT 2987 02:12:09,277 --> 02:12:11,045 BUT I THINK WHAT WE'RE MOVING 2988 02:12:11,045 --> 02:12:15,917 INTO IS A NEW ERA. 2989 02:12:15,917 --> 02:12:18,186 SO ANU HAS BEEN PLAYING AROUND 2990 02:12:18,186 --> 02:12:20,521 WITH DEEP LEARNING MODELS SINCE 2991 02:12:20,521 --> 02:12:23,991 SHE WAS 14 YEARS OLD AND 2992 02:12:23,991 --> 02:12:26,694 CURRENTLY AN UNDERGRADUATE AT 2993 02:12:26,694 --> 02:12:29,263 GEORGIA INSTITUTE TECHNOLOGY AND 2994 02:12:29,263 --> 02:12:29,964 THE FIRST AUTHOR OF AN 2995 02:12:29,964 --> 02:12:32,166 UNIVERSITY OF ARKANSAS 2996 02:12:32,166 --> 02:12:35,069 PUBLICATION THAT DETECTS 2997 02:12:35,069 --> 02:12:36,871 PARKINSON'S DISEASE INVOICE 2998 02:12:36,871 --> 02:12:40,174 RECORDINGS WHICH I THINK IS 2999 02:12:40,174 --> 02:12:41,142 INCREDIBLY INTRIGUING BECAUSE 3000 02:12:41,142 --> 02:12:43,911 IT'S VERY ATYPICAL FROM WHAT WE 3001 02:12:43,911 --> 02:12:49,584 WOULD EXPECT. 3002 02:12:49,584 --> 02:12:52,753 A LOT OF PEOPLE I SEE AND MY 3003 02:12:52,753 --> 02:12:54,088 COLLEAGUES THINK OF A.I. OF 3004 02:12:54,088 --> 02:12:55,590 DOING SOMETHING I DO NOW FASTER 3005 02:12:55,590 --> 02:12:57,992 OR WITH FEWER PEOPLE IF YOU'RE 3006 02:12:57,992 --> 02:12:59,760 TALKING ABOUT ANALYZING X-RAYS 3007 02:12:59,760 --> 02:13:01,596 OR SOMETHING LIKE THAT BUT THIS 3008 02:13:01,596 --> 02:13:03,898 IS DOING SOMETHING ENTIRELY NEW. 3009 02:13:03,898 --> 02:13:05,032 SOMETHING ENTIRELY DIFFERENT. 3010 02:13:05,032 --> 02:13:06,868 I DON'T THINK ANYBODY WOULD HAVE 3011 02:13:06,868 --> 02:13:08,836 THOUGHT YOU WOULD DO THIS. 3012 02:13:08,836 --> 02:13:11,038 I DON'T KNOW IF PEOPLE WHO 3013 02:13:11,038 --> 02:13:13,508 SPECIALIZE IN PARKINSON'S WOULD 3014 02:13:13,508 --> 02:13:16,177 AGREE OR WOULD THINK THIS IS AT 3015 02:13:16,177 --> 02:13:17,411 ALL POSSIBLE. 3016 02:13:17,411 --> 02:13:19,247 INTERESTINGLY THERE'S A SMALL 3017 02:13:19,247 --> 02:13:20,815 COMPANY IN CANADA THAT HAS 3018 02:13:20,815 --> 02:13:24,952 PUBLISHED WORK IN BEING ABLE TO 3019 02:13:24,952 --> 02:13:27,688 DIAGNOSIS HIGH BLOOD PRESSURE 3020 02:13:27,688 --> 02:13:30,324 AND TYPE II DIABETES BY VOICE 3021 02:13:30,324 --> 02:13:32,160 RECORDINGS AS WELL. 3022 02:13:32,160 --> 02:13:34,695 WE MAY BE ON THE CUSP OF 3023 02:13:34,695 --> 02:13:36,898 APPROACHING HOW IT'S REIMAGINING 3024 02:13:36,898 --> 02:13:38,032 HOW WE DELIVER HEALTH CARE. 3025 02:13:38,032 --> 02:13:40,134 NOW JUST GETTING SOMEBODY TO 3026 02:13:40,134 --> 02:13:43,838 TALK TO YOU MAY BE ENOUGH TO 3027 02:13:43,838 --> 02:13:45,206 PROVIDE VALUABLE DIAGNOSTIC 3028 02:13:45,206 --> 02:13:49,277 INPUT INTO WHAT IS GOING ON WITH 3029 02:13:49,277 --> 02:13:51,579 THEM AND SO I THINK THESE 3030 02:13:51,579 --> 02:13:53,414 OPPORTUNITIES FOR HIGH SCHOOL 3031 02:13:53,414 --> 02:13:56,751 KIDS ARE REALLY -- IT REMINDS ME 3032 02:13:56,751 --> 02:13:58,786 OF THIS STEVE JOBS COMMENT HE 3033 02:13:58,786 --> 02:14:00,821 SAID WHEN HE FIRST RELEASED THE 3034 02:14:00,821 --> 02:14:02,823 MAC BOOK AND GAVE IT TO OLDER 3035 02:14:02,823 --> 02:14:05,960 ADULTS THEY ASKED WHAT DOES IT 3036 02:14:05,960 --> 02:14:08,629 DO BUT WHEN HE GAVE IT TO 3037 02:14:08,629 --> 02:14:10,464 CHILDREN, CHILDREN ASKED WHAT 3038 02:14:10,464 --> 02:14:11,432 CAN I DO WITH IT. 3039 02:14:11,432 --> 02:14:12,066 I THINK THAT'S WHAT WE'RE 3040 02:14:12,066 --> 02:14:18,539 LOOKING FOR. 3041 02:14:18,539 --> 02:14:21,676 LASTLY TO HIGHLIGHT THE FALL 3042 02:14:21,676 --> 02:14:23,211 MEETING WILL BE HERE IN EVERYONE 3043 02:14:23,211 --> 02:14:25,780 SAYS NORTH BETHESDA. 3044 02:14:25,780 --> 02:14:30,685 I PREFER TO SAY SOUTH BROCKVILLE 3045 02:14:30,685 --> 02:14:31,385 NOVEMBER 14th THROUGH THE 15th. 3046 02:14:31,385 --> 02:14:37,892 THAT'S IT. 3047 02:14:37,892 --> 02:14:38,025 3048 02:14:38,025 --> 02:14:42,129 >> THANK YOU, MIKE. 3049 02:14:42,129 --> 02:14:47,468 THANK YOU FOR THE TOUR DE FORCE 3050 02:14:47,468 --> 02:14:49,437 OF THE EARLY CAREER INDIVIDUALS. 3051 02:14:49,437 --> 02:14:52,173 I'D LIKE TO OPEN IT UP FOR 3052 02:14:52,173 --> 02:14:52,974 QUESTIONS FROM COUNCIL. 3053 02:14:52,974 --> 02:14:54,141 ANY QUESTIONS? 3054 02:14:54,141 --> 02:14:59,280 GO AHEAD. 3055 02:14:59,280 --> 02:15:03,150 >> THIS MAY BE TOO PROVOCATIVE 3056 02:15:03,150 --> 02:15:04,452 FOR 3:00 IN THE AFTERNOON. 3057 02:15:04,452 --> 02:15:05,920 FIRST IT WAS A PHENOMENAL 3058 02:15:05,920 --> 02:15:07,154 PRESENTATION. 3059 02:15:07,154 --> 02:15:10,024 THE WORK IS INCREDIBLE, THANK 3060 02:15:10,024 --> 02:15:10,191 YOU. 3061 02:15:10,191 --> 02:15:14,462 JUST A THOUGHT IN THINKING ABOUT 3062 02:15:14,462 --> 02:15:15,429 THIS OPPORTUNITIES OF MACHINE 3063 02:15:15,429 --> 02:15:17,198 LEARNING PRESENTATION AND FOR 3064 02:15:17,198 --> 02:15:20,668 CONTEXT I'M DEEPLY INVESTED IN 3065 02:15:20,668 --> 02:15:22,103 SHORTENING THE DIAGNOSTIC 3066 02:15:22,103 --> 02:15:23,738 ODYSSEY ESPECIALLY IN RARE 3067 02:15:23,738 --> 02:15:24,839 DISEASE AND LED WORK IN RARE 3068 02:15:24,839 --> 02:15:25,473 DISEASE MYSELF. 3069 02:15:25,473 --> 02:15:27,041 ONE OF THE THINGS THAT OCCURS TO 3070 02:15:27,041 --> 02:15:29,810 ME AND I LOVED YOUR FRAMING THAT 3071 02:15:29,810 --> 02:15:31,012 LAST QUESTION BEYOND WHAT CAN I 3072 02:15:31,012 --> 02:15:33,748 DO BUT WHAT CAN I DO WITH IT, 3073 02:15:33,748 --> 02:15:39,820 ONE OF THE THINGS I WORRY ABOUT 3074 02:15:39,820 --> 02:15:41,889 AND I THINK ABOUT IS HOW DO WE 3075 02:15:41,889 --> 02:15:44,158 ENSURE WE PROTECT PEOPLE FROM 3076 02:15:44,158 --> 02:15:45,793 THOSE WHO WILL USE THE 3077 02:15:45,793 --> 02:15:51,198 TECHNOLOGY NOT FOR GOOD BUT FOR 3078 02:15:51,198 --> 02:15:51,399 HARM. 3079 02:15:51,399 --> 02:15:53,367 AND SO IN THE PATIENT COMMUNITY 3080 02:15:53,367 --> 02:15:57,171 AND IN THE ECO SYSTEMS WE HAVE 3081 02:15:57,171 --> 02:15:58,172 PRACTICES THAT ARE VERY HARMFUL 3082 02:15:58,172 --> 02:16:01,275 AS PRODUCTS ARE MOVING FROM 3083 02:16:01,275 --> 02:16:03,010 REGULATORY TO ACCESS PACES AND 3084 02:16:03,010 --> 02:16:11,018 HEALTH INSURERS NOW CAN 3085 02:16:11,018 --> 02:16:11,786 ANTICIPATE THERE ARE PRODUCTS 3086 02:16:11,786 --> 02:16:14,655 CAN LASER COMMUNITIES OUT OF 3087 02:16:14,655 --> 02:16:19,860 THEIR PLANS SO THEY DON'T HAVE 3088 02:16:19,860 --> 02:16:24,899 TO PAY FOR AND REIMBURSE FOR 3089 02:16:24,899 --> 02:16:29,870 THOSE PRODUCTS BY CUTTING THE 3090 02:16:29,870 --> 02:16:34,041 PRODUCT OUT OF THEIR PLAN OR THE 3091 02:16:34,041 --> 02:16:37,978 DISEASE IN A PARTICIPATORY WAY. 3092 02:16:37,978 --> 02:16:40,181 AND WHAT I WORRY IT MAY BE A 3093 02:16:40,181 --> 02:16:42,283 HEALTH CARE SYSTEM THAT'S PART 3094 02:16:42,283 --> 02:16:46,821 OF THESE TECHNOLOGIES, HOW LONG 3095 02:16:46,821 --> 02:16:48,189 WILL IT BE BEFORE PEOPLE START 3096 02:16:48,189 --> 02:16:50,991 TO USE THE TECHNOLOGY NOT JUST 3097 02:16:50,991 --> 02:16:52,793 TO SHORTEN THE DIAGNOSTIC 3098 02:16:52,793 --> 02:16:55,029 ODYSSEY WHICH IS INCREDIBLY 3099 02:16:55,029 --> 02:16:56,364 IMPORTANT AND SUPPORT SHORTENING 3100 02:16:56,364 --> 02:16:57,665 ODDITIES AND OPTIMIZING OUTCOMES 3101 02:16:57,665 --> 02:17:02,570 AND GETTING TREATMENTS TO PEOPLE 3102 02:17:02,570 --> 02:17:03,104 FACIL 3103 02:17:03,104 --> 02:17:04,171 FASTER AND INTERVENTIONS AND NOT 3104 02:17:04,171 --> 02:17:08,175 JUST APPROVED TREATMENTS BUT 3105 02:17:08,175 --> 02:17:10,411 THIS TECHNOLOGY COULD BE USE TO 3106 02:17:10,411 --> 02:17:11,912 IDENTIFY PEOPLE BEFORE THEY HAVE 3107 02:17:11,912 --> 02:17:13,814 A DIAGNOSIS AND ELIMINATE THEM 3108 02:17:13,814 --> 02:17:15,249 FROM A HEALTH CARE ENVIRONMENT 3109 02:17:15,249 --> 02:17:15,649 OR MILLION. 3110 02:17:15,649 --> 02:17:19,387 I WONDER WHERE THE FUND BEING OF 3111 02:17:19,387 --> 02:17:22,590 THAT SCIENCE POLICY AND THE 3112 02:17:22,590 --> 02:17:24,058 RESPONSIBILITY TO FUND THE 3113 02:17:24,058 --> 02:17:26,394 POLICIES THAT PROTECT PATIENTS 3114 02:17:26,394 --> 02:17:29,663 FROM THAT ALSO RUNS ALONGSIDE 3115 02:17:29,663 --> 02:17:29,864 THIS. 3116 02:17:29,864 --> 02:17:31,665 WHILE WE NEED IT MAKE SURE WE 3117 02:17:31,665 --> 02:17:33,667 USE THE TECHNOLOGY TO SOLVE FOR 3118 02:17:33,667 --> 02:17:34,902 THE DIAGNOSTIC ODYSSEYS WE HAVE 3119 02:17:34,902 --> 02:17:38,072 TO MAKE SURE WE PROTECT PEOPLE 3120 02:17:38,072 --> 02:17:39,273 WHO DON'T EVEN KNOW THE 3121 02:17:39,273 --> 02:17:42,309 TECHNOLOGY IS BEING ADVANCED AND 3122 02:17:42,309 --> 02:17:42,843 DEVELOPED. 3123 02:17:42,843 --> 02:17:44,678 THIS IS HAPPENING AND IT WILL BE 3124 02:17:44,678 --> 02:17:48,149 HAPPENING AND I ASK THE QUESTION 3125 02:17:48,149 --> 02:17:50,751 OF IS THAT AN NCATS 3126 02:17:50,751 --> 02:17:52,686 RESPONSIBILITY FOR SOMEBODY 3127 02:17:52,686 --> 02:17:54,588 ELSE'S RESPONSIBILITY BUT NEEDS 3128 02:17:54,588 --> 02:18:00,161 TO BE SOMEBODY'S RESPONSIBILITY. 3129 02:18:00,161 --> 02:18:02,797 >> YOU THINK IN MANY WAYS WHAT 3130 02:18:02,797 --> 02:18:04,465 YOU'RE REALLY ASKING IS SIMILAR 3131 02:18:04,465 --> 02:18:08,969 TO WHAT WAS INITIALLY FEARED 3132 02:18:08,969 --> 02:18:10,571 WITH THE BRINGING ON BOARDS AND 3133 02:18:10,571 --> 02:18:14,308 THE ABILITY TO DO GENOME 3134 02:18:14,308 --> 02:18:18,345 SEQUENCES AND SOMEHOW I THINK WE 3135 02:18:18,345 --> 02:18:22,783 HAD THE NAIVE APPROACH THAT 3136 02:18:22,783 --> 02:18:24,685 MAYBE A SMALL FRACTION OF THE 3137 02:18:24,685 --> 02:18:28,155 POPULATION WILL HAVE GENETIC 3138 02:18:28,155 --> 02:18:30,324 DISORDERS AND EXCLUDED FROM 3139 02:18:30,324 --> 02:18:31,058 HEALTH INSURANCE BECAUSE IT 3140 02:18:31,058 --> 02:18:33,294 WOULD BE CALLED A QUOTE, 3141 02:18:33,294 --> 02:18:34,128 PREEXISTING CONDITION. 3142 02:18:34,128 --> 02:18:35,329 CONGRESS HAS SAID YOU CAN'T DO 3143 02:18:35,329 --> 02:18:37,164 THAT BUT SUBSEQUENTLY WHAT WE 3144 02:18:37,164 --> 02:18:43,103 LEARNED IN TERMS OF GENOME 3145 02:18:43,103 --> 02:18:51,712 SEQUENCING IS AND WE'RE NOT AND 3146 02:18:51,712 --> 02:18:53,047 THERE'S GENETIC MUTATIONS THAT 3147 02:18:53,047 --> 02:18:57,751 ALL HAVE A SUBTLE IMPACT ON 3148 02:18:57,751 --> 02:18:59,720 INFLUENCE THE RISK FACTORS WHICH 3149 02:18:59,720 --> 02:19:03,657 IS WHY THERE'S A VARIETY OF 3150 02:19:03,657 --> 02:19:04,959 CONDITIONS. 3151 02:19:04,959 --> 02:19:07,895 SO I THINK FROM THE GENETIC 3152 02:19:07,895 --> 02:19:10,664 STANDPOINT AND THAT WAS SOLVED 3153 02:19:10,664 --> 02:19:12,333 BY CONGRESS SIMPLY SAYING 3154 02:19:12,333 --> 02:19:13,400 ELIMINATE THE PREEXISTING 3155 02:19:13,400 --> 02:19:13,734 CONDITIONS. 3156 02:19:13,734 --> 02:19:17,538 I THINK WHAT YOU'RE GETTING AT 3157 02:19:17,538 --> 02:19:22,710 IS WITH A.I. YOU HAVE THE 3158 02:19:22,710 --> 02:19:24,278 POTENTIAL TO DEVELOP ALGORITHMS 3159 02:19:24,278 --> 02:19:25,446 WHETHER THE MEDICAL COMMUNITY 3160 02:19:25,446 --> 02:19:27,047 WANTS THEM OR USING THEM TO 3161 02:19:27,047 --> 02:19:30,551 POTENTIALLY CAUSE PROBLEMS. 3162 02:19:30,551 --> 02:19:33,020 I THINK THAT'S A REALISTIC 3163 02:19:33,020 --> 02:19:34,188 POSSIBILITY. 3164 02:19:34,188 --> 02:19:37,091 IN MANY WAYS ULTIMATELY IT COMES 3165 02:19:37,091 --> 02:19:42,463 DOWN TO WHEN I TALK ABOUT 3166 02:19:42,463 --> 02:19:45,566 REIMAGINING ABOUT HEALTH CARE 3167 02:19:45,566 --> 02:19:46,967 I'M TALKING ABOUT HOW WE 3168 02:19:46,967 --> 02:19:48,102 RE-ENVISION OUR HEALTH CARE 3169 02:19:48,102 --> 02:19:50,771 SYSTEM AND WE AT LEAST THE 3170 02:19:50,771 --> 02:19:56,143 ACADEMIC COMMUNITY NEEDS TO BE 3171 02:19:56,143 --> 02:19:57,912 PROVIDING THE EVIDENCE TO 3172 02:19:57,912 --> 02:20:00,147 SUPPORT WAYS TO BE OPERATING. 3173 02:20:00,147 --> 02:20:01,849 NOW IN THE END THAT'S A POLICY 3174 02:20:01,849 --> 02:20:03,517 DECISION AND IT'S WELL BEYOND 3175 02:20:03,517 --> 02:20:05,519 THE ACADEMIC OR MEDICAL 3176 02:20:05,519 --> 02:20:08,088 COMMUNITY TO MAKE THIS CALL BUT 3177 02:20:08,088 --> 02:20:12,159 I THINK IT BEHOOVES US TO 3178 02:20:12,159 --> 02:20:14,461 PROVIDE RIGOROUS EVIDENCE TO 3179 02:20:14,461 --> 02:20:16,163 SUPPORT THE MIGRATION TO WHAT 3180 02:20:16,163 --> 02:20:19,500 WOULD BE A MORE EQUITABLE HEALTH 3181 02:20:19,500 --> 02:20:22,570 CARE SYSTEM THAT WOULD BE 3182 02:20:22,570 --> 02:20:23,270 BENEFICIAL TO EVERYONE. 3183 02:20:23,270 --> 02:20:26,307 >> YEAH, AND I WOULD JUST SAY I 3184 02:20:26,307 --> 02:20:27,942 AGREE WITH YOU BUT THE 3185 02:20:27,942 --> 02:20:30,277 ELIMINATION OF PREEXISTING 3186 02:20:30,277 --> 02:20:32,079 CONDITIONS AND GENETIC NON 3187 02:20:32,079 --> 02:20:37,017 DISCRIMINATION WERE LAWS AND 3188 02:20:37,017 --> 02:20:39,253 PROTECTIONS PUT IN PLACE BY 3189 02:20:39,253 --> 02:20:40,154 CONGRESS BECAUSE THE COMMUNITY 3190 02:20:40,154 --> 02:20:42,122 BROUGHT THAT AS PROTECTIONS THAT 3191 02:20:42,122 --> 02:20:44,058 NEEDED TO BE IN PLACE INCLUDING 3192 02:20:44,058 --> 02:20:47,828 THOSE AT NIH AND FRANCIS COLLINS 3193 02:20:47,828 --> 02:20:49,663 WAS A PART OF THE LEADERSHIP AND 3194 02:20:49,663 --> 02:20:53,767 THE PROTECTIONS COULD BE 3195 02:20:53,767 --> 02:20:55,469 REVERSED. 3196 02:20:55,469 --> 02:20:58,706 AND SO I'LL PLUG THAT THE 3197 02:20:58,706 --> 02:21:00,641 COMMUNITY IS DEVELOPING THE 3198 02:21:00,641 --> 02:21:01,809 SCIENCE WHEN EXTENDED 3199 02:21:01,809 --> 02:21:05,079 PROTECTIONS MIGHT BE NECESSARY. 3200 02:21:05,079 --> 02:21:07,915 >> I THINK IT'S A GREAT COMMENT 3201 02:21:07,915 --> 02:21:11,452 AND IT REMINDS ME OF THE 3202 02:21:11,452 --> 02:21:13,621 DISCUSSIONS THAT WE HAD WITH FDA 3203 02:21:13,621 --> 02:21:14,388 AND CMS. 3204 02:21:14,388 --> 02:21:16,156 IT'S NOT THE SAME THING BUT IT'S 3205 02:21:16,156 --> 02:21:20,160 REMINISCENT OF THE TREATMENTS 3206 02:21:20,160 --> 02:21:23,831 BEING DEVELOPED FOR COMMUNITIES 3207 02:21:23,831 --> 02:21:25,699 OR WITH RARE DISEASES AND THE 3208 02:21:25,699 --> 02:21:27,668 CLINICAL TRIALS NOT NECESSARILY 3209 02:21:27,668 --> 02:21:30,771 REFLECTING THE AGE GROUPS THAT 3210 02:21:30,771 --> 02:21:35,242 ARE IN NEED OF SAID THERAPIES. 3211 02:21:35,242 --> 02:21:38,679 SO WE'RE NOT QUITE ON THE RIGHT 3212 02:21:38,679 --> 02:21:40,147 TRACK HERE FOR DECISIONS TO BE 3213 02:21:40,147 --> 02:21:42,816 MADE ABOUT ACCESS TO THOSE 3214 02:21:42,816 --> 02:21:48,422 THERAPIES BECAUSE WE HAVE TESTED 3215 02:21:48,422 --> 02:21:54,261 THEM. 3216 02:21:54,261 --> 02:21:56,230 AND THINK ABOUT THE FORWARD 3217 02:21:56,230 --> 02:21:57,598 LOOKING POLICIES THAT MIGHT ALSO 3218 02:21:57,598 --> 02:22:02,770 BE NEEDED. 3219 02:22:02,770 --> 02:22:07,641 AND I THINK THAT THESE ARE 3220 02:22:07,641 --> 02:22:09,777 QUESTIONS WE'RE STARTING TO ASK 3221 02:22:09,777 --> 02:22:11,412 AND THOSE SORTS OF MODALITIES 3222 02:22:11,412 --> 02:22:17,484 BUT ALSO NEED TO DO IT IN THE 3223 02:22:17,484 --> 02:22:18,452 DIGITAL HEALTH SPACE AND FOR US 3224 02:22:18,452 --> 02:22:21,455 THE COMMENT IS JUST A REMINDER 3225 02:22:21,455 --> 02:22:22,990 THAT THIS IS SOMETHING WE NEED 3226 02:22:22,990 --> 02:22:26,093 TO THINK ABOUT AS WE START TO 3227 02:22:26,093 --> 02:22:27,728 SUPPORT MORE OF THESE ACTIVES TO 3228 02:22:27,728 --> 02:22:29,029 AN INDIVIDUAL SPACE. 3229 02:22:29,029 --> 02:22:34,168 >> I THINK ONE OF THE THINGS I 3230 02:22:34,168 --> 02:22:40,741 THINK IF WE TEST AN INTERVENTION 3231 02:22:40,741 --> 02:22:43,077 THE CRITERIA FOR THAT IS THE 3232 02:22:43,077 --> 02:22:45,145 RIGOROUS DESIGN AND EXECUTION OF 3233 02:22:45,145 --> 02:22:50,284 THAT TRIAL THAT'S GOING TO GET 3234 02:22:50,284 --> 02:22:51,852 IT PUBLISHED IN THE JOURNAL LIKE 3235 02:22:51,852 --> 02:22:53,087 NEW ENGLAND JOURNAL OF MEDICINE 3236 02:22:53,087 --> 02:22:55,556 AND YET WHAT I THINK WE DON'T 3237 02:22:55,556 --> 02:22:59,927 ALWAYS THINK ABOUT IS THAT OTHER 3238 02:22:59,927 --> 02:23:02,429 ENTITIES LIKE INSURERS, CMS, IF 3239 02:23:02,429 --> 02:23:04,164 YOU'RE TALKING ABOUT SOMETHING 3240 02:23:04,164 --> 02:23:06,934 IN THE OPIOID REALM MAY BE LAW 3241 02:23:06,934 --> 02:23:09,002 ENFORCEMENT OR THE JUSTICE 3242 02:23:09,002 --> 02:23:10,304 COMMUNITY, THOSE ENTITIES HAVE 3243 02:23:10,304 --> 02:23:11,638 DIFFERENT STANDARDS OF EVIDENCE 3244 02:23:11,638 --> 02:23:16,910 WE NEED TO UNDERSTAND SO THAT WE 3245 02:23:16,910 --> 02:23:18,545 CAN DESIGN TRIALS SO THAT IT 3246 02:23:18,545 --> 02:23:20,180 WILL NOT ONLY GET THE TRIAL 3247 02:23:20,180 --> 02:23:21,782 PUBLISHED AND RECOGNIZED BY THE 3248 02:23:21,782 --> 02:23:23,317 ACADEMIC AND MEDICAL COMMUNITY 3249 02:23:23,317 --> 02:23:24,785 BUT RECOGNIZED AS EVIDENCE FOR 3250 02:23:24,785 --> 02:23:26,487 THOSE OTHER COMMUNITIES BECAUSE 3251 02:23:26,487 --> 02:23:29,623 MORE OFTEN NAN NOT, WHAT ENDS UP 3252 02:23:29,623 --> 02:23:33,293 HAPPENING IS WE PUBLISH A STUDY. 3253 02:23:33,293 --> 02:23:35,729 THE MEDICAL COMMUNITY SAYS YES 3254 02:23:35,729 --> 02:23:37,931 AND THEN CMS SAYS, YEAH, BUT YOU 3255 02:23:37,931 --> 02:23:41,235 DIDN'T DO THIS AND THIS. 3256 02:23:41,235 --> 02:23:44,838 THE INSURERS SAY YOU WERE 3257 02:23:44,838 --> 02:23:46,140 WORRIED ABOUT THIS BUT YOU 3258 02:23:46,140 --> 02:23:47,674 DIDN'T DO THAT. 3259 02:23:47,674 --> 02:23:51,578 IT'S INTERESTING IN TERMS OF 3260 02:23:51,578 --> 02:23:54,548 VACCINES, FOR EXAMPLE, YOU KNOW 3261 02:23:54,548 --> 02:23:57,851 GETTING PAST THE FDA INCREDIBLY 3262 02:23:57,851 --> 02:24:00,621 HIGH BAR BUT TO VACCINE 3263 02:24:00,621 --> 02:24:06,360 MANUFACTURERS THERE'S ACTUALLY A 3264 02:24:06,360 --> 02:24:08,762 HIGHER BAR THE ADVISORY COUNCIL 3265 02:24:08,762 --> 02:24:15,869 AT IMMUNIZATIONSS AND THEIR 3266 02:24:15,869 --> 02:24:16,637 RECOMMENDATIONS THAT DETERMINES 3267 02:24:16,637 --> 02:24:17,971 WHO WILL BE REIMBURSED. 3268 02:24:17,971 --> 02:24:19,840 THE FDA PLAY SAY THIS IS A 3269 02:24:19,840 --> 02:24:22,976 PROVED BUT IF ACIP DOESN'T 3270 02:24:22,976 --> 02:24:24,912 RECOMMEND THAT FOR THAT 3271 02:24:24,912 --> 02:24:25,579 PARTICULAR POPULATION IT WON'T 3272 02:24:25,579 --> 02:24:35,956 BE REIMBURSED OR USED. 3273 02:24:38,458 --> 02:24:40,127 THE RECOMMENDATIONS ARE 3274 02:24:40,127 --> 02:24:43,197 INSUFFICIENT TO GET IT PAST ACIP 3275 02:24:43,197 --> 02:24:45,999 AND IT'S INCUMBENT TO RECOGNIZE 3276 02:24:45,999 --> 02:24:47,868 THEY'RE ADDRESSING MORE THAN THE 3277 02:24:47,868 --> 02:24:48,836 MEDICAL COMMUNITY AND JOURNALS. 3278 02:24:48,836 --> 02:24:51,872 WE NEED TO REACH OUT AND 3279 02:24:51,872 --> 02:24:53,740 UNDERSTAND ALL THESE DIFFERENT 3280 02:24:53,740 --> 02:24:53,974 GROUPS. 3281 02:24:53,974 --> 02:24:55,676 WE TALK ABOUT ENGAGING WITH 3282 02:24:55,676 --> 02:24:58,045 PATIENT GROUPS AND NEED TO THINK 3283 02:24:58,045 --> 02:25:00,013 ABOUT ENGAGING WITH INSURERS, 3284 02:25:00,013 --> 02:25:01,915 CMS, ALL THESE OTHER GROUPS TO 3285 02:25:01,915 --> 02:25:02,516 UNDERSTAND THEIR REQUIREMENTS 3286 02:25:02,516 --> 02:25:11,758 AND THEIR NEEDS. 3287 02:25:11,758 --> 02:25:22,302 >> ANY OTHER QUESTION FOR MIKE? 3288 02:25:25,906 --> 02:25:27,140 WE'RE A LITTLE BIT AHEAD OF 3289 02:25:27,140 --> 02:25:28,175 SCHEDULE BUT ALSO BEHIND 3290 02:25:28,175 --> 02:25:28,442 SCHEDULE. 3291 02:25:28,442 --> 02:25:29,509 THAT DOESN'T MAKE SENSE. 3292 02:25:29,509 --> 02:25:31,845 BECAUSE WE HAD A 10 MINUTE BREAK 3293 02:25:31,845 --> 02:25:33,247 IF YOU'D LIKE TO PROCEED OR PUSH 3294 02:25:33,247 --> 02:25:33,847 FORWARD. 3295 02:25:33,847 --> 02:25:36,984 IF YOU WANT A FIVE-MINUTE BREAK 3296 02:25:36,984 --> 02:25:40,153 WE CAN DO THAT NOW OR PUSH 3297 02:25:40,153 --> 02:25:40,921 FORWARD. 3298 02:25:40,921 --> 02:25:44,157 WE'LL TAKE A FIVE-MINUTE BREAK 3299 02:25:44,157 --> 02:25:45,692 AND THEN COME BACK. 3300 02:25:45,692 --> 02:25:46,260 AND WE'LL GO TO THE NEXT 3301 02:25:46,260 --> 02:25:46,593 PRESENTATION. 3302 02:25:46,593 --> 02:25:48,773 THANK YOU. 3303 02:25:59,141 --> 02:26:05,314 >> CHRISTINE CLOVIS WILL KICK US 3304 02:26:05,314 --> 02:26:08,517 OFF AND INTRODUCE KARLIE. 3305 02:26:08,517 --> 02:26:09,418 >> THANK YOU. 3306 02:26:09,418 --> 02:26:11,887 I AM CHRISTINE CLOVIS. 3307 02:26:11,887 --> 02:26:13,556 I THINK EVERYBODY HERE KNOWS ME 3308 02:26:13,556 --> 02:26:17,393 BUT MAYBE FOLKS ONLINE DON'T. 3309 02:26:17,393 --> 02:26:22,264 I'LL TEE SOME STUFF UP FOR 3310 02:26:22,264 --> 02:26:22,498 KARLIE. 3311 02:26:22,498 --> 02:26:24,900 SHE'LL GIVE US A NICE CLOSE UP 3312 02:26:24,900 --> 02:26:26,535 REPORT ON THE GENOME PROGRAM. 3313 02:26:26,535 --> 02:26:29,238 A PROGRAM ONGOING ABOUT 10 YEARS 3314 02:26:29,238 --> 02:26:30,172 NOW. 3315 02:26:30,172 --> 02:26:32,775 O AND THEN IF THERE'S TIME I'LL 3316 02:26:32,775 --> 02:26:34,477 COME BACK AND GIVE A TEASER WHAT 3317 02:26:34,477 --> 02:26:41,751 YOU MIGHT HERE ABOUT NEXT TIME 3318 02:26:41,751 --> 02:26:49,258 NEXT YEAR. 3319 02:26:49,258 --> 02:26:51,560 FIRST, WE HAVE FOUR PROGRAM 3320 02:26:51,560 --> 02:26:53,596 OFFICERS. 3321 02:26:53,596 --> 02:26:55,564 THERE'S INCREDIBLY PRODUCTIVE 3322 02:26:55,564 --> 02:27:00,736 THANKS TO THE OFFICE OF 3323 02:27:00,736 --> 02:27:01,570 COORDINATOR AND PROGRAM ANALYST. 3324 02:27:01,570 --> 02:27:06,442 WE'RE FORTUNATE FOR A COUPLE 3325 02:27:06,442 --> 02:27:10,479 YEARS WE'VE SHERAT WORKING WITH 3326 02:27:10,479 --> 02:27:15,117 US ON THE BIOMEDICAL TRANS DATA 3327 02:27:15,117 --> 02:27:16,519 PROGRAM WITH THE OFFICE OF DATA 3328 02:27:16,519 --> 02:27:18,487 STRATEGY AS A DATA SCHOLAR. 3329 02:27:18,487 --> 02:27:20,489 HE'S BEEN WORKING WITH US THE 3330 02:27:20,489 --> 02:27:20,990 LAST TWO YEARS. 3331 02:27:20,990 --> 02:27:25,394 HIS TENURE IS ABOUT TO END AND 3332 02:27:25,394 --> 02:27:27,730 AARON BERNSTEIN HAS BEEN A DATA 3333 02:27:27,730 --> 02:27:29,865 SCHOLAR FOR 10 MONTHS THE PAST 3334 02:27:29,865 --> 02:27:40,342 YEAR ALSO AS A DATA SCHOLAR. 3335 02:27:48,584 --> 02:27:51,554 AND WE BREAK IT DOWN FROM BIG 3336 02:27:51,554 --> 02:27:53,689 ANNOUNCEMENTS AND SHOW GENERAL 3337 02:27:53,689 --> 02:27:53,889 AREAS. 3338 02:27:53,889 --> 02:27:57,159 FIRST WE HAVE EXPANDING THE 3339 02:27:57,159 --> 02:27:59,128 TARGET LANDSCAPE FOCUSSED ONLY 3340 02:27:59,128 --> 02:28:00,696 EARLY DISCOVERY TYPE THINGS. 3341 02:28:00,696 --> 02:28:01,997 IT WILL BE THE FOCUS OF WHAT YOU 3342 02:28:01,997 --> 02:28:04,400 HEAR ABOUT TODAY. 3343 02:28:04,400 --> 02:28:06,502 AND THEN DRUG DEVELOPMENT 3344 02:28:06,502 --> 02:28:07,670 PARTNERSHIPS THAT WOULD PICK UP 3345 02:28:07,670 --> 02:28:12,374 A BALL FROM THERE ONCE WE HIT 3346 02:28:12,374 --> 02:28:19,582 DEVELOPMENT AND IDENTIFY EARLY 3347 02:28:19,582 --> 02:28:29,792 PHASE TO CLINICAL TRIALS AND IT 3348 02:28:29,792 --> 02:28:31,327 TAKES SKILL SETS AND THE PEOPLE 3349 02:28:31,327 --> 02:28:33,496 WHO DO TALKS ARE NOT THE SAME 3350 02:28:33,496 --> 02:28:34,497 WHO DO THE CHEMISTRY. 3351 02:28:34,497 --> 02:28:36,966 IT TAKES A TEAM. 3352 02:28:36,966 --> 02:28:39,535 WE I HAVE TO DEVELOP PROGRAMS 3353 02:28:39,535 --> 02:28:41,103 THAT WILL SUPPORT AND ENCOURAGE 3354 02:28:41,103 --> 02:28:43,639 AND INCENTIVIZE PEOPLE TO 3355 02:28:43,639 --> 02:28:46,475 ACTUALLY WORK TOGETHER TO DO 3356 02:28:46,475 --> 02:28:48,177 THAT DEVELOPMENT. 3357 02:28:48,177 --> 02:28:50,613 AND WE HAVE TECHNOLOGY 3358 02:28:50,613 --> 02:28:53,149 DEVELOPMENT AND ASSETS PROGRAM 3359 02:28:53,149 --> 02:28:55,551 AND OUR TECHNOLOGY FOR 3360 02:28:55,551 --> 02:28:58,487 TRANSLATIONAL SCIENCE THAT CAN 3361 02:28:58,487 --> 02:29:09,031 SPAN THE ENTIRE PIPELINE AND SO 3362 02:29:14,203 --> 02:29:18,474 AS I SAID THE THEME WILL BE 3363 02:29:18,474 --> 02:29:20,543 EXPANDING THE TARGET LANDSCAPE 3364 02:29:20,543 --> 02:29:21,977 IN WHAT YOU'LL HEAR IN CONCEPT 3365 02:29:21,977 --> 02:29:22,311 CLEARANCE. 3366 02:29:22,311 --> 02:29:24,346 SO WE TAKE A TWO-PRONGED 3367 02:29:24,346 --> 02:29:26,649 APPROACH WHEN WE THINK ABOUT 3368 02:29:26,649 --> 02:29:28,117 EXPANDING THE TARGET LANDSCAPE. 3369 02:29:28,117 --> 02:29:31,587 ONE IS TO EXPLORE UNDER STUDIED 3370 02:29:31,587 --> 02:29:32,021 DRUGGABLE PROTEINS. 3371 02:29:32,021 --> 02:29:34,490 A LOT OF THE WORK STARTED UNDER 3372 02:29:34,490 --> 02:29:40,696 THE DRUGGABLE GENOME PROGRAM THE 3373 02:29:40,696 --> 02:29:43,632 IDEA IS YOU FOCUS ON PROTEINS 3374 02:29:43,632 --> 02:29:46,902 THAT HAVE A BINDING SITE INTO 3375 02:29:46,902 --> 02:29:54,476 WHICH A SMALL MOLECULE, CHEMICAL 3376 02:29:54,476 --> 02:29:58,480 COULD MODULATE RECEPTORS, 3377 02:29:58,480 --> 02:30:04,220 ENZYMES, ION CHANNELS. 3378 02:30:04,220 --> 02:30:10,392 THE BOTTOM LINE IS IT MAKES IT 3379 02:30:10,392 --> 02:30:11,460 ACCESSIBLE AND THE SECOND IS 3380 02:30:11,460 --> 02:30:15,030 APPROACH IS DRUGGING THE 3381 02:30:15,030 --> 02:30:16,866 UNDRUGGABLE. 3382 02:30:16,866 --> 02:30:18,767 THE THINGS THAT DON'T HAVE 3383 02:30:18,767 --> 02:30:22,004 BINDING SITE FOR US TO ACTUALLY 3384 02:30:22,004 --> 02:30:32,481 CREATE A SMALL MOLECULE FOR. 3385 02:30:39,221 --> 02:30:44,693 THEY COULD BE NON-PROTEIN 3386 02:30:44,693 --> 02:30:49,698 TARGETS AND WE HAVE TOUGH 3387 02:30:49,698 --> 02:30:51,267 TARGETS. 3388 02:30:51,267 --> 02:31:01,810 SO THESE ARE THE TWO PRONGS FOR 3389 02:31:03,979 --> 02:31:05,314 EXPANDING THE LANDSCAPE AND 3390 02:31:05,314 --> 02:31:06,715 YOU'LL HEAR FROM KARLIE IN A 3391 02:31:06,715 --> 02:31:08,183 COUPLE MINUTES AND WHEN WE GET 3392 02:31:08,183 --> 02:31:11,053 TO THE CONCEPT CLEARANCE, THE 3393 02:31:11,053 --> 02:31:12,988 CONCEPT WE'RE CLEARING IS TO 3394 02:31:12,988 --> 02:31:13,722 ADDRESS THE SECOND PRONG 3395 02:31:13,722 --> 02:31:18,460 APPROACH. 3396 02:31:18,460 --> 02:31:22,531 SO, FOCUSSING NOW ON THE FIRST 3397 02:31:22,531 --> 02:31:26,135 PRONG ELIMINATING THE DRUGGABLE 3398 02:31:26,135 --> 02:31:26,468 GENOME. 3399 02:31:26,468 --> 02:31:28,604 THINK OF IT AS THE LOW HANGING 3400 02:31:28,604 --> 02:31:31,173 FRUIT WHEN IT COMES TO DRUG 3401 02:31:31,173 --> 02:31:33,175 DEVELOPMENT. 3402 02:31:33,175 --> 02:31:36,245 WE HAVE THE CONVENIENT BINDING 3403 02:31:36,245 --> 02:31:37,746 SITE AND LOOKING AT UNDER 3404 02:31:37,746 --> 02:31:39,748 STUDIED DRUGGABLE PROTEINS. 3405 02:31:39,748 --> 02:31:42,484 WHEN WE SAY UNDER STUDIED WE 3406 02:31:42,484 --> 02:31:45,287 MEAN THINGS FOR WHICH THERE ARE 3407 02:31:45,287 --> 02:31:50,092 VERY FEW PUBLICATION OR RO1 OR 3408 02:31:50,092 --> 02:31:53,162 SUBSTANTIAL SUPPORT FROM THE 3409 02:31:53,162 --> 02:31:53,429 NIH. 3410 02:31:53,429 --> 02:31:55,564 THE IEG PROGRAM WAS TO STIMULATE 3411 02:31:55,564 --> 02:31:57,666 RESEARCH ON UNDER STUDIED 3412 02:31:57,666 --> 02:32:02,471 LOW-HANGING FRUIT. 3413 02:32:02,471 --> 02:32:05,908 THIS IS AN NIH COMMON FUND 3414 02:32:05,908 --> 02:32:06,141 PROGRAM. 3415 02:32:06,141 --> 02:32:08,644 COMMON FUND PROGRAMS TYPICALLY 3416 02:32:08,644 --> 02:32:11,013 HAVE A 10 YEAR LIFE SPAN. 3417 02:32:11,013 --> 02:32:14,049 THEY CAN ONLY LAST FOR 10 YEARS. 3418 02:32:14,049 --> 02:32:19,788 THEY HAVE FIVE CRITERIA THEY 3419 02:32:19,788 --> 02:32:23,859 REALLY AIM TO MEET TO FIT THEIR 3420 02:32:23,859 --> 02:32:25,227 MODEL WHICH IS THE PROGRAM HAS 3421 02:32:25,227 --> 02:32:28,731 TO BE CATALYTIC, GOAL DRIVEN, 3422 02:32:28,731 --> 02:32:31,166 SYNERGISTIC WITH THE OTHER 3423 02:32:31,166 --> 02:32:35,671 INSTITUTES AND SCIENCE THAT'S BE 3424 02:32:35,671 --> 02:32:39,141 DONE ACROSS THE NIH 3425 02:32:39,141 --> 02:32:42,478 TRANSFORMATIVE AND NOVEL. 3426 02:32:42,478 --> 02:32:45,447 I THINK OF THE PROGRAM AS BEING 3427 02:32:45,447 --> 02:32:45,914 VERY TRANSFORMATIVE. 3428 02:32:45,914 --> 02:32:48,417 IT WAS DESIGNED TO SUPPORT THE 3429 02:32:48,417 --> 02:32:50,519 EXPLORATION OF THE UNKNOWN. 3430 02:32:50,519 --> 02:32:52,955 IT'S SUPPORTING A GENERATION OF 3431 02:32:52,955 --> 02:32:54,523 PRELIMINARY DATA FOR SUBSEQUENT 3432 02:32:54,523 --> 02:32:54,757 AWARDS. 3433 02:32:54,757 --> 02:32:58,527 THIS IS WHERE I FEEL IT CAN BE 3434 02:32:58,527 --> 02:33:02,531 TRANSFORMATIVE AND GET US OUT OF 3435 02:33:02,531 --> 02:33:04,600 THE MODE OF ME TOO DRUGS AND 3436 02:33:04,600 --> 02:33:06,802 WORK ON THINGS THAT MOVE BEYOND 3437 02:33:06,802 --> 02:33:07,903 THAT. 3438 02:33:07,903 --> 02:33:12,074 AGAIN IT'S RELATIVELY LOW 3439 02:33:12,074 --> 02:33:15,077 HANGING FRUIT. 3440 02:33:15,077 --> 02:33:18,514 THE IG COORDINATOR IS 3441 02:33:18,514 --> 02:33:20,716 RESPONSIBLE FOR COORDINATION OF 3442 02:33:20,716 --> 02:33:29,892 A LARGE TRANS-NIH TEAM OF 3443 02:33:29,892 --> 02:33:33,128 PROGRAM STAFF, SENIOR STAFF AND 3444 02:33:33,128 --> 02:33:34,496 OVERSIGHT OVER THE PROGRAM. 3445 02:33:34,496 --> 02:33:45,040 ONE THING I WANT TO MENTION THE 3446 02:33:46,575 --> 02:33:52,147 PROGRAM FOR SMALL AWARDS THE 3447 02:33:52,147 --> 02:33:54,950 SUCCESS WE SAW WITH THE MODEST 3448 02:33:54,950 --> 02:33:59,621 INVESTMENTS $100,000 IT'S A YEAR 3449 02:33:59,621 --> 02:34:01,924 AND WE SAID LET'S A VERSION AT 3450 02:34:01,924 --> 02:34:02,124 NCATS. 3451 02:34:02,124 --> 02:34:05,494 NOW WE HAVE THE ONE WE DO AT 3452 02:34:05,494 --> 02:34:07,930 NCATS FOCUSSED ON RARE DISEASES. 3453 02:34:07,930 --> 02:34:10,532 DRUGGABLE PROTEINS THAT ARE 3454 02:34:10,532 --> 02:34:11,567 ASSOCIATED WITHRARE DISEASES. 3455 02:34:11,567 --> 02:34:12,734 WITH RARE DISEASES. 3456 02:34:12,734 --> 02:34:15,070 SO WITH THAT I'LL HAND IT OVER 3457 02:34:15,070 --> 02:34:25,247 TO KARLIE. 3458 02:34:26,815 --> 02:34:29,451 >> OKAY. 3459 02:34:29,451 --> 02:34:31,620 I JUST WANT TO MENTION THAT THE 3460 02:34:31,620 --> 02:34:34,423 DRUGGABLE GENOME EXPRESSES 3461 02:34:34,423 --> 02:34:36,225 PROTEINS POTENTIALLY ABLE TO 3462 02:34:36,225 --> 02:34:37,326 BIND DRUG LIKE COMPOUNDS. 3463 02:34:37,326 --> 02:34:39,728 WHILE THE EXISTING NUMBER OF 3464 02:34:39,728 --> 02:34:42,531 PROTEINS IS ESTIMATED TO BE 3465 02:34:42,531 --> 02:34:44,700 BETWEEN 3,000 AND 4500, WE ONLY 3466 02:34:44,700 --> 02:34:46,835 HAVE EXISTED PHARMACOPEIA FOR A 3467 02:34:46,835 --> 02:34:48,704 FEW HUNDRED OF THE TARGETS. 3468 02:34:48,704 --> 02:34:49,905 THERE'S A LOT OF BIOLOGY WE 3469 02:34:49,905 --> 02:34:50,973 HAVEN'T EXPLOITED YET. 3470 02:34:50,973 --> 02:34:55,611 SO THE GOAL OF THE PROGRAM WAS 3471 02:34:55,611 --> 02:34:57,379 TO IMPROVE UNDERSTANDING OF 3472 02:34:57,379 --> 02:34:59,781 PROPERTIES AND FUNCTIONS OF 3473 02:34:59,781 --> 02:35:01,950 PROTEINS NOT WELL STUDIED WITHIN 3474 02:35:01,950 --> 02:35:07,623 PROTEIN FAMILIES. 3475 02:35:07,623 --> 02:35:11,493 QUE LOOKED AT THE ION CHANNELS 3476 02:35:11,493 --> 02:35:22,037 AND KINASES AND G PROTEINS AND 3477 02:35:33,182 --> 02:35:36,018 THIS IS A COMMON FUND AND THIS 3478 02:35:36,018 --> 02:35:37,786 HAS BROAD APPLICABILITY. 3479 02:35:37,786 --> 02:35:39,755 AS THE PROTEINS ARE VERY UNDER 3480 02:35:39,755 --> 02:35:42,758 STUDIED THEY DON'T HAVE A CLEAR 3481 02:35:42,758 --> 02:35:44,293 FIT WITHIN AN I.C. MISSION. 3482 02:35:44,293 --> 02:35:48,330 WE RECOGNIZE THROUGH DISCOVERY 3483 02:35:48,330 --> 02:35:50,165 OF THE ROLE WE CAN GET A HANDLE 3484 02:35:50,165 --> 02:35:53,602 ON THE FUNCTION AND WHERE THEY 3485 02:35:53,602 --> 02:35:55,771 FIT WITHIN NIH AND DESPITE SO 3486 02:35:55,771 --> 02:36:02,010 MANY DRUG PROTEIN FAMILIES 3487 02:36:02,010 --> 02:36:02,945 THERE'S PROTEIN FAMILIES AND 3488 02:36:02,945 --> 02:36:06,048 WANTED TO TEST THE IDEA IT WOULD 3489 02:36:06,048 --> 02:36:07,416 STIMULATE RESEARCH AND OVER ALL 3490 02:36:07,416 --> 02:36:10,419 IT'S BEEN A SIGNIFICANT SUCCESS. 3491 02:36:10,419 --> 02:36:12,588 I SHOW THE SLIDE TO GIVE AN IDEA 3492 02:36:12,588 --> 02:36:16,225 OF EXACTLY HOW WIDE SPANNING THE 3493 02:36:16,225 --> 02:36:16,558 PROGRAM WAS. 3494 02:36:16,558 --> 02:36:18,460 WE HAVE INDIVIDUALS FROM ALL 3495 02:36:18,460 --> 02:36:20,395 OVER THE DIFFERENT INSTITUTES 3496 02:36:20,395 --> 02:36:22,497 AND CENTERS INVOLVED, OUR 3497 02:36:22,497 --> 02:36:28,370 WORKING GROUP SPANNED DIFFERENT 3498 02:36:28,370 --> 02:36:28,670 AREAS. 3499 02:36:28,670 --> 02:36:36,912 WE ALSO A MULTI INSTITUTE GROUP 3500 02:36:36,912 --> 02:36:37,980 SO THERE WAS INTEREST FROM A LOT 3501 02:36:37,980 --> 02:36:39,114 OF GROUP. 3502 02:36:39,114 --> 02:36:41,683 AND THIS IS THE TIME LINE AN 3503 02:36:41,683 --> 02:36:42,517 BUDGET. 3504 02:36:42,517 --> 02:36:53,061 WE HAD A PILOT PHASE OF 25.5 TO 3505 02:36:54,596 --> 02:37:00,369 ADAPT SCALABLE IDG FAMILIES AND 3506 02:37:00,369 --> 02:37:02,504 PLATFORM AND MOVED TO THE 3507 02:37:02,504 --> 02:37:04,439 IMPLEMENTATION PHASE IN 2018 3508 02:37:04,439 --> 02:37:07,109 WITH THE $71 MILLION TO IDENTIFY 3509 02:37:07,109 --> 02:37:09,444 PHENOTYPES OF THESE UNDER 3510 02:37:09,444 --> 02:37:10,612 STUDIED PROTEIN FAMILIES. 3511 02:37:10,612 --> 02:37:13,248 THE ONES FROM PREVIOUS SLIDE AND 3512 02:37:13,248 --> 02:37:14,316 ALSO PROVIDE TOOLS AROUND THE 3513 02:37:14,316 --> 02:37:16,451 PROTEIN FAMILIES TO THE 3514 02:37:16,451 --> 02:37:16,918 SCIENTIFIC COMMUNITY. 3515 02:37:16,918 --> 02:37:24,526 WE'RE ALSO WORKING TO CREATE AN 3516 02:37:24,526 --> 02:37:27,696 ENRICHED KNOWLEDGE BASE WITH 3517 02:37:27,696 --> 02:37:29,598 SUBSEQUENT DATABASE BEHIND THIS 3518 02:37:29,598 --> 02:37:31,133 I'LL GO OVER AND MAKE YOU AWARE 3519 02:37:31,133 --> 02:37:31,667 OF THE MAIN GOALS IN THE 3520 02:37:31,667 --> 02:37:34,069 PROGRAM. 3521 02:37:34,069 --> 02:37:39,408 AND WHAT I THINK THIS TELLS US 3522 02:37:39,408 --> 02:37:41,276 IS THAT NCATS IS LEADING THE WAY 3523 02:37:41,276 --> 02:37:44,579 IN IDENTIFYING THE DARK AND LOST 3524 02:37:44,579 --> 02:37:45,681 PROTEINS AND PUTTING THEM IN THE 3525 02:37:45,681 --> 02:37:50,018 CONTEXT OF HUMAN DISEASE. 3526 02:37:50,018 --> 02:37:52,754 SO THE PROGRAM DEPENDED ON THE 3527 02:37:52,754 --> 02:37:53,889 CONSORTIUM STRUCTURE FOR 3528 02:37:53,889 --> 02:37:54,156 SUCCESS. 3529 02:37:54,156 --> 02:37:56,692 EACH COMPONENT REQUIRED THE 3530 02:37:56,692 --> 02:37:58,126 EFFORTS OF THE OTHERS IN ORDER 3531 02:37:58,126 --> 02:38:00,162 TO EFFECTIVELY GENERATE THE 3532 02:38:00,162 --> 02:38:01,763 RESOURCES, PROVIDER RESOURCES 3533 02:38:01,763 --> 02:38:02,831 PUBLICALLY IN AN ORGANIZED 3534 02:38:02,831 --> 02:38:03,932 MANNER AND ALSO ENSURE THE 3535 02:38:03,932 --> 02:38:05,567 PUBLIC WAS AWARE OF THE 3536 02:38:05,567 --> 02:38:08,303 RESOURCES BY OUR OUTREACH. 3537 02:38:08,303 --> 02:38:10,105 SO THERE WERE THREE MAIN TYPES. 3538 02:38:10,105 --> 02:38:12,007 THE FIRST WAS DATA AND RESOURCE 3539 02:38:12,007 --> 02:38:13,608 GENERATION CENTERS. 3540 02:38:13,608 --> 02:38:14,743 ONE FOR EACH OF THE DIFFERENT 3541 02:38:14,743 --> 02:38:16,278 PROTEIN FAMILIES AND THESE ARE 3542 02:38:16,278 --> 02:38:17,312 THE WET LABS. 3543 02:38:17,312 --> 02:38:20,048 THE ONCE MOSTLY IN CHARGE OF 3544 02:38:20,048 --> 02:38:21,483 GENERATING THE RESOURCES SUCH AS 3545 02:38:21,483 --> 02:38:23,118 THE MOUSE MODELS AND THINGS 3546 02:38:23,118 --> 02:38:25,053 ALONG THOSE LINES. 3547 02:38:25,053 --> 02:38:27,422 WE HAD THE KNOWLEDGE MANAGEMENT 3548 02:38:27,422 --> 02:38:27,656 CENTER. 3549 02:38:27,656 --> 02:38:30,559 THE BIO INFORMATICS WING AND 3550 02:38:30,559 --> 02:38:34,396 THEY FOCUSSED ON THE INTERPHASE 3551 02:38:34,396 --> 02:38:35,430 AND RESOURCE DISSEMINATION 3552 02:38:35,430 --> 02:38:36,665 CENTER WHICH WITH US CRITICAL IN 3553 02:38:36,665 --> 02:38:38,033 TERMS OF THE ADMINISTRATION AND 3554 02:38:38,033 --> 02:38:41,636 OUTREACH PART OF THE PROGRAM. 3555 02:38:41,636 --> 02:38:43,105 OUTSIDE THE CENTERS WE ALSO HAD 3556 02:38:43,105 --> 02:38:44,373 A NUMBER OF OTHER AWARDS THAT 3557 02:38:44,373 --> 02:38:46,908 WENT OUT. 3558 02:38:46,908 --> 02:38:48,744 WE HAD CUTTING EDGE INFORMATICS 3559 02:38:48,744 --> 02:38:53,715 TOOLS AWARD TO HELP THE 3560 02:38:53,715 --> 02:38:56,084 SCIENTIFIC COMMUNITY BETTER 3561 02:38:56,084 --> 02:38:58,754 ANALYZE AND VISUALIZE DATA AND 3562 02:38:58,754 --> 02:39:01,890 THE PROGRAM I'LL GO MORE IN 3563 02:39:01,890 --> 02:39:03,492 DEPTH ON IN A LITTLE BIT. 3564 02:39:03,492 --> 02:39:05,660 THE PURPOSE WAS TO HELP 3565 02:39:05,660 --> 02:39:07,295 ELUCIDATE THE DARK PROTEINS IN 3566 02:39:07,295 --> 02:39:12,467 THE CONTEXT OF HUMAN DISEASE. 3567 02:39:12,467 --> 02:39:14,503 FINALLY, WE HAD SOMETHING WE DID 3568 02:39:14,503 --> 02:39:18,440 ADJACENT TO THE IDG PROGRAM. 3569 02:39:18,440 --> 02:39:21,576 THIS WAS THE SPIR FUNDING BUT 3570 02:39:21,576 --> 02:39:23,044 FOR A SMALL BUSINESS FUNDING 3571 02:39:23,044 --> 02:39:24,646 OPPORTUNITY BASED ON THE 3572 02:39:24,646 --> 02:39:25,514 PROTEINS THAT WERE HIGHLIGHTED 3573 02:39:25,514 --> 02:39:28,550 IN THE IDG PROGRAM. 3574 02:39:28,550 --> 02:39:30,719 ESSENTIALLY COMMERCIALIZING SOME 3575 02:39:30,719 --> 02:39:32,554 ASSAYS AND RESOURCES AROUND 3576 02:39:32,554 --> 02:39:37,793 THOSE UNDER STUDIED PROTEINS. 3577 02:39:37,793 --> 02:39:39,161 JUST TO GIVE AN IDEA OF THE 3578 02:39:39,161 --> 02:39:41,396 IMPACT WE'VE HAD ON THE FIELD. 3579 02:39:41,396 --> 02:39:44,065 ON THE LEFT IS AN INCREASED IN 3580 02:39:44,065 --> 02:39:47,636 PUBLICATION AROUND THE IDG UNDER 3581 02:39:47,636 --> 02:39:48,737 STUDIED PROTEINS. 3582 02:39:48,737 --> 02:39:49,805 THE RED LINE IS THE 3583 02:39:49,805 --> 02:39:52,207 IMPLEMENTATION PHASE WHEN THEY 3584 02:39:52,207 --> 02:39:52,707 STARTED. 3585 02:39:52,707 --> 02:39:54,242 I WANT TO EMPHASIZE THIS 3586 02:39:54,242 --> 02:39:55,076 ANALYSIS DOES NOT INCLUDE 3587 02:39:55,076 --> 02:39:57,012 PUBLICATIONS FROM THE AWARDEES 3588 02:39:57,012 --> 02:39:57,946 TO THE IDG PROGRAM. 3589 02:39:57,946 --> 02:39:59,414 WE DID THAT BECAUSE WE DON'T 3590 02:39:59,414 --> 02:40:01,650 WANT TO SKEW THE DATA. 3591 02:40:01,650 --> 02:40:02,818 THIS IS ONLY GOING TO THE 3592 02:40:02,818 --> 02:40:03,051 PROGRAM. 3593 02:40:03,051 --> 02:40:04,686 YOU CAN SEE THE PUBLICATIONS 3594 02:40:04,686 --> 02:40:10,525 AROUND THESE UNDER STUDIED 3595 02:40:10,525 --> 02:40:18,500 PROTEINS DID AND YOU CAN SEE A 3596 02:40:18,500 --> 02:40:21,570 NICE STEADY PUBLICATION RATE 3597 02:40:21,570 --> 02:40:22,170 THROUGHOUT THE SPAN OF THE 3598 02:40:22,170 --> 02:40:26,107 PROGRAM AND THE CRITATIONS 3599 02:40:26,107 --> 02:40:31,880 CONTINUE TO INCREASE EVERY YEAR. 3600 02:40:31,880 --> 02:40:32,447 WE'RE CONSIDERING INTEREST 3601 02:40:32,447 --> 02:40:35,784 AROUND THE PROGRAM. 3602 02:40:35,784 --> 02:40:40,689 I WANT TO GIVE YOU AN IDEA OF 3603 02:40:40,689 --> 02:40:43,725 THIS INTERFACE. 3604 02:40:43,725 --> 02:40:46,461 THIS IS SOMETHING DEVELOPED BY 3605 02:40:46,461 --> 02:40:47,929 THE DEVELOPING GROUP AND PULLS 3606 02:40:47,929 --> 02:40:55,704 DATA NOT JUST FROM IDG BUT OTHER 3607 02:40:55,704 --> 02:40:57,305 COMMON FUND PROGRAMS AND KIMBALL 3608 02:40:57,305 --> 02:40:59,307 AND PUB MED AND THERE'S I THINK 3609 02:40:59,307 --> 02:41:02,110 80 RESOURCES AT THIS POINT BUT 3610 02:41:02,110 --> 02:41:05,914 FEED INTO THE INTERFACE TO 3611 02:41:05,914 --> 02:41:08,750 SEARCH THE ENTIRE HUMAN GENOME 3612 02:41:08,750 --> 02:41:12,754 IN HERE NOT JUST THE UNDER 3613 02:41:12,754 --> 02:41:13,154 STUDIED PROTEINS. 3614 02:41:13,154 --> 02:41:14,723 SO YOU CAN GO HERE AND SEARCH 3615 02:41:14,723 --> 02:41:17,325 AND IT WILL GIVE ALL THE 3616 02:41:17,325 --> 02:41:18,393 INFORMATION THAT HAS BEEN 3617 02:41:18,393 --> 02:41:22,364 CLEANED FROM THE 80 PLUS 3618 02:41:22,364 --> 02:41:22,631 RESOURCES. 3619 02:41:22,631 --> 02:41:26,101 WE ALSO HAVE THE CAPACITY FOR 3620 02:41:26,101 --> 02:41:30,505 SEARCHS ASSOCIATED WITH 3621 02:41:30,505 --> 02:41:40,682 DISEASES. 3622 02:41:46,588 --> 02:41:57,065 THIS IS UNIQUE TO THESE ARE WHAT 3623 02:42:00,368 --> 02:42:02,070 WE CONSIDER DARK VIRTUALLY 3624 02:42:02,070 --> 02:42:05,840 NOTHING KNOWN AND THE NEXT STEP 3625 02:42:05,840 --> 02:42:10,512 IS THE T BIO PROTEINS THE T 3626 02:42:10,512 --> 02:42:13,848 STAND FOR TARGETS AND THERE MAY 3627 02:42:13,848 --> 02:42:21,523 BE PUBLICATIONS AND MAY BE SOME 3628 02:42:21,523 --> 02:42:23,525 R01s AND THEN T CHECK WITH ONE 3629 02:42:23,525 --> 02:42:27,095 AT LEAST ONE BIO ACTIVE COMPOUND 3630 02:42:27,095 --> 02:42:30,198 AND THE LEAST STUDIED ARE THE 3631 02:42:30,198 --> 02:42:31,433 TCLIN PROTEINS THAT USUALLY HAVE 3632 02:42:31,433 --> 02:42:34,502 AT LEAST ONE APPROVED DRUG. 3633 02:42:34,502 --> 02:42:36,905 SO THIS IS ONE OF THE TOOLS 3634 02:42:36,905 --> 02:42:38,673 THAT'S INCLUDED IN PHAROS. 3635 02:42:38,673 --> 02:42:40,775 I CAN'T GO COMPREHENSIVELY OVER 3636 02:42:40,775 --> 02:42:43,411 ALL THE TOOLS IN PHAROS BUT I 3637 02:42:43,411 --> 02:42:45,513 WANTED TO HIGHLIGHT SOME TOOLS 3638 02:42:45,513 --> 02:42:48,683 THAT HAVE GONE THROUGH SOME 3639 02:42:48,683 --> 02:42:59,294 EALLITERATIONSS -- IL ITERATION 3640 02:42:59,294 --> 02:43:01,963 AND ON THE RIGHT YOU CAN SEE 3641 02:43:01,963 --> 02:43:03,531 THIS ALLOWS YOU TO SEE EXACTLY 3642 02:43:03,531 --> 02:43:10,238 WHERE YOUR PROTEIN EXPRESSED IN 3643 02:43:10,238 --> 02:43:12,807 THE BODY AND LIGHTER TISSUES ARE 3644 02:43:12,807 --> 02:43:15,010 LESS EXPRESSION AND WE HAVE THIS 3645 02:43:15,010 --> 02:43:17,979 AVAILABLE FOR REGIONS OF THE 3646 02:43:17,979 --> 02:43:18,313 BRAIN. 3647 02:43:18,313 --> 02:43:19,948 IF YOU ARE TRYING TO LOOK MORE 3648 02:43:19,948 --> 02:43:23,118 OF A CELL TYPE OR PARTICULAR 3649 02:43:23,118 --> 02:43:24,653 AREA OF A PARTICULAR TISSUE YOU 3650 02:43:24,653 --> 02:43:26,321 WANT TO SEE IF YOUR PROTEIN IS 3651 02:43:26,321 --> 02:43:27,756 EXPRESSED, THIS ALLOWS YOU TO 3652 02:43:27,756 --> 02:43:28,456 DRILL DOWN. 3653 02:43:28,456 --> 02:43:29,991 THIS IS THE CIRCLE PART. 3654 02:43:29,991 --> 02:43:31,292 IT ALLOWS YOU TO -- YOU CAN 3655 02:43:31,292 --> 02:43:34,062 START AT THE ORGAN LEVEL BUT IT 3656 02:43:34,062 --> 02:43:36,364 LETS YOU DRILL DOWN TO CELL TYPE 3657 02:43:36,364 --> 02:43:37,732 AND SEE WHERE YOUR PROTEIN IS 3658 02:43:37,732 --> 02:43:41,870 EXPRESSED. 3659 02:43:41,870 --> 02:43:45,674 A FEW OTHER NOTABLE FEATURES OF 3660 02:43:45,674 --> 02:43:46,508 PHAROS. 3661 02:43:46,508 --> 02:43:49,377 IF YOUR PROTEIN HAS APPROVED 3662 02:43:49,377 --> 02:43:51,646 DRUGS OR LIGANDS ARE LISTED AND 3663 02:43:51,646 --> 02:43:53,014 CLICK ON THEM AND IT WILL TAKE 3664 02:43:53,014 --> 02:43:54,916 YOU TO THE WEB PAGE TO LEARN 3665 02:43:54,916 --> 02:43:57,352 MORE ABOUT THE LIGANDS OR DRUGS 3666 02:43:57,352 --> 02:44:01,089 AND THERE'S A PROTEIN-PROTEIN 3667 02:44:01,089 --> 02:44:02,157 INTERACTION TOOLS AND SHOW OTHER 3668 02:44:02,157 --> 02:44:04,092 PROTEINS YOUR PARTICULAR PROTEIN 3669 02:44:04,092 --> 02:44:05,593 MAY INTERACT WITH. 3670 02:44:05,593 --> 02:44:07,095 YOU CAN CLICK AND TAKE YOU TO 3671 02:44:07,095 --> 02:44:08,697 THE WEB PAGE TO LEARN MORE. 3672 02:44:08,697 --> 02:44:17,072 ON THE RIGHT ARE DYNAMIC TOOLS 3673 02:44:17,372 --> 02:44:17,906 PHAROS. 3674 02:44:17,906 --> 02:44:20,175 THIS IS FROM ONE OF OUR CIT 3675 02:44:20,175 --> 02:44:23,678 AWARDEES PULLED FROM THE TOOL 3676 02:44:23,678 --> 02:44:25,647 CALLED REACTOME AND SEE WHERE 3677 02:44:25,647 --> 02:44:28,783 YOUR PROTEIN SITS IN TERMS OF A 3678 02:44:28,783 --> 02:44:30,185 PARTICULAR PATHWAY AND BUILDS IN 3679 02:44:30,185 --> 02:44:31,653 THE TARGET DEVELOPMENT LEVEL 3680 02:44:31,653 --> 02:44:32,187 INTO THAT. 3681 02:44:32,187 --> 02:44:36,057 YOU CAN SEE WHAT OTHER PROTEINS 3682 02:44:36,057 --> 02:44:38,226 YOU'RE INTERACTING WITH AND WHAT 3683 02:44:38,226 --> 02:44:42,263 WE KNOW ABOUT THEM. 3684 02:44:42,263 --> 02:44:44,833 IF IT'S A DARK PROTEIN IT WILL 3685 02:44:44,833 --> 02:44:46,301 PROVIDE PREDICTIVE PATHWAYS AS 3686 02:44:46,301 --> 02:44:46,735 WELL. 3687 02:44:46,735 --> 02:44:48,803 WE ALSO HAVE STRUCTURES BUILT 3688 02:44:48,803 --> 02:44:50,205 IN. 3689 02:44:50,205 --> 02:44:54,342 THE STRUCTURES IF KNOWN WILL BE 3690 02:44:54,342 --> 02:44:57,412 PROVIDED HOWEVER, WE HAVE 3691 02:44:57,412 --> 02:44:59,414 ALPOPOL IN THE INTERFACE. 3692 02:44:59,414 --> 02:45:01,549 IF THERE'S NOT A STRUCTURE IT 3693 02:45:01,549 --> 02:45:03,518 WILL PROVIDE PREDICTIVE 3694 02:45:03,518 --> 02:45:04,352 STRUCTURE. 3695 02:45:04,352 --> 02:45:07,622 IF IT'S AN IDG ELIGIBLE PROTEIN 3696 02:45:07,622 --> 02:45:09,624 YOU'LL SEE RESOURCES SUCH AS 3697 02:45:09,624 --> 02:45:11,359 CELL LINES, MOUSE MODELS, 3698 02:45:11,359 --> 02:45:12,761 ASSAYS, CONSTRUCTS. 3699 02:45:12,761 --> 02:45:14,362 THINGS ALONG THAT LINE. 3700 02:45:14,362 --> 02:45:16,965 SO JUST WANT IT GIVE YOU AN 3701 02:45:16,965 --> 02:45:17,565 IDEA. 3702 02:45:17,565 --> 02:45:20,268 THIS IS ESSENTIALLY A PRETTY 3703 02:45:20,268 --> 02:45:21,269 POPULAR TOOL. 3704 02:45:21,269 --> 02:45:26,107 STEADY USERSHIP OVER TIME AROUND 3705 02:45:26,107 --> 02:45:27,108 6,000 A MONTH. 3706 02:45:27,108 --> 02:45:29,844 WE ARE HAPPY IT SEE THIS IS 3707 02:45:29,844 --> 02:45:31,079 REMAINING POPULAR AMONG THE 3708 02:45:31,079 --> 02:45:32,113 SCIENTIFIC COMMUNITY. 3709 02:45:32,113 --> 02:45:34,949 AND THEN ON THE RIGHT IS REALLY 3710 02:45:34,949 --> 02:45:36,084 AN IDEA OF WHERE THINGS ARE 3711 02:45:36,084 --> 02:45:38,253 SHIFTING IN TERMS OF THOSE 3712 02:45:38,253 --> 02:45:40,054 TARGET DEVELOPMENT LEVELS. 3713 02:45:40,054 --> 02:45:44,626 IN 2018 THOSE ARE THE T DARK 3714 02:45:44,626 --> 02:45:47,495 PROTEINS TO REMIND YOU THE 3715 02:45:47,495 --> 02:45:49,631 BEGINNING OF THE IMPLEMENTATION 3716 02:45:49,631 --> 02:45:52,901 PHASE AND IN 2023, 50% FROM 3717 02:45:52,901 --> 02:45:57,539 MOVED TO THE T BIO OR T KIM 3718 02:45:57,539 --> 02:45:57,839 DESIGNATION. 3719 02:45:57,839 --> 02:46:02,577 THAT'S INDICATING THEY'RE 3720 02:46:02,577 --> 02:46:11,152 GETTING SOME LOVE AND ATTENTION 3721 02:46:11,152 --> 02:46:14,823 AND SEEING HOW THEY FIT INTO 3722 02:46:14,823 --> 02:46:15,824 HUMAN DISEASE. 3723 02:46:15,824 --> 02:46:17,992 NOT ALL THIS CAN BE ATTRIBUTED 3724 02:46:17,992 --> 02:46:22,163 TO JUST THE IDG PROGRAM BECAUSE 3725 02:46:22,163 --> 02:46:24,032 IT'S PART OF A MOVEMENT TO 3726 02:46:24,032 --> 02:46:26,501 ILLUMINATE THE STRUCTURE 3727 02:46:26,501 --> 02:46:29,904 PROTEINS AND OPEN TARGET AND 3728 02:46:29,904 --> 02:46:31,372 TARGET 25 AMONG OTHERS. 3729 02:46:31,372 --> 02:46:33,775 IT TELLS US WE'RE MAKING 3730 02:46:33,775 --> 02:46:34,409 PROGRESS IN BRINGING ATTENTION 3731 02:46:34,409 --> 02:46:44,819 TO THE UNDER STUDIED PROTEINS. 3732 02:46:44,819 --> 02:46:47,989 JUST AN OVERVIEW OF THE R3 PILOT 3733 02:46:47,989 --> 02:46:51,759 PROGRAMS AND THESE ARE 100,000S 3734 02:46:51,759 --> 02:46:54,495 CAN DIRECT COST AWARDS FOR ONE 3735 02:46:54,495 --> 02:46:55,697 YEAR. 3736 02:46:55,697 --> 02:46:57,465 -- $100,000. 3737 02:46:57,465 --> 02:46:59,734 WE WERE ABLE TO OBTAIN HIGH 3738 02:46:59,734 --> 02:47:02,070 LEVELS OF SCIENTIFIC OUTPUT FOR 3739 02:47:02,070 --> 02:47:03,404 LITTLE INVESTMENT. 3740 02:47:03,404 --> 02:47:06,507 THESE WILL SUPPORT THE 3741 02:47:06,507 --> 02:47:08,243 GENERATION OF PRELIMINARY DATA 3742 02:47:08,243 --> 02:47:10,078 AND TOOLS WITH PROTEINS IN THE 3743 02:47:10,078 --> 02:47:14,148 CONTEXT OF HUMAN DISEASE AND 3744 02:47:14,148 --> 02:47:15,350 WORKED ON DATA. 3745 02:47:15,350 --> 02:47:18,186 THE AWARDEES OBTAINED RESEARCH 3746 02:47:18,186 --> 02:47:19,954 RESOURCES FOR SUBSEQUENT LARGER 3747 02:47:19,954 --> 02:47:21,256 AWARDS FOR DRUG DISCOVERY 3748 02:47:21,256 --> 02:47:22,023 PROJECTS. 3749 02:47:22,023 --> 02:47:26,261 AND WE WERE ABLE TO FUND 9 8 3750 02:47:26,261 --> 02:47:28,129 AWARDS AND OVER 100 SPECIFIC 3751 02:47:28,129 --> 02:47:30,064 DARK PROTEINS VIA THE AWARDS 3752 02:47:30,064 --> 02:47:31,766 WITH OVER 100 PUBLICATIONS TO 3753 02:47:31,766 --> 02:47:33,201 DATE. 3754 02:47:33,201 --> 02:47:34,402 WE WERE ALSO ABLE TO FUND 29 3755 02:47:34,402 --> 02:47:38,539 EARLY STAGE OR NEW INVESTIGATORS 3756 02:47:38,539 --> 02:47:44,379 AND PULL IN EARLY STAGE 3757 02:47:44,379 --> 02:47:46,681 INVESTIGATORS, EARLY CAREER 3758 02:47:46,681 --> 02:47:48,549 INVESTIGATORS AND GET THEM 3759 02:47:48,549 --> 02:47:51,519 STUDYING THE PROTEINS AND BASED 3760 02:47:51,519 --> 02:47:54,155 ON DATA COLLECTED UNDER THE R3 3761 02:47:54,155 --> 02:47:57,325 PILOT AWARD PROJECT AWARDS. 3762 02:47:57,325 --> 02:47:59,794 AND SOME AWARDS ARE STILL ACTIVE 3763 02:47:59,794 --> 02:48:02,263 AND IT CAN TAKE TIME FOR 3764 02:48:02,263 --> 02:48:06,501 APPLICATIONS TO BE SUBMITTED AND 3765 02:48:06,501 --> 02:48:08,269 AWARDS TO BE MADE. 3766 02:48:08,269 --> 02:48:09,704 ONE PARTICULAR PROJECT THAT WENT 3767 02:48:09,704 --> 02:48:13,741 FROM PRETTY MUCH DARK UP TO 3768 02:48:13,741 --> 02:48:18,413 POTENTIAL CLINICAL TARGET IS 3769 02:48:18,413 --> 02:48:21,015 WORK DONE BY DR. STEVE LAUDNALL 3770 02:48:21,015 --> 02:48:26,521 AT THE UNIVERSITY OF MONTANA. 3771 02:48:26,521 --> 02:48:32,126 HE WORKED ON THE VIRAL IMMUNITY 3772 02:48:32,126 --> 02:48:32,994 AND INFLAMMATORY REACTION. 3773 02:48:32,994 --> 02:48:36,965 HE HAD A PRESENTATION AT THE 3774 02:48:36,965 --> 02:48:38,499 UNIVERSITY OF MONTANA AND THE 3775 02:48:38,499 --> 02:48:43,604 MAN ON THE BOTTOM HAS A SMALL 3776 02:48:43,604 --> 02:48:45,239 COMPANY AND PROPOSED WORKING 3777 02:48:45,239 --> 02:48:48,376 TOGETHER ON LOOKING AT AUTO 3778 02:48:48,376 --> 02:48:50,078 IMMUNE DISEASES SPECIFICALLY 3779 02:48:50,078 --> 02:48:51,145 CUTANEOUS LUPUS. 3780 02:48:51,145 --> 02:48:52,780 THEY WORKED WITH A SMALL COMPANY 3781 02:48:52,780 --> 02:48:59,454 AT THE TIME KNOWN AS VANT A.I. 3782 02:48:59,454 --> 02:49:01,589 AND THEY WORKED TO DESIGN 3783 02:49:01,589 --> 02:49:02,490 PROTEIN INHIBITORS AND THEY WERE 3784 02:49:02,490 --> 02:49:04,459 LOOKING FOR SOMEBODY TO GIVE 3785 02:49:04,459 --> 02:49:06,194 THEM ESSENTIALLY PROOF OF 3786 02:49:06,194 --> 02:49:08,262 CONCEPT STUDY TO TEST THEIR 3787 02:49:08,262 --> 02:49:09,464 INHIBITORS AND VALIDATE THEM AND 3788 02:49:09,464 --> 02:49:10,832 LOOK AT THE QUALITY. 3789 02:49:10,832 --> 02:49:14,268 THEY WERE ABLE TO OBTAIN THE 3790 02:49:14,268 --> 02:49:17,005 INHIBITORS FREE OF CHARGE. 3791 02:49:17,005 --> 02:49:19,173 AND IT WAS A COOL THING THAT 3792 02:49:19,173 --> 02:49:20,475 EMERGED DURING THE PARTNERSHIP. 3793 02:49:20,475 --> 02:49:24,212 AND THESE WERE REALLY THE FIRST 3794 02:49:24,212 --> 02:49:25,246 BINDERS THAT SHOWED SELECTIVITY. 3795 02:49:25,246 --> 02:49:27,715 SO THEY SUBMITTED AND WERE 3796 02:49:27,715 --> 02:49:29,684 AWARDED IN SBIR TO DESIGN SMALL 3797 02:49:29,684 --> 02:49:31,519 MOLECULES TO BLOCK FOR THE 3798 02:49:31,519 --> 02:49:33,554 TREATMENT OF CUTANEOUS LUPUS NOT 3799 02:49:33,554 --> 02:49:36,357 JUST IN ADULT BUT PEDIATRIC 3800 02:49:36,357 --> 02:49:38,259 PATIENT GROUPS AS WELL. 3801 02:49:38,259 --> 02:49:40,261 THEIR NEXT STEPS WILL BE IN VIVO 3802 02:49:40,261 --> 02:49:40,695 VALIDATION. 3803 02:49:40,695 --> 02:49:46,501 THEY WANT TO LOOK AT A ROLE FOR 3804 02:49:46,501 --> 02:49:50,471 RO3 IN ULCERATIVE COLITIS AS 3805 02:49:50,471 --> 02:49:53,007 WELL. 3806 02:49:53,007 --> 02:49:54,308 WITHIN COMMON FUND WE PARTNERED 3807 02:49:54,308 --> 02:49:57,111 WITH ANOTHER GROUP WORKING TO 3808 02:49:57,111 --> 02:50:02,316 MAKE ESSENTIALLY A GIANT 3809 02:50:02,316 --> 02:50:04,886 KNOCKOUT MOUSE RESOURCE. 3810 02:50:04,886 --> 02:50:06,654 THIS IS THE KNOCKOUT MOUSE 3811 02:50:06,654 --> 02:50:08,289 PHENOTYPING PROGRAM AND WE 3812 02:50:08,289 --> 02:50:09,624 INITIATED A PARTNERSHIP WITH 3813 02:50:09,624 --> 02:50:13,327 THEM IN SEPTEMBER OF 2022 TO TRY 3814 02:50:13,327 --> 02:50:17,498 TO DEVELOP 27 DIFFERENT UNDER 3815 02:50:17,498 --> 02:50:18,866 STUDIED ION CHANNEL KNOCKOUT 3816 02:50:18,866 --> 02:50:20,568 MOUSE AND IT'S IN PROGRESS BUT 3817 02:50:20,568 --> 02:50:23,671 THIS ONE IS ACTUALLY ONE OF THE 3818 02:50:23,671 --> 02:50:27,141 UNDER STUDIED ION CHANNELS A 3819 02:50:27,141 --> 02:50:29,577 PLLP AND THEY DO A LIMITED 3820 02:50:29,577 --> 02:50:31,813 PHENOTYPIC SUMMARY ON THE MOUSE 3821 02:50:31,813 --> 02:50:34,382 AND WHEN KNOCKED OUT HAS AN 3822 02:50:34,382 --> 02:50:38,519 EFFECT ON KIDNEY, TESTEES AND 3823 02:50:38,519 --> 02:50:39,087 PROVIDES THE SCIENTIFIC 3824 02:50:39,087 --> 02:50:40,354 COMMUNITY A STARTING POINT TO 3825 02:50:40,354 --> 02:50:41,923 UNDERSTAND WHERE THIS PARTICULAR 3826 02:50:41,923 --> 02:50:42,557 PROTEIN MAY BE INVOLVED IN HUMAN 3827 02:50:42,557 --> 02:50:46,627 DISEASE. 3828 02:50:46,627 --> 02:50:53,801 SO I'M GOING TO WRAP UP WITH ONE 3829 02:50:53,801 --> 02:50:56,270 LAST COOL THING WE'VE BEEN DOING 3830 02:50:56,270 --> 02:50:59,540 WITH THE GROUP IN ITALY. 3831 02:50:59,540 --> 02:51:06,514 SO THIS ACTUALLY A GROUP THAT IS 3832 02:51:06,514 --> 02:51:09,851 WITH THE ITALIAN GOVERNMENT AND 3833 02:51:09,851 --> 02:51:11,986 SAW VALUE IN THE INVESTMENT AND 3834 02:51:11,986 --> 02:51:15,857 THEY HAD A CALL RELEASED IN 3835 02:51:15,857 --> 02:51:16,958 ALLIANCE WITH RESPONSE TO A 3836 02:51:16,958 --> 02:51:18,526 GROWING NEED FOR TREATMENTS FOR 3837 02:51:18,526 --> 02:51:19,127 PATIENTS WHO SUFFER FROM RARE 3838 02:51:19,127 --> 02:51:22,029 DISEASE. 3839 02:51:22,029 --> 02:51:24,732 SO IT'S AN ITALIAN NON-PROFIT 3840 02:51:24,732 --> 02:51:26,234 ORGANIZATION WITH A FOCUS ON 3841 02:51:26,234 --> 02:51:28,002 FUNDING RESEARCH AND SUPPORTING 3842 02:51:28,002 --> 02:51:31,539 PATIENT GROUPS WITH RARE GENETIC 3843 02:51:31,539 --> 02:51:35,409 DISEASE AND FONDAZIONE IS IN THE 3844 02:51:35,409 --> 02:51:35,743 ORGANIZATION. 3845 02:51:35,743 --> 02:51:38,446 THE TWO OF THESE HAVE WORKED 3846 02:51:38,446 --> 02:51:39,981 TOGETHER TO HAVE SEVERAL FUNDING 3847 02:51:39,981 --> 02:51:42,550 CALLS AND I THINK IT'S THREE TO 3848 02:51:42,550 --> 02:51:45,286 DATE THAT UTILIZE PHAROS TO LOOK 3849 02:51:45,286 --> 02:51:47,522 AT T DARK PROTEINS WITHIN THE 3850 02:51:47,522 --> 02:51:48,289 CONTEXT OF RARE DISEASE AND 3851 02:51:48,289 --> 02:51:51,259 GENETIC AND NON-GENETIC ORIGIN. 3852 02:51:51,259 --> 02:51:55,296 THEY'VE BEEN ABLE TO PUT IN 3853 02:51:55,296 --> 02:52:00,134 ABOUT $13.4 MILLION EUROS AND 3854 02:52:00,134 --> 02:52:02,303 STUDY THE ROLE FOR T DARK 3855 02:52:02,303 --> 02:52:04,105 PROTEINS IN DIFFERENT AREAS OF 3856 02:52:04,105 --> 02:52:06,507 RARE DISEASE INCLUDING 3857 02:52:06,507 --> 02:52:09,677 MITOCHONDRIAL DISORDERS, MYELOID 3858 02:52:09,677 --> 02:52:14,348 NEOPLASMS AND NEUROLOGICAL 3859 02:52:14,348 --> 02:52:14,982 DISORDERS AMONG SEVERAL OTHERS. 3860 02:52:14,982 --> 02:52:17,485 THIS IS REALLY A NOTABLE EXAMPLE 3861 02:52:17,485 --> 02:52:20,288 OF HOW PHAROS AND THE STUDY OF 3862 02:52:20,288 --> 02:52:25,693 DARK PROTEINS CAN HELP MOVE THE 3863 02:52:25,693 --> 02:52:26,327 HUMAN DISEASE RESEARCH FORWARD. 3864 02:52:26,327 --> 02:52:27,428 AS CHRISTINE MENTIONED THE 3865 02:52:27,428 --> 02:52:28,296 COMMON FUND IS WRAPPING UP. 3866 02:52:28,296 --> 02:52:30,298 IT'S COMING TO AN END. 3867 02:52:30,298 --> 02:52:32,033 WE'RE AT THE END OF THE 10-YEAR 3868 02:52:32,033 --> 02:52:33,267 TIME LINE. 3869 02:52:33,267 --> 02:52:35,970 I WANT TO GIVE AN IDEA WHERE 3870 02:52:35,970 --> 02:52:38,739 THINGS SIT EITHER NOW OR IN THE 3871 02:52:38,739 --> 02:52:40,141 FUTURE. 3872 02:52:40,141 --> 02:52:44,345 SO BECAUSE AS YOU'VE SEEN THE 3873 02:52:44,345 --> 02:52:48,583 CAREER USEFULNESS OF PHAROS 3874 02:52:48,583 --> 02:52:50,351 THERE'S SEVERAL OPTIONS WE'RE 3875 02:52:50,351 --> 02:52:53,120 EXPLORING TO EXTEND IT AFTER THE 3876 02:52:53,120 --> 02:52:55,089 PROGRAM AND WE HAD GROUPS 3877 02:52:55,089 --> 02:52:56,924 UTILIZE IT AND USED FOR FUNDING 3878 02:52:56,924 --> 02:52:57,124 CALLS. 3879 02:52:57,124 --> 02:53:01,128 WE'RE GOING TO WORK HARD TO -- 3880 02:53:01,128 --> 02:53:10,404 WE ARE WORKING HARD TO LOOK AT 3881 02:53:10,404 --> 02:53:13,608 DIFFERENT SUSTAINABILITY 3882 02:53:13,608 --> 02:53:14,242 INITIATIVES FOR PHAROS AND ON 3883 02:53:14,242 --> 02:53:16,244 THE RIGHT I WANT TO GIVE AN IDEA 3884 02:53:16,244 --> 02:53:19,614 WHERE ALL THE PROJECTS FALL. 3885 02:53:19,614 --> 02:53:21,349 THAT'S A WHEEL -- A CIRCLE PLOT 3886 02:53:21,349 --> 02:53:24,485 OF ALL THE DIFFERENT DISEASES 3887 02:53:24,485 --> 02:53:27,455 THAT WERE TOUCHED ON DURING THE 3888 02:53:27,455 --> 02:53:30,491 PROGRAM AND REALLY THAT PROGRAM 3889 02:53:30,491 --> 02:53:31,259 HAS ENCOURAGED OTHER GROUPS TO 3890 02:53:31,259 --> 02:53:37,298 TAKE ON THE FORMAT. 3891 02:53:37,298 --> 02:53:39,900 AND THERE'S AN A FORMAT TO OTHER 3892 02:53:39,900 --> 02:53:40,201 INITIATIVE. 3893 02:53:40,201 --> 02:53:44,138 WHAT IT DOES IS IT HELPS TO 3894 02:53:44,138 --> 02:53:46,507 INCORPORATE EARLY CAREER 3895 02:53:46,507 --> 02:53:48,943 INVESTIGATORS IN THE INITIATIVES 3896 02:53:48,943 --> 02:53:52,013 AND STIMULATE RESEARCH ON 3897 02:53:52,013 --> 02:53:52,313 INVESTMENT. 3898 02:53:52,313 --> 02:53:54,515 AND WE HAVE THE NCATS RARE 3899 02:53:54,515 --> 02:53:55,916 DISEASE NOFO WHICH HAS BEEN OUT 3900 02:53:55,916 --> 02:53:58,119 A COUPLE YEARS NOW AND WE LIKE 3901 02:53:58,119 --> 02:54:02,356 TO THANK COUNCIL FOR APPROVING 3902 02:54:02,356 --> 02:54:06,027 THE CONCEPT BECAUSE THAT HAS LAD 3903 02:54:06,027 --> 02:54:06,927 A TREMENDOUS IMPACT. 3904 02:54:06,927 --> 02:54:07,995 IN TERMS OF THE RESOURCES 3905 02:54:07,995 --> 02:54:09,297 DEVELOPED BY THE PROGRAM WE'RE 3906 02:54:09,297 --> 02:54:11,532 WORKING TO SUSTAIN THOSE THROUGH 3907 02:54:11,532 --> 02:54:13,034 THE UTILIZATION OF PUBLIC 3908 02:54:13,034 --> 02:54:14,869 REPOSITORIES AND OVER ALL WE 3909 02:54:14,869 --> 02:54:16,537 FEEL LIKE WE'VE HOPEFULLY 3910 02:54:16,537 --> 02:54:17,171 INCREASED INTEREST AROUND THE 3911 02:54:17,171 --> 02:54:19,907 UNDER STUDIED PROTEINS AND 3912 02:54:19,907 --> 02:54:22,109 REALLY DEMONSTRATED THE VALUE OF 3913 02:54:22,109 --> 02:54:26,347 LOOKING INTO THE PROTEINS IN 3914 02:54:26,347 --> 02:54:26,847 TERMS OF HUMAN DISEASE. 3915 02:54:26,847 --> 02:54:28,582 I'LL LEAVE YOU WITH THIS. 3916 02:54:28,582 --> 02:54:31,585 THIS IS A DRUGGABLE GENOME 3917 02:54:31,585 --> 02:54:33,287 SPECIAL SERIES WITH DRUG 3918 02:54:33,287 --> 02:54:34,488 DISCOVERY TODAY. 3919 02:54:34,488 --> 02:54:36,657 THE TOP PUBLICATION IS ONE THE 3920 02:54:36,657 --> 02:54:38,292 NIH PUT OUT AND THAT GOES OVER A 3921 02:54:38,292 --> 02:54:40,494 LOT OF THE OVERVIEWS IN TERMS OF 3922 02:54:40,494 --> 02:54:42,296 SUCCESSES AROUND THE PROGRAM AS 3923 02:54:42,296 --> 02:54:45,166 A WHOLE BUT THERE ARE A NUMBER 3924 02:54:45,166 --> 02:54:46,000 OF ADDITIONAL ARTICLES IN THE 3925 02:54:46,000 --> 02:54:48,369 SERIES THAT CAME OUT AND FROM 3926 02:54:48,369 --> 02:54:49,170 OUR SPECIFIC AWARDEES. 3927 02:54:49,170 --> 02:54:51,072 I'D ENCOURAGE YOU ALL TO TAKE A 3928 02:54:51,072 --> 02:54:52,707 LOOK AT THAT AND EXPLORE THE 3929 02:54:52,707 --> 02:54:54,408 SUCCESSES AND RESOURCES THE 3930 02:54:54,408 --> 02:54:56,110 PROGRAM PUT OUT. 3931 02:54:56,110 --> 02:54:57,378 SO I'M GOING TO HAND IT BACK TO 3932 02:54:57,378 --> 02:55:07,054 CHRISTINE. 3933 02:55:07,054 --> 02:55:10,658 >> BACK WITH A TEASER FOR NEXT 3934 02:55:10,658 --> 02:55:11,058 YEAR. 3935 02:55:11,058 --> 02:55:13,794 I'LL TRY TO GIVE A QUICK UPDATE 3936 02:55:13,794 --> 02:55:22,837 ON WHAT HAS HAPPENED TO LITCOIN 3937 02:55:22,837 --> 02:55:24,739 WITH AARON BERNSTEIN AND WAS 3938 02:55:24,739 --> 02:55:27,441 ONLY WITH US 10 MONTHS AND WAS 3939 02:55:27,441 --> 02:55:28,909 IMPRESSIVE AND TYLER BECK HAS 3940 02:55:28,909 --> 02:55:30,511 BEEN OVERSEEING THE PROGRAM AND 3941 02:55:30,511 --> 02:55:32,646 THE FOLKS YOU SEE NAMED ACROSS 3942 02:55:32,646 --> 02:55:38,419 THE BOTTOM ARE WORKING WITH US 3943 02:55:38,419 --> 02:55:49,230 THROUGH CONTRACT MECHANISMSS HEL 3944 02:55:52,133 --> 02:55:52,867 IS PAYING FOR AND THE BOTTOM 3945 02:55:52,867 --> 02:55:56,504 LINE IS THE IDEA IS TO CREATE 3946 02:55:56,504 --> 02:55:58,272 MACHINE READABLE, A.I. READY 3947 02:55:58,272 --> 02:55:59,206 KNOWLEDGE FROM LITERATURE. 3948 02:55:59,206 --> 02:56:03,077 WE CAN DO THIS PROSPECTIVELY 3949 02:56:03,077 --> 02:56:04,912 WITH NEWLY SUBMITTED MANUSCRIPTS 3950 02:56:04,912 --> 02:56:06,080 AND THIS IS WHAT WE HOPE TO DO 3951 02:56:06,080 --> 02:56:06,680 IN THE FUTURE. 3952 02:56:06,680 --> 02:56:08,616 ONE ASPECT IS WHAT WE REFER TO 3953 02:56:08,616 --> 02:56:13,454 AS A LITCOIN PUBLICATION FOR 3954 02:56:13,454 --> 02:56:13,621 MAT. 3955 02:56:13,621 --> 02:56:15,689 LITCOIN PROPER. 3956 02:56:15,689 --> 02:56:18,993 WE CAN DO THIS RETROSPECTIVELY 3957 02:56:18,993 --> 02:56:21,262 WORKING WITH THE ABSTRACT FROM 3958 02:56:21,262 --> 02:56:21,862 PUBLICATIONS ALREADY OUT AND 3959 02:56:21,862 --> 02:56:25,966 AVAILABLE. 3960 02:56:25,966 --> 02:56:29,303 WE'RE REFERRING TO THIS 3961 02:56:29,303 --> 02:56:32,440 RETROSPECTIVE PIECE AS LIT TO 3962 02:56:32,440 --> 02:56:38,446 GRAPH AND MAKING THE DISTINCTION 3963 02:56:38,446 --> 02:56:41,916 BETWEEN THE LIT COIN. 3964 02:56:41,916 --> 02:56:43,851 LIT2GRAPH GOES FROM AN ABSTRACT 3965 02:56:43,851 --> 02:56:50,458 HUMAN READABLE ABSTRACT TO 3966 02:56:50,458 --> 02:57:00,000 MACHINE READABLE GRAPHS. 3967 02:57:00,000 --> 02:57:02,002 YOU PROBABLY CAN'T READ THIS BUT 3968 02:57:02,002 --> 02:57:06,540 ON THE LEFT SIDE WE SEE AN 3969 02:57:06,540 --> 02:57:06,807 ABSTRACT. 3970 02:57:06,807 --> 02:57:13,447 ON THE RIGHT SIDE I WANT TO USE 3971 02:57:13,447 --> 02:57:15,683 THIS TO ILLUSTRATE TO COULD BE 3972 02:57:15,683 --> 02:57:17,751 VERT THIS TO A MACHINE READABLE 3973 02:57:17,751 --> 02:57:27,828 PIECE OF NFK. 3974 02:57:27,828 --> 02:57:30,998 WHAT'S THE NOVEL THING IN THE 3975 02:57:30,998 --> 02:57:32,233 ABSTRACT. 3976 02:57:32,233 --> 02:57:33,467 WHAT IS THE BOTTOM LINE OF THE 3977 02:57:33,467 --> 02:57:35,069 THING WE'RE TRYING TO PRESENT 3978 02:57:35,069 --> 02:57:40,541 AND WANT TO DO THAT COMPUTATION 3979 02:57:40,541 --> 02:57:43,744 AND IT'S TOO HARD FOR HUMANS TO 3980 02:57:43,744 --> 02:57:44,178 DO THIS. 3981 02:57:44,178 --> 02:57:45,746 IT'S TIME CONSUMING. 3982 02:57:45,746 --> 02:57:50,451 ON THE LEFT SIDE UNDER THAT 3983 02:57:50,451 --> 02:57:53,521 ABSTRACT I'M CIRCLING THIS 3984 02:57:53,521 --> 02:57:55,189 PARTICULAR STATEMENT. 3985 02:57:55,189 --> 02:58:02,496 ITS IS STATING HYPERTENSION DOES 3986 02:58:02,496 --> 02:58:05,633 NOT ABROGATE EDEMA AND SHOWS IT 3987 02:58:05,633 --> 02:58:13,707 WITH THE ARROW AND THE YELLOW 3988 02:58:13,707 --> 02:58:14,675 BOXES. 3989 02:58:14,675 --> 02:58:17,444 THE CURRENT STANDARD IS SEMMED. 3990 02:58:17,444 --> 02:58:18,512 IT'S BEEN AROUND SINCE 2008. 3991 02:58:18,512 --> 02:58:21,081 AT THE TIME IT WAS VERY CUTTING 3992 02:58:21,081 --> 02:58:21,282 EDGE. 3993 02:58:21,282 --> 02:58:28,822 IT WAS VERY FORWARD THINKING BUT 3994 02:58:28,822 --> 02:58:34,495 STRUGGLES IN A WAY TO GET THE 3995 02:58:34,495 --> 02:58:37,331 INFORMATION AND IT STRUGGLED TO 3996 02:58:37,331 --> 02:58:41,001 IDENTIFY WHAT IT THE POINT OF 3997 02:58:41,001 --> 02:58:44,004 THE PAPER AND WHAT IS BEING 3998 02:58:44,004 --> 02:58:44,505 RECORDED. 3999 02:58:44,505 --> 02:58:48,042 WE WANTED TO BENCHMARK AGAINST 4000 02:58:48,042 --> 02:58:48,943 SEMMED SINCE THAT'S THE 4001 02:58:48,943 --> 02:58:50,210 STANDARD. 4002 02:58:50,210 --> 02:58:51,579 ON THE RIGHT I'M SHOWING WHAT 4003 02:58:51,579 --> 02:58:53,981 AARON WAS ABLE TO DO IN 10 4004 02:58:53,981 --> 02:58:58,519 MONTHS WORKING WITH OUR 4005 02:58:58,519 --> 02:59:05,426 CONTRACTORS FOR LITCOIN AND THE 4006 02:59:05,426 --> 02:59:06,493 OTHER BENCHMARK YOU REALLY WANT 4007 02:59:06,493 --> 02:59:11,465 TO HAVE IS HUMAN. 4008 02:59:11,465 --> 02:59:14,001 HOW DOES WHAT WE DO WITH OUR S 4009 02:59:14,001 --> 02:59:19,406 COMPARE TO WHAT A HUMAN WOULD 4010 02:59:19,406 --> 02:59:20,474 ACTUALLY DO? 4011 02:59:20,474 --> 02:59:22,409 AND THERE'S THREE DIFFERENT 4012 02:59:22,409 --> 02:59:29,116 TRIPLES THAT GOT EXTRACTED FROM 4013 02:59:29,116 --> 02:59:30,951 THE SAME ABSTRACT AND ON THE 4014 02:59:30,951 --> 02:59:35,456 LEFT SIDE WITH THE SEMMED 4015 02:59:35,456 --> 02:59:38,525 THERE'S COLUMNS THAT SAY SUBJECT 4016 02:59:38,525 --> 02:59:44,498 CONTEXT, RELATION CONTEXT AND 4017 02:59:44,498 --> 02:59:44,698 BLANK. 4018 02:59:44,698 --> 02:59:49,870 ON THE RIGHT SIDE WE ARE GETTING 4019 02:59:49,870 --> 02:59:51,238 THE CONTEXT BEING IMPORTANT AND 4020 02:59:51,238 --> 02:59:52,806 TELLING YOU IN WHAT TISSUE THE 4021 02:59:52,806 --> 02:59:54,508 OBSERVATION WAS MADE OR IN WHAT 4022 02:59:54,508 --> 02:59:56,977 CELL TYPE OR IN WHAT POPULATION. 4023 02:59:56,977 --> 03:00:02,516 IT ENDS UP BEING VERY 4024 03:00:02,516 --> 03:00:04,918 SIGNIFICANT INFORMATION TO THE 4025 03:00:04,918 --> 03:00:07,054 TRIPLE THAT GETS EXTRACTED. 4026 03:00:07,054 --> 03:00:10,190 IF WE LOOK AT JUST NEXT TO WHERE 4027 03:00:10,190 --> 03:00:12,793 I HAVE CIRCLED HUMAN. 4028 03:00:12,793 --> 03:00:14,595 THE SUBJECT THE HUMANS 4029 03:00:14,595 --> 03:00:23,937 IDENTIFIED WAS HYPERTENSION. 4030 03:00:23,937 --> 03:00:29,343 WHEN I DO THIS WITH THE TOOL ON 4031 03:00:29,343 --> 03:00:32,980 WHICH WE'RE GOING TO BASE WHAT 4032 03:00:32,980 --> 03:00:36,483 WE CALL THE TOOL DOING THE 4033 03:00:36,483 --> 03:00:39,553 EXTRACTIONS IT COMES UP WITH 4034 03:00:39,553 --> 03:00:42,489 INDUCED HYPERTENSION WHICH IS 4035 03:00:42,489 --> 03:00:43,524 MORE ACCURATE. 4036 03:00:43,524 --> 03:00:45,359 SO THIS IS TOO EXCITING FOR ME 4037 03:00:45,359 --> 03:00:47,428 TO NOT TELL YOU ABOUT AND 4038 03:00:47,428 --> 03:00:49,863 HOPEFULLY IT MEANS EVEN IF 4039 03:00:49,863 --> 03:00:51,098 YOU'RE NOT GOING TO BE A COUNCIL 4040 03:00:51,098 --> 03:00:52,499 MEMBER NEXT YEAR YOU CAN TUNE IN 4041 03:00:52,499 --> 03:00:55,202 FOR THE UPDATE NEXT WE'RE. 4042 03:00:55,202 --> 03:00:58,305 SO WITH THAT I WILL CLOSE AND 4043 03:00:58,305 --> 03:00:58,939 KARLIE AND I HAVE AVAILABLE FOR 4044 03:00:58,939 --> 03:01:06,046 QUESTIONS. 4045 03:01:06,046 --> 03:01:07,815 >> ANY QUESTIONS FOR KARLIE OR 4046 03:01:07,815 --> 03:01:16,757 CHRISTINE? 4047 03:01:16,757 --> 03:01:21,962 >> THINK THE LITCOIN IS IMPR 4048 03:01:21,962 --> 03:01:24,264 IMPRESSIVE WE CAN HAVE A RICH 4049 03:01:24,264 --> 03:01:29,069 DATA SET AND BEING ABLE TO PULL 4050 03:01:29,069 --> 03:01:30,504 IN DATA FROM THE LITERATURE LIKE 4051 03:01:30,504 --> 03:01:32,005 LARGE LANGUAGE MODELS DO AND 4052 03:01:32,005 --> 03:01:34,041 WHAT WE'RE LOOKING AT IS TAKING 4053 03:01:34,041 --> 03:01:36,810 LARGE LANGUAGE MODELS TO 4054 03:01:36,810 --> 03:01:41,715 INTEGRATE ALL OF THESE DIFFERENT 4055 03:01:41,715 --> 03:01:42,950 DATA SETS TO BE QUERIABLE AND 4056 03:01:42,950 --> 03:01:46,587 ALL THAT IS A HUGE LEAP FORWARD. 4057 03:01:46,587 --> 03:01:48,322 WHEN DO YOU THINK YOU'LL BE 4058 03:01:48,322 --> 03:01:53,427 PUTTING IT OUT THERE? 4059 03:01:53,427 --> 03:01:56,630 >> UM, THAT'S A GOOD QUESTION WE 4060 03:01:56,630 --> 03:01:58,699 HAVE ANOTHER YEAR OF SUPPORT 4061 03:01:58,699 --> 03:02:00,601 FROM THE HEAL INITIATIVE. 4062 03:02:00,601 --> 03:02:06,240 DURING THAT TIME OUR GOAL IS TO 4063 03:02:06,240 --> 03:02:08,208 ACTUALLY WORK ON VERY FOCUSSED 4064 03:02:08,208 --> 03:02:10,544 LITERATURE THAT'S GOING TO BE 4065 03:02:10,544 --> 03:02:13,247 RELEVANT FOR PAIN AND SOME WITH 4066 03:02:13,247 --> 03:02:13,413 OUD. 4067 03:02:13,413 --> 03:02:16,083 AND WHAT WE WANT TO DO IS WORK 4068 03:02:16,083 --> 03:02:21,054 WITH THE RESEARCHERS TO BEGIN TO 4069 03:02:21,054 --> 03:02:24,458 SOCIALIZE THIS TO THE COMMUNITY 4070 03:02:24,458 --> 03:02:27,628 AND ALSO TO START TO TEST AND 4071 03:02:27,628 --> 03:02:29,696 FEEL OUT THE SYSTEM. 4072 03:02:29,696 --> 03:02:33,600 TYLER HAS BEEN BUSY TALKING WITH 4073 03:02:33,600 --> 03:02:35,469 PUBLISHERS AND EVERYTHING AND 4074 03:02:35,469 --> 03:02:36,370 WE'RE GETTING TRACTION THERE. 4075 03:02:36,370 --> 03:02:38,105 I DON'T KNOW IF YOU WANT TO COME 4076 03:02:38,105 --> 03:02:41,041 UP AND SAY A FEW WORDS BECAUSE 4077 03:02:41,041 --> 03:02:42,209 YOU'RE THE ONE WHO'S BEEN DOING 4078 03:02:42,209 --> 03:02:46,013 THE DAY TO DAY ON THIS. 4079 03:02:46,013 --> 03:02:51,285 >> SO, WITH THIS WE ARE PROBABLY 4080 03:02:51,285 --> 03:02:55,589 LOOKING TO SEE A FIRST HEAL 4081 03:02:55,589 --> 03:02:58,258 FOCUS GRAPH OF PAIN IN THE EARLY 4082 03:02:58,258 --> 03:02:58,492 SPRING. 4083 03:02:58,492 --> 03:03:02,529 AND THE GOAL IS TO GET AS MANY 4084 03:03:02,529 --> 03:03:05,098 HEAL INVESTIGATORS AS POSSIBLE 4085 03:03:05,098 --> 03:03:08,502 TO FINE TUNE THE GRAPH FROM THE 4086 03:03:08,502 --> 03:03:12,506 HEAL RESEARCHER AND RETRAINING 4087 03:03:12,506 --> 03:03:14,274 THE MODEL TO IMPROVE ITS 4088 03:03:14,274 --> 03:03:16,677 ACCURACY MORE BASED ON THAT 4089 03:03:16,677 --> 03:03:18,478 FEEDBACK AND THEN WE WOULD 4090 03:03:18,478 --> 03:03:20,113 EXPECT TO BE ABLE TO EXPAND TO 4091 03:03:20,113 --> 03:03:30,524 OTHER FIELDS AFTER THAT. 4092 03:03:39,132 --> 03:03:41,835 >> IS THAT A LOWER LIMIT IN 4093 03:03:41,835 --> 03:03:44,171 TERMS OF PERCENTAGE COVERAGE 4094 03:03:44,171 --> 03:03:48,742 THAT'S NEEDED TO MAKE THE LITHO 4095 03:03:48,742 --> 03:03:54,248 GRAPH USEFUL? 4096 03:03:54,248 --> 03:03:54,781 100% 4097 03:03:54,781 --> 03:03:55,983 100% COVERAGE IS NOT POSSIBLE 4098 03:03:55,983 --> 03:03:58,485 BUT IS 50% OR 60% DECENT TO GIVE 4099 03:03:58,485 --> 03:03:59,052 YOU ANSWERS? 4100 03:03:59,052 --> 03:04:06,493 >> I CAN TELL YOU RIGHT NOW I 4101 03:04:06,493 --> 03:04:17,037 THINK WE COULD MAKE USE OF THE 4102 03:04:19,006 --> 03:04:20,807 ALGORITHM BECAUSE THE DIFFERENCE 4103 03:04:20,807 --> 03:04:27,581 BETWEEN THE ACCURACY AND 4104 03:04:27,581 --> 03:04:30,517 CONTEXTUAL KNOWLEDGE IS SO VAST 4105 03:04:30,517 --> 03:04:36,123 WITH SOME OF THE PROJECTS. 4106 03:04:36,123 --> 03:04:38,525 THERE'S BEEN TOOLS FOR FINDING 4107 03:04:38,525 --> 03:04:41,128 RESULTS BUT CAN GO LEAPS AND 4108 03:04:41,128 --> 03:04:43,563 BOUNDS AHEAD ON THE VALUE BY 4109 03:04:43,563 --> 03:04:44,464 PULLING THIS KIND OF INFORMATION 4110 03:04:44,464 --> 03:04:47,234 EVEN IF IT WAS JUST FROM A 4111 03:04:47,234 --> 03:04:49,369 SINGLE SUB FIELD AT FIRST. 4112 03:04:49,369 --> 03:04:50,704 I DON'T THINK THERE'S A LOWER 4113 03:04:50,704 --> 03:04:53,540 LIMIT ON THAT REALLY. 4114 03:04:53,540 --> 03:04:54,841 >> AND YOU'RE ONLY LOOKING AT 4115 03:04:54,841 --> 03:05:03,383 PEER REVIEWED LITERATURE. 4116 03:05:03,383 --> 03:05:06,386 WE DON'T WANT TO NECESSARY START 4117 03:05:06,386 --> 03:05:11,959 LOOKING AT THINGS LIKE BIO 4118 03:05:11,959 --> 03:05:18,699 ARCHIVE UNTIL WE HAVE LAID THE 4119 03:05:18,699 --> 03:05:20,701 GROUND WORK FOR THE GRAPHS THAT 4120 03:05:20,701 --> 03:05:26,106 COME OUT OF AND FEEL CONFIDENCE 4121 03:05:26,106 --> 03:05:26,807 IN THE VALUE. 4122 03:05:26,807 --> 03:05:30,377 >> IF GRAPH-BASED SYSTEMS 4123 03:05:30,377 --> 03:05:34,481 WEREN'T ALREADY IN PLACE WE'D 4124 03:05:34,481 --> 03:05:36,383 TALKING ABOUT MEETING CRITICAL 4125 03:05:36,383 --> 03:05:38,218 MASS BUT THEY CAN GET INGESTED 4126 03:05:38,218 --> 03:05:39,319 AS WE GO AND SHOULD HAVE INSTANT 4127 03:05:39,319 --> 03:05:49,429 VALUE. 4128 03:05:54,968 --> 03:05:56,903 >> TALK ABOUT THE PROGRAM. 4129 03:05:56,903 --> 03:06:07,314 >> WE ARE WORKING WITH 4130 03:06:07,681 --> 03:06:12,386 SUBCONTRACTORS WORKING ON 4131 03:06:12,386 --> 03:06:13,587 GENERATING THE WEB INTERGRAPH 4132 03:06:13,587 --> 03:06:17,858 AND ABLE TO SHOW THE RESEARCHERS 4133 03:06:17,858 --> 03:06:19,393 WHO WELL EITHER OFFER OR 4134 03:06:19,393 --> 03:06:20,827 SOMETIMES ASSOCIATE THE WORK 4135 03:06:20,827 --> 03:06:29,569 FROM THE ORIGINAL ABSTRACT. 4136 03:06:29,569 --> 03:06:31,772 SHOW THEM WHAT THE OUTCOMES ARE 4137 03:06:31,772 --> 03:06:34,141 AND IF WE DO A GOOD JOB OR IF 4138 03:06:34,141 --> 03:06:39,012 THERE'S SOMETHING WE CKCAN EXTRT 4139 03:06:39,012 --> 03:06:41,715 BETTER AND USING THE 4140 03:06:41,715 --> 03:06:42,049 RELATIONSHIP. 4141 03:06:42,049 --> 03:06:46,453 USING THAT THEY'LL BE AUTOMOBILE 4142 03:06:46,453 --> 03:06:49,823 TOO -- ABLE TO GET THE FEEDBACK 4143 03:06:49,823 --> 03:06:51,958 AND IMPROVE IT ITERATIVELY. 4144 03:06:51,958 --> 03:06:57,898 >> THEY'LL WORK WITH BASICALLY 4145 03:06:57,898 --> 03:07:00,834 PUBLICATIONS THAT HAVE COME FROM 4146 03:07:00,834 --> 03:07:02,536 THE HEAL INVESTIGATOR LAB AND 4147 03:07:02,536 --> 03:07:05,405 WANT TO DO HACKATHONS WITH 4148 03:07:05,405 --> 03:07:06,606 POSTDOCS AND STUDENTS TO SAY 4149 03:07:06,606 --> 03:07:10,010 HEY, CAN YOU TAKE A LOOK AT THE 4150 03:07:10,010 --> 03:07:11,044 GRAPH ASSOCIATED WITH THE FAST 4151 03:07:11,044 --> 03:07:11,411 TRACK. 4152 03:07:11,411 --> 03:07:12,846 THAT INDIVIDUAL MAY NOT HAVE 4153 03:07:12,846 --> 03:07:14,314 BEEN AN AUTHOR BUT THEY'RE FROM 4154 03:07:14,314 --> 03:07:14,915 THAT LAB. 4155 03:07:14,915 --> 03:07:16,450 THEY SHOULD BE SOMEWHAT FAMILIAR 4156 03:07:16,450 --> 03:07:20,153 AND BE ABLE TO TELL US HOW WE'RE 4157 03:07:20,153 --> 03:07:23,156 DOING AND I THINK AS WE GO ALONG 4158 03:07:23,156 --> 03:07:27,094 THE ARLING ALGORITHM WILL GET 4159 03:07:27,094 --> 03:07:28,095 BETTER AND BETTER. 4160 03:07:28,095 --> 03:07:29,763 >> THE LONGER TERM EXPECTATION 4161 03:07:29,763 --> 03:07:32,732 IS WE HAVE A TRUE WEB INTERFACE 4162 03:07:32,732 --> 03:07:34,401 WHERE ANY RESEARCHER COULD DO, 4163 03:07:34,401 --> 03:07:36,136 FIND THE PAPERS THEY WERE 4164 03:07:36,136 --> 03:07:38,438 ASSOCIATED WITH AND THEY HELPED 4165 03:07:38,438 --> 03:07:42,509 PUBLISH AND DO THE CURATION ON 4166 03:07:42,509 --> 03:07:44,411 WHATEVER RESEARCH THEY PUBLISHED 4167 03:07:44,411 --> 03:07:47,414 TO THEN FEEDBACK INTO THE 4168 03:07:47,414 --> 03:07:50,484 SYSTEM. 4169 03:07:50,484 --> 03:07:59,559 >> THAT'S GREAT. 4170 03:07:59,559 --> 03:08:00,760 >> I MADE A COMMENT HOW YOU HAVE 4171 03:08:00,760 --> 03:08:02,462 ANOTHER YEAR OF FUNDING ON THIS. 4172 03:08:02,462 --> 03:08:04,397 IT SOUNDS LIKE IT HAS THE 4173 03:08:04,397 --> 03:08:07,868 POTENTIAL FOR BEING ALMOST A 4174 03:08:07,868 --> 03:08:09,769 WIKIPEDIA LIKE OPEN SOURCE. 4175 03:08:09,769 --> 03:08:13,373 I DON'T MEAN WIKIPEDIA BUT THE 4176 03:08:13,373 --> 03:08:14,174 CONCEPT OF THE COMMUNITY 4177 03:08:14,174 --> 03:08:15,142 ENRICHED AND IMPROVE. 4178 03:08:15,142 --> 03:08:17,511 DID I HEAR A HINT OF THE 4179 03:08:17,511 --> 03:08:19,246 FUNDING'S GOING AWAY? 4180 03:08:19,246 --> 03:08:20,814 IT'S SUCH AN EXCITING PROJECT 4181 03:08:20,814 --> 03:08:22,349 AND IT'S WONDERFUL TO WATCH IT 4182 03:08:22,349 --> 03:08:23,316 EVOLVE OVER THE PAST COUPLE 4183 03:08:23,316 --> 03:08:23,750 YEARS. 4184 03:08:23,750 --> 03:08:25,018 >> IT'S PAINFUL TO HAVE THIS 4185 03:08:25,018 --> 03:08:28,855 HAPPEN AT A TIME WHEN THE NIH IS 4186 03:08:28,855 --> 03:08:30,056 FACING A TIME WHEN WE'RE GOING 4187 03:08:30,056 --> 03:08:35,896 TO BE REALLY STRUGGLING FOR 4188 03:08:35,896 --> 03:08:36,596 FUNDING. 4189 03:08:36,596 --> 03:08:38,098 THERE'S BEEN SO MUCH IS INTEREST 4190 03:08:38,098 --> 03:08:42,502 AND ENTHUSIASM. 4191 03:08:42,502 --> 03:08:43,436 I'M FEELING OPTIMISTIC WE'LL BE 4192 03:08:43,436 --> 03:08:47,908 ABLE TO FIND A FUNDING SOURCE TO 4193 03:08:47,908 --> 03:08:49,476 KEEP THIS GOING AND TO BUILD IT 4194 03:08:49,476 --> 03:08:50,777 OUT FURTHER. 4195 03:08:50,777 --> 03:08:55,815 I HAVE TO MENTION WE PRESENTED 4196 03:08:55,815 --> 03:09:05,458 THIS TO DR. LANGEVIN THE HEAD OF 4197 03:09:05,458 --> 03:09:08,795 NCCIH AND HAD AN IDEA OF 4198 03:09:08,795 --> 03:09:13,099 INCORPORATING TEXTBOOK KNOWLEDGE 4199 03:09:13,099 --> 03:09:18,471 INTO THIS. 4200 03:09:18,471 --> 03:09:21,675 IF WE DO THAT THEN THE POWER IS 4201 03:09:21,675 --> 03:09:23,743 BLOWN OUT OF THE WATER. 4202 03:09:23,743 --> 03:09:24,611 WHAT WE DO WITH SCIENTIFIC 4203 03:09:24,611 --> 03:09:28,248 LITERATURE IS GOING TO GET 4204 03:09:28,248 --> 03:09:33,853 MARRIED WITH HUMAN USER'S 4205 03:09:33,853 --> 03:09:43,463 KNOWLEDGE. 4206 03:09:43,463 --> 03:09:47,467 AND IF WE CAN INCORPORATE 4207 03:09:47,467 --> 03:09:48,168 TEXTBOOK KNOWLEDGE IT WILL BE 4208 03:09:48,168 --> 03:09:58,545 PHENOMENALLY POWERFUL. 4209 03:10:02,515 --> 03:10:07,053 AND THE RATE AT WHICH WE CAN 4210 03:10:07,053 --> 03:10:08,855 ACCELERATE RESEARCH -- I 4211 03:10:08,855 --> 03:10:10,290 ANTICIPATE IT WILL BE LIKE 4212 03:10:10,290 --> 03:10:11,258 NOTHING WE'VE SEEN BEFORE BUT 4213 03:10:11,258 --> 03:10:19,866 I'M PROBABLY BIASSED. 4214 03:10:19,866 --> 03:10:21,868 >> ANY OTHER QUESTIONS? 4215 03:10:21,868 --> 03:10:29,709 THANK YOU, CHRISTINE AND KARLIE. 4216 03:10:29,709 --> 03:10:32,846 I THINK WE'RE NOW TRANSITIONING 4217 03:10:32,846 --> 03:10:38,652 TO OUR CONCEPT CLEARANCES. 4218 03:10:38,652 --> 03:10:41,121 THERE'S A VARIETY FOR EACH 4219 03:10:41,121 --> 03:10:41,955 CONCEPT CLEARANCE. 4220 03:10:41,955 --> 03:10:42,589 CHRISTINE HASN'T MOVED BECAUSE 4221 03:10:42,589 --> 03:10:44,357 SHE'S GOING TO GO FIRST. 4222 03:10:44,357 --> 03:10:46,493 SO CHRISTINE, GO AHEAD AND KICK 4223 03:10:46,493 --> 03:10:47,894 OFF THE CONCEPT. 4224 03:10:47,894 --> 03:10:52,332 >> THANK YOU. 4225 03:10:52,332 --> 03:10:59,105 AS PROMISED, THE WHY UPDATE WAS 4226 03:10:59,105 --> 03:11:01,007 ON THE FIRST PRONG AND NOW WE'LL 4227 03:11:01,007 --> 03:11:05,779 TALK ABOUT THE SECOND PRONG. 4228 03:11:05,779 --> 03:11:07,314 I'VE SHOWED YOU THIS AND I'LL 4229 03:11:07,314 --> 03:11:10,617 BLOW PAST IT BECAUSE WE TALKED 4230 03:11:10,617 --> 03:11:14,487 ABOUT IT ALREADY. 4231 03:11:14,487 --> 03:11:18,224 BASICALLY WE HAVE VARIOUS THINGS 4232 03:11:18,224 --> 03:11:20,694 WE'RE ARE USING EXPLORING 4233 03:11:20,694 --> 03:11:22,829 DRUGGABLE PROTEINS AS WELL AS 4234 03:11:22,829 --> 03:11:26,499 MODULATING TARGETS IS WHAT 4235 03:11:26,499 --> 03:11:36,876 YOU'LL HEAR ABOUT NOW. 4236 03:11:38,078 --> 03:11:38,912 AND TRYING TO CAPITALIZE ON 4237 03:11:38,912 --> 03:11:49,155 SPEED AND A.I. 4238 03:11:50,957 --> 03:11:52,625 SO THIS IS A CONCEPT CLEARANCE 4239 03:11:52,625 --> 03:11:54,327 FOR EXPANDING THE TARGET 4240 03:11:54,327 --> 03:12:02,068 LANDSCAPE BY DRUGGING THE 4241 03:12:02,068 --> 03:12:02,402 UNDRUGGABLE. 4242 03:12:02,402 --> 03:12:05,505 THIS IS SOMETHING THAT'S THE 4243 03:12:05,505 --> 03:12:07,841 DRUG DISCOVERY WHEEL AND RELIES 4244 03:12:07,841 --> 03:12:09,943 ON SMALL MOLECULES AN BIOLOGICS 4245 03:12:09,943 --> 03:12:11,878 AND WHAT IT MEANS IS THAT YOU 4246 03:12:11,878 --> 03:12:14,013 FIND A TARGET THAT'S RELATED TO 4247 03:12:14,013 --> 03:12:17,584 HUMAN DISEASE AND USUALLY 4248 03:12:17,584 --> 03:12:18,485 PROTEIN AND GENERATE WAYS 4249 03:12:18,485 --> 03:12:20,887 AGAINST THE TARGET AND OPTIMIZED 4250 03:12:20,887 --> 03:12:22,989 AND TAKE THEM TO THE PRE 4251 03:12:22,989 --> 03:12:23,957 CLINICAL STAGE. 4252 03:12:23,957 --> 03:12:25,158 HOPEFULLY TO THE CLINICAL STAGE 4253 03:12:25,158 --> 03:12:32,899 AND IN THEORY GET TO A DRUG. 4254 03:12:32,899 --> 03:12:43,443 THE PROBLEM IS THEY'RE CAUSED BY 4255 03:12:44,944 --> 03:12:49,115 GENES AND AN INTRACTABLE DISEASE 4256 03:12:49,115 --> 03:12:53,153 IS UNABLE TO BE RELIEVED OR 4257 03:12:53,153 --> 03:12:55,555 CURED THROUGH CURRENT THERAPIES. 4258 03:12:55,555 --> 03:12:59,292 10% ARE DRUGGABLE AND 5% IS 4259 03:12:59,292 --> 03:13:00,326 DRUGGABLE AND DISEASE RELEVANT. 4260 03:13:00,326 --> 03:13:03,096 FROM THE PROTEINS ON THE RIGHT 4261 03:13:03,096 --> 03:13:06,499 ABOUT 60% ARE BELIEVED TO BE 4262 03:13:06,499 --> 03:13:07,167 UNDRUGGABLE. 4263 03:13:07,167 --> 03:13:09,636 WE DON'T HAVE A WHOLE LOT OF 4264 03:13:09,636 --> 03:13:09,936 DRUGS. 4265 03:13:09,936 --> 03:13:14,474 MAYBE 13% HAVE LAUNCH DRUGS. 4266 03:13:14,474 --> 03:13:20,780 THERE'S A LOT TO EXPLORE. 4267 03:13:20,780 --> 03:13:23,983 THE CLASSICALLY DRUGGABLE 4268 03:13:23,983 --> 03:13:26,486 TARGETS ARE ABLE TO FIND 4269 03:13:26,486 --> 03:13:26,719 LIGANDS. 4270 03:13:26,719 --> 03:13:28,354 THOSE ARE THINGS LIKE RECEPTORS 4271 03:13:28,354 --> 03:13:29,989 AND ENZYME. 4272 03:13:29,989 --> 03:13:32,926 THERE'S AN ENTIRE GROUP OF 4273 03:13:32,926 --> 03:13:34,961 PROTEINS THAT CAUSE HUMAN 4274 03:13:34,961 --> 03:13:37,497 DISEASE AND FALL IN THE DISEASE 4275 03:13:37,497 --> 03:13:39,032 CATEGORY CAUSED BY THE 4276 03:13:39,032 --> 03:13:41,468 PROTEIN-PROTEIN INTERACTIONS AND 4277 03:13:41,468 --> 03:13:45,472 CAN BE CAUSED BY PROTEINS OR 4278 03:13:45,472 --> 03:13:48,508 OTHER PROTEINS THAT DON'T HAVE 4279 03:13:48,508 --> 03:13:49,309 BINDING POCKETS. 4280 03:13:49,309 --> 03:13:50,977 NOW, OUTSIDE OF THE PROTEINS WE 4281 03:13:50,977 --> 03:13:53,413 KNOW A NUMBER OF DISEASES CAUSED 4282 03:13:53,413 --> 03:13:54,447 DIRECTLY BY RNA. 4283 03:13:54,447 --> 03:13:55,315 AND SO THAT'S ANOTHER 4284 03:13:55,315 --> 03:13:59,619 OPPORTUNITY IN TERMS OF ONE OF 4285 03:13:59,619 --> 03:14:05,758 THESE HOPEFULLY TARGETS WE CAN 4286 03:14:05,758 --> 03:14:09,729 IDENTIFY AND TAKE TA FORWARD 4287 03:14:09,729 --> 03:14:11,197 FOR TREATMENT AND WE CAN 4288 03:14:11,197 --> 03:14:14,167 ESSENTIALLY IDENTIFY A WAY OF 4289 03:14:14,167 --> 03:14:15,335 DRUGGING UPSTREAM SOME 4290 03:14:15,335 --> 03:14:18,471 UNDRUGGABLE PROTEIN TARGETS. 4291 03:14:18,471 --> 03:14:22,475 FINALLY I WANT TO HIGHLIGHT 4292 03:14:22,475 --> 03:14:25,011 MOLECULAR ENTITIES INCLUDING 4293 03:14:25,011 --> 03:14:30,183 LIPIDS AND METABOLITES AND 4294 03:14:30,183 --> 03:14:31,784 ORGANELLES 4295 03:14:31,784 --> 03:14:37,690 AND AND THES IS JUST A SMALL 4296 03:14:37,690 --> 03:14:40,093 SNAPSHOT BUT THERE'S DISEASES 4297 03:14:40,093 --> 03:14:43,329 CAUSED BY UNDRUGGABLE TARGETS 4298 03:14:43,329 --> 03:14:48,001 AND MANY THAT ARE ZEETZS CAUSED 4299 03:14:48,001 --> 03:14:50,503 DIRECTLY BY RNA EXPANSIONS AND 4300 03:14:50,503 --> 03:14:53,139 THERE'S NEUROLOGICAL DISEASES 4301 03:14:53,139 --> 03:14:55,975 LIKE ALZHEIMER'S DISEASE AND 4302 03:14:55,975 --> 03:14:57,310 PARKINSON'S CAUSED BY PROTEINS 4303 03:14:57,310 --> 03:14:58,912 AND BUILD UP OF THESE PLAQUES. 4304 03:14:58,912 --> 03:15:02,382 AND THE DISEASES SUCH AS CANCER 4305 03:15:02,382 --> 03:15:04,417 NEURO PATHIC PAIN AND INFECTIONS 4306 03:15:04,417 --> 03:15:06,386 AND OTHERS CAUSED BY OTHER 4307 03:15:06,386 --> 03:15:16,262 ENTITIES LIKE PATHOLOGICAL 4308 03:15:16,262 --> 03:15:18,331 LITHOGRAPHS AND THERE'S BEEN 4309 03:15:18,331 --> 03:15:18,531 KRAS. 4310 03:15:18,531 --> 03:15:20,600 IT WAS THOUGHT TO BE UNDRUGGABLE 4311 03:15:20,600 --> 03:15:23,970 BUT HE WAS ABLE TO IDENTIFY A 4312 03:15:23,970 --> 03:15:26,506 WAY TO EDIT AND IT'S PROMISING 4313 03:15:26,506 --> 03:15:32,078 IN THE WAY OF TUMORS. 4314 03:15:32,078 --> 03:15:33,947 THERE'S BEEN WORK TOWARDS 4315 03:15:33,947 --> 03:15:40,019 DEGRADING RNA AND THAT CAN BE A 4316 03:15:40,019 --> 03:15:46,059 GAME CHANGER IN CONTRIBUTORS AND 4317 03:15:46,059 --> 03:15:47,493 ALSO DISEASES WHERE PROTEINS 4318 03:15:47,493 --> 03:15:50,396 CANNOT BE TARGET AND THE RNA CAN 4319 03:15:50,396 --> 03:15:54,734 BE TARGETED INSTEAD. 4320 03:15:54,734 --> 03:15:57,704 AT THE BOTTOM THEY IDENTIFY A 4321 03:15:57,704 --> 03:15:59,739 WAY TO STABILIZE PROTEINS SUCH 4322 03:15:59,739 --> 03:16:07,981 AS IN CYSTIC FIBROSIS AND WHERE 4323 03:16:07,981 --> 03:16:10,483 ARE OPPORTUNITIES IN IDENTIFYING 4324 03:16:10,483 --> 03:16:14,487 NEW TARGETS AND NEW PLATFORMS 4325 03:16:14,487 --> 03:16:21,260 AND MODALITIES WE COULD LEVERAGE 4326 03:16:21,260 --> 03:16:23,796 TO DRUG UNDRUGGABLE TARGETS. 4327 03:16:23,796 --> 03:16:26,966 THIS WAS THE QUEST FOR TREATMENT 4328 03:16:26,966 --> 03:16:28,001 MODALITIES FOR INTRACTABLE 4329 03:16:28,001 --> 03:16:30,570 DISEASE TARGETS IN COLLABORATION 4330 03:16:30,570 --> 03:16:37,977 WITH NCI, NINDS AND NIAID. 4331 03:16:37,977 --> 03:16:39,545 WE WORKED TO IDENTIFY FAMILIES 4332 03:16:39,545 --> 03:16:40,647 IN TERMS OF THERAPEUTIC 4333 03:16:40,647 --> 03:16:42,115 MODALITIES AND NEW OR EMERGING 4334 03:16:42,115 --> 03:16:43,483 TECHNOLOGIES THAT COULD BE 4335 03:16:43,483 --> 03:16:46,486 LEVERAGED TO ADDRESS LIMITATIONS 4336 03:16:46,486 --> 03:16:50,490 OF TREATMENT MODALITIES. 4337 03:16:50,490 --> 03:16:51,624 AND PREVENT OR SLOW THE 4338 03:16:51,624 --> 03:16:53,760 DEVELOPMENT OF STRATEGIES FOR 4339 03:16:53,760 --> 03:16:55,395 TREATING HUMAN DISEASES 4340 03:16:55,395 --> 03:16:59,899 ASSOCIATED WITH THE UNDRUGGABLE 4341 03:16:59,899 --> 03:17:00,199 TARGETS. 4342 03:17:00,199 --> 03:17:02,502 AS A RESULT CAN BE SEEN HERE. 4343 03:17:02,502 --> 03:17:04,003 WE PUBLISHED A PAPER IN DRUG 4344 03:17:04,003 --> 03:17:04,637 DISCOVERY TODAY. 4345 03:17:04,637 --> 03:17:05,905 IF YOU'RE CURIOUS TO LEARN WHAT 4346 03:17:05,905 --> 03:17:08,608 ALL THE RESULTS OF THE WORKSHOP 4347 03:17:08,608 --> 03:17:10,843 WERE, TAKE A LOOK AT THE PAPER. 4348 03:17:10,843 --> 03:17:13,046 WHAT IT TOLD US IS THAT THE 4349 03:17:13,046 --> 03:17:17,650 FIELD IS PRIME FOR NEW CLASSES 4350 03:17:17,650 --> 03:17:26,159 OF ME MODALITIES AND TARGETS. 4351 03:17:26,159 --> 03:17:28,761 SO NCATS LOOKS AT NOVEL TARGET 4352 03:17:28,761 --> 03:17:30,496 CLASSES TO TREAT HUMAN DISEASE. 4353 03:17:30,496 --> 03:17:31,931 THE OBJECTIVE IS TO SUPPORT PRE 4354 03:17:31,931 --> 03:17:34,500 CLINICAL DEVELOPMENT OF 4355 03:17:34,500 --> 03:17:37,170 TREATMENTS FOR DISEASES FOR 4356 03:17:37,170 --> 03:17:39,072 PREVIOUSLY UNDRUGGABLE TARGETS 4357 03:17:39,072 --> 03:17:40,440 AND RNAs AND PROTEINS AND THINGS 4358 03:17:40,440 --> 03:17:43,109 OF THAT NATURE AND THIS IS A NEW 4359 03:17:43,109 --> 03:17:44,977 INITIATIVE THAT WOULD FILL GAPS 4360 03:17:44,977 --> 03:17:46,179 AND RELIEF PRESSURE POINTS 4361 03:17:46,179 --> 03:17:47,780 PREVENTING OR SLOWING THE 4362 03:17:47,780 --> 03:17:49,515 DEVELOPMENT OF TREATMENT FOR 4363 03:17:49,515 --> 03:17:52,185 INTRACTABLE HUMAN DISEASES AB 4364 03:17:52,185 --> 03:17:55,555 THOSE ASSOCIATED WITH 4365 03:17:55,555 --> 03:17:56,956 UNTREATABLE DRUGGABLE TARGETS 4366 03:17:56,956 --> 03:18:00,159 AND HOPE IT PROVES MODULATION OF 4367 03:18:00,159 --> 03:18:02,395 A PREVIOUSLY UNDRUGGABLE TARGETS 4368 03:18:02,395 --> 03:18:04,897 AND BRING IN IDEAS HOW TO DRUG 4369 03:18:04,897 --> 03:18:07,066 AN UNDRUGGABLE TARGET CLASS. 4370 03:18:07,066 --> 03:18:10,203 THERE ARE ASPECTS OF THE 4371 03:18:10,203 --> 03:18:10,503 INITIATIVE. 4372 03:18:10,503 --> 03:18:11,871 IT FILLS THE NEED FOR AN 4373 03:18:11,871 --> 03:18:14,340 INITIATIVE ON ENCOURAGING THE 4374 03:18:14,340 --> 03:18:15,742 SCIENTIFIC COMMUNITY TO EXPLORE 4375 03:18:15,742 --> 03:18:17,677 NOVEL UNCONVENTIONAL RESEARCH 4376 03:18:17,677 --> 03:18:19,812 STRATEGIES TO EXPAND THE 4377 03:18:19,812 --> 03:18:22,482 THERAPEUTIC TARGETS AND 4378 03:18:22,482 --> 03:18:23,516 DISEASES. 4379 03:18:23,516 --> 03:18:24,817 AND ENCOURAGES SIGNIFICANT 4380 03:18:24,817 --> 03:18:26,018 PROCESS IMPROVEMENT FOR 4381 03:18:26,018 --> 03:18:27,253 IDENTIFYING NOVEL TARGETS FOR 4382 03:18:27,253 --> 03:18:29,455 DISEASE AND OPENS NEW AREAS OF 4383 03:18:29,455 --> 03:18:32,592 RESEARCH IN DRUG DISCOVERY 4384 03:18:32,592 --> 03:18:32,892 MODALITIES 4385 03:18:32,892 --> 03:18:38,164 AND WHAT WE'RE WORKING TOWARDS 4386 03:18:38,164 --> 03:18:45,004 IS ADDRESSING PATIENT PONGSES. 4387 03:18:45,004 --> 03:18:45,304 POPULATIONS. 4388 03:18:45,304 --> 03:18:46,739 WE EXPECTS IT WILL ADDRESS 4389 03:18:46,739 --> 03:18:49,208 CLASSES WITH PATIENT GROUPS OF 4390 03:18:49,208 --> 03:18:53,379 UNMET NEEDS AND PROVIDE PROOF OF 4391 03:18:53,379 --> 03:18:57,250 CONCEPT STUDIES AND SPUR 4392 03:18:57,250 --> 03:19:02,188 INNOVATION IN THE NEW TREATMENTS 4393 03:19:02,188 --> 03:19:04,023 AND TREAT THOSE WHO SUFFER FROM 4394 03:19:04,023 --> 03:19:06,092 THESE INTRACTABLE DISEASES. 4395 03:19:06,092 --> 03:19:07,393 IN SUMMARY WE'RE WORKING TO 4396 03:19:07,393 --> 03:19:09,262 SUPPORT PRECLINICAL DEVELOPMENT 4397 03:19:09,262 --> 03:19:12,732 FOR TREATMENTS OF DISEASES WITH 4398 03:19:12,732 --> 03:19:14,734 TRADITIONALLY UNDRUGGABLE 4399 03:19:14,734 --> 03:19:16,602 TARGETS AND NEURO DEGENERATIVE 4400 03:19:16,602 --> 03:19:17,937 DISEASE AND MITOCHONDRIAL 4401 03:19:17,937 --> 03:19:18,805 DISEASES AND PAIN AND THERE'S 4402 03:19:18,805 --> 03:19:21,507 MORE I HAVE NOT MENTIONED. 4403 03:19:21,507 --> 03:19:24,410 THERE'S A NEED TO ADDRESS THE 4404 03:19:24,410 --> 03:19:26,112 DISEASE GROUPS BECAUSE THERE'S 4405 03:19:26,112 --> 03:19:27,313 LITTLE TO NO THERAPEUTIC 4406 03:19:27,313 --> 03:19:32,485 DEVELOPMENT DUE TO THE UND 4407 03:19:32,485 --> 03:19:34,487 UNDRUGABILITY OF THE CLASSES. 4408 03:19:34,487 --> 03:19:37,523 WE'RE LOOKING TO EXPAND THE 4409 03:19:37,523 --> 03:19:40,693 GROUP AND INCLUDING PROTEIN 4410 03:19:40,693 --> 03:19:42,495 DEGRADATION METHODS AND 4411 03:19:42,495 --> 03:19:43,830 STABILIZATION TECHNOLOGIES, 4412 03:19:43,830 --> 03:19:47,934 MOLECULES AND MINI PROTEINS. 4413 03:19:47,934 --> 03:19:50,303 WE'RE EXPANDING SOME OF THE 4414 03:19:50,303 --> 03:19:52,738 BASIC DRUG DISCOVERY PLATFORMS. 4415 03:19:52,738 --> 03:19:53,806 WHAT MIGHT IMPROVE THE 4416 03:19:53,806 --> 03:19:55,274 INITIATIVE AND WHAT ARE KEY 4417 03:19:55,274 --> 03:19:56,509 POINTS TO CONSIDER AND WHAT DOES 4418 03:19:56,509 --> 03:19:57,610 SUCCESS LOOK LIKE BUT WE HAVE A 4419 03:19:57,610 --> 03:20:02,148 COUPLE SPECIFIC ONES TOO. 4420 03:20:02,148 --> 03:20:03,416 WHAT OTHER INTRACTABLE DISEASE 4421 03:20:03,416 --> 03:20:04,884 GROUPS SHOULD WE BE CONSIDERING 4422 03:20:04,884 --> 03:20:06,886 AND SHOULD WE CONSIDER WORKING 4423 03:20:06,886 --> 03:20:17,597 WITH BIO FRAR PHARMA AND WELCOME 4424 03:20:18,564 --> 03:20:28,908 ANY OTHER QUESTIONS TOO. 4425 03:20:54,166 --> 03:20:56,335 >> SUCCESS IS SOMETHING KARLIE 4426 03:20:56,335 --> 03:20:56,936 LEADS. 4427 03:20:56,936 --> 03:20:58,771 WHILE I HAVE NOTHING TO RAD BUT 4428 03:20:58,771 --> 03:20:59,672 WHILE YOU WERE SPEAKING ABOUT 4429 03:20:59,672 --> 03:21:04,243 WHAT IS THE GAME PLAN TO WORK 4430 03:21:04,243 --> 03:21:06,712 WITH THE PHARMACEUTICAL INDUSTRY 4431 03:21:06,712 --> 03:21:15,354 TO IMPLEMENT AT SCALE. 4432 03:21:15,354 --> 03:21:25,464 YOU 4433 03:21:26,732 --> 03:21:29,335 >> THE IDEA IS TO TRY TO GET THE 4434 03:21:29,335 --> 03:21:32,371 PLATFORMS AND SHOW THE PROOF OF 4435 03:21:32,371 --> 03:21:38,110 CONCEPTS TO GO TO PHARMA OR 4436 03:21:38,110 --> 03:21:40,947 SMALL COMPANIES OR WHOEVER AND 4437 03:21:40,947 --> 03:21:41,914 TELL THEM THEY WORK. 4438 03:21:41,914 --> 03:21:44,550 THREES A CLEAR PATHWAY HERE ALSO 4439 03:21:44,550 --> 03:21:46,986 IN TERMS OF SETTING UP THE 4440 03:21:46,986 --> 03:21:50,856 PLATFORM AND GOING TO SBIR. 4441 03:21:50,856 --> 03:21:54,493 THAT'S ALSO A WAY TO GET THIS 4442 03:21:54,493 --> 03:21:57,930 STUFF OFF THE GROUND. 4443 03:21:57,930 --> 03:21:59,031 >> GREAT. 4444 03:21:59,031 --> 03:22:04,570 FOR ME, PERSPECTIVE OF THE 4445 03:22:04,570 --> 03:22:05,638 INTRACTABLE DISEASE GROUP IT'S 4446 03:22:05,638 --> 03:22:06,472 INTERESTING YOU HIGHLIGHTED 4447 03:22:06,472 --> 03:22:09,275 DISEASES OF AGING. 4448 03:22:09,275 --> 03:22:10,176 BETWEEN COVERING THOSE MASSIVE 4449 03:22:10,176 --> 03:22:12,511 DISEASES OF AGING AND THINKING 4450 03:22:12,511 --> 03:22:15,281 ABOUT THE NEURAL DEVELOPMENT AT 4451 03:22:15,281 --> 03:22:18,250 OTHER END OF THE LIFE SPAN WHICH 4452 03:22:18,250 --> 03:22:20,686 INCORPORATES SO MANY OF THE RARE 4453 03:22:20,686 --> 03:22:22,521 DISEASE CATEGORIES WHERE 4454 03:22:22,521 --> 03:22:26,492 FAMILIES SUFFER. 4455 03:22:26,492 --> 03:22:26,759 >> GOT IT. 4456 03:22:26,759 --> 03:22:35,768 >> I HAVE NO OTHER COMMENTS. 4457 03:22:35,768 --> 03:22:39,238 WE HAVE TWO OTHER DISCUSSANTS. 4458 03:22:39,238 --> 03:22:41,540 >> THANK YOU. 4459 03:22:41,540 --> 03:22:41,874 FABULOUS JOB. 4460 03:22:41,874 --> 03:22:45,911 THAT WAS AWESOME. 4461 03:22:45,911 --> 03:22:56,455 GETTING THIS READY TO HEAR ANDS 4462 03:22:57,156 --> 03:23:02,495 SHOWING A GREAT MODEL FOR 4463 03:23:02,495 --> 03:23:03,029 SUCCESS. 4464 03:23:03,029 --> 03:23:12,371 GREAT JOB. 4465 03:23:12,371 --> 03:23:15,141 WHAT IF IF YOU USED THE TOOL WE 4466 03:23:15,141 --> 03:23:18,477 PRESENTED TO US EARLIER AS A WAY 4467 03:23:18,477 --> 03:23:20,413 OF INTEGRATING AND EVALUATING 4468 03:23:20,413 --> 03:23:23,983 AND I LOVE THE IDEA OF THE 4469 03:23:23,983 --> 03:23:24,583 DEVELOPMENT LIFE SPAN 4470 03:23:24,583 --> 03:23:26,352 PERSPECTIVE BUT WHAT IF YOU USE 4471 03:23:26,352 --> 03:23:28,587 THAT AS WELL AND LOOKED AMOUNT 4472 03:23:28,587 --> 03:23:31,323 THAT INTERSECTION PERHAPS? 4473 03:23:31,323 --> 03:23:33,726 >> WE COULD DO THAT. 4474 03:23:33,726 --> 03:23:35,761 ONE GREAT THING ABOUT THE 4475 03:23:35,761 --> 03:23:36,796 CONCEPT IS THERE'S A LOT OF 4476 03:23:36,796 --> 03:23:38,097 DIRECTIONS TO GO. 4477 03:23:38,097 --> 03:23:41,133 THERE'S UNDRUGGABLE TARGETS AND 4478 03:23:41,133 --> 03:23:42,468 WAYS TO LOOK AT THOSE. 4479 03:23:42,468 --> 03:23:45,438 I MADE A NOTE. 4480 03:23:45,438 --> 03:23:48,874 WE'LL CHECK IT OUT. 4481 03:23:48,874 --> 03:23:52,044 >> THAT'S AN EXCELLENT 4482 03:23:52,044 --> 03:23:52,378 PRESENTATION. 4483 03:23:52,378 --> 03:23:55,948 I DO THINK THE PLATFORMS ARE 4484 03:23:55,948 --> 03:23:56,215 CRITICAL. 4485 03:23:56,215 --> 03:23:59,518 WE DO METABOLOMICS AND 4486 03:23:59,518 --> 03:24:00,419 PROTEOMICS AND SINGLE CELL 4487 03:24:00,419 --> 03:24:01,954 ANALYSIS AND ALL OF THAT. 4488 03:24:01,954 --> 03:24:03,122 BEING ABLE TO HAVE A PLATFORM 4489 03:24:03,122 --> 03:24:05,291 WHERE SOMEONE DOESN'T VA TO BE 4490 03:24:05,291 --> 03:24:09,795 AN EXPERT IN DOING THAT BUT CAN 4491 03:24:09,795 --> 03:24:13,065 HAVE A GREAT IDEA AND MOVING IT 4492 03:24:13,065 --> 03:24:13,666 FORWARD. 4493 03:24:13,666 --> 03:24:15,201 WE SAW THAT WITH THE COVID 4494 03:24:15,201 --> 03:24:15,634 VACCINE. 4495 03:24:15,634 --> 03:24:19,772 WE'VE SEEN THIS WITH DIFFERENT 4496 03:24:19,772 --> 03:24:20,072 ASPECTS. 4497 03:24:20,072 --> 03:24:21,507 YOU'RE GOING TO FIND I THINK 4498 03:24:21,507 --> 03:24:23,876 WE'LL LOOK DEEPER AT THE STUFF 4499 03:24:23,876 --> 03:24:25,010 WE JUST TALKED ABOUT JUST 4500 03:24:25,010 --> 03:24:27,480 SCRATCHES THE SURFACE OF WHAT 4501 03:24:27,480 --> 03:24:29,815 WOULD BE DRUGGABLE IN TREATING A 4502 03:24:29,815 --> 03:24:30,049 DISEASE. 4503 03:24:30,049 --> 03:24:32,818 I DO THINK A KEY ASPECT OF THIS 4504 03:24:32,818 --> 03:24:36,288 IS THE PLATFORMS FOR DOING THIS 4505 03:24:36,288 --> 03:24:39,625 STUDIES AND TESTING IT AND MASS, 4506 03:24:39,625 --> 03:24:41,694 IF YOU WILL, BEING ABLE TOO RUN 4507 03:24:41,694 --> 03:24:43,929 THROUGH A LIPID PLATFORM, 4508 03:24:43,929 --> 03:24:45,264 RUNNING THROUGH LIPIDS AND VICE 4509 03:24:45,264 --> 03:24:50,469 VERSA FOR PRETTY MUCH ANY OTHER 4510 03:24:50,469 --> 03:24:52,638 TARGET YOU CAN THINK OF. 4511 03:24:52,638 --> 03:24:54,473 >> I WILL MENTION ONE OF THE 4512 03:24:54,473 --> 03:24:57,510 OUTCOMES WAS ABOUT PLATFORMS AND 4513 03:24:57,510 --> 03:24:59,879 THE OBSERVATION WAS WITH THE 4514 03:24:59,879 --> 03:25:01,313 DRUG DISCOVERY -- THE REASON I 4515 03:25:01,313 --> 03:25:03,415 SHOWED THAT WHEEL IS A LOT OF 4516 03:25:03,415 --> 03:25:05,651 THE PLATFORMS BUILT INTO THE 4517 03:25:05,651 --> 03:25:08,487 DRUG DISCOVERY ODYSSEY NOW ARE 4518 03:25:08,487 --> 03:25:10,256 SPECIFICALLY FOCUSSED ON A SMALL 4519 03:25:10,256 --> 03:25:12,625 MOLECULE OR BIOLOGIC 4520 03:25:12,625 --> 03:25:12,925 DEVELOPMENT. 4521 03:25:12,925 --> 03:25:14,760 THAT MEANS THERE'S NOT A LOT OF 4522 03:25:14,760 --> 03:25:15,594 OPPORTUNITIES IN TERMS OF 4523 03:25:15,594 --> 03:25:17,229 GETTING WAYS IN IN TERMS OF 4524 03:25:17,229 --> 03:25:20,099 OTHER TARGET CLASSES THAT MAY 4525 03:25:20,099 --> 03:25:22,434 NOT FALL INTO A BINDING POCKET 4526 03:25:22,434 --> 03:25:26,272 OR A WAY A BIOLOGY CAN ATTENUATE 4527 03:25:26,272 --> 03:25:26,472 IT. 4528 03:25:26,472 --> 03:25:27,506 YEAH. 4529 03:25:27,506 --> 03:25:29,275 >> ONE MORE COMMENT BECAUSE IT 4530 03:25:29,275 --> 03:25:33,312 GETS BACK TO THE LITCOIN, A.I., 4531 03:25:33,312 --> 03:25:34,580 YOU CAN'T ALWAYS TRUST IT. 4532 03:25:34,580 --> 03:25:37,082 IN FACT OFTEN YOU CAN'T TRUST 4533 03:25:37,082 --> 03:25:37,383 IT. 4534 03:25:37,383 --> 03:25:38,684 IT WILL COME UP WITH THINGS NO 4535 03:25:38,684 --> 03:25:42,121 ONE IN OUR RIGHT MINDS OR EVEN 4536 03:25:42,121 --> 03:25:43,355 WRONG MINDS WOULD THINK OF, 4537 03:25:43,355 --> 03:25:43,556 RIGHT. 4538 03:25:43,556 --> 03:25:47,726 SO SOME OF THE OBSERVATIONS THAT 4539 03:25:47,726 --> 03:25:48,827 WILL COME OUT A LOT OF THEM WILL 4540 03:25:48,827 --> 03:25:51,497 BE CRAZY AND WRONG BUT THE VOICE 4541 03:25:51,497 --> 03:25:54,500 IN THE WILDERNESS IS THE STUFF 4542 03:25:54,500 --> 03:25:58,671 OF NOBEL PRIZES. 4543 03:25:58,671 --> 03:26:03,676 ULCERS BEING CAUSED BY A 4544 03:26:03,676 --> 03:26:06,111 BACTERIA, THAT'S STUPID. 4545 03:26:06,111 --> 03:26:08,380 WELL, GUESS WHAT, IT'S NOT. 4546 03:26:08,380 --> 03:26:11,150 WE HAVE TO BE CAREFUL NOT TO GO 4547 03:26:11,150 --> 03:26:15,521 DOWN TOO MANY WRONG PATHWAYS BUT 4548 03:26:15,521 --> 03:26:18,157 INTERESTED TO SEE HOW TO MERGE 4549 03:26:18,157 --> 03:26:18,657 LITCOIN WITH ALSO THIS 4550 03:26:18,657 --> 03:26:20,726 INITIATIVE. 4551 03:26:20,726 --> 03:26:25,998 >> ANY OTHER COMMENTS OR 4552 03:26:25,998 --> 03:26:29,168 QUESTIONS? 4553 03:26:29,168 --> 03:26:29,668 >> THANK YOU FOR THE 4554 03:26:29,668 --> 03:26:30,469 PRESENTATIONS. 4555 03:26:30,469 --> 03:26:32,371 GREAT. 4556 03:26:32,371 --> 03:26:34,106 JUST THINKING ABOUT THE 4557 03:26:34,106 --> 03:26:38,244 INTRODUCTION TO THIS IN IDG, 4558 03:26:38,244 --> 03:26:40,412 THAT SPEAKS FOR POTENTIAL 4559 03:26:40,412 --> 03:26:41,480 SACRIFICE FOR A PROGRAM. 4560 03:26:41,480 --> 03:26:43,849 I'M NOT SURE YOU ANTICIPATED NOT 4561 03:26:43,849 --> 03:26:45,784 JUST WHAT WOULD BE DRUGGED BUT 4562 03:26:45,784 --> 03:26:51,190 HOW THEY'LL BE DRUGGED. 4563 03:26:51,190 --> 03:26:54,927 THEY DIDN'T EVEN REALLY EXIST 4564 03:26:54,927 --> 03:26:58,464 WHEN IDG WAS LAUNCHED. 4565 03:26:58,464 --> 03:27:00,266 YOU GAVE AN EXAMPLE AND I KNOW 4566 03:27:00,266 --> 03:27:01,767 PEOPLE WHO A TARGET FOR RARE 4567 03:27:01,767 --> 03:27:03,369 DISEASE AND WOULD LOVE A 4568 03:27:03,369 --> 03:27:04,737 MOLECULE AND YOU USED IT AS AN 4569 03:27:04,737 --> 03:27:07,506 EXAMPLE AND WE HAVE TO CONNECT 4570 03:27:07,506 --> 03:27:07,973 THEM UP. 4571 03:27:07,973 --> 03:27:08,374 >> YEAH. 4572 03:27:08,374 --> 03:27:14,013 >> JUST IN THE LAST HOUR. 4573 03:27:14,013 --> 03:27:17,182 I THINK IT'S EXCITING YOUR 4574 03:27:17,182 --> 03:27:17,449 EXPANDING. 4575 03:27:17,449 --> 03:27:20,452 YOU KNOW HOW I THINK ABOUT 4576 03:27:20,452 --> 03:27:21,587 UNDRUGGABLE AND THIS MAKES THEM 4577 03:27:21,587 --> 03:27:21,920 DRUGS. 4578 03:27:21,920 --> 03:27:24,223 >> WE'RE EXCITED. 4579 03:27:24,223 --> 03:27:29,395 I THINK IT'S ONE OF THOSE THINGS 4580 03:27:29,395 --> 03:27:32,631 IT'S LIKE AN OLD-NEW TECHNOLOGY. 4581 03:27:32,631 --> 03:27:34,800 I SAY THAT BECAUSE IT'S CUTTING 4582 03:27:34,800 --> 03:27:36,769 EDGE AND BECOMING OLD IN THE 4583 03:27:36,769 --> 03:27:38,637 SENSE IT'S BEEN AROUND FOR A 4584 03:27:38,637 --> 03:27:38,837 WHILE. 4585 03:27:38,837 --> 03:27:40,406 THEY'RE CONSTANTLY COMING UP 4586 03:27:40,406 --> 03:27:45,611 WITH NEW WAYS TO USE IT AND IT'S 4587 03:27:45,611 --> 03:27:47,613 NOT CALLED PROTAX BUT IT'S A 4588 03:27:47,613 --> 03:27:49,048 SIMILAR SYSTEM USED FOR 4589 03:27:49,048 --> 03:27:49,615 DEGRADING RNA. 4590 03:27:49,615 --> 03:27:54,486 THE OTHER GROUP I SHOWED YOU, 4591 03:27:54,486 --> 03:27:58,524 DAN AND LYDIA THEIR TECHNOLOGY 4592 03:27:58,524 --> 03:28:00,726 IS ALSO RELATED AND RATHER THAN 4593 03:28:00,726 --> 03:28:03,095 DEGRADING THE PROTEINS, 4594 03:28:03,095 --> 03:28:04,430 STABILIZES THE PROTEIN. 4595 03:28:04,430 --> 03:28:07,566 IT'S WAYS TO USE SOMETHING WE 4596 03:28:07,566 --> 03:28:09,868 ALREADY HAVE. 4597 03:28:09,868 --> 03:28:15,140 PROTAC IT ALMOST CAME OUT OF 4598 03:28:15,140 --> 03:28:18,410 NOWHERE AND HAS BEEN USEFUL AND 4599 03:28:18,410 --> 03:28:20,679 HOPING THOSE WILL BE THE TYPES 4600 03:28:20,679 --> 03:28:22,014 OF THINGS TO STIMULATE. 4601 03:28:22,014 --> 03:28:24,183 >> I THINK IT'S POSSIBLE WITH 4602 03:28:24,183 --> 03:28:25,951 WHAT YOU OUTLINE IF YOUR PAST 4603 03:28:25,951 --> 03:28:28,554 SUCCESS IS PREDICTIVE OF YOUR 4604 03:28:28,554 --> 03:28:30,456 FUTURE SUCCESS YOU MAY END UP 4605 03:28:30,456 --> 03:28:33,992 WITH A RATE OF DISCOVERY SO FAR 4606 03:28:33,992 --> 03:28:35,327 OUTPACED BY THE FUNDING 4607 03:28:35,327 --> 03:28:37,396 MECHANISMS AND IT'S GOING TO BE 4608 03:28:37,396 --> 03:28:38,497 SOMETHING INSTITUTIONAL TO THINK 4609 03:28:38,497 --> 03:28:43,102 ABOUT. 4610 03:28:43,102 --> 03:28:44,536 IF THE MISSION IS TO GET MORE 4611 03:28:44,536 --> 03:28:47,106 THINGS TO MORE PEOPLE THE OLD 4612 03:28:47,106 --> 03:28:50,476 WAY -- HOW DO YOU SHRINK THE 4613 03:28:50,476 --> 03:28:51,243 FUNDING CYCLES? 4614 03:28:51,243 --> 03:28:54,446 THIS REALLY IS AN ACCELERATOR 4615 03:28:54,446 --> 03:28:57,516 AND YOUR OTHER PREDICTIONS IS 4616 03:28:57,516 --> 03:28:59,318 MORE IS TO COME. 4617 03:28:59,318 --> 03:29:00,753 A NOTE OF RISK AND TO THINK 4618 03:29:00,753 --> 03:29:01,620 ABOUT THE FUNDING. 4619 03:29:01,620 --> 03:29:02,488 >> YEP. 4620 03:29:02,488 --> 03:29:02,654 YEP. 4621 03:29:02,654 --> 03:29:12,865 DEFINITELY. 4622 03:29:13,232 --> 03:29:15,601 >> THANK YOU. 4623 03:29:15,601 --> 03:29:18,203 AND I LOVE THE RECOMMENDATIONS 4624 03:29:18,203 --> 03:29:18,971 TO SYNERGIZE. 4625 03:29:18,971 --> 03:29:21,540 >> IF THERE'S NO FURTHER 4626 03:29:21,540 --> 03:29:22,207 DISCUSSION COULD WE HAVE A 4627 03:29:22,207 --> 03:29:26,779 MOTION TO APPROVE THE CONCEPT. 4628 03:29:26,779 --> 03:29:27,279 SECOND. 4629 03:29:27,279 --> 03:29:32,751 ALL IN FAVOR. 4630 03:29:32,751 --> 03:29:33,685 ANY OPPOSED? 4631 03:29:33,685 --> 03:29:37,856 ANY ABSTENTIONS? 4632 03:29:37,856 --> 03:29:39,124 WITH THAT THE CONCEPT IS 4633 03:29:39,124 --> 03:29:39,391 APPROVED. 4634 03:29:39,391 --> 03:29:39,792 >> THANK YOU ALL. 4635 03:29:39,792 --> 03:29:42,027 >> THANK YOU. 4636 03:29:42,027 --> 03:29:46,498 THE NEXT CONCEPT WE HAVE TWO. 4637 03:29:46,498 --> 03:29:48,834 THIS IS THE SECOND OF THREE 4638 03:29:48,834 --> 03:29:53,806 MOVING ON TO THE OFFICE OF 4639 03:29:53,806 --> 03:30:01,513 SPECIAL INITIATIVES WITH DAN 4640 03:30:01,513 --> 03:30:01,713 TAGLE. 4641 03:30:01,713 --> 03:30:05,451 >> I'M THE DIRECTOR FOR THE 4642 03:30:05,451 --> 03:30:11,023 OFFICE OF SPECIAL INITIATIVES 4643 03:30:11,023 --> 03:30:11,790 AND TELL YOU MORE ABOUT OUR 4644 03:30:11,790 --> 03:30:21,934 OFFICE. 4645 03:30:24,169 --> 03:30:27,673 OUR OFFICE MISSION IS TO ADDRESS 4646 03:30:27,673 --> 03:30:29,575 TRANSLATIONAL PROBLEMS WITHIN 4647 03:30:29,575 --> 03:30:31,243 INNOVATIVE SOLUTIONS THROUGH 4648 03:30:31,243 --> 03:30:32,444 DISRUPTIVE TECHNOLOGIES. 4649 03:30:32,444 --> 03:30:34,746 WE DO THIS BY NOVEL 4650 03:30:34,746 --> 03:30:36,014 PARTNERSHIPS. 4651 03:30:36,014 --> 03:30:38,016 OUR ANTICIPATED END GOAL IS TO 4652 03:30:38,016 --> 03:30:42,287 CREATE A PARADIGM SHIFT IN THE 4653 03:30:42,287 --> 03:30:42,488 FIELD. 4654 03:30:42,488 --> 03:30:42,554 6: 4655 03:30:44,890 --> 03:30:50,062 SO, WHAT WE HAVE BEEN DOING OVER 4656 03:30:50,062 --> 03:31:00,539 THE PAST 10 YEARS THE FUND 4657 03:31:00,939 --> 03:31:03,342 RESEARCH TO ACCEPTANCE ADHERING 4658 03:31:03,342 --> 03:31:05,244 TO THE PRINCIPLES OF DEVELOPING 4659 03:31:05,244 --> 03:31:09,147 THE TECHNOLOGY, DEMONSTRATING 4660 03:31:09,147 --> 03:31:12,651 THE UTILITY IN RESEARCH AND THEN 4661 03:31:12,651 --> 03:31:14,353 EVENTUALLY DISSEMINATING IT FOR 4662 03:31:14,353 --> 03:31:15,888 USE BY THE BIOMEDICAL RESEARCH 4663 03:31:15,888 --> 03:31:16,421 COMMUNITY. 4664 03:31:16,421 --> 03:31:19,091 YOU CAN SEE HERE A NUMBER OF 4665 03:31:19,091 --> 03:31:21,460 DIFFERENT PROGRAMS THAT WE HAVE 4666 03:31:21,460 --> 03:31:24,563 AT VARIOUS STAGES. 4667 03:31:24,563 --> 03:31:26,265 WE ARE GRATEFUL TO COUNCIL AT 4668 03:31:26,265 --> 03:31:28,467 THE LAST COUNCIL ROUND FOR 4669 03:31:28,467 --> 03:31:30,202 APPROVING OUR QUANTUM 4670 03:31:30,202 --> 03:31:31,069 TECHNOLOGIES YOU CAN SEE IN PINK 4671 03:31:31,069 --> 03:31:34,439 IS ONE OF OUR YOUNGEST PROGRAMS 4672 03:31:34,439 --> 03:31:37,009 AND WE'RE ABOUT TO LARGE A PRICE 4673 03:31:37,009 --> 03:31:38,677 COMPETITION AT THE END OF THE 4674 03:31:38,677 --> 03:31:43,015 MONTH ON QUANTUM TECHNOLOGIES. 4675 03:31:43,015 --> 03:31:46,485 WHAT THE PROPOSED CONCEPT THIS 4676 03:31:46,485 --> 03:31:48,987 AFTERNOON IS ALL ABOUT, TWO 4677 03:31:48,987 --> 03:31:50,489 TECHNOLOGIES. 4678 03:31:50,489 --> 03:31:53,659 TWO EXCITING AREAS. 4679 03:31:53,659 --> 03:31:59,164 ONE CALLED EXTREME OR EXOSOME 4680 03:31:59,164 --> 03:32:02,467 THERAPY AND EXTRA CELLULAR RNA. 4681 03:32:02,467 --> 03:32:04,570 THIS IS A COMMON FUND PROGRAM 4682 03:32:04,570 --> 03:32:07,039 THAT NCATS IS LEADING. 4683 03:32:07,039 --> 03:32:13,712 IT'S BEEN USEFUL IN ELUCIDATING 4684 03:32:13,712 --> 03:32:16,481 HOW EXTRA CELLULAR RNA WITH THE 4685 03:32:16,481 --> 03:32:18,951 VESICLES ARE BEING USED BY OUR 4686 03:32:18,951 --> 03:32:21,420 CELLS FOR INTRACELLULAR 4687 03:32:21,420 --> 03:32:21,753 COMMUNICATION. 4688 03:32:21,753 --> 03:32:24,923 THAT'S A PARADIGM SHIFT IN HOW 4689 03:32:24,923 --> 03:32:26,858 WE THOUGHT ABOUT COMMUNICATION 4690 03:32:26,858 --> 03:32:32,598 WITHIN CELLS. 4691 03:32:32,598 --> 03:32:36,501 THEN THE OTHER PROGRAM AS BEING 4692 03:32:36,501 --> 03:32:38,370 USEFUL TOOLS TO REPRESENT HUMAN 4693 03:32:38,370 --> 03:32:38,670 PHYSIOLOGY. 4694 03:32:38,670 --> 03:32:40,772 THE CONCEPT IS REALLY AN 4695 03:32:40,772 --> 03:32:42,140 EXCITING AND PROMISING MERGER OF 4696 03:32:42,140 --> 03:32:44,176 THE TWO TECHNOLOGIES IN SOME 4697 03:32:44,176 --> 03:32:49,147 WAYS IT'S A SYNERGISM OF THE TWO 4698 03:32:49,147 --> 03:32:49,481 TECHNOLOGIES. 4699 03:32:49,481 --> 03:32:50,515 AND LEADING TO A MUCH MORE 4700 03:32:50,515 --> 03:32:52,384 POWERFUL APPROACH. 4701 03:32:52,384 --> 03:32:57,823 WITH THAT IT WILL BE PRESENTED 4702 03:32:57,823 --> 03:33:00,459 BY CHRISTINE HAPPEL THE PROGRAM 4703 03:33:00,459 --> 03:33:02,928 OFFICER THAT LEADS THE EXTRA 4704 03:33:02,928 --> 03:33:08,133 CELLULAR RNA PROGRAM AND 4705 03:33:08,133 --> 03:33:12,938 FOLLOWED BY DR. HARGROVE-GRIMES 4706 03:33:12,938 --> 03:33:13,572 WHO LEADS A CLINICAL TRIAL. 4707 03:33:13,572 --> 03:33:14,473 WITH THAT I'LL TURN IT OVER TO 4708 03:33:14,473 --> 03:33:24,650 CHRISTINE. 4709 03:33:27,119 --> 03:33:27,586 THANK YOU. 4710 03:33:27,586 --> 03:33:30,055 SO MY NAME IS CHRISTINE HAPPEL. 4711 03:33:30,055 --> 03:33:31,957 IN COLLABORATIVE SPIRIT I'LL BE 4712 03:33:31,957 --> 03:33:38,530 TAG TEAMING WITH MY COLLEAGUE, 4713 03:33:38,530 --> 03:33:43,935 DR. PASSLY HARGROVE-GRIMES. 4714 03:33:43,935 --> 03:33:45,871 I'LL TALK ABOUT SELECTIVE 4715 03:33:45,871 --> 03:33:47,039 PRECISION TARGETING. 4716 03:33:47,039 --> 03:33:51,743 NCATS SPENT YEARS LEADING 4717 03:33:51,743 --> 03:33:54,046 TISSUES ON A CHIP. 4718 03:33:54,046 --> 03:33:55,747 IN ADDITION TO LEADING MULTIPLE 4719 03:33:55,747 --> 03:33:58,050 PROGRAM ON EXTRA CELLULAR 4720 03:33:58,050 --> 03:33:58,383 COMMUNICATION. 4721 03:33:58,383 --> 03:34:01,453 WE NOW AIM TO CAPITALIZE ON THE 4722 03:34:01,453 --> 03:34:03,488 DATA WE HAVE DEVELOPED IN THE 4723 03:34:03,488 --> 03:34:05,090 PROGRAMS AND MERGE THE AREAS TO 4724 03:34:05,090 --> 03:34:06,525 ADDRESS A MAJOR CHALLENGE. 4725 03:34:06,525 --> 03:34:09,161 AND THAT CHALLENGE IS THAT SOME 4726 03:34:09,161 --> 03:34:10,095 INTERVENTIONS REQUIRE THE SAFE 4727 03:34:10,095 --> 03:34:12,397 AND EFFECTIVE DELIVERY OF 4728 03:34:12,397 --> 03:34:14,533 MOLECULES TO SPECIFIC CELLS AND 4729 03:34:14,533 --> 03:34:17,636 TISSUES. 4730 03:34:17,636 --> 03:34:20,072 NOW THESE CAN INCLUDE THINGS 4731 03:34:20,072 --> 03:34:23,575 LIKE GENE EDITING FOR MUSCULAR 4732 03:34:23,575 --> 03:34:24,242 DYSTROPHY. 4733 03:34:24,242 --> 03:34:25,544 IT COULD INCLUDE MONOCLONAL 4734 03:34:25,544 --> 03:34:27,279 ANTIBODIES OR INTERVENTIONS THAT 4735 03:34:27,279 --> 03:34:28,880 REGULATE GENE EXPRESSION FOR A 4736 03:34:28,880 --> 03:34:31,616 GROWING NUMBER OF PATHOLOGIES 4737 03:34:31,616 --> 03:34:36,421 FROM CANCER TO NEURODEGENERATIVE 4738 03:34:36,421 --> 03:34:38,223 DISEASES. 4739 03:34:38,223 --> 03:34:39,524 WE PROPOSE TARGETED DRUG 4740 03:34:39,524 --> 03:34:40,459 DELIVERY SYSTEMS. 4741 03:34:40,459 --> 03:34:42,160 WHAT'S THAT MEAN? 4742 03:34:42,160 --> 03:34:43,495 TARGETED DRUG DELIVERY SYSTEMS 4743 03:34:43,495 --> 03:34:44,896 ARE A METHOD OF DELIVERING 4744 03:34:44,896 --> 03:34:46,798 MEDICATIONS TO A SPECIFIC AREA 4745 03:34:46,798 --> 03:34:47,666 OF THE BODY. 4746 03:34:47,666 --> 03:34:50,802 SO THIS COULD BE AN ORGAN, A 4747 03:34:50,802 --> 03:34:51,937 TISSUE OR CELL TO INCREASE THE 4748 03:34:51,937 --> 03:34:55,107 CONCENTRATION OF THE DRUG IN 4749 03:34:55,107 --> 03:34:56,341 THAT PARTICULAR AREA. 4750 03:34:56,341 --> 03:34:58,310 SO WITH THAT WE'RE PROPOSING THE 4751 03:34:58,310 --> 03:35:00,178 CONCEPT COLLECTIVE PRECISION 4752 03:35:00,178 --> 03:35:01,780 TARGETING TOO DETERMINE THE 4753 03:35:01,780 --> 03:35:04,416 MECHANISM FOR PRECISE ON TARGET 4754 03:35:04,416 --> 03:35:06,551 THERAPEUTIC DRUG DELIVERY TO 4755 03:35:06,551 --> 03:35:09,554 SPECIFIC HARD TO REACH LOCATIONS 4756 03:35:09,554 --> 03:35:10,455 USING NPS. 4757 03:35:10,455 --> 03:35:12,190 SO WE'RE TRYING TO DELIVER 4758 03:35:12,190 --> 03:35:14,526 THERAPEUTICS TO THE RIGHT TISSUE 4759 03:35:14,526 --> 03:35:16,361 ADDRESS. 4760 03:35:16,361 --> 03:35:18,730 NOW TARGETED DRUG DELIVERY 4761 03:35:18,730 --> 03:35:24,569 SYSTEMS COULD INCLUDE NANO 4762 03:35:24,569 --> 03:35:25,103 PARTI 4763 03:35:25,103 --> 03:35:27,339 PARTICLES, SYNTHETIC OR THINGS 4764 03:35:27,339 --> 03:35:29,508 LIKE ANTIBODIES, CARRIERS AND 4765 03:35:29,508 --> 03:35:31,309 TECHNOLOGIES SUCH AS FOCUSSED 4766 03:35:31,309 --> 03:35:31,610 ULTRASOUND. 4767 03:35:31,610 --> 03:35:33,945 SO FOCUSSED ULTRASOUND IS A 4768 03:35:33,945 --> 03:35:35,180 TECHNOLOGY THAT GUIDES 4769 03:35:35,180 --> 03:35:38,517 THERAPEUTIC TO SPECIFIC 4770 03:35:38,517 --> 03:35:44,723 LOCATIONS AND CAN ACROSS THE 4771 03:35:44,723 --> 03:35:45,957 BLOOD BRAIN BARRIER. 4772 03:35:45,957 --> 03:35:49,795 THE MODALITIES SHOULD BE BIO 4773 03:35:49,795 --> 03:35:51,696 COMPATIBLE AND BIOLOGICAL 4774 03:35:51,696 --> 03:35:55,500 BARRIERS AND TARGET A SPECIFIC 4775 03:35:55,500 --> 03:35:58,136 CELL TISSUE OR ORGAN OF 4776 03:35:58,136 --> 03:36:00,739 INTEREST. 4777 03:36:00,739 --> 03:36:05,710 WE THINK THE MULTI-ORGAN NPS CAN 4778 03:36:05,710 --> 03:36:08,113 SERVE AS A VALUABLE TOOL FOR 4779 03:36:08,113 --> 03:36:09,047 THIS ENDEAVOR. 4780 03:36:09,047 --> 03:36:13,285 SO WHAT ARE MICROPHYSIOLOGICAL 4781 03:36:13,285 --> 03:36:13,518 SYSTEMS. 4782 03:36:13,518 --> 03:36:15,320 THEY'RE TISSUE CHIPS OR BIO 4783 03:36:15,320 --> 03:36:17,189 ENGINEERED DEVICES THE SIZE OF A 4784 03:36:17,189 --> 03:36:19,191 USB THUMB DRIVE TO GROW HUMAN 4785 03:36:19,191 --> 03:36:20,992 CELLS AND TISSUES AND TEST THEM 4786 03:36:20,992 --> 03:36:24,229 FOR TARGETING WITH SAFETY, 4787 03:36:24,229 --> 03:36:25,730 EFFICACY AND TOXICITY 4788 03:36:25,730 --> 03:36:26,031 ASSESSMENTS. 4789 03:36:26,031 --> 03:36:30,535 THEY CONTAIN CELL TYPES AND MORE 4790 03:36:30,535 --> 03:36:31,102 PREDICTIVE OF IN VIVO LIKE 4791 03:36:31,102 --> 03:36:37,876 BIOLOGY THAN TRADITIONAL MODELS. 4792 03:36:37,876 --> 03:36:42,514 YOU CAN SEE AN EXAMPLE OF A 4793 03:36:42,514 --> 03:36:47,085 HUMAN MULTI-ORGAN SYSTEM FOR 4794 03:36:47,085 --> 03:36:49,221 HEART, BLOOD BRAIN BARRIER AND 4795 03:36:49,221 --> 03:36:49,588 SKIN. 4796 03:36:49,588 --> 03:36:53,892 ONE INTEGRATED THE FLOW ALLOWS 4797 03:36:53,892 --> 03:36:54,526 TISSUE COMMUNICATION ACROSS 4798 03:36:54,526 --> 03:36:56,094 DIVERSE BIOLOGICAL BARRIERS. 4799 03:36:56,094 --> 03:36:58,129 YOU CAN SEE AN INLET AREA TO ADD 4800 03:36:58,129 --> 03:37:00,031 OUR THERAPEUTIC MODALITY OF 4801 03:37:00,031 --> 03:37:00,265 CHOICE. 4802 03:37:00,265 --> 03:37:01,900 NOW, I WANT TO BE CLEAR THIS IS 4803 03:37:01,900 --> 03:37:03,235 JUST AN EXAMPLE AND THIS IS NOT 4804 03:37:03,235 --> 03:37:07,005 THE FULL GAMUT OF WHAT WE COULD 4805 03:37:07,005 --> 03:37:07,205 TEST. 4806 03:37:07,205 --> 03:37:09,040 WE WERE INTERESTED 4807 03:37:09,040 --> 03:37:10,041 IMMUNOGENICITY AND NEED THE 4808 03:37:10,041 --> 03:37:11,109 IMMUNE COMPONENT. 4809 03:37:11,109 --> 03:37:13,612 IF WE WERE INTERESTED IN 4810 03:37:13,612 --> 03:37:15,213 MODELLING WOULD BE THE LIVER 4811 03:37:15,213 --> 03:37:17,048 COMPONENT TO ADDRESS BIO 4812 03:37:17,048 --> 03:37:19,985 DISTRIBUTION OR VASCULATURE TO 4813 03:37:19,985 --> 03:37:20,785 ADDRESS SYSTEMIC ADMINISTRATION 4814 03:37:20,785 --> 03:37:24,923 THEN GOAL IS TO USE THE HIGHLY 4815 03:37:24,923 --> 03:37:26,157 PREDICTIVE MICROORGAN SYSTEMS TO 4816 03:37:26,157 --> 03:37:28,126 PROVIDE EVIDENCE OF THERAPEUTIC 4817 03:37:28,126 --> 03:37:29,327 TARGETING TO HARD TO REACH 4818 03:37:29,327 --> 03:37:31,663 LOCATIONS WITHIN THE HUMAN BODY 4819 03:37:31,663 --> 03:37:36,134 AND MAY INCLUDE RETINA, BLOOD 4820 03:37:36,134 --> 03:37:39,037 BRAIN BARRIER, CNS TISSUE AND 4821 03:37:39,037 --> 03:37:41,106 PLACENTA AND WE'LL TARGET THE 4822 03:37:41,106 --> 03:37:44,075 SYSTEMS USING A BROAD SPECTRUM 4823 03:37:44,075 --> 03:37:48,613 OF THERAPEUTIC CARGO, DRUGS, SN 4824 03:37:48,613 --> 03:37:53,718 RNAs AND GENE EDITING TOOLS. 4825 03:37:53,718 --> 03:37:57,088 WE HAVE FOUR GOALS TARGET TO THE 4826 03:37:57,088 --> 03:38:00,792 ORGAN OR CELL OF INTEREST. 4827 03:38:00,792 --> 03:38:04,629 ASSESS OFF TARGET AFFECTS IN THE 4828 03:38:04,629 --> 03:38:06,097 SYSTEM AND EVIDENCE OF CARGO 4829 03:38:06,097 --> 03:38:07,832 ACTIVITY AND FOURTH IS TO 4830 03:38:07,832 --> 03:38:09,801 DETERMINE THE OPTIMAL ROOT OF 4831 03:38:09,801 --> 03:38:10,335 ADMINISTRATION. 4832 03:38:10,335 --> 03:38:11,569 METRICS FOR SUCCESS WILL INCLUDE 4833 03:38:11,569 --> 03:38:12,604 THE ADMINISTRATION OF THE 4834 03:38:12,604 --> 03:38:17,242 ABILITY TO PRECISELY TARGET A 4835 03:38:17,242 --> 03:38:18,977 CELL OR TISSUE TYPE OF INTEREST 4836 03:38:18,977 --> 03:38:19,744 USING THE SYSTEMS. 4837 03:38:19,744 --> 03:38:21,279 RESEARCH ACTIVITIES AND RESULTS 4838 03:38:21,279 --> 03:38:22,447 ARE EXPECTED TO ENABLE 4839 03:38:22,447 --> 03:38:24,182 TREATMENTS FOR HARD TO TREAT 4840 03:38:24,182 --> 03:38:25,750 DISEASES SUCH AS PRETERM BIRTH 4841 03:38:25,750 --> 03:38:28,420 WHICH CURRENTLY HAS NO CURRENT 4842 03:38:28,420 --> 03:38:34,125 TREATMENTS AND HOW DO WE GET 4843 03:38:34,125 --> 03:38:36,962 MOW -- MODALITIES TO THE 4844 03:38:36,962 --> 03:38:45,036 PLACENTA AND A DISEASE CONTEXT. 4845 03:38:45,036 --> 03:38:48,440 SO TO SUMMARIZE TARGETING DRUG 4846 03:38:48,440 --> 03:38:50,675 DELIVERY PLATFORMS ARE APP 4847 03:38:50,675 --> 03:38:53,345 APPLICABLE TO DISEASES AN 4848 03:38:53,345 --> 03:38:53,645 CONDITIONS. 4849 03:38:53,645 --> 03:38:55,280 THEY AFFECT SAFETY AND TOXICITY 4850 03:38:55,280 --> 03:38:58,183 AND CAN ALSO IMPROVE EFFICACY AS 4851 03:38:58,183 --> 03:39:00,485 WELL AS DOSING AND ADDRESS OFF 4852 03:39:00,485 --> 03:39:02,520 TARGET EFFECTS. 4853 03:39:02,520 --> 03:39:04,089 THERE'S REALLY MANY ADVANTAGES. 4854 03:39:04,089 --> 03:39:06,091 AND IN SUMMARY, WE ARE POSING 4855 03:39:06,091 --> 03:39:08,226 SELECTIVE PRECISION TARGETING AS 4856 03:39:08,226 --> 03:39:10,495 THE END GOAL OF THE PROGRAM TO 4857 03:39:10,495 --> 03:39:13,631 ENABLE PRECISE ON TARGET DRUG 4858 03:39:13,631 --> 03:39:14,699 DELIVERY TO SPECIFIC HARD TO 4859 03:39:14,699 --> 03:39:18,336 REACH LOCATIONS WITHIN THE HUMAN 4860 03:39:18,336 --> 03:39:24,342 BODY USING MULTIORGAN NPF AND 4861 03:39:24,342 --> 03:39:24,909 DELIVER TO THE RIGHT TISSUE 4862 03:39:24,909 --> 03:39:26,911 ADDRESS. 4863 03:39:26,911 --> 03:39:30,181 SO WITH THAT, WE DO HAVE A FEW 4864 03:39:30,181 --> 03:39:31,950 QUESTIONS WE'D LIKE TO ADDRESS 4865 03:39:31,950 --> 03:39:33,184 TO COUNCIL. 4866 03:39:33,184 --> 03:39:35,754 FIRST, WHAT MIGHT IMPROVE THE 4867 03:39:35,754 --> 03:39:36,554 INITIATIVE AND WHAT ARE KEY 4868 03:39:36,554 --> 03:39:38,523 POINTS FOR US TO CONSIDER. 4869 03:39:38,523 --> 03:39:40,959 AND THEN SPECIFICALLY WHO ARE 4870 03:39:40,959 --> 03:39:42,494 POTENTIAL PARTNERS OR 4871 03:39:42,494 --> 03:39:43,395 STAKEHOLDERS THAT SHOULD BE 4872 03:39:43,395 --> 03:39:43,962 INVOLVED? 4873 03:39:43,962 --> 03:39:45,196 WITH THAT, THANK YOU AND WE'LL 4874 03:39:45,196 --> 03:39:52,103 BE HAPPY TO ACHE ANY QUESTIONS. 4875 03:39:52,103 --> 03:39:52,437 >> THANK YOU. 4876 03:39:52,437 --> 03:39:56,474 THAT WAS VERY GOOD. 4877 03:39:56,474 --> 03:39:59,944 SO WE'LL HAVE OUR THREE 4878 03:39:59,944 --> 03:40:00,245 DISCUSSANTS. 4879 03:40:00,245 --> 03:40:01,046 PAUL. 4880 03:40:01,046 --> 03:40:02,514 >> FIRST A QUESTION. 4881 03:40:02,514 --> 03:40:05,817 DO YOU HAVE PILOT DATA THAT SHOW 4882 03:40:05,817 --> 03:40:11,389 WHEN YOU DELIVER THESE 4883 03:40:11,389 --> 03:40:13,458 INTERVENTIONS TO MULTI-CELL 4884 03:40:13,458 --> 03:40:16,394 TISSUE ON CHIP ECO SYSTEM THAT 4885 03:40:16,394 --> 03:40:24,936 THOSE CELLS BEHAVE DIFFERENTLY? 4886 03:40:24,936 --> 03:40:27,505 CAN YOU REPHRASE YOUR QUESTION, 4887 03:40:27,505 --> 03:40:28,006 I'M SORRY. 4888 03:40:28,006 --> 03:40:31,676 THEY BEHAVE DIFFERENTLY THAN IN 4889 03:40:31,676 --> 03:40:33,411 VIVO. 4890 03:40:33,411 --> 03:40:36,247 >> YOU'VE DONE THE WORK WITH 4891 03:40:36,247 --> 03:40:37,182 SINGLE CHIP. 4892 03:40:37,182 --> 03:40:40,752 THE NOVELTY WHAT I'M HEARING IS 4893 03:40:40,752 --> 03:40:43,855 YOU'RE NOW CREATING MULTI-CHIP 4894 03:40:43,855 --> 03:40:44,456 TO SIMULATE A MORE COMPLEX IN 4895 03:40:44,456 --> 03:40:54,766 VIVO ENVIRONMENT. 4896 03:40:55,366 --> 03:41:00,905 THE DIFFERENT REACTION TO THOSE 4897 03:41:00,905 --> 03:41:01,606 INTERVENTIONS. 4898 03:41:01,606 --> 03:41:04,476 HAVE YOU SHOWN IT MAKES A 4899 03:41:04,476 --> 03:41:06,111 DIFFERENCE WHEN YOU COMBINE THE 4900 03:41:06,111 --> 03:41:07,912 MULTI-CELL APPROACH AND YOU GET 4901 03:41:07,912 --> 03:41:08,746 DIFFERENT RESULTS THAN IN THE 4902 03:41:08,746 --> 03:41:10,215 SINGLE CELLS? 4903 03:41:10,215 --> 03:41:13,952 >> ABSOLUTELY. 4904 03:41:13,952 --> 03:41:15,854 WHEN WE COMBINE THE 4905 03:41:15,854 --> 03:41:16,554 MULTI-TISSUES INTO INTEGRATED 4906 03:41:16,554 --> 03:41:17,622 PLATFORMS WE HAVE A BETTER 4907 03:41:17,622 --> 03:41:21,759 UNDERSTANDING OF WHERE THE DRUG 4908 03:41:21,759 --> 03:41:26,798 WILL GO SYSTEMICALLY AND WHERE 4909 03:41:26,798 --> 03:41:30,969 THE A GOOD EXAMPLE THERE WAS A 4910 03:41:30,969 --> 03:41:37,308 LINK OF A KIDNEY AND LIVER CHIP 4911 03:41:37,308 --> 03:41:40,278 AND AEROSTOLIC ACID COMMON IN 4912 03:41:40,278 --> 03:41:44,649 THE ENVIRONMENT ESPECIALLY WITH 4913 03:41:44,649 --> 03:41:50,121 FARMERS THE THE METABOLISM OF 4914 03:41:50,121 --> 03:41:52,957 THE DRUG AND WERE ABLE TO 4915 03:41:52,957 --> 03:41:58,696 UNDERSTAND HOW IT IMPACTED THE 4916 03:41:58,696 --> 03:42:00,398 NEPHROTOXICITY OF THE DRUG WHICH 4917 03:42:00,398 --> 03:42:01,866 THEY WOULD NOT HAVE SHOWN ONE 4918 03:42:01,866 --> 03:42:03,134 JUST A KIDNEY MODEL. 4919 03:42:03,134 --> 03:42:03,535 >> THANKS. 4920 03:42:03,535 --> 03:42:06,171 IT LOOKS LIKE A GREAT PROGRAM. 4921 03:42:06,171 --> 03:42:07,038 THE TISSUE CHIP INNOVATION AT 4922 03:42:07,038 --> 03:42:09,641 NCATS IS WELL KNOWN. 4923 03:42:09,641 --> 03:42:10,308 IT'S BEEN GOING ON FOR SOME 4924 03:42:10,308 --> 03:42:15,380 TIME. 4925 03:42:15,380 --> 03:42:17,182 I LIKE THE FACT YOU HAVE THE 4926 03:42:17,182 --> 03:42:19,417 PIPELINE OF PROJECTS AND 4927 03:42:19,417 --> 03:42:21,753 INNOVATION AND THE 3-Ds AS 4928 03:42:21,753 --> 03:42:22,954 MENTIONED EARLIER AND THEY WILL 4929 03:42:22,954 --> 03:42:25,790 NEXT WAVE SEEMS LOGICAL AND FITS 4930 03:42:25,790 --> 03:42:28,693 VERY WELL WITHIN THE MAIN GOAL. 4931 03:42:28,693 --> 03:42:31,796 ONE OF THE MAIN GOALS OF THE 4932 03:42:31,796 --> 03:42:34,299 MISSION WITH MORE TREATMENTS AND 4933 03:42:34,299 --> 03:42:35,099 FITS IN LINE WITH GOALS. 4934 03:42:35,099 --> 03:42:38,503 NICE JOB. 4935 03:42:38,503 --> 03:42:41,372 >> DID YOU HAVE SOMETHING? 4936 03:42:41,372 --> 03:42:42,507 ALL RIGHT. 4937 03:42:42,507 --> 03:42:45,310 GREAT. 4938 03:42:45,310 --> 03:42:46,644 >> TO ADD THERE'S BEEN DIFFERENT 4939 03:42:46,644 --> 03:42:49,480 CHIPS THAT EXIST NOT ONLY IN 4940 03:42:49,480 --> 03:42:51,482 TERMS OF DEVELOPMENT ACTUALLY 4941 03:42:51,482 --> 03:42:54,018 COMMERCIALLY AVAILABLE AT THIS 4942 03:42:54,018 --> 03:42:54,852 POINT. 4943 03:42:54,852 --> 03:43:00,291 IT'S BEEN GOING ON SINCE 2017. 4944 03:43:00,291 --> 03:43:02,694 >> THANK YOU. 4945 03:43:02,694 --> 03:43:07,065 KELLY. 4946 03:43:07,065 --> 03:43:10,335 ONE QUESTION THAT RELATES AS 4947 03:43:10,335 --> 03:43:13,137 WELL AS EARLIER WORK AS SINGLE 4948 03:43:13,137 --> 03:43:14,505 TISSUE ON CHIP, HOW TO YOU 4949 03:43:14,505 --> 03:43:18,509 ADDRESS THE CONCEPT OF AN 4950 03:43:18,509 --> 03:43:22,013 AVERAGE SKIN CELL OR LIVER CELL 4951 03:43:22,013 --> 03:43:24,382 AND GROUNDED INTO A PATIENT SO 4952 03:43:24,382 --> 03:43:27,452 THE SIMULATION IS -- I'VE BEEN 4953 03:43:27,452 --> 03:43:27,685 CURIOUS. 4954 03:43:27,685 --> 03:43:30,521 THE SECOND QUESTION IS WHAT 4955 03:43:30,521 --> 03:43:31,990 WOULD HAPPEN IF THE STARTING 4956 03:43:31,990 --> 03:43:33,992 POINT THERE ARE THE TISSUE OB 4957 03:43:33,992 --> 03:43:44,469 CHIP WAS A PLURIPOTENT STEM 4958 03:43:48,973 --> 03:43:49,507 CELL. 4959 03:43:49,507 --> 03:43:52,343 >> NINE OF THIS TEN TEAMS HAVE 4960 03:43:52,343 --> 03:43:59,017 GONE FROM PRIMARY CELLS TO APFCs 4961 03:43:59,017 --> 03:44:01,052 TO CREATE MORE PATIENT-MODEL ON 4962 03:44:01,052 --> 03:44:03,688 CHIP BUT THAT'S NOT POSSIBLE FOR 4963 03:44:03,688 --> 03:44:04,822 SOME CHIPS. 4964 03:44:04,822 --> 03:44:07,558 FOR CANCER YOU HAVE TO USE 4965 03:44:07,558 --> 03:44:08,326 PRIMARY TISSUE BUT FOR A LOT OF 4966 03:44:08,326 --> 03:44:10,495 TISSUE IT'S BEEN ABLE TO GO IN 4967 03:44:10,495 --> 03:44:13,831 AND SHOW THE VALUE OF THAT. 4968 03:44:13,831 --> 03:44:15,900 THAT'S WHAT THE PROGRAM WILL END 4969 03:44:15,900 --> 03:44:18,503 IN ONE MORE YEAR AND WE'LL 4970 03:44:18,503 --> 03:44:20,071 FINALLY HAVE DATA. 4971 03:44:20,071 --> 03:44:21,939 YOU ASKED SO I'M REPEATING IT 4972 03:44:21,939 --> 03:44:22,206 CORRECTLY. 4973 03:44:22,206 --> 03:44:25,243 YOU ASKED HOW THE SINGLE TISSUE 4974 03:44:25,243 --> 03:44:28,379 CHIPS HOW TO KNOW THE CELL 4975 03:44:28,379 --> 03:44:30,515 ITSELF HOW DO YOU KNOW WHICH 4976 03:44:30,515 --> 03:44:34,285 CELL TO USE OR -- 4977 03:44:34,285 --> 03:44:36,954 >> I GUESS I'VE ALWAYS WONDERED 4978 03:44:36,954 --> 03:44:40,391 AND -- THIS IS NOT AN AREA OF 4979 03:44:40,391 --> 03:44:46,164 EXPERTISE BUT I'VE ALWAYS 4980 03:44:46,164 --> 03:44:47,899 WONDERED ABOUT AN AVERAGE CELL 4981 03:44:47,899 --> 03:44:49,667 THAT'S EXPERIMENTAL VERSUS A 4982 03:44:49,667 --> 03:44:50,201 DISEASE CELL. 4983 03:44:50,201 --> 03:44:53,971 IT'S REALLY THE EXPERIMENTAL 4984 03:44:53,971 --> 03:44:55,740 CONDITIONS AND IT WAS I THINK MY 4985 03:44:55,740 --> 03:44:56,841 SECOND QUESTION WAS REALLY 4986 03:44:56,841 --> 03:44:59,811 GETTING TO THE HEART OF THE 4987 03:44:59,811 --> 03:45:05,450 FIRST QUESTION I , MAYBE MAYOR 4988 03:45:05,450 --> 03:45:07,051 THE FIRST QUESTION. 4989 03:45:07,051 --> 03:45:08,586 >> YOU'RE ASKING HOW IS A 4990 03:45:08,586 --> 03:45:10,455 TYPICAL CELL, HOW DO YOU KNOW 4991 03:45:10,455 --> 03:45:11,989 IT'S DIFFERENT THAN THE DISEASED 4992 03:45:11,989 --> 03:45:14,258 CELL? 4993 03:45:14,258 --> 03:45:15,960 >> I'LL GIVE A SPECIFIC EXAMPLE. 4994 03:45:15,960 --> 03:45:21,799 I DO A GREAT DEAL WITH LUPUS 4995 03:45:21,799 --> 03:45:22,233 RESEARCH. 4996 03:45:22,233 --> 03:45:26,270 AND WE HAVE MODELS OF TISSUE ON 4997 03:45:26,270 --> 03:45:33,911 CHIP THAT LOOK AT KIDNEY ISSUES. 4998 03:45:33,911 --> 03:45:34,946 WHEN THEY WERE SHOWING US THIS 4999 03:45:34,946 --> 03:45:39,050 WAS A WAY TO START TO DO SOME 5000 03:45:39,050 --> 03:45:43,588 MODELLING IN LUPUS, THEY WEREN'T 5001 03:45:43,588 --> 03:45:45,022 DOING IT BASED ON CELLS THAT HAD 5002 03:45:45,022 --> 03:45:50,495 COME FROM LUPUS PATIENTS. 5003 03:45:50,495 --> 03:45:52,997 IT WAS -- 5004 03:45:52,997 --> 03:45:54,465 >> CELL LINES, BASICALLY. 5005 03:45:54,465 --> 03:45:55,566 >> YES. 5006 03:45:55,566 --> 03:45:57,802 HOW DOES THIS RELATE AND HOW 5007 03:45:57,802 --> 03:46:01,172 DOES THAT IMPACT WHEN YOU'RE 5008 03:46:01,172 --> 03:46:02,507 STARTING TO CREATE THESE 5009 03:46:02,507 --> 03:46:06,511 MULTI-CELL SYSTEMS? 5010 03:46:06,511 --> 03:46:10,281 >> SO, ONE THING WE'VE 5011 03:46:10,281 --> 03:46:13,718 ENCOURAGED IS TO NOT USE CELL 5012 03:46:13,718 --> 03:46:18,489 LINES I WAS AT A CONFERENCE 5013 03:46:18,489 --> 03:46:22,460 WHERE THE CELL LINES WE USE ARE 5014 03:46:22,460 --> 03:46:23,761 MALE CAUCASIAN AND DON'T 5015 03:46:23,761 --> 03:46:24,862 REPRESENT GENETIC DIVERSITY. 5016 03:46:24,862 --> 03:46:26,164 ENCOURAGING THEM TO USE PRIMARY 5017 03:46:26,164 --> 03:46:32,603 CELLS FROM PATIENTS OR TO TAKE 5018 03:46:32,603 --> 03:46:38,876 CELL LINES AND THEN USE AN AGENT 5019 03:46:38,876 --> 03:46:41,446 TO CREATE A DISEASE STATE. 5020 03:46:41,446 --> 03:46:43,915 SO USING LPS FOR EXAMPLE TO 5021 03:46:43,915 --> 03:46:44,582 CREATE AN INFLAMMATORY STATE AND 5022 03:46:44,582 --> 03:46:48,319 SEE IF THAT MIMICS THE NEVER 5023 03:46:48,319 --> 03:46:48,953 CONDITION AND THEN TEST AGAINST 5024 03:46:48,953 --> 03:46:54,826 THAT. 5025 03:46:54,826 --> 03:46:56,727 >> I WANTED THE CLARIFICATION. 5026 03:46:56,727 --> 03:47:01,332 IT'S A WONDERFUL PROJECT. 5027 03:47:01,332 --> 03:47:04,469 >> JUST TO ADD, THE ADVANTAGE OF 5028 03:47:04,469 --> 03:47:06,938 TISSUE CHIPS IS YOU CAN TAKE 5029 03:47:06,938 --> 03:47:08,806 PATIENT DERIVED MATERIALS 5030 03:47:08,806 --> 03:47:12,143 WHETHER PRIMARY OR BLOOD AND 5031 03:47:12,143 --> 03:47:22,687 MAKE THAT INTO PLURIPOTENT STEM 5032 03:47:26,557 --> 03:47:29,060 CELLS AND TAKE A CONTROLLED IPS 5033 03:47:29,060 --> 03:47:32,330 LINE AND DO SOMATIC CELL GENE 5034 03:47:32,330 --> 03:47:34,499 EDITING AND INTRODUCE THE 5035 03:47:34,499 --> 03:47:36,701 MUTATION TO HAVE A CONTROL IN 5036 03:47:36,701 --> 03:47:42,507 THE BACKGROUND AS PART OF THE 5037 03:47:42,507 --> 03:47:44,575 REPLICATES. 5038 03:47:44,575 --> 03:47:46,644 YOU CAN ELIMINATE CONTRIBUTIONS 5039 03:47:46,644 --> 03:47:57,188 FROM OTHER ALLELES AND CUT DOWN 5040 03:47:57,822 --> 03:48:06,497 ON THE MECHANISM OF 5041 03:48:06,497 --> 03:48:07,365 PATHOGENESIS. 5042 03:48:07,365 --> 03:48:17,775 >> WE'RE GETTING TO THE POINT 5043 03:48:17,775 --> 03:48:20,478 WHERE YOU'RE STIMULATING THE 5044 03:48:20,478 --> 03:48:26,584 HUMAN AND ELIMINATING THE -- I 5045 03:48:26,584 --> 03:48:31,956 MEAN YOU'RE PARALYZING CLINICAL 5046 03:48:31,956 --> 03:48:32,189 TRIALS. 5047 03:48:32,189 --> 03:48:33,224 >> THAT'S A PLACE WHERE WE'D 5048 03:48:33,224 --> 03:48:35,159 LIKE TO SEE HOW CLOSE WE CAN GET 5049 03:48:35,159 --> 03:48:39,163 BUT I THINK WE HAVE A LONG WAY. 5050 03:48:39,163 --> 03:48:40,264 WE'RE STILL COMPARING THE MODELS 5051 03:48:40,264 --> 03:48:45,436 TOO. 5052 03:48:45,436 --> 03:48:52,577 HOW CAN WE INCORPORATE IN THIS 5053 03:48:52,577 --> 03:48:55,546 NEW CONCEPT OR FOA TO 5054 03:48:55,546 --> 03:48:56,547 INCORPORATE THE STANDARDS. 5055 03:48:56,547 --> 03:48:58,349 HOW DO WE MAKE SURE WE'RE 5056 03:48:58,349 --> 03:49:00,518 COMPARING APPLES TO APPLES WHEN 5057 03:49:00,518 --> 03:49:03,154 WE'RE LOOKING AT IPS CELLS FROM 5058 03:49:03,154 --> 03:49:04,221 TWO PATIENTS WITH THE SAME 5059 03:49:04,221 --> 03:49:06,157 DISEASE? 5060 03:49:06,157 --> 03:49:08,826 ARE WE COMPARING APPLES TO 5061 03:49:08,826 --> 03:49:14,332 APPLES AND WHAT WOULD BE THE 5062 03:49:14,332 --> 03:49:15,466 CHARACTERISTIC OF THAT WHERE WE 5063 03:49:15,466 --> 03:49:16,200 WOULDN'T SAY THAT? 5064 03:49:16,200 --> 03:49:26,744 IF WE CAN INFUSE THAT INTO THE 5065 03:49:27,144 --> 03:49:28,879 DESIGN CONCEPT IS THE STANDARD 5066 03:49:28,879 --> 03:49:31,616 OF WHAT IT MEANS TO GET TYPICAL 5067 03:49:31,616 --> 03:49:34,518 OR NOT TYPICAL CELL AND ALSO 5068 03:49:34,518 --> 03:49:36,354 JUST THINKING ABOUT THE EARLIER 5069 03:49:36,354 --> 03:49:41,959 PRESENTATION FROM JEANITA AND 5070 03:49:41,959 --> 03:49:42,493 SL 5071 03:49:42,493 --> 03:49:49,767 SHARI IS INFUSING THE EQUITY 5072 03:49:49,767 --> 03:49:52,370 DESIGN AND STANDARDS IN THESE 5073 03:49:52,370 --> 03:49:53,471 MODEL DEVELOPMENTS WILL BE 5074 03:49:53,471 --> 03:49:56,007 IMPORTANT AND HOW TO HELP THE 5075 03:49:56,007 --> 03:50:02,480 FIELD DERIVE THAT. 5076 03:50:02,480 --> 03:50:04,715 THE OTHER FEATURE IS IN THE 5077 03:50:04,715 --> 03:50:10,921 BACKGROUND OF ALL THIS IS THE 5078 03:50:10,921 --> 03:50:12,089 COMMON FUND PROGRAM 5079 03:50:12,089 --> 03:50:18,496 COMPLEMENTARY. 5080 03:50:18,496 --> 03:50:20,631 AND HELP DRIVE THE STANDARDS 5081 03:50:20,631 --> 03:50:22,500 THERE WILL BE OPPORTUNITIES FOR 5082 03:50:22,500 --> 03:50:26,504 INTEGRATING THOSE FINDINGS ALONG 5083 03:50:26,504 --> 03:50:26,737 THE WAY. 5084 03:50:26,737 --> 03:50:29,707 >> HOPEFULLY THAT ANSWERS YOUR 5085 03:50:29,707 --> 03:50:30,074 QUESTION. 5086 03:50:30,074 --> 03:50:31,609 >> IT WAS GREAT. 5087 03:50:31,609 --> 03:50:37,715 I HAVE FOLLOW-UPS WE'LL TALK 5088 03:50:37,715 --> 03:50:39,850 ABOUT OFFLINE WITH RARE DISEASE 5089 03:50:39,850 --> 03:50:40,217 COLLABORATIONS. 5090 03:50:40,217 --> 03:50:44,021 >> THE MOST WE HAVE IN TERMS OF 5091 03:50:44,021 --> 03:50:46,857 PATIENT DIVERSITY IS ABOUT 250 5092 03:50:46,857 --> 03:50:55,566 IPS LINES THAT IS BEING USED FOR 5093 03:50:55,566 --> 03:50:58,469 METABOLIC ASSOCIATED FATTY LIVER 5094 03:50:58,469 --> 03:50:58,703 DISEASE. 5095 03:50:58,703 --> 03:51:01,238 IT'S PRIMARILY FROM HISPANIC 5096 03:51:01,238 --> 03:51:03,040 POPULATION BECAUSE THEY ARE IN 5097 03:51:03,040 --> 03:51:05,342 SOME WAYS THE MOST VULNERABLE 5098 03:51:05,342 --> 03:51:05,976 POPULATION FOR THIS PARTICULAR 5099 03:51:05,976 --> 03:51:07,812 DISORDER. 5100 03:51:07,812 --> 03:51:11,882 AND THEN WE HAVE OTHER DISEASES 5101 03:51:11,882 --> 03:51:15,319 AS WELL WHERE LIKE PROSTATE 5102 03:51:15,319 --> 03:51:20,591 CANCER UP TO 50 MALE DONORS. 5103 03:51:20,591 --> 03:51:22,493 WE ARE INCORPORATING DIVERSITY 5104 03:51:22,493 --> 03:51:24,028 BOTH IN TERMS OF ETHNICITY AS 5105 03:51:24,028 --> 03:51:24,695 WELL AS SEX AND GENDER. 5106 03:51:24,695 --> 03:51:26,497 >> GREAT, THANK YOU. 5107 03:51:26,497 --> 03:51:28,666 >> GREAT DISCUSSION. 5108 03:51:28,666 --> 03:51:30,701 PAULA. 5109 03:51:30,701 --> 03:51:32,303 >> I THINK IT'S A VERY 5110 03:51:32,303 --> 03:51:33,437 INTERESTING CONCEPT AND IT HAS 5111 03:51:33,437 --> 03:51:36,273 GREAT POTENTIAL. 5112 03:51:36,273 --> 03:51:40,144 I KIND OF DOUBT THE TYPICAL CELL 5113 03:51:40,144 --> 03:51:42,079 ACTUALLY EXISTS BECAUSE 5114 03:51:42,079 --> 03:51:43,614 DEPENDING UPON WHO THE NEAREST 5115 03:51:43,614 --> 03:51:45,449 NEIGHBOR IS IT WILL ACT 5116 03:51:45,449 --> 03:51:46,350 DIFFERENTLY LIKE KID AND WHOEVER 5117 03:51:46,350 --> 03:51:49,587 YOU PUT THEM IN THE ROOM WITH. 5118 03:51:49,587 --> 03:51:52,656 THAT'S MAKE A MACRO VIEW AND 5119 03:51:52,656 --> 03:51:54,425 YOU'RE LOOKING AT MICRO. 5120 03:51:54,425 --> 03:51:58,295 ONE OTHER PART IS IN POTENTIAL 5121 03:51:58,295 --> 03:51:58,562 PARTNERS. 5122 03:51:58,562 --> 03:52:00,064 SO WE AS CLINICIANS DEAL WITH 5123 03:52:00,064 --> 03:52:01,632 THE AVERAGE RESPONSE TO A 5124 03:52:01,632 --> 03:52:03,634 CLINICAL TRIAL AND SO YOU HAVE 5125 03:52:03,634 --> 03:52:06,036 PEOPLE WHO RESPOND REALLY WELL 5126 03:52:06,036 --> 03:52:08,372 AND PEOPLE WHO DON'T RESPOND AT 5127 03:52:08,372 --> 03:52:08,706 ALL. 5128 03:52:08,706 --> 03:52:10,508 I THINK SOME OF YOUR POTENTIAL 5129 03:52:10,508 --> 03:52:13,010 PARTNERS ARE TO TAKE SOME OF 5130 03:52:13,010 --> 03:52:16,380 THESE TRIALS WHERE YOU HAVE A 5131 03:52:16,380 --> 03:52:17,281 DIVERGENT EITHER A NEGATIVE 5132 03:52:17,281 --> 03:52:20,184 RESPONSE OR POSITIVE RESPONSE 5133 03:52:20,184 --> 03:52:21,619 AND TRY TO GET THOSE TWO 5134 03:52:21,619 --> 03:52:22,787 EXTREMES AND TRY TO USE THAT IN 5135 03:52:22,787 --> 03:52:27,291 YOUR SYSTEM TO TRY TO UNDERSTAND 5136 03:52:27,291 --> 03:52:29,960 WHY I DIDN'T REACT VERY WELL TO 5137 03:52:29,960 --> 03:52:32,329 THIS DRUG AND YET WORKED 5138 03:52:32,329 --> 03:52:33,697 BEAUTIFULLY ON SOMEBODY ELSE. 5139 03:52:33,697 --> 03:52:35,499 THAT'S A HUGE POTENTIAL PARTNER 5140 03:52:35,499 --> 03:52:39,336 SO WE COULD LOOK AT SUBGROUPS AT 5141 03:52:39,336 --> 03:52:40,538 TRIALS AND KNOW SOMETHING ABOUT 5142 03:52:40,538 --> 03:52:42,339 THE DRUG WORKED FOR YOU OR NOT. 5143 03:52:42,339 --> 03:52:46,477 BUT I DO THINK THAT'S ONE OF 5144 03:52:46,477 --> 03:52:48,112 YOUR POTENTIAL STAKEHOLDERS IS 5145 03:52:48,112 --> 03:52:49,980 LOOKING AT CLINICAL TRIALS AND 5146 03:52:49,980 --> 03:52:53,617 TRYING TO FIND THE EXTREMES AND 5147 03:52:53,617 --> 03:52:54,485 TESTING THE CHIP ON THAT. 5148 03:52:54,485 --> 03:52:55,953 >> THANK YOU. 5149 03:52:55,953 --> 03:52:57,188 THAT'S A GREAT SUGGESTION. 5150 03:52:57,188 --> 03:52:58,689 I THINK THAT'S ALSO WHY WE LOVE 5151 03:52:58,689 --> 03:53:06,497 THE IDEA OF USING MULTI-ORGAN 5152 03:53:06,497 --> 03:53:15,639 NPS AND HONE IN ON THOSE AND 5153 03:53:15,639 --> 03:53:20,578 ADDRESS OFF TARGET EFFECTS AND 5154 03:53:20,578 --> 03:53:24,548 THINGS YOU SEE AND NOT SEE IN 5155 03:53:24,548 --> 03:53:29,753 TRADITIONAL IN VITRO STUDIES. 5156 03:53:29,753 --> 03:53:30,721 >> ANY OTHER COMMENTS OR 5157 03:53:30,721 --> 03:53:40,898 QUESTIONS? 5158 03:53:44,068 --> 03:53:45,369 >> OKAY. 5159 03:53:45,369 --> 03:53:49,740 IS THERE ANY JUSTIFICATION FOR 5160 03:53:49,740 --> 03:53:51,408 YOUR BUILDING THOSE MODELS TO 5161 03:53:51,408 --> 03:53:51,575 MIX? 5162 03:53:51,575 --> 03:53:54,511 OF AS A WAY TO SCREEN THROUGH 5163 03:53:54,511 --> 03:54:01,318 AND THEN DETERMINE THE NOISE? 5164 03:54:01,318 --> 03:54:04,688 >> THE DIFFERENT ORGAN SYSTEMS 5165 03:54:04,688 --> 03:54:08,792 ARE REALLY MEANT TO RECAPITULATE 5166 03:54:08,792 --> 03:54:11,896 NORMAL HUMAN PHYSIOLOGY AND THAT 5167 03:54:11,896 --> 03:54:13,831 MEANS MULTIPLE CELL TYPES TO 5168 03:54:13,831 --> 03:54:18,702 MAKE SURE WE'RE ACCURATELY 5169 03:54:18,702 --> 03:54:18,969 MODELLING. 5170 03:54:18,969 --> 03:54:22,273 >> WE HAVE SYSTEMS WHERE PEOPLE 5171 03:54:22,273 --> 03:54:24,375 HAVE COMBINED DIFFERENT 5172 03:54:24,375 --> 03:54:24,642 PATIENTS. 5173 03:54:24,642 --> 03:54:26,243 THAT'S GOING TO BE HARD TO TEASE 5174 03:54:26,243 --> 03:54:28,746 ANYTHING OUT OF BECAUSE YOU'RE 5175 03:54:28,746 --> 03:54:30,814 GOING TO GET THE NOISE FROM 5176 03:54:30,814 --> 03:54:33,083 DIFFERENT PATIENT POPULATIONS. 5177 03:54:33,083 --> 03:54:37,588 WE HAVE DEVICES WHERE THEY'VE 5178 03:54:37,588 --> 03:54:38,522 DONE THAT AND SOME ARE RESPONSES 5179 03:54:38,522 --> 03:54:44,395 WE KNOW. 5180 03:54:44,395 --> 03:54:47,431 >> THANK YOU FOR YOUR QUESTIONS. 5181 03:54:47,431 --> 03:54:47,865 ANYTHING ELSE? 5182 03:54:47,865 --> 03:54:50,134 >> WE NEED TO MOVE ON. 5183 03:54:50,134 --> 03:54:51,602 >> IF THERE'S NO FURTHER 5184 03:54:51,602 --> 03:54:54,104 DISCUSSION AND I BELIEVE THERE 5185 03:54:54,104 --> 03:54:57,741 IS ANY RIGHT NOW CAN I HAVE A 5186 03:54:57,741 --> 03:55:02,513 MOTION TO APPROVE THE CONCEPT. 5187 03:55:02,513 --> 03:55:02,746 SECOND. 5188 03:55:02,746 --> 03:55:06,350 ALL IN FAVOR? 5189 03:55:06,350 --> 03:55:08,953 ANY OPPOSED? 5190 03:55:08,953 --> 03:55:09,853 ANY ABSTENTIONS? 5191 03:55:09,853 --> 03:55:11,221 WITH THAT THE SECOND CONCEPT IS 5192 03:55:11,221 --> 03:55:12,089 APPROVED. 5193 03:55:12,089 --> 03:55:14,491 THANK YOU VERY MUCH. 5194 03:55:14,491 --> 03:55:17,061 >> THANK YOU. 5195 03:55:17,061 --> 03:55:17,561 >> OKAY. 5196 03:55:17,561 --> 03:55:21,198 AND LAST BUT NOT LEAST, IS OUR 5197 03:55:21,198 --> 03:55:24,601 THIRD CONCEPT OF THE DAY THIS IS 5198 03:55:24,601 --> 03:55:26,370 COMING FROM THE RARE DISEASE 5199 03:55:26,370 --> 03:55:30,140 DIVISION A CONCEPT CLEARANCE PJ 5200 03:55:30,140 --> 03:55:30,708 BROOKS WILL BE PRESENTING. 5201 03:55:30,708 --> 03:55:31,709 >> THANKS, JONI. 5202 03:55:31,709 --> 03:55:33,377 GOOD AFTERNOON EVERYONE. 5203 03:55:33,377 --> 03:55:35,479 HAPPY TO PRESENT THE LAST 5204 03:55:35,479 --> 03:55:36,246 CONCEPT CLEARANCE OF THE DAY. 5205 03:55:36,246 --> 03:55:46,657 ONE WE'RE EXCITED ABOUT. 5206 03:55:53,831 --> 03:55:55,332 A LITTLE OVERVIEW. 5207 03:55:55,332 --> 03:56:00,938 ONE IS FOCUSSED ON PATIENT 5208 03:56:00,938 --> 03:56:03,040 SUPPORT AND INFORMATION AND THE 5209 03:56:03,040 --> 03:56:03,974 MAIN RESEARCH INCLUDING A 5210 03:56:03,974 --> 03:56:07,411 VARIETY OF PROJECTS FOCUSSED ON 5211 03:56:07,411 --> 03:56:08,812 DEVELOPING TREATMENTS FOR A 5212 03:56:08,812 --> 03:56:10,414 DISEASE AT A TIME AND HAVE 5213 03:56:10,414 --> 03:56:12,950 CONVENING AND PARTNERING 5214 03:56:12,950 --> 03:56:13,250 ACTIVITIES. 5215 03:56:13,250 --> 03:56:15,085 THE CONCEPTUAL HEAR ABOUT CUTS 5216 03:56:15,085 --> 03:56:18,589 ACROSS THE FIRST AND THIRD 5217 03:56:18,589 --> 03:56:21,859 PILLARS BUT REINFORCES AN IDEA 5218 03:56:21,859 --> 03:56:22,593 THAT GOES THROUGH A LOT OF THAT 5219 03:56:22,593 --> 03:56:24,862 MANY DISEASE AT A TIME THINKING. 5220 03:56:24,862 --> 03:56:27,364 WITH THAT LET ME HAND IT OVER TO 5221 03:56:27,364 --> 03:56:37,841 AINSLIE TISDALE TO PRESENT. 5222 03:56:38,575 --> 03:56:41,345 >> SO, I'M BRINGING UP THE REAR 5223 03:56:41,345 --> 03:56:43,714 AND THING THIS CONCEPT IS A FUN 5224 03:56:43,714 --> 03:56:45,182 WAY TO END THE DAY. 5225 03:56:45,182 --> 03:56:46,784 HOPEFULLY YOU'LL AGREE. 5226 03:56:46,784 --> 03:56:49,887 I'M ALSO PRESENTING ON BEHALF OF 5227 03:56:49,887 --> 03:56:51,121 MY COLLEAGUE JOINING VIRTUALLY 5228 03:56:51,121 --> 03:56:52,523 AND WILL BE ABLE TO JOIN IN THE 5229 03:56:52,523 --> 03:56:53,123 DISCUSSION SESSION IF WE HAVE 5230 03:56:53,123 --> 03:56:56,660 QUESTIONS. 5231 03:56:56,660 --> 03:57:01,498 I AM PRESENTING A RENEWAL OF THE 5232 03:57:01,498 --> 03:57:02,399 RARE DISEASES ARE NOT RARE 5233 03:57:02,399 --> 03:57:03,867 CHALLENGE SOME MAY REMEMBER FROM 5234 03:57:03,867 --> 03:57:05,602 YEARS AGO. 5235 03:57:05,602 --> 03:57:07,137 IT'S AN EDUCATIONAL AND 5236 03:57:07,137 --> 03:57:10,140 AWARENESS TOOL FOR THE RARE 5237 03:57:10,140 --> 03:57:10,474 DISEASE SPACE. 5238 03:57:10,474 --> 03:57:15,512 SO JUST TO GIVE CONTEXT ON WHY 5239 03:57:15,512 --> 03:57:16,246 THIS AWARENESS EDUCATIONAL 5240 03:57:16,246 --> 03:57:18,248 CAMPAIGN IS NEEDED AND 5241 03:57:18,248 --> 03:57:18,882 IMPORTANT. 5242 03:57:18,882 --> 03:57:20,984 THERE'S BEEN A GROUND SWELL IN 5243 03:57:20,984 --> 03:57:22,619 THE ATTENTION TO THE COLLECTIVE 5244 03:57:22,619 --> 03:57:23,921 BURDEN OF RARE DISEASES 5245 03:57:23,921 --> 03:57:24,221 RECENTLY. 5246 03:57:24,221 --> 03:57:27,191 THERE'S FOUR STUDIES PUBLISHED 5247 03:57:27,191 --> 03:57:28,192 IN 2021 THAT BROUGHT ATTENTION 5248 03:57:28,192 --> 03:57:28,725 TO THIS. 5249 03:57:28,725 --> 03:57:33,330 AND THE OVER ALL MESSAGE WAS 5250 03:57:33,330 --> 03:57:34,731 RARE DISEASE COSTLY ECONOMIC AND 5251 03:57:34,731 --> 03:57:38,502 IN HUMAN TERMS. 5252 03:57:38,502 --> 03:57:40,170 PATIENTS ARE UNDER RECOGNIZED IN 5253 03:57:40,170 --> 03:57:42,506 THE HEALTH CARE SYSTEMS AND 5254 03:57:42,506 --> 03:57:46,510 DATABASES AND ACTIONABLE BUT 5255 03:57:46,510 --> 03:57:49,079 UNDER PRIORITIZED. 5256 03:57:49,079 --> 03:57:51,648 THIS SHOWED RARE DISEASES ARE A 5257 03:57:51,648 --> 03:57:52,783 PUBLIC HEALTH PROBLEM THAT 5258 03:57:52,783 --> 03:57:54,518 REQUIRE INCREASED ATTENTION, 5259 03:57:54,518 --> 03:57:59,156 AWARENESS AND EDUCATION. 5260 03:57:59,156 --> 03:58:00,724 NCATS HOSTED THE RARE DISEASES 5261 03:58:00,724 --> 03:58:02,292 ARE NOT RARE CHALLENGE IN 2018 5262 03:58:02,292 --> 03:58:03,460 AND 2020. 5263 03:58:03,460 --> 03:58:06,096 THESE CHALLENGES WERE CENTERED 5264 03:58:06,096 --> 03:58:10,134 AROUND RAISING AWARENESS AND 5265 03:58:10,134 --> 03:58:11,235 FOSTERING COLLABORATION ACROSS 5266 03:58:11,235 --> 03:58:12,603 RARE DISEASE COMMUNITIES 5267 03:58:12,603 --> 03:58:14,271 INCLUDING PATIENTS, CAREGIVERS 5268 03:58:14,271 --> 03:58:16,140 AND ADVOCATES AND RESULTED IN 5269 03:58:16,140 --> 03:58:17,541 SEVERAL COMMUNICATION PIECES 5270 03:58:17,541 --> 03:58:18,509 SHARED WIDELY. 5271 03:58:18,509 --> 03:58:22,079 SUCH AS POSTERS, VIDEOS, INFO 5272 03:58:22,079 --> 03:58:25,382 GRAPHICS, THINGS OF THAT NATURE. 5273 03:58:25,382 --> 03:58:26,583 THE SUBMISSIONS OF THIS WINNERS 5274 03:58:26,583 --> 03:58:32,556 AND HONORABLE MENTIONS WERE 5275 03:58:32,556 --> 03:58:33,891 FEATURED AT OUR RARE DISEASE DAY 5276 03:58:33,891 --> 03:58:36,560 NIH EVENT AND THE WINNER WAS 5277 03:58:36,560 --> 03:58:38,262 ABLE TO SPEAK AND RECEIVE AN 5278 03:58:38,262 --> 03:58:38,462 AWARD. 5279 03:58:38,462 --> 03:58:42,499 FOR CONTEXT THE LAST TIME THIS 5280 03:58:42,499 --> 03:58:46,503 CONCEPT WAS CLEARED WAS IN 5281 03:58:46,503 --> 03:58:49,740 SEPTEMBER OF 2019. 5282 03:58:49,740 --> 03:58:51,008 JACOB THOMPSON A RARE DISEASE 5283 03:58:51,008 --> 03:58:52,042 PATIENT AND ADVOCATE WAS OUR 5284 03:58:52,042 --> 03:58:55,579 FIRST PLACE WINNER IN 2020. 5285 03:58:55,579 --> 03:58:59,750 HE PERFORMED SPOKEN WORD POETRY 5286 03:58:59,750 --> 03:59:01,552 HE WROTE HIMSELF ABOUT RAISING 5287 03:59:01,552 --> 03:59:02,986 AWARENESS ON RARE DISEASED AND 5288 03:59:02,986 --> 03:59:04,788 HAD HIM SPEAK AT THE RARE 5289 03:59:04,788 --> 03:59:07,724 DISEASE DAY AND HIS VIDEO IS 5290 03:59:07,724 --> 03:59:09,493 STILL UP ON THE NCATS WEBSITE 5291 03:59:09,493 --> 03:59:13,063 AND YOUTUBE WITH OVER 3,000 5292 03:59:13,063 --> 03:59:13,330 VIEWS. 5293 03:59:13,330 --> 03:59:16,500 OUR 2018 WINNER WAS A PARENT OF 5294 03:59:16,500 --> 03:59:17,568 A CHILD WITH A RARE DISEASE WHO 5295 03:59:17,568 --> 03:59:18,435 CREATED FIVE OR SIX OF THESE 5296 03:59:18,435 --> 03:59:21,238 POSTERS HERE. 5297 03:59:21,238 --> 03:59:22,506 RAISING AWARENESS FOR RARE 5298 03:59:22,506 --> 03:59:23,373 DISEASES AND THE PEOPLE THEY 5299 03:59:23,373 --> 03:59:26,343 EFFECT DRIVING HOME THE MESSAGE 5300 03:59:26,343 --> 03:59:28,312 THAT RARE DISEASES ARE IN FACT 5301 03:59:28,312 --> 03:59:30,047 NOT RARE. 5302 03:59:30,047 --> 03:59:32,449 WE HAD HARD COPIES OF THE 5303 03:59:32,449 --> 03:59:34,484 POSTERS FOR THE 2019 RARE 5304 03:59:34,484 --> 03:59:36,653 DISEASE DAY AND THEY'RE STILL 5305 03:59:36,653 --> 03:59:37,221 AVAILABLE ON THE WEBSITE AS 5306 03:59:37,221 --> 03:59:38,655 WELL. 5307 03:59:38,655 --> 03:59:43,360 SO THESE WINNERS WERE 5308 03:59:43,360 --> 03:59:44,895 EXCEPTIONAL PIECES BUT AS YOU 5309 03:59:44,895 --> 03:59:46,330 SAW WITH OTHER SUBMISSIONS 5310 03:59:46,330 --> 03:59:50,500 DURING THE CHALLENGES AND FROM 5311 03:59:50,500 --> 03:59:54,871 ANECDOTAL EXPERIENCE AS WELL 5312 03:59:54,871 --> 03:59:56,373 PATIENT ADVOCACY GROUPS AND 5313 03:59:56,373 --> 03:59:58,375 PARENTS APPROACH RARE DISEASES A 5314 03:59:58,375 --> 04:00:00,310 LOT OF THE TIME SINGLE DISEASE 5315 04:00:00,310 --> 04:00:02,512 AT A TIME WITH AN UNDERSTANDABLE 5316 04:00:02,512 --> 04:00:04,248 APPROACH ON GETTING THEIR 5317 04:00:04,248 --> 04:00:05,682 SPECIFIC RARE DISEASE ATTENTION, 5318 04:00:05,682 --> 04:00:08,485 TREATMENTS, A CURE, ETCETERA. 5319 04:00:08,485 --> 04:00:10,053 AND WE THINK THIS IS 5320 04:00:10,053 --> 04:00:12,723 CONSEQUENTLY LED TO A PUBLIC 5321 04:00:12,723 --> 04:00:14,491 PERCEPTION THAT RARE DISEASES 5322 04:00:14,491 --> 04:00:15,959 ARE INDIVIDUAL PROBLEMS TO BE 5323 04:00:15,959 --> 04:00:16,827 ADDRESSED AND RATHER THAN A 5324 04:00:16,827 --> 04:00:19,563 COLLECTIVE. 5325 04:00:19,563 --> 04:00:21,665 SO WE WOULD LIKE TO THINK ABOUT 5326 04:00:21,665 --> 04:00:25,535 THIS IN TERMS OF HOW CANCER HAS 5327 04:00:25,535 --> 04:00:27,337 PORTRAYED THEIR MESSAGING AND 5328 04:00:27,337 --> 04:00:29,840 CONTRAST HOW THEY MARK CANCERS 5329 04:00:29,840 --> 04:00:32,376 AS COLLECTIVE ITEM INSTEAD OF A 5330 04:00:32,376 --> 04:00:34,511 DIVERSE SET OF INDIVIDUAL 5331 04:00:34,511 --> 04:00:34,845 DISEASES. 5332 04:00:34,845 --> 04:00:35,912 CONTRAST THAT WITH THE STARK 5333 04:00:35,912 --> 04:00:37,281 TRUTH IN RARE DISEASES. 5334 04:00:37,281 --> 04:00:40,517 AS YOU KNOW THERE'S MORE THAN 5335 04:00:40,517 --> 04:00:42,052 10,000 RARE DISEASES WITH 5% 5336 04:00:42,052 --> 04:00:42,653 HAVING TREATMENTS. 5337 04:00:42,653 --> 04:00:44,621 IF WE APPROACH THEM ONE AT A 5338 04:00:44,621 --> 04:00:46,356 TIME WE WON'T MEET OUR GOALS OF 5339 04:00:46,356 --> 04:00:49,960 GETTING MORE TREATMENTS TO ALL 5340 04:00:49,960 --> 04:00:50,394 PEOPLE MORE QUICKLY. 5341 04:00:50,394 --> 04:00:51,328 HOW CAN WE CHANGE? 5342 04:00:51,328 --> 04:00:54,298 HOW CAN WE CHANGE THE MESSAGING 5343 04:00:54,298 --> 04:00:55,799 AROUND RARE DISEASES AS 5344 04:00:55,799 --> 04:00:56,500 SOMETHING TO BE APPROACHED 5345 04:00:56,500 --> 04:01:00,070 COLLECTIVELY MANY AT A TIME? 5346 04:01:00,070 --> 04:01:03,907 TO GIVE HISTORY ON HOW MESSAGING 5347 04:01:03,907 --> 04:01:06,076 AROUND RARE DISEASES BEGAN, IT 5348 04:01:06,076 --> 04:01:09,246 STARTED TO GAIN TRACTION IN THE 5349 04:01:09,246 --> 04:01:10,814 1980s WHEN THE DRUG ACT CAME 5350 04:01:10,814 --> 04:01:12,916 INTO EFFECT IN 1983 AND 5351 04:01:12,916 --> 04:01:14,518 FOLLOWING THAT UMBRELLA 5352 04:01:14,518 --> 04:01:19,256 ORGANIZATIONS WERE FOUNDED. 5353 04:01:19,256 --> 04:01:24,728 SOON AFTER NIH ESTABLISHED ORD 5354 04:01:24,728 --> 04:01:27,064 NOW DRDRI AND THERE'S BEEN 40 5355 04:01:27,064 --> 04:01:28,765 YEARS OF SOME FORM OF MESSAGING 5356 04:01:28,765 --> 04:01:29,700 AROUND RARE DISEASE AND RESEARCH 5357 04:01:29,700 --> 04:01:32,269 AND THAT MESSAGE HAS NOT BEEN 5358 04:01:32,269 --> 04:01:34,871 UNIFIED LUKE OUR CANCER 5359 04:01:34,871 --> 04:01:35,205 COUNTERPARTS. 5360 04:01:35,205 --> 04:01:37,774 IT'S HAD IMPLICATIONS ON THE 5361 04:01:37,774 --> 04:01:38,508 FUNDING RECEIVED FOR RARE 5362 04:01:38,508 --> 04:01:43,814 DISEASE RESEARCH. 5363 04:01:43,814 --> 04:01:46,750 SO WE PROPOSED THIS CONCEPT AND 5364 04:01:46,750 --> 04:01:49,252 ITERATION OF THE CHALLENGE TO DO 5365 04:01:49,252 --> 04:01:50,454 JUST THAT. 5366 04:01:50,454 --> 04:01:52,789 WE HOPE TO ONE, RAISE AWARENESS 5367 04:01:52,789 --> 04:01:54,491 FOR RARE DISEASES AND THE PEOPLE 5368 04:01:54,491 --> 04:01:55,759 THEY EFFECT AND HIGHLIGHT THE 5369 04:01:55,759 --> 04:01:57,561 NEED FOR CROSS-CUTTING RESEARCH 5370 04:01:57,561 --> 04:02:00,964 AND DEVELOPMENT OF NEW TREATMENT 5371 04:02:00,964 --> 04:02:02,766 USING MULTIDISEASE MODEL AND 5372 04:02:02,766 --> 04:02:04,801 ENGAGEMENT WITH THE RARE DISEASE 5373 04:02:04,801 --> 04:02:05,202 COMMUNITY. 5374 04:02:05,202 --> 04:02:06,503 SO WHAT'S DIFFERENT WITH THIS 5375 04:02:06,503 --> 04:02:07,537 ITERATION OF THE CHALLENGE? 5376 04:02:07,537 --> 04:02:09,239 THIS FOCUS OF THE CHALLENGE WILL 5377 04:02:09,239 --> 04:02:10,941 BE ON RAISING AWARENESS FOR 5378 04:02:10,941 --> 04:02:11,975 DEVELOPING TREATMENT 5379 04:02:11,975 --> 04:02:13,176 TECHNOLOGIES FOR MULTIPLE RARE 5380 04:02:13,176 --> 04:02:14,478 DISEASES AT A TIME. 5381 04:02:14,478 --> 04:02:16,113 AS WE SEE THERE'S A LACK OF 5382 04:02:16,113 --> 04:02:16,913 MESSAGING AND PUBLIC 5383 04:02:16,913 --> 04:02:19,516 UNDERSTANDING OF THE IMPORTANCE 5384 04:02:19,516 --> 04:02:22,919 OF ADDRESSING MANY DISEASES AT A 5385 04:02:22,919 --> 04:02:23,320 TIME. 5386 04:02:23,320 --> 04:02:25,622 THE GAPS THE CHALLENGE WILL 5387 04:02:25,622 --> 04:02:26,957 ADDRESS ARE FIRST INCREASING 5388 04:02:26,957 --> 04:02:28,892 EDUCATIONAL OUTREACH TO THE 5389 04:02:28,892 --> 04:02:30,527 PUBLIC. 5390 04:02:30,527 --> 04:02:32,896 ARTISTIC REPRESENTATIONS CAN 5391 04:02:32,896 --> 04:02:35,399 HELP EDUCATE THE LAY PUBLIC AND 5392 04:02:35,399 --> 04:02:36,032 HEALTH CARE PROFESSIONALS AND 5393 04:02:36,032 --> 04:02:37,901 POLICY MAKE ABOUT THE IMPACT OF 5394 04:02:37,901 --> 04:02:40,137 RARE DISEASES ON PATIENTS AND 5395 04:02:40,137 --> 04:02:42,906 THEIR FAMILIES AND AMPLIFY THE 5396 04:02:42,906 --> 04:02:44,174 PATIENT VOICE PARTICULARLY 5397 04:02:44,174 --> 04:02:45,409 WITHIN THE REALM OF RARE 5398 04:02:45,409 --> 04:02:47,811 DISEASES AND THE VOICES OF 5399 04:02:47,811 --> 04:02:50,213 PATIENTS AND FAMILIES ARE 5400 04:02:50,213 --> 04:02:50,514 INVALUABLE. 5401 04:02:50,514 --> 04:02:53,417 THE INDIVIDUALS OFFER INSIGHTS 5402 04:02:53,417 --> 04:02:54,484 ON LIVED EXPERIENCE CRUCIAL FOR 5403 04:02:54,484 --> 04:02:57,888 SHAPING POLICIES AND ADVANCING 5404 04:02:57,888 --> 04:02:58,155 RESEARCH. 5405 04:02:58,155 --> 04:03:01,158 BY AMPLIFYING THE PATIENT VOICE 5406 04:03:01,158 --> 04:03:01,992 THROUGH ACTIVE GOVERNMENT 5407 04:03:01,992 --> 04:03:04,728 ENGAGEMENT WE CAN FOSTER AN 5408 04:03:04,728 --> 04:03:07,297 ENVIRONMENT NOT ONLY MORE 5409 04:03:07,297 --> 04:03:10,500 RESPONSIVE BUT MORE 5410 04:03:10,500 --> 04:03:14,504 COMPASSIONATE AND INCLUSIVE. 5411 04:03:14,504 --> 04:03:17,541 THE OBJECTIVE TO COMMUNICATE AND 5412 04:03:17,541 --> 04:03:20,010 EDUCATE THE PUBLIC THROUGH ART 5413 04:03:20,010 --> 04:03:21,611 DISSEMINATED ON VARIOUS 5414 04:03:21,611 --> 04:03:23,613 PLATFORMS ABOUT RARE DISEASE. 5415 04:03:23,613 --> 04:03:24,648 SLAFT PUB LUCK PERCEPTION IN HOW 5416 04:03:24,648 --> 04:03:27,350 WE THINK ABOUT THE RARE DISEASE 5417 04:03:27,350 --> 04:03:28,885 PROBLEM COLLECTED INSTEAD OF 5418 04:03:28,885 --> 04:03:30,487 INDIVIDUAL AND MAKE RARE DISEASE 5419 04:03:30,487 --> 04:03:31,822 DRUG DEVELOPMENT NOR EFFICIENT 5420 04:03:31,822 --> 04:03:33,390 BRINGING ATTENTION TO RARE 5421 04:03:33,390 --> 04:03:36,226 DISEASES TO GAIN MORE MEDICAL 5422 04:03:36,226 --> 04:03:38,495 RESEARCH INTERESTS AND SUPPORT 5423 04:03:38,495 --> 04:03:40,697 THERE BE IMPROVING LIVES. 5424 04:03:40,697 --> 04:03:42,499 CHALLENGE OFFERS AN OPPORTUNITY 5425 04:03:42,499 --> 04:03:45,502 FOR PATIENTS TO BE FUNDED BY 5426 04:03:45,502 --> 04:03:45,735 NCATS. 5427 04:03:45,735 --> 04:03:48,205 IT'S STILL FUNDING. 5428 04:03:48,205 --> 04:03:51,107 THE KEY AREAS OF THE CHALLENGE 5429 04:03:51,107 --> 04:03:53,977 ARE THAT THE FOCUS IS ALAINED 5430 04:03:53,977 --> 04:03:56,213 WITH OUR NCATS STRATEGIC PLAN WE 5431 04:03:56,213 --> 04:03:58,381 SPEND TIME TALKING ABOUT TODAY 5432 04:03:58,381 --> 04:04:00,250 AND GOAL 1 OF APPLYING 5433 04:04:00,250 --> 04:04:03,119 APPROACHES TO FOSTER THE 5434 04:04:03,119 --> 04:04:04,054 IDENTIFICATION, DEVELOPMENT OF 5435 04:04:04,054 --> 04:04:06,022 AND ACCESS TO MORE TREATMENTS 5436 04:04:06,022 --> 04:04:08,258 AND THE THEME OF DEVELOPING 5437 04:04:08,258 --> 04:04:09,693 TREATMENT STRATEGIES TO ADDRESS 5438 04:04:09,693 --> 04:04:14,197 MULTIPLE DISEASES AT A TIME. 5439 04:04:14,197 --> 04:04:19,469 THE CHALLENGE COULD IMPACT THE 5440 04:04:19,469 --> 04:04:21,371 COMMUNITY WITH COLLABORATION AND 5441 04:04:21,371 --> 04:04:23,206 HIGHLIGHTING POTENTIAL FUNDING 5442 04:04:23,206 --> 04:04:24,274 OPPORTUNITIES, BUILDING A NEW 5443 04:04:24,274 --> 04:04:25,809 JERSEY BASE OF HOW THE COMMUNITY 5444 04:04:25,809 --> 04:04:27,544 IS APPROACHING THERAPIES FOR 5445 04:04:27,544 --> 04:04:29,779 MANY DISEASES AT A TIME AND 5446 04:04:29,779 --> 04:04:32,249 ENCOURAGING CROSS-DISCIPLINARY 5447 04:04:32,249 --> 04:04:35,619 RESEARCH WITH NOVEL PERSPECTIVES 5448 04:04:35,619 --> 04:04:42,459 AND PRO -- APPROACHES WE EXPECT 5449 04:04:42,459 --> 04:04:44,928 VARIOUS MEDIA TYPES LIKE SHORT 5450 04:04:44,928 --> 04:04:48,164 VIDEOS, POSTERS, INFOGRAPHICS AN 5451 04:04:48,164 --> 04:04:50,634 ANIMATED GRAPHICS AS A FEW 5452 04:04:50,634 --> 04:04:52,903 EXAMPLES. 5453 04:04:52,903 --> 04:04:56,406 IN REGARDS TO THE ONGOING 5454 04:04:56,406 --> 04:05:01,645 ACTIVITIES AND HOW THE CHALLENGE 5455 04:05:01,645 --> 04:05:09,252 FITS, MANY DISEASES IS A THEME 5456 04:05:09,252 --> 04:05:16,860 WITH MANY PROGRAMS AND IT MEANS 5457 04:05:16,860 --> 04:05:19,896 TO BROADCAST HOW IT'S PORTRAYED 5458 04:05:19,896 --> 04:05:21,665 AND ACCELERATED IN THE 5459 04:05:21,665 --> 04:05:21,932 COMMUNITY. 5460 04:05:21,932 --> 04:05:23,567 THE NCATS COMMUNICATIONS BRANCH 5461 04:05:23,567 --> 04:05:24,901 HAS HAD A CONSISTENT CAMPAIGN TO 5462 04:05:24,901 --> 04:05:27,504 EDUCATE THE COMMUNITY ABOUT RARE 5463 04:05:27,504 --> 04:05:28,872 DISEASES AND RAISE AWARENESS 5464 04:05:28,872 --> 04:05:29,139 GENERALLY. 5465 04:05:29,139 --> 04:05:32,008 THE CHALLENGE WOULD FIT IN WITH 5466 04:05:32,008 --> 04:05:33,510 THOSE EFFORTS REGARDING TAPPING 5467 04:05:33,510 --> 04:05:39,449 IN FOR SUGGESTS AND INPUT. 5468 04:05:39,449 --> 04:05:39,916 WHY NCATS? 5469 04:05:39,916 --> 04:05:43,720 IT'S SEEN AS THE HOME FOR RARE 5470 04:05:43,720 --> 04:05:46,489 DISEASE AT NIH AND AS PART OF 5471 04:05:46,489 --> 04:05:48,024 THE CHALLENGE WE COULD RAISE 5472 04:05:48,024 --> 04:05:49,960 TRUST GIVING THE COMMUNITY THE 5473 04:05:49,960 --> 04:05:51,394 ABILITY TO SHAPE THE RHETORIC 5474 04:05:51,394 --> 04:05:52,529 AROUND RARE DISEASES. 5475 04:05:52,529 --> 04:05:53,563 DEMONSTRATE THE VALUE OF THEIR 5476 04:05:53,563 --> 04:05:56,333 INPUT AND ENGAGEMENT AND AGAIN 5477 04:05:56,333 --> 04:05:58,201 THE THEME IS WELL INTEGRATED 5478 04:05:58,201 --> 04:06:01,838 WITH OUR STRATEGIC GOAL ONE THE 5479 04:06:01,838 --> 04:06:04,240 THEME OF DEVELOPING TREATMENT 5480 04:06:04,240 --> 04:06:04,975 STRATEGIES FOR ADDRESSING 5481 04:06:04,975 --> 04:06:06,142 DISEASES AT A TIME AND THE THEME 5482 04:06:06,142 --> 04:06:07,110 FOR ALL PEOPLE WHO HAVE A 5483 04:06:07,110 --> 04:06:12,549 VARIETY OF DISEASES. 5484 04:06:12,549 --> 04:06:15,752 THE IMPACT ON THE RESEARCH 5485 04:06:15,752 --> 04:06:16,853 COMMUNITY. 5486 04:06:16,853 --> 04:06:18,355 WE SEE THE CHALLENGE FOSTERING 5487 04:06:18,355 --> 04:06:19,723 INNOVATION AND COLLABORATION AND 5488 04:06:19,723 --> 04:06:21,291 INCREASE AWARENESS AND HIGHLIGHT 5489 04:06:21,291 --> 04:06:23,526 POTENTIAL FUNDING OPPORTUNITIES, 5490 04:06:23,526 --> 04:06:25,895 ACT AS A TOUCH POINT TO BUILD 5491 04:06:25,895 --> 04:06:28,098 THE KNOWLEDGE BASE HOW THE 5492 04:06:28,098 --> 04:06:29,399 ACOMMUNITY IS APPROACHING MANY 5493 04:06:29,399 --> 04:06:32,302 DISEASES AND RAISE AWARENESS 5494 04:06:32,302 --> 04:06:34,504 ABOUT NCATS' ROLE IN THE RARE 5495 04:06:34,504 --> 04:06:37,340 DISEASE COMMUNITY. 5496 04:06:37,340 --> 04:06:37,574 SUCCESS. 5497 04:06:37,574 --> 04:06:39,009 WE SEE SUCCESS LOOKING AT 5498 04:06:39,009 --> 04:06:39,943 GREATER THAN 30 SUBMISSIONS 5499 04:06:39,943 --> 04:06:41,044 WHICH IS MORE THAN WE HAVE IN 5500 04:06:41,044 --> 04:06:42,078 THE PAST. 5501 04:06:42,078 --> 04:06:44,948 WE'D LIKE TO SEE INCREASED 5502 04:06:44,948 --> 04:06:45,949 VISITS TO THE NCATS RARE DISEASE 5503 04:06:45,949 --> 04:06:50,487 WEB PANEL TO REFLECT THE 5504 04:06:50,487 --> 04:06:53,923 INCREASED AWARENESS AND USE THE 5505 04:06:53,923 --> 04:06:57,160 SUBMISSIONS AS CREATIVE 5506 04:06:57,160 --> 04:06:59,529 MECHANISMS WORKING TOGETHER AND 5507 04:06:59,529 --> 04:07:00,864 PUSH THE NARRATIVES THAT RARE 5508 04:07:00,864 --> 04:07:01,998 DISEASE CAN BE ADDRESSED MANY AT 5509 04:07:01,998 --> 04:07:05,635 A TIME AND HAVE WINNERS AND 5510 04:07:05,635 --> 04:07:06,503 HONORABLE MENTIONS SHARED ON 5511 04:07:06,503 --> 04:07:08,104 SOCIAL MEDIA AS PART OF THE 5512 04:07:08,104 --> 04:07:09,639 AWARENESS CAMPAIGN AND 5513 04:07:09,639 --> 04:07:10,206 ULTIMATELY HAVE INCREASED 5514 04:07:10,206 --> 04:07:16,012 COLLABORATION AND NETWORKING. 5515 04:07:16,012 --> 04:07:19,115 SO, SO I'LL END WITH A FEW OVER 5516 04:07:19,115 --> 04:07:21,918 ARCHING AREAS OF IMPACT. 5517 04:07:21,918 --> 04:07:24,087 WE WANT TO HIGHLIGHT NCATS ROLE 5518 04:07:24,087 --> 04:07:25,288 IN THE RARE DISEASE COMMUNITY AS 5519 04:07:25,288 --> 04:07:28,191 STATED WITH THE HOME FOR RARE 5520 04:07:28,191 --> 04:07:29,592 DISEASES AT NIH. 5521 04:07:29,592 --> 04:07:30,560 AS A GOVERNMENT RESEARCH AGENCY 5522 04:07:30,560 --> 04:07:33,363 WE WANT TO PUT THE MESSAGE OUT 5523 04:07:33,363 --> 04:07:36,366 HOW IMPORTANT THE PATIENT VOICE 5524 04:07:36,366 --> 04:07:39,402 IS AND AMPLIFY THE PATIENT VOICE 5525 04:07:39,402 --> 04:07:42,706 AND INCREASE AWARENESS AND 5526 04:07:42,706 --> 04:07:46,176 VISIBILITY OF RARE DISEASE TO 5527 04:07:46,176 --> 04:07:50,480 GAIN MORE INTEREST AND SUPPORT 5528 04:07:50,480 --> 04:07:51,281 THERE BE IMPROVING LIVES. 5529 04:07:51,281 --> 04:07:52,816 IN THE RARE DISEASE SPACE 5530 04:07:52,816 --> 04:07:53,917 COMMUNITY IS THE DRIVER OF 5531 04:07:53,917 --> 04:07:54,484 RESEARCH. 5532 04:07:54,484 --> 04:07:56,519 WE SEE THEM AS THE ONCE WHO 5533 04:07:56,519 --> 04:07:57,921 APPROACH SCIENTISTS AND SAY HEY, 5534 04:07:57,921 --> 04:08:00,490 MY DAUGHTER HAS THIS DISEASE AND 5535 04:08:00,490 --> 04:08:01,925 I'VE DONE THIS AMOUNT OF 5536 04:08:01,925 --> 04:08:02,559 RESEARCH AND THINK YOU'RE LAB 5537 04:08:02,559 --> 04:08:05,195 SPECIFICALLY CAN HELP ME. 5538 04:08:05,195 --> 04:08:06,496 THIS CHALLENGE IS SUCH A 5539 04:08:06,496 --> 04:08:08,064 MEANINGFUL WAY TO COLLABORATE 5540 04:08:08,064 --> 04:08:09,132 WITH THE RARE DISEASE COMMUNITY 5541 04:08:09,132 --> 04:08:11,501 AND CREATE A MESSAGING CAMPAIGN 5542 04:08:11,501 --> 04:08:14,037 TOGETHER WHICH IS WHAT I'M MOST 5543 04:08:14,037 --> 04:08:14,704 EXCITED ABOUT WITH THIS 5544 04:08:14,704 --> 04:08:18,274 CHALLENGE AND ULTIMATE CHANGE 5545 04:08:18,274 --> 04:08:19,909 THE PUBLIC PERCEPTION OF RARE 5546 04:08:19,909 --> 04:08:24,380 DISEASES BRINGING MORE TRE 5547 04:08:24,380 --> 04:08:25,582 TREATMENTS TO MORE PEOPLE MORE 5548 04:08:25,582 --> 04:08:25,815 QUICKLY. 5549 04:08:25,815 --> 04:08:27,617 I'LL END WITH OUR DISCUSSION 5550 04:08:27,617 --> 04:08:27,817 SLIDE. 5551 04:08:27,817 --> 04:08:29,686 ALONG WITH THE GENERAL QUESTIONS 5552 04:08:29,686 --> 04:08:32,822 WE HAVE FOR COUNCIL WE HAVE TWO 5553 04:08:32,822 --> 04:08:33,256 SPECIFIC QUESTION. 5554 04:08:33,256 --> 04:08:38,027 THE FIRST BEING IF THERE'S ANY 5555 04:08:38,027 --> 04:08:39,963 SUGGESTIONS FOR PATIENT ADVOCACY 5556 04:08:39,963 --> 04:08:45,268 GROUPS OR ORGANIZATIONS NOTIFY 5557 04:08:45,268 --> 04:08:45,935 TO COORDINATE SUBMISSION AND IF 5558 04:08:45,935 --> 04:08:48,638 YOU HAVE SUGGESTIONS HOW TO SET 5559 04:08:48,638 --> 04:08:51,941 UP THE CHALLENGE WEBSITE WITH 5560 04:08:51,941 --> 04:08:54,043 THE DESCRIPTION TO GET RESPONSES 5561 04:08:54,043 --> 04:08:56,513 THAT GET AT THE COLLECTIVE 5562 04:08:56,513 --> 04:08:59,048 APPROACH INSTEAD OF THE PREVIOUS 5563 04:08:59,048 --> 04:09:00,850 RESPONSES WE GOT BEFORE THAT 5564 04:09:00,850 --> 04:09:03,019 WERE MORE TARGETED ON INDIVIDUAL 5565 04:09:03,019 --> 04:09:04,120 APPROACH. 5566 04:09:04,120 --> 04:09:05,355 AND OF COURSE ANY OTHER 5567 04:09:05,355 --> 04:09:06,489 COMMENTS. 5568 04:09:06,489 --> 04:09:14,497 I'LL END THERE. 5569 04:09:14,497 --> 04:09:17,033 >> THANK YOU. 5570 04:09:17,033 --> 04:09:20,069 STARTING WITH AMY. 5571 04:09:20,069 --> 04:09:22,505 >> YOU PROBABLY WON'T BE 5572 04:09:22,505 --> 04:09:24,007 SURPRISED BUT I LOVE THIS. 5573 04:09:24,007 --> 04:09:33,883 IN ALL SINCERITY I THINK FULL 5574 04:09:33,883 --> 04:09:36,553 DISCLOSURE I WAS PART OF TWO AND 5575 04:09:36,553 --> 04:09:37,587 THE FACT THAT AN PUBLIC AGENCY 5576 04:09:37,587 --> 04:09:40,056 WANT TO DO A CAMPAIGN ABOUT THE 5577 04:09:40,056 --> 04:09:45,728 FACT THAT RARE DISEASE IS A 5578 04:09:45,728 --> 04:09:47,063 PUBLIC HEALTH CRISIS AND THAT IN 5579 04:09:47,063 --> 04:09:50,834 AND OF ITSELF IS AMAZING. 5580 04:09:50,834 --> 04:09:56,339 THAT SAID I THINK THE FACT THAT 5581 04:09:56,339 --> 04:09:58,141 THE NATIONAL ECONOMIC BURDEN OF 5582 04:09:58,141 --> 04:09:59,809 RARE DISEASE STUDY WAS CONDUCT 5583 04:09:59,809 --> 04:10:00,877 AND INFORMED BY THE RARE DISEASE 5584 04:10:00,877 --> 04:10:01,144 COMMUNITY. 5585 04:10:01,144 --> 04:10:04,547 FOR THOSE WHO MAY NOT BE AWARE 5586 04:10:04,547 --> 04:10:08,518 THE FIRST STUDY ON THE SLIDE 5587 04:10:08,518 --> 04:10:09,586 INCLUDED DIRECT MEDICAL COST 5588 04:10:09,586 --> 04:10:11,588 DATA AND INDIRECT AND 5589 04:10:11,588 --> 04:10:13,990 NON-MEDICAL DATA. 5590 04:10:13,990 --> 04:10:18,061 TO COLLECT THAT DATA INCLUDED A 5591 04:10:18,061 --> 04:10:20,163 SURVEY CREATED BY BIG COMMUNITY. 5592 04:10:20,163 --> 04:10:21,764 WE WORKED TOGETHER TO DEVELOP 5593 04:10:21,764 --> 04:10:23,600 THE SURVEY AND DATA ELEMENTS WE 5594 04:10:23,600 --> 04:10:27,704 WOULD DISSEMINATE THROUGHOUT THE 5595 04:10:27,704 --> 04:10:27,971 COMMUNITY. 5596 04:10:27,971 --> 04:10:29,606 AND DISSEMINATE IT TO THOSE 5597 04:10:29,606 --> 04:10:34,777 REGISTERED WITHIN THEIR 5598 04:10:34,777 --> 04:10:35,411 MEMBERSHIP. 5599 04:10:35,411 --> 04:10:40,083 THE TAGS DISSEMINATED IT AND 5600 04:10:40,083 --> 04:10:44,020 COLLECTED DATA TO WORK TO DO THE 5601 04:10:44,020 --> 04:10:46,155 DATA ANALYSIS AND USED THE 5602 04:10:46,155 --> 04:10:46,422 DATABASES. 5603 04:10:46,422 --> 04:10:47,724 THAT'S HOW THE STUDY WAS DONE. 5604 04:10:47,724 --> 04:10:52,762 AS WE DISSEMINATED THE FINDINGS 5605 04:10:52,762 --> 04:10:59,602 WE WORKED WITH MANY LEADERS TO 5606 04:10:59,602 --> 04:11:00,904 DO THE DISSEMINATION. 5607 04:11:00,904 --> 04:11:02,272 THE RARE DISEASE COMMUNITY HAS 5608 04:11:02,272 --> 04:11:05,241 BECOME VERY ADEPT AT 5609 04:11:05,241 --> 04:11:10,780 COMMUNICATING ABOUT THE IMPACT 5610 04:11:10,780 --> 04:11:14,183 OF THE COLLECTIVE ECONOMIC 5611 04:11:14,183 --> 04:11:14,684 BURDEN OF RARE DISEASE. 5612 04:11:14,684 --> 04:11:16,519 AND ALSO LEARNED BURDEN DOESN'T 5613 04:11:16,519 --> 04:11:19,622 MEAN IT'S A BURDEN TO HAVE A 5614 04:11:19,622 --> 04:11:20,356 LOVED ONE WITH RARE DISEASE BUT 5615 04:11:20,356 --> 04:11:21,925 FINANCIAL BURDEN. 5616 04:11:21,925 --> 04:11:23,459 IT'S A VERY DIFFERENT CLIMATE TO 5617 04:11:23,459 --> 04:11:25,595 THINK ABOUT PUTTING THIS OUT NOW 5618 04:11:25,595 --> 04:11:29,098 THAN IT WAS WHEN YOU DID IT THE 5619 04:11:29,098 --> 04:11:29,966 LAST TIME. 5620 04:11:29,966 --> 04:11:33,436 THEN THAT PAIRED WITH THE STUDY 5621 04:11:33,436 --> 04:11:38,508 NCATS LED AND PUBLISHED AND 5622 04:11:38,508 --> 04:11:40,276 OTHER OP-EDS. 5623 04:11:40,276 --> 04:11:41,811 WE'VE CHANGE THE WAY WE TALK 5624 04:11:41,811 --> 04:11:42,812 ABOUT RARE DISEASE IN THE U.S. 5625 04:11:42,812 --> 04:11:43,846 THAT'S THE FIRST THING. 5626 04:11:43,846 --> 04:11:48,117 THE OTHER THING IS AS FAR AS 5627 04:11:48,117 --> 04:11:49,652 PARTNERING MANY TAGS AS PART OF 5628 04:11:49,652 --> 04:11:53,823 THE WORK, US INCLUDED, WHO WOULD 5629 04:11:53,823 --> 04:11:55,325 BE EXCITED HELPING DISSEMINATE 5630 04:11:55,325 --> 04:11:56,359 AND PUSH THIS OUT. 5631 04:11:56,359 --> 04:11:59,996 I WOULD ALSO FLAG WE HELP 5632 04:11:59,996 --> 04:12:00,763 COORDINATE THE RARE DISEASE 5633 04:12:00,763 --> 04:12:06,369 CAUCUS AND ALSO LEAD A RARE 5634 04:12:06,369 --> 04:12:08,037 ARTIST CAMPAIGN EVERY YEAR AND 5635 04:12:08,037 --> 04:12:12,342 DURING RARE DISEASE WEEK MARRIED 5636 04:12:12,342 --> 04:12:13,409 TO YOUR RARE DISEASE DAY WE HAVE 5637 04:12:13,409 --> 04:12:17,613 A RARE ARTIST RECEPTION ON 5638 04:12:17,613 --> 04:12:18,614 CAPITOL HILL ATTENDED BY CAUCUS 5639 04:12:18,614 --> 04:12:23,119 MEMBERS AND THAT MAY BE A NICE 5640 04:12:23,119 --> 04:12:24,754 OPPORTUNITY TO HAVE WHOEVER THE 5641 04:12:24,754 --> 04:12:28,624 WINNER OF THE CHALLENGE TO 5642 04:12:28,624 --> 04:12:34,230 FEATURE THEIR ART. 5643 04:12:34,230 --> 04:12:44,774 THERE MAY BE NICE SYNERGIES AND 5644 04:12:46,509 --> 04:12:50,279 TALKING ABOUT RAISING THE SCO ON 5645 04:12:50,279 --> 04:12:53,916 YOUR WEB PAGES HAVING THEM 5646 04:12:53,916 --> 04:12:56,052 INCLUDED ON OUR WEB PAGES IS 5647 04:12:56,052 --> 04:12:58,187 ANOTHER PARTNER TO INCLUDE HERE. 5648 04:12:58,187 --> 04:12:58,788 THEY'RE INTERESTED IN THESE 5649 04:12:58,788 --> 04:12:59,856 PUBLIC HEALTH CAMPAIGNS AND 5650 04:12:59,856 --> 04:13:04,327 MAKING SURE PEOPLE KNOW RARE IS 5651 04:13:04,327 --> 04:13:05,495 NOT RARE. 5652 04:13:05,495 --> 04:13:07,230 THERE'S NATURAL PARTNERS TO 5653 04:13:07,230 --> 04:13:09,032 THINK OF. 5654 04:13:09,032 --> 04:13:09,565 AMAZING PROGRAM. 5655 04:13:09,565 --> 04:13:14,470 >> THANKS, ANNIE. 5656 04:13:14,470 --> 04:13:14,804 >> THANK YOU. 5657 04:13:14,804 --> 04:13:19,475 KELLY. 5658 04:13:19,475 --> 04:13:21,844 >> I'M SO EXCITED YOU'RE 5659 04:13:21,844 --> 04:13:22,478 AMPLIFYING THE VOICE OF THE 5660 04:13:22,478 --> 04:13:24,080 PATIENT IN THIS WAY AND HAVE A 5661 04:13:24,080 --> 04:13:25,014 TECHNICAL QUESTION. 5662 04:13:25,014 --> 04:13:28,718 WOULD YOU CONSIDER ALLOWING THE 5663 04:13:28,718 --> 04:13:30,219 SUBMISSIONS IN EN ALL THE MEDIA 5664 04:13:30,219 --> 04:13:32,121 THAT COULD HAVE A DIGITAL 5665 04:13:32,121 --> 04:13:34,791 COMPONENT TO BE MINTED RATHER 5666 04:13:34,791 --> 04:13:40,763 THAN SUBMITTED TO BECOME A 5667 04:13:40,763 --> 04:13:44,801 NON-FUNGIBLE TOKEN TO PRESERVE 5668 04:13:44,801 --> 04:13:46,102 THE PROPERTY RIGHTS OF THE 5669 04:13:46,102 --> 04:13:46,636 PEOPLE GENERATING THE ART? 5670 04:13:46,636 --> 04:13:50,473 >> GOOD QUESTION. 5671 04:13:50,473 --> 04:13:52,175 THE PAST TWO CHALLENGES WE HAD 5672 04:13:52,175 --> 04:13:54,277 SPECIFIC LANGUAGE THAT SAID WE 5673 04:13:54,277 --> 04:13:58,481 NOW OWN IT SO I DON'T KNOW HOW 5674 04:13:58,481 --> 04:14:02,485 WE'D GO ABOUT DOING IT FOR THIS 5675 04:14:02,485 --> 04:14:03,886 UPCOMING CHALLENGE. 5676 04:14:03,886 --> 04:14:11,160 >> ANNA IS OUR 5677 04:14:11,160 --> 04:14:11,561 CHIEF-LOOKER-INTO. 5678 04:14:11,561 --> 04:14:14,730 GREAT IDEA. 5679 04:14:14,730 --> 04:14:15,098 GREAT QUESTION. 5680 04:14:15,098 --> 04:14:22,472 WE'LL GET BACK TO YOU. 5681 04:14:22,472 --> 04:14:27,076 >> THANK YOU. 5682 04:14:27,076 --> 04:14:31,747 HAVE OUR FINAL DISCUSSANT IS 5683 04:14:31,747 --> 04:14:32,582 ROBIN. 5684 04:14:32,582 --> 04:14:33,049 >> THANKS. 5685 04:14:33,049 --> 04:14:34,517 I SUPPORT THIS LOVELY CONCEPT 5686 04:14:34,517 --> 04:14:41,390 AND IT'S NICE TO END THE DAY ON 5687 04:14:41,390 --> 04:14:44,727 AN UPBEAT CONCEPT. 5688 04:14:44,727 --> 04:14:46,329 I'LL PUSH YOU A LITTLE BIT GIVEN 5689 04:14:46,329 --> 04:14:47,563 IT'S YOUR THIRD ROUND OF DOING 5690 04:14:47,563 --> 04:14:49,432 THIS AND HELP YOU THINK THROUGH 5691 04:14:49,432 --> 04:14:52,635 HOW TO EVALUATE IT IN TERMS OF 5692 04:14:52,635 --> 04:14:54,403 REACHING DIVERSITY BECAUSE YOU 5693 04:14:54,403 --> 04:14:57,073 DON'T WANT THE SAME PEOPLE 5694 04:14:57,073 --> 04:14:59,876 SUBMITTING AND HAVE YOU 5695 04:14:59,876 --> 04:15:05,114 BROADENED YOUR REACH AND WHO'S 5696 04:15:05,114 --> 04:15:07,016 INCLUDED AND EXCLUDED AND 5697 04:15:07,016 --> 04:15:10,486 LOOKING AT THAT FROM MULTIPLE 5698 04:15:10,486 --> 04:15:11,487 DIMENSIONS WHAT ARE DISEASES 5699 04:15:11,487 --> 04:15:13,856 THAT ALWAYS COME UP AND 5700 04:15:13,856 --> 04:15:15,791 OVERREPRESENTED. 5701 04:15:15,791 --> 04:15:17,793 WHO WITHIN THE DISEASE GROUPS 5702 04:15:17,793 --> 04:15:19,562 YOU WANT IT TALK ABOUT 5703 04:15:19,562 --> 04:15:20,930 MINORITIZED COMMUNITIES HAVING 5704 04:15:20,930 --> 04:15:22,899 FINANCIAL TOXICITY FOR RARE 5705 04:15:22,899 --> 04:15:24,133 DISEASE AS EXCESSIVE. 5706 04:15:24,133 --> 04:15:27,236 MAYBE MAKING AN EFFORT TO 5707 04:15:27,236 --> 04:15:30,406 BROWEDEN THE REACH THIS TIME TO 5708 04:15:30,406 --> 04:15:32,942 GET -- BROADEN THE REACH TO GET 5709 04:15:32,942 --> 04:15:34,810 THE UNSEEN ONES AND ELEVATE 5710 04:15:34,810 --> 04:15:35,278 THEM. 5711 04:15:35,278 --> 04:15:36,746 >> YEAH. 5712 04:15:36,746 --> 04:15:42,485 I APPRECIATE THAT SUGGESTION. 5713 04:15:42,485 --> 04:15:43,953 IT'S SOMETHING WE WILL CONSIDER 5714 04:15:43,953 --> 04:15:45,555 WHEN WE'RE PLANNING THE 5715 04:15:45,555 --> 04:15:46,489 PROMOTION AND DISSEMINATION OF 5716 04:15:46,489 --> 04:15:47,290 THE CHALLENGE. 5717 04:15:47,290 --> 04:15:53,296 I THINK WE ALSO BROUGHT UP 5718 04:15:53,296 --> 04:15:55,598 INTERNATIONAL EFFORTS AS WELL. 5719 04:15:55,598 --> 04:15:56,933 PJ'S A PART OF. 5720 04:15:56,933 --> 04:15:58,034 WE HAD CONVERSATION ABOUT RARE 5721 04:15:58,034 --> 04:15:59,569 DISEASE DISEASE AND EXPANDING 5722 04:15:59,569 --> 04:16:00,203 THE REACH. 5723 04:16:00,203 --> 04:16:02,738 I THINK SUGGESTIONS MADE IN THE 5724 04:16:02,738 --> 04:16:05,308 CONVERSATION COULD PLAY IN THE 5725 04:16:05,308 --> 04:16:08,611 CHALLENGE AS WELL. 5726 04:16:08,611 --> 04:16:10,479 >> WITH THE INTERNATIONAL 5727 04:16:10,479 --> 04:16:13,950 APPROACHES WE CAN EXPAND TO 5728 04:16:13,950 --> 04:16:14,584 INTERNATIONAL GROUPS BUT THEY 5729 04:16:14,584 --> 04:16:17,119 WILL NOT BE ELIGIBLE TO RECEIVE 5730 04:16:17,119 --> 04:16:19,322 A PRIZE BUT WOULD STILL BE 5731 04:16:19,322 --> 04:16:22,491 ELIGIBLE TO SUBMIT. 5732 04:16:22,491 --> 04:16:24,260 >> AND NOT TO RECEIVE THE 5733 04:16:24,260 --> 04:16:27,330 FINANCIAL PRIZE BUT IF THEY WERE 5734 04:16:27,330 --> 04:16:30,399 TO WIN, WE COULD TRAVEL THEM TO 5735 04:16:30,399 --> 04:16:32,001 SPEAK AT RARE DISEASE DAY. 5736 04:16:32,001 --> 04:16:33,402 >> THERE'S AN INTERNATIONAL 5737 04:16:33,402 --> 04:16:34,503 BURDEN OF RARE DISEASE STUDY 5738 04:16:34,503 --> 04:16:38,507 ABOUT TO BE SUBMITTED FOR 5739 04:16:38,507 --> 04:16:39,875 PUBLICATION. 5740 04:16:39,875 --> 04:16:41,077 WE'VE BEEN PARTNERING WITH 5741 04:16:41,077 --> 04:16:51,454 OTHERS ON THAT STUDY. 5742 04:16:53,256 --> 04:16:56,092 >> WE'D LOVE AN ON TIME EARLY 5743 04:16:56,092 --> 04:16:56,292 COPY. 5744 04:16:56,292 --> 04:16:58,094 >> WE WOULD. 5745 04:16:58,094 --> 04:17:02,465 >> OR SAME TIME. 5746 04:17:02,465 --> 04:17:02,965 OKAY. 5747 04:17:02,965 --> 04:17:05,334 I TOOK OVER. 5748 04:17:05,334 --> 04:17:08,771 YOU'RE DOING GREAT. 5749 04:17:08,771 --> 04:17:09,905 WE'RE DONE. 5750 04:17:09,905 --> 04:17:10,773 >> ALL RIGHT. 5751 04:17:10,773 --> 04:17:11,340 IF THERE'S NO ADDITIONAL 5752 04:17:11,340 --> 04:17:12,441 DISCUSSION CAN I HAVE A MOTION 5753 04:17:12,441 --> 04:17:15,544 TO APPROVE THE LAST CONCEPT OF 5754 04:17:15,544 --> 04:17:17,613 THE DAY. 5755 04:17:17,613 --> 04:17:19,682 SECOND? 5756 04:17:19,682 --> 04:17:21,884 ALL IN FAVOR? 5757 04:17:21,884 --> 04:17:22,485 ANY ABSTENTIONS? 5758 04:17:22,485 --> 04:17:23,719 WITH THAT THE LAST CONCEPT OF 5759 04:17:23,719 --> 04:17:26,489 THE DAY IS APPROVED. 5760 04:17:26,489 --> 04:17:33,362 THANK YOU VERY MUCH. 5761 04:17:33,362 --> 04:17:33,696 >> OKAY. 5762 04:17:33,696 --> 04:17:36,932 I THINK THAT DOES IT FOR THE DAY 5763 04:17:36,932 --> 04:17:37,867 EXCEPT FOR ANOTHER HOUR OF 5764 04:17:37,867 --> 04:17:39,902 PRESENTATION -- JUST KIDDING. 5765 04:17:39,902 --> 04:17:43,639 I WANTED TO JUST REMIND YOU TO 5766 04:17:43,639 --> 04:17:44,874 FILL OUT YOUR FORMS. 5767 04:17:44,874 --> 04:17:50,379 MAKE THE COUNCIL TEAM HAS THEM. 5768 04:17:50,379 --> 04:17:52,515 PLEASE ALSO GIVE YOUR BADGES 5769 04:17:52,515 --> 04:17:54,483 BACK TO THE FRONT DESK. 5770 04:17:54,483 --> 04:17:55,251 WE RECYCLE THOSE. 5771 04:17:55,251 --> 04:17:58,487 AND ALSO I WANT TO TAKE A MOMENT 5772 04:17:58,487 --> 04:18:00,656 TO THANK AGAIN THE COUNCIL TEAM 5773 04:18:00,656 --> 04:18:02,058 FOR PREPARING FOR TODAY. 5774 04:18:02,058 --> 04:18:03,759 I KNOW THIS IS ALWAYS A BIG 5775 04:18:03,759 --> 04:18:06,662 MEETING TO PREPARE FOR. 5776 04:18:06,662 --> 04:18:10,499 JUST THANK YOU AGAIN FOR THE 5777 04:18:10,499 --> 04:18:12,101 COUNCIL'S WORK. 5778 04:18:12,101 --> 04:18:13,903 THANK YOU FOR THE GREAT CONCEPT 5779 04:18:13,903 --> 04:18:14,203 DISCUSSIONS. 5780 04:18:14,203 --> 04:18:17,006 THIS IS REALLY WHAT'S SO 5781 04:18:17,006 --> 04:18:20,042 IMPORTANT AND WHAT MAKES NCATS 5782 04:18:20,042 --> 04:18:22,478 SO SUCCESSFUL. 5783 04:18:22,478 --> 04:18:25,114 I APPRECIATE YOUR PARTICIPATION 5784 04:18:25,114 --> 04:18:25,314 TODAY. 5785 04:18:25,314 --> 04:18:26,182 ALSO, TWO MORE THINGS. 5786 04:18:26,182 --> 04:18:28,551 ONE IS I WANT TO THANK OUR 5787 04:18:28,551 --> 04:18:31,120 COUNCIL FOR YOUR TREMENDOUS 5788 04:18:31,120 --> 04:18:32,188 LEADERSHIP AND SEEING WHAT'S 5789 04:18:32,188 --> 04:18:32,455 POSSIBLE. 5790 04:18:32,455 --> 04:18:37,626 AND HELPING US TO DRIVE NCATS I 5791 04:18:37,626 --> 04:18:39,495 THINK MORE THAN WHERE WE THINK 5792 04:18:39,495 --> 04:18:41,697 WE CAN EVEN GO. 5793 04:18:41,697 --> 04:18:43,199 THE LETTER YOU SENT US THIS WEEK 5794 04:18:43,199 --> 04:18:46,936 WAS A BIG WAY OF SHOWING THIS. 5795 04:18:46,936 --> 04:18:48,971 AND I FEEL VERY FORTUNATE TO 5796 04:18:48,971 --> 04:18:51,874 HAVE SUCH A DYNAMIC COUNCIL 5797 04:18:51,874 --> 04:18:53,342 MEMBERS AND TEAM WHO REALLY 5798 04:18:53,342 --> 04:18:54,810 BRINGS IT EVERY TIME. 5799 04:18:54,810 --> 04:18:59,215 SO THANK YOU FOR DOING THAT. 5800 04:18:59,215 --> 04:19:04,754 AND ANNIE, JUST ANOTHER REMINDER 5801 04:19:04,754 --> 04:19:06,489 OR PERHAPS THE REMINDER IS 5802 04:19:06,489 --> 04:19:10,459 YOU'RE NOT GOING TO GO FAR. 5803 04:19:10,459 --> 04:19:10,960 WE KNOW WHERE YOU LIVE. 5804 04:19:10,960 --> 04:19:11,627 BUT WE'LL MISS YOU AND THOUGH 5805 04:19:11,627 --> 04:19:13,529 YOU WON'T BE A MEMBER ANY 5806 04:19:13,529 --> 04:19:15,898 LONGER, WE KNOW AGAIN HOW TO 5807 04:19:15,898 --> 04:19:18,267 CONTINUE TO WORK WITH YOU IN THE 5808 04:19:18,267 --> 04:19:19,969 SPACES WE CARE ABOUT MUTUALLY. 5809 04:19:19,969 --> 04:19:21,837 THANK YOU FOR YOUR EFFORTS ON 5810 04:19:21,837 --> 04:19:24,106 THE COUNCIL AND WE WERE YOU THE 5811 04:19:24,106 --> 04:19:26,475 BEST IN YOUR NEXT ENDEAVORS. 5812 04:19:26,475 --> 04:19:33,082 THANK YOU. 5813 04:19:33,082 --> 04:19:43,559 WITH THAT I'LL GAVEL US OUT. 5814 04:19:46,562 --> 04:19:47,997 OH, PUBLIC COMMENTS. 5815 04:19:47,997 --> 04:19:50,166 YES, WE HAVE TIME. 5816 04:19:50,166 --> 04:19:53,936 ARE THERE ANY PUBLIC COMMENTS? 5817 04:19:53,936 --> 04:19:56,772 >> WOULD ANY MEMBER OF THE 5818 04:19:56,772 --> 04:19:58,474 PUBLIC LIKE TO MAKE A COMMENT? 5819 04:19:58,474 --> 04:20:00,276 ALL RIGHT. 5820 04:20:00,276 --> 04:20:02,812 >> IN THAT CASE, I'LL GAVEL US 5821 04:20:02,812 --> 04:20:03,078 OUT. 5822 04:20:03,078 --> 04:20:03,412 THANK YOU ALL. 5823 04:20:03,412 --> 04:20:05,548 SEE YOU NEXT TIME. 5824 04:20:05,548 --> 04:20:05,614